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Abstract 
Background 
Rheumatoid arthritis (RA) is a common autoimmune disease characterised by joint 
inflammation and systemic manifestations.  Remission is achievable with disease-modifying 
anti-rheumatic drugs (DMARDs) prescribed in modern treat-to-target strategies, albeit with 
potential side effects, and inconvenient and expensive safety monitoring. Half of patients can 
maintain remission following DMARD cessation, though this cannot be reliably predicted. 
Clinicians and patients thus face a dilemma – when is it appropriate to stop DMARDs in RA 
remission?  
In this Thesis, I explore biomarkers of drug-free remission in RA in the setting of a 
prospective interventional cohort study of conventional synthetic DMARD (csDMARD) 
cessation. 
Method 
Patients with established RA satisfying clinical and ultrasound remission criteria discontinued 
all csDMARDs and were monitored for six months. The primary outcome was time-to-flare, 
defined as DAS28-CRP (disease activity score in 28 joints with C-reactive protein) ≥ 2.4. 
Baseline clinical and ultrasound measures, circulating cytokines, and peripheral CD4+ T cell 
gene expression were assessed for their ability to predict time-to-flare and flare/remission 
status by Cox regression and receiver-operating characteristic (ROC) analysis. 
Results 
23/44 (52%) eligible patients experienced an arthritis flare at a median (IQR) of 48 (31.5 – 
86.5) days following csDMARD cessation. A composite score incorporating five baseline 
variables (three genes, one cytokine, one clinical, no ultrasound) differentiated future flare 
and drug-free remission with an area under the ROC curve of 0.96 (95% CI 0.92-1.00), 
sensitivity 0.91 (0.78 – 1.00) and specificity 0.95 (0.84 – 1.00). Longitudinal analysis 
identified increased concentrations of circulating pro-inflammatory cytokines, and 
upregulation of proliferative genes by CD4+ T cells at the onset of flare. 
Conclusions 
This study provides proof-of-concept evidence for the existence of biomarkers of drug-free 
remission in RA, and offers insights to the pathophysiology of arthritis flare. If validated, 
these biomarkers may help guide csDMARD withdrawal, with consequent minimisation of 
medication side effects and healthcare costs. 
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Chapter 1. Introduction 
 
1.1 General Introduction to Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterised by inflammation in 
the lining of joints termed synovitis (Smolen et al., 2016a). Chronic synovitis causes joint 
pain, stiffness, swelling and ultimately erosions leading to irreversible joint deformity 
(McInnes and Schett, 2011).  In addition to physical disability, additional extra-articular 
features such as accelerated atherosclerosis add to the excess morbidity and mortality of the 
disease (Turesson, 2013). 
In this opening chapter, I will provide a brief clinical overview of the epidemiology, 
presentation, diagnosis and management of RA aimed at a general audience, in order to 
provide the necessary context to the subsequent background chapters in my thesis. 
 
1.1.1 Prevalence and Incidence  
RA is a common autoimmune disease, with an estimated worldwide prevalence of 0.24% 
(Cross et al., 2014). Nevertheless, is recognised that this may under-represent the true 
prevalence of the disease due to low reporting in developing countries. In the UK and other 
developed Western countries, RA is estimated to affect between 0.5 and 1% of the adult 
population (Symmons et al., 2002). Several worldwide retrospective cohort studies place the 
incidence of RA between 20 and 60 cases per 100,000 adults per year (Eriksson et al., 2013; 
Humphreys et al., 2013; Rossini et al., 2014; Widdifield et al., 2014). 
RA has a female propensity with a female : male ratio of 3 : 1 (Scott et al., 2010). The onset 
of RA can occur at any age, and peaks around the 45-75 years of age (Humphreys et al., 
2013). Thus with an increasingly ageing population, the cumulative lifetime risk of RA can be 
expected to increase over the next few decades (van Onna and Boonen, 2016). 
 
1.1.2 Morbidity and mortality 
RA inflicts a substantial burden of illness – in 2010 alone, it was the cause of an estimated 3.7 
million years lived with disability worldwide (Cross et al., 2014). The best-recognised 
morbidities associated with RA are physical disability and pain resulting from the progressive 
joint destruction associated with uncontrolled synovitis. Nevertheless, there is an equally 
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important wider spectrum of morbidity associated with this systemic autoimmune disease, 
ranging from accelerated atherosclerosis and ischaemic cardiovascular events, through to 
fatigue and depression (Scott et al., 2010). 
The causes of death in patients with RA are largely similar to the general population, namely 
cardiovascular disease, cancer, infection and respiratory disease (Radovits et al., 2010). 
However, numerous studies have shown an excess age-standardised mortality ratio in RA of 
between 1.2 to 2 times that of the general population (Dadoun et al., 2013). The reasons 
behind this so-called ‘mortality gap’ are complex, and likely reflect a combination of the 
deleterious effects of sustained immune dysregulation combined with other factors including 
medication side-effects and cigarette smoking, which is strongly implicated in the 
pathogenesis of RA (see Introduction 1.2.3). Crucially, whereas general mortality rates have 
significantly reduced over past decades, this rate of decline has been much slower in the RA 
population leading to a widening of this mortality gap (Gonzalez et al., 2007; Humphreys et 
al., 2014; Widdifield et al., 2014). 
 
1.1.3 Socioeconomic impact 
The socioeconomic impact of RA is disproportionate to its prevalence, owing to its wide age 
range of onset and propensity to cause chronic disability and premature mortality. The direct 
healthcare costs of treating RA are substantial, and include inpatient and outpatient episodes, 
medication prescriptions and frequent drug monitoring. Furthermore, there is an enormous 
indirect economic impact of RA owing to the costs of lost work productivity, disability 
welfare allowances and social care. Indeed, the healthcare needs of RA sufferers, combined 
with societal consequences of long-term disability and lost work productivity, is estimated to 
cost the UK economy £4.75 billion per annum (National Institute for Health and Care 
Excellence, 2009). 
 
1.1.4 Clinical Presentation 
RA typically presents with an insidious onset of joint pain and swelling. Any synovial joint 
can be involved, but typically RA manifests symmetrically in the wrists and small joints of 
the hands and feet (Feist and Burmester, 2013). Several additional patterns of onset have also 
been described, including: acute systemic onset, migratory (palindromic) onset, and 
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polymyalgic RA, the latter of which is more commonly encountered in the elderly (Feist and 
Burmester, 2013). 
The hallmark clinical features of active RA are pain, warmth, erythema and swelling of the 
affected joints (synovitis) (Maini, 2012). In addition, inflammation can occur in the tendon 
sheaths (tenosynovitis) resulting in pain, swelling and mechanical obstruction. If left 
untreated, irreversible joint and tendon damage can occur, leading to a stereotypical 
destructive pattern of arthritis (Figure 1.1). Furthermore, extra-articular inflammation leads to 
a constellation of associated pathology that can affect virtually any organ system (Table 1.1). 
1.1.5 Diagnosis 
There is no single investigation that is diagnostic of RA, which remains a clinical diagnosis 
based largely upon medical history and examination findings. Nevertheless, there are several 
biochemical, serological and radiological investigations that can provide evidence to support 
the diagnostic process (Table 1.2). 
 
 
Figure 1.1 – Photograph (A) and plain radiograph (B) demonstrating the typical joint 
destruction seen in established uncontrolled rheumatoid arthritis. Severe ulnar deviation and 
palmar subluxation is evident at the metacarpophalangeal joints, together with radiographic 
evidence of bone erosions and periarticular osteopenia. Reproduced from Ishikawa (2017) 
under the terms of a CC BY-NC-ND 4.0 license (http://creativecommons.org/licenses/by-nc-
nd/4.0/). © 2017 The Japanese Orthopaedic Association. Published by Elsevier B.V. 
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Table 1.1 – The extra-articular manifestations of rheumatoid arthritis. Adapted from Scott et 
al. (2010). 
Organ system Manifestation 
Respiratory 
Pulmonary fibrosis 
Pleural effusion 
Pulmonary nodules 
Caplan syndrome 
Cardiovascular 
Vasculitis 
Pericarditis 
Conduction defects 
Neurological 
Compression neuropathy 
Mononeuritis multiplex 
Cervical myelopathy 
Skin 
Rheumatoid nodules 
Neutrophilic dermatoses 
Vasculitic rash 
Ocular 
Scleritis 
Episcleritis 
Keratoconjunctivitis sicca 
Systemic 
Fatigue 
Depression 
Amyloidosis 
Osteoporosis 
 
The diagnosis of RA has been formalised for research purposes by the creation of 
classification criteria endorsed by leading rheumatology societies. Until recently, the most 
widely used of these was the 1987 American College of Rheumatology (ACR) RA 
classification criteria (Table 1.3). Whilst providing a sensitivity and specificity of around 90% 
for the diagnosis of established RA versus non-RA rheumatic disease controls, the 1987 
criteria relied heavily upon features of advanced disease such as radiographic joint damage. 
Consequently, the 1987 criteria were criticised for their insensitivity to early disease, which 
made them out-dated with a later evolution towards intervention at earlier stages of clinical 
presentation. 
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Table 1.2 – Key investigations that can aid the diagnosis of rheumatoid arthritis. 
Category Investigation 
Laboratory measures of the 
 acute-phase response 
C-reactive protein 
Erythrocyte sedimentation rate 
Serology 
Rheumatoid factor 
Anti-citrullinated peptide autoantibodies 
Imaging 
Plain radiographs 
Musculoskeletal ultrasound 
 
To address this shortfall, the ACR in collaboration with the European League Against 
Rheumatism (EULAR) released updated RA classification criteria in 2010 (Aletaha et al., 
2010). The 2010 criteria use a point-based system to define RA across four domains: joint 
involvement, serological status, biochemical inflammatory markers and symptom duration 
(Table 1.4). Whilst representing a significant advance on previous criteria, the 2010 criteria 
may still under-diagnose early RA, particularly in the approximately 25% of patients who are 
seronegative for rheumatoid factor (RhF) and anti-citrullinated peptide antibodies (ACPA). 
 
1.1.6 Management 
There are two principal aims in the management of RA, namely the alleviation of joint 
symptoms, and a reduction (ideally prevention) of joint damage and systemic disease 
manifestations. Long-term outcomes are more favourable when treatment is started early in 
the course of disease, and when there is comprehensive suppression of inflammation 
(discussed further in Introduction 1.3). Indeed, disease remission is now a realistic target of 
treatment for RA in the modern era (Smolen et al., 2016b). 
As a multi-faceted systemic autoimmune disease, RA is best managed in a multi-disciplinary 
approach incorporating rheumatologists, specialist nurses, physiotherapists, occupational 
therapists and podiatrists (National Institute for Health and Care Excellence, 2009). Up until 
the latter half of the 20th century, medical treatment was traditionally focussed on medications 
such as non-steroidal anti-inflammatory drugs (NSAIDs) which, although providing 
symptomatic relief, afford little if any protection against disease progression (Scott et al., 
2010).  From the 1970s onwards, increasing emphasis was placed on the use of drugs that 
were able to modify the underlying disease process and hence prevent joint damage – the  
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Table 1.3 – The 1987 American College of Rheumatology (ACR) classification criteria for 
RA. MCP: metacarpophalangeal; MTP: metatarsophalangeal; PIP: proximal interphalangeal. 
Reproduced with permission from Arnett et al. (1988). Copyright © 1988 American College 
of Rheumatology. 
 
Criterion Definition 
Morning stiffness 
“Morning stiffness in and around the joints, lasting at least 1 hour 
before maximal improvement” 
Arthritis of 3 or more 
joint areas 
“At least 3 joint areas simultaneously have had soft tissue 
swelling or fluid (not bony overgrowth alone) observed by a 
physician. The 14 possible areas are right or left PIP, MCP, wrist, 
elbow, knee, ankle, and MTP joints” 
Arthritis of hand 
joints 
“At least 1 area swollen (as defined above) in a wrist, MCP, or 
PIP joint” 
Symmetric arthritis 
“Simultaneous involvement of the same joint areas (as defined in 
2) on both sides of the body (bilateral involvement of PIPs, 
MCPs, or MTPs is acceptable without absolute symmetry)” 
Rheumatoid nodules 
“Subcutaneous nodules, over bony prominences, or extensor 
surfaces, or in juxta-articular regions, observed by a physician” 
Serum rheumatoid 
factor 
“Demonstration of abnormal amounts of serum rheumatoid factor 
by any method for which the result has been positive in <5% of 
normal control subjects” 
Radiographic changes 
“Radiographic changes typical of rheumatoid arthritis on 
posteroanterior hand and wrist radiographs, which must include 
erosions or unequivocal bony decalcification localized in or most 
marked adjacent to the involved joints (osteoarthritis changes 
alone do not qualify)” 
* “For classification purposes, a patient shall be said to have rheumatoid arthritis if he/she 
has satisfied at least 4 or these 7 criteria. Criteria 1 through 4 must have been present for at 
least 6 weeks. Patients with 2 clinical diagnoses are not excluded.” 
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Table 1.4 – The 2010 American College of Rheumatology (ACR) and European League Against 
Rheumatism (EULAR) classification criteria for RA. ACPA: anti-citrullinated peptide antibody; CRP: 
C-reactive protein; ESR: erythrocyte sedimentation rate; RhF: rheumatoid factor. Table and footnotes 
are reproduced from ‘2010 Rheumatoid arthritis classification criteria: an American College of 
Rheumatology/European League Against Rheumatism collaborative initiative’, Aletaha et al., Annals 
of the Rheumatic Diseases, vol 69, pages 1580-1588, copyright 2010, with permission from BMJ 
Publishing Group Limited.  
A total score of ≥ 6 is required for a diagnosis of rheumatoid arthritis Score 
A. Joint involvement §  
• 1 large joint ¶ 0 
• 2-10 large joints 1 
• 1-3 small joints (with or without involvement of large joints) # 2 
• 4-10 small joints (with or without involvement of large joints) 3 
• >10 joints (at least 1 small joint) ** 5 
  
B. Serology †† 
(at least 1 test result is needed for classification) 
 
• Negative RhF and negative ACPA 0 
• Low-positive RhF or low-positive ACPA 2 
• High-positive RhF or high-positive ACPA 3 
  
C. Acute phase reactants ‡‡ 
(at least 1 test result is needed for classification)  
 
• Normal CRP AND normal ESR 0 
• Abnormal CRP OR abnormal ESR 1 
  
D. Duration of symptoms §§  
• <6 weeks 0 
• ≥6 weeks 1 
“The criteria are aimed at classification of newly presenting patients. In addition, patients with erosive 
disease typical of rheumatoid arthritis (RA) with a history compatible with prior fulfilment of the 2010 
criteria should be classified as having RA. Patients with longstanding disease, including those whose 
disease is inactive (with or without treatment) who, based on retrospectively available data, have 
previously fulfilled the 2010 criteria should be classified as having RA. Although patients with a score of 
<6/10 are not classifiable as having RA, their status can be reassessed and the criteria might be fulfilled 
cumulatively over time. § Joint involvement refers to any swollen or tender joint on examination, which 
may be confirmed by imaging evidence of synovitis. Distal interphalangeal joints, first carpometacarpal 
joints, and first metatarsophalangeal joints are excluded from assessment. Categories of joint distribution 
are classified according to the location and number of involved joints, with placement into the highest 
category possible based on the pattern of joint involvement. ¶ "Large joints" refers to shoulders, elbows, 
hips, knees, and ankles. # "Small joints" refers to the metacarpophalangeal joints, proximal 
interphalangeal joints, second through fifth metatarsophalangeal joints, thumb interphalangeal joints, and 
wrists.** In this category, at least 1 of the involved joints must be a small joint; the other joints can 
include any combination of large and additional small joints, as well as other joints not specifically listed 
elsewhere (e.g., temporomandibular, acromioclavicular, sternoclavicular, etc.). †† Negative refers to IU 
values that are less than or equal to the upper limit of normal (ULN) for the laboratory and assay; low-
positive refers to IU values that are higher than the ULN but ≤3 times the ULN for the laboratory and 
assay; high-positive refers to IU values that are >3 times the ULN for the laboratory and assay. Where 
rheumatoid factor (RF) information is only available as positive or negative, a positive result should be 
scored as low-positive for RF.‡‡ Normal/abnormal is determined by local laboratory standards.§§ 
Duration of symptoms refers to patient self-report of the duration of signs or symptoms of synovitis (e.g., 
pain, swelling, tenderness) of joints that are clinically involved at the time of assessment, regardless of 
treatment status.” 
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so-called disease modifying anti-rheumatic drugs (DMARDs) (Moreland et al., 2001). Many 
of the early DMARDs including methotrexate, sulphasalazine and hydroxychloroquine are 
still in widespread use today, although their mechanisms of action remain largely obscure 
(Scott et al., 2010). Whilst often effective in attenuating the progression of synovitis and joint 
damage, DMARDs carry a wide spectrum of potential adverse effects ranging from 
gastrointestinal upset to serious complications including hepatitis and bone marrow 
suppression (Moreland et al., 2001; Ledingham et al., 2017). For this reason, the majority of 
DMARDs require regular blood test safety monitoring (Ledingham et al., 2017). 
Over the past two decades, increasing knowledge of the molecular basis of inflammation in 
RA, coupled with technological advances in therapeutic antibody production, have led to the 
development of novel biopharmaceutical agents. The mechanisms of action of these so-called 
“biologics” are typified by the potent but selective blockade of an inflammatory mediator, 
usually by means of a specific antibody or receptor fusion protein (McInnes and Schett, 
2017). The first of these agents to be licensed for use in RA was infliximab, a chimeric 
monoclonal antibody directed against tumour necrosis factor α (TNF-α) (Elliott et al., 1994). 
The following years have seen an explosion in the number of biologic agents, and their potent 
action has revolutionised the treatment of RA resistant to conventional synthetic DMARD 
therapy. Although more specific in their action and hence more widely tolerated than their 
small-molecule DMARD counterparts, biologics still carry risks of serious adverse events, 
most notably an increased risk of severe infection (Ramiro et al., 2014). More recently still, 
the development of novel small molecule inhibitors of cell signalling pathways involved in 
the inflammatory response, such as the Janus kinase inhibitors, offer the possibility of 
selective immunosuppression with orally-available drugs (Baker and Isaacs, 2018). 
Surgery in the form of arthrodesis, arthroplasty, tendon reconstruction and nerve 
decompression are generally considered interventions of last resort when all options of 
medical therapy have been exhausted. Indeed, with increasing potency of immunosuppressive 
medications and their more aggressive and earlier use, rates of orthopaedic intervention in RA 
have declined significantly in the previous two decades (Kievit et al., 2013). 
 
1.1.7 Summary 
RA is a common autoimmune disease with a potentially devastating impact upon the lives of 
individual patients, as well as posing a substantial burden to healthcare systems and the wider 
society. RA was historically a disease characterised by inexorable joint destruction and 
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disability with few effective treatments. However, early and aggressive immunosuppression 
has afforded unparalleled advances in disease control, such that disease remission is now a 
realistic and achievable target for the majority of patients. Nevertheless, such treatments are 
not without the risk of serious side effects and require close and frequent clinical monitoring. 
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1.2 Immunopathogenesis of Rheumatoid Arthritis 
The pathological hallmark of RA is the rheumatoid pannus – a dense inflammatory cellular 
proliferation found at sites of synovial joint destruction. The RA pannus is an amorphous mix 
of both of joint stromal cells (e.g. synoviocytes, osteocytes etc.) as well as extra-articular cells 
recruited to the joint (e.g. lymphocytes, macrophages etc.) (Smolen et al., 2016a). The 
temporal order, relative importance and redundancy of this plethora of autoimmune processes 
underlying the pathogenesis of RA has long provided a challenge to resolve in a unifying 
model of RA pathogenesis. Indeed, it is becoming increasingly apparent that RA is a dynamic 
and fluid process that is different both between individual patients and even within the same 
patient over time. In this respect, RA is perhaps best conceptualised as a clinical syndrome 
which encompasses multiple distinct immune pathologies under a unifying phenotypical 
umbrella (McInnes and Schett, 2011). 
In this chapter, I present a concise review of the key players in RA immunopathogenesis, with 
a particular focus upon an increasing weight of evidence that supports a central orchestrating 
role for the CD4+ T cell. 
 
1.2.1 CD4+ T cell and the initiation of adaptive immunity 
CD4+ T cells play a unique and crucial role in the initiation of the adaptive immune response. 
Antigen-presenting cells (APCs), including macrophages and dendritic cells, take up and 
process proteins which are presented as antigenic peptide fragments bound to surface-
expressed major histocompatibility (MHC) class II molecules (Murphy and Weaver, 2016). 
Each clone of CD4+ T cell expresses a unique T cell receptor (TCR), which binds to its 
cognate antigen:MHC-II complex. Once activated by further co-stimulatory surface 
interactions with the APC, CD4+ T cells can release large amounts of immunomodulatory 
cytokines and provide further co-stimulation to activate other arms of the adaptive immune 
response including CD8+ cytotoxic T cells, plasma cells and B lymphocytes (Murphy and 
Weaver, 2016). CD4+ T cells are thus crucially placed both to initiate adaptive immunity and 
to direct or polarise the ensuing immune response. 
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1.2.2 The ‘shared epitope’ hypothesis 
Early studies of twin discordance highlighted the association of RA with an abundance of 
haplotypes of the major histocompatibility (MHC) locus (Gregersen et al., 1987). The MHC 
is located on the short arm of chromosome 6, and mainly encodes the human leukocyte 
antigen (HLA) molecules, classified as MHC class I (HLA-A, HLA-B and HLA-C in 
humans) and MHC class II (HLA-DP, HLA-DQ, HLA-DR in humans) (Fernando et al., 
2008). MHC-II are of particular importance in autoimmunity, given their critical role in the 
presentation of exogenous antigen by APCs to CD4+ T cells, and thus the initiation of the 
adaptive immune response. MHC-II molecules comprise two chains – α and β – the latter of 
which contains a highly variable region known as the ‘peptide-binding groove’ (Brown et al., 
1993). Variability in this peptide-binding groove affects the affinity to which different 
antigenic peptide fragments can bind and so be presented to CD4+ T cells, thus providing a 
mechanistic model to account for the genetic propensity towards autoimmunity associated 
with certain MHC haplotypes (Fernando et al., 2008). 
The so-called ‘shared epitope’ describes a common amino acid motif in residues 70 to 74 in 
various alleles of HLA-DRB1 (e.g. *0101, *0401 and *0404) which have been strongly 
associated with the development of seropositive RA (Holoshitz, 2010). Although the exact 
nature of the autoantigens important in the initiation of RA are not clear, it has been 
demonstrated that citrullination can increase the binding affinity of peptides with the MHC 
shared-epitope (Hill et al., 2003). This is an important observation given the abundance of 
anti-citrullinated peptide antibodies that can be detected in the sera of many patients with RA. 
Cigarette smoking, which is strongly associated with seropositive RA in epidemiological 
studies, is also known to promote peptide citrullination via peptidyl-arginase deiminase 
(PADI) enzymes, and smoking interacts with HLA-DRB1 status to promote risk of RA in a 
multiplicative manner (Klareskog et al., 2006). Furthermore, the bacterium Porphyromonas 
gingivalis, which is also associated with seropositive RA, contains a PADI enzyme which can 
citrullinate human host peptides (Wegner et al., 2010). The shared epitope thus provides an 
attractive unifying hypothesis to link the environmental agents such as cigarette smoke 
together with MHC genotype, albeit only in the case of seropositive RA. 
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1.2.3 CD4+ T cells are key players in RA pathogenesis 
1.2.3a Genetic and epigenetic evidence supports a central involvement of CD4+ T cells in the 
development of RA 
A growing body of evidence places CD4+ T cells at the heart of RA pathogenesis. First, the 
shared-epitope hypothesis demonstrates the importance of antigen presentation via MHC-II in 
the pathogenesis of RA, and thus the importance of CD4+ T cells in this process. Indeed, 
blockade of CD28:CD80/86 co-stimulation between antigen presenting cells and effector T 
cells has been exploited therapeutically by abatacept, a cytotoxic T lymphocyte associated 
protein 4 (CTLA-4):Ig Fc fusion protein licensed for the treatment of RA and juvenile 
idiopathic arthritis (Keating, 2013). 
Second, single nucleotide polymorphisms (SNPs) found outside the MHC that are associated 
with RA in genome-wide association studies (GWAS) are disproportionately located within 
chromosome loci enriched for genes that are important in CD4+ T cell function (Diogo et al., 
2014). For example, the strongest genetic association with RA outside of the MHC complex 
that has been identified to-date is an SNP (1858C to T) in the PTPN22 gene. This leads to an 
amino acid substitution (R620W) in the enzyme lymphoid phosphatase, which is likely to 
play an important role in the regulation of T cell function (Begovich et al., 2004). 
Furthermore, the R620W allele of PTPN22 has been shown to interact with shared epitope 
alleles of HLA-DRB1 and cigarette smoking, such that the odds ratio of developing ACPA-
positive RA in an individual with all three risk factors is over 20 times that of an individual 
with none (Kallberg et al., 2007). 
Third, many of the SNPs associated with RA overlap with regions of altered chromatin 
methylation, known as “chromatin marks”, in CD4+ T cells implicating their roles in cell-
specific altered gene regulation (Trynka et al., 2013). For example, demethylation of the 
promoter of CD40LG, a gene located on the X chromosome which encodes the co-stimulatory 
molecule CD40L, has been observed in the CD4+ T cell subset of female RA patients (Liao et 
al., 2012). As discussed by Zhang and Zhang (2015), this observation suggests a possible 
mechanistic link between over-expression of CD40L in CD4+ T cells and increased 
susceptibility to RA in women. This is further supported by the link between CD40/CD40L 
interactions and Th17 differentiation in mice (Iezzi et al., 2009) and the production of the pro-
Th17 cytokine IL-23 by human DCs upon CD40 ligation in vitro (Sender et al., 2010). 
Fourth, patterns of gene expression by CD4+ T cells have been associated with an increased 
risk of developing RA. Using a genome-wide microarray analysis of CD4+ T cell gene 
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expression in cohort of 173 patients with undifferentiated arthritis, Pratt et al. (2012) 
identified a 12-gene signature that could predict the subsequent development of RA. This 
signature included several STAT3-inducible genes, and constitutive phosphorylation of 
STAT3 within CD4+ T cells showed a strong correlation with circulating IL-6 levels 
(Anderson et al., 2016). Interestingly, these observations were strongest for ACPA-negative 
individuals, and provide a potential mechanistic basis by which upregulated IL-6 signalling 
via CD4+ T cells could promote the development of RA (Anderson et al., 2016). 
Fifth, several observations converge to suggest that CD4+ T cell proliferation is a central 
feature of RA pathogenesis. CD4+ T cells are found within RA synovium and produce pro-
inflammatory cytokines (Steiner et al., 1999). Furthermore, oligoclonal populations of CD4+ 
T cells with reduced T cell receptor diversity have been observed in the circulation (Wagner 
et al., 1998) and joints (Khazaei et al., 1995) of patients with RA, in keeping antigen-driven 
clonal expansion as part the disease process. Indeed, chronic activation and proliferation is 
thought to underpin the premature immunosenescence seen in CD4+ T cell populations in RA 
patients (Weyand et al., 2014), thought in part to be due to defective telomerase activity 
within these cells (Fujii et al., 2009). Whether immunosenescence contributes to the 
pathogenesis of RA or is merely a downstream consequence of the disease is unknown; 
nevertheless, both possibilities implicate CD4+ T cells in the immunopathology of the disease. 
 
1.2.3b Potential roles of CD4+ T cell subsets in RA pathogenesis 
Over past decades there has been much effort to categorise CD4+ T cells into functional 
subsets defined by the nature of immunity they induce (Gizinski and Fox, 2014). Initial 
attempts to categorise CD4+ T cells focussed on defining two subsets: Th1 or Th2, responsible 
for cell-mediated and humoral immunity respectively (Gizinski and Fox, 2014). This model 
later proved to be overly simplistic, and recent years have witnessed an expanding range of 
proposed CD4+ cellular subsets, including Th17, Th9, T follicular helper (TFH), and various 
subdivisions of regulatory T cells (Treg) (Hirahara and Nakayama, 2016). The translation of 
murine and in vitro observations to human immunity is at times obtuse, and limited by 
uncertainty regarding the plasticity of such cellular subsets. Nevertheless, with such 
classifications it has been possible to demonstrate that certain subsets of CD4+ T cell are 
strongly implicated in RA pathogenesis. 
Arguably the most strongly associated with the development of RA is the Th17 cell, so-called 
because of  their propensity to secrete the pro-inflammatory cytokine interleukin-17 (IL-17) 
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and further defined by their expression of the transcription factor retinoic acid-related orphan 
receptor γ (RORγ) (Gizinski and Fox, 2014). Elevated levels of IL-17 isoforms have been 
observed in the plasma and synovial fluid of RA patients (Jain et al., 2015), and in vitro co-
culture of human Th17 cells and synovial fibroblasts can induce the production of 
inflammatory cytokines and destructive matrix metalloproteinases (MMPs) in an IL-17 
dependent manner (van Hamburg et al., 2011). Blockade of IL-17 can ameliorate 
inflammatory arthritis in animal models (Lubberts et al., 2001), and a reduction in plasma IL-
17 levels has been observed in RA patients following drug therapy (Jain et al., 2015). 
Although IL17 blockade has been therapeutically disappointing in RA, several specific anti-
IL-17 therapeutics are either licensed or currently in clinical development for the treatment of 
other autoimmune diseases including psoriasis, psoriatic arthritis and ankylosing spondylitis 
(Baker and Isaacs, 2018). 
More recently, a further CD4+ T cell subset implicated in autoimmunity has been described – 
the Th22 cell (Azizi et al., 2015). These cells are characterised by their secretion of IL-22, and 
absence of other CD4+ subset markers. Circulating Th22 cells are increased in RA patients, 
and have been shown to correlate with the levels of IL-22 and clinical disease activity scores 
(Zhang et al., 2011; Zhang et al., 2012; Zhao et al., 2013). Nevertheless, the prevalence of 
Th22 cells appears to correlate with Th17 cells, and the extent to which these different subsets 
are independently associated with the development of RA remains debateable. 
Contrary to the pro-inflammatory action of subsets such as Th17 cells, it is now well 
established that a further subset of CD4+ T cells known as regulatory T cells (Treg) act to 
maintain immunological tolerance to autoantigens and play an important role in the 
prevention of autoimmune diseases such as RA. Tregs can develop centrally in the thymus 
(natural Tregs), or can develop peripherally (induced Tregs) under the influence of anti-
inflammatory cytokines such as IL-10 and transforming growth factor β (TGF-β) (Noack and 
Miossec, 2014). Human Tregs are characterised by the expression of the transcription factor 
forkhead box P3 (FoxP3), and can actively suppress the inflammatory response through 
production of cytokines such as IL-10 and TGF-β and by directly suppressing the action of 
effector T cells (Noack and Miossec, 2014). Indeed, the adoptive transfer of Tregs, or their 
differentiation in vivo, can protect against experimentally-induced inflammatory arthritis in 
animal models and holds promise as a potential avenue of future tolerogenic therapy in human 
rheumatic diseases (Miyara et al., 2014). Nevertheless, the plasticity between effector and 
regulatory T cells and the often obscure nature of the autoantigens driving the immune 
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response in RA pose significant challenges to the clinical translation of Treg therapy (Baker 
and Isaacs, 2014). 
 
1.2.4 B lymphocytes and plasma cells 
Despite substantive evidence to support the role of T cells in the pathogenesis of RA, they are 
by no means the only immune cell type to play a role in disease pathogenesis. B lymphocytes, 
and their derivative plasma cells, have long been known to contribute to the development of 
autoimmunity in RA. Indeed, one of the first insights in to the immune pathogenesis of RA 
came in the 1940s with the observation that sera from patients with RA could induce 
haemagglutination when mixed with sheep blood (Alexander, 1967). The precipitating agent 
was named rheumatoid factor, which was later identified to be a range of autoantibodies 
directed against the Fc portion of IgG (immunoglobulin G). More recently, autoantibodies 
directed against modified protein epitopes such as anti-citrullinated peptide antibodies 
(ACPA) and anti-carbamylated protein antibodies have also been identified, and assays of 
ACPA titres are now routinely used in clinical diagnosis of RA. Retrospective studies of 
stored serum samples have demonstrated that autoantibodies such as ACPA develop up to a 
decade before the onset of clinical disease, and undergo class-switching and affinity 
maturation in the few years prior to symptom onset (Rantapaa-Dahlqvist et al., 2003; van der 
Woude et al., 2010). Furthermore, there is now some evidence to support a direct pathogenic 
role of ACPA in the development of rheumatoid synovitis (Kocijan et al., 2013). 
Nevertheless, up to a third of patients with RA are seronegative for both RhF and ACPA, 
highlighting that these autoantibodies are not necessary for the development of clinical 
disease. 
The therapeutic depletion of B cells by use of the monoclonal antibody rituximab has now 
been routinely used for over a decade to control severe RA. Rituximab binds to CD20 which, 
interestingly, is only expressed on immature pro/pre-B lymphocytes and not by antibody-
producing mature plasma cells (Cohen and Keystone, 2015). This highlights the pleiotropic 
effects of B cells beyond antibody production alone, which include antigen presentation and 
potent secretion of cytokines and chemokines (Cohen and Keystone, 2015). In addition to 
forming a major constituent of reactive lymph node follicles, B cells and plasma cells can 
often be found organised within ectopic lymphoid structures within inflamed RA synovium, 
the presence of which may hold promise as a biomarker of therapeutic response to B cell 
depletion (Humby et al., 2017). Correspondingly, circulating levels of the B cell chemokine 
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C-X-C Motif Chemokine Ligand 13 (CXCL13) have been shown to correlate with clinical 
and imaging measures of synovitis in RA (Bugatti et al., 2012), and the return of B cells 
following rituximab treatment (Rosengren et al., 2011). 
 
1.2.5 Innate immune cells 
Although adaptive immune cells are believed to be the key initiators of autoimmunity in RA, 
they are hugely outnumbered in the rheumatoid pannus by their innate immune counterparts. 
Macrophages feature prominently in inflamed synovium, and secrete both tissue-damaging 
matrix metalloproteinases (MMPs) as well as pro-inflammatory chemokines and cytokines, 
such as tumour necrosis factor alpha (TNF-α) and interleukin 6 (IL-6), which serve to amplify 
the immune response (McInnes and Schett, 2017). Neutrophils are not constitutively present 
within the joint, but are recruited in large numbers to the synovial fluid during joint 
inflammation. As well as releasing pro-inflammatory reactive oxygen species, deranged 
necrosis and the formation of DNA-containing neutrophil extracellular traps (NETs) may play 
a role in RA pathogenesis as in other related connective tissue diseases such as systemic lupus 
erythematosus (Mitsios et al., 2016). Further innate immune cells are found within the 
rheumatoid pannus and play a role in perpetuating inflammation and promoting tissue 
damage, including both mast cells and natural killer cells (McInnes and Schett, 2011). 
Dendritic cells (DCs), either resident within the synovium or recruited to the joint, sample 
antigenic peptides and present these to CD4+ T cells. Both the local environment in which 
antigen uptake occurs, together with the inherent pro- or anti-inflammatory propensity of the 
DC, are thought to be important to the priming and polarisation of the ensuing adaptive 
immune response (Ganguly et al., 2013). Indeed, several groups are actively investigating the 
potential of ex-vivo tolerogenic conditioning of DCs as a future cellular therapy for RA 
(Raker et al., 2015). 
 
1.2.6 Fibroblast-like synoviocytes 
The cells of the joint parenchyma, including synoviocytes, fibroblasts, chondrocytes, 
osteoblasts and osteoclasts, were historically viewed in RA as the passive victims of an 
externally mediated immune attack. However, emerging evidence particularly over the past 
decade implicates many of these cells within disease pathogenesis, not least the synoviocyte. 
Two types of synoviocyte have been characterised: type A and type B (Iwanaga et al., 2000). 
Type-A synoviocytes bear macrophage-specific surface markers and are thought to represent 
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the tissue-resident macrophages of the joint, responsible for phagocytosis of cellular debris 
and capable of antigen presentation through MHC-II molecules. Type-B synoviocytes closely 
resemble fibroblasts, and in health function to secrete lubricating proteoglycans and 
glycosaminoglycans (Iwanaga et al., 2000). However, in RA these fibroblast-like 
synoviocytes (FLS) can become grossly dysregulated and produce large amounts of pro-
inflammatory cytokines and chemokines together with destructive MMPs (Bottini and 
Firestein, 2013). Furthermore, observations of epigenetic modifications in FLS isolated from 
RA pannus are thought to be important in maintaining their pro-inflammatory phenotype 
(Frank-Bertoncelj and Gay, 2014). Furthermore, human FLS can migrate between joints via 
the vasculature when experimentally grafted to mice (Lefevre et al., 2009), although it is 
unknown whether this malignant-like behaviour occurs in human disease. 
 
1.2.7 Environmental associations 
Epidemiological studies have identified several environmental factors associated with the 
development of RA, especially seropositive disease. As already discussed (see Introduction 
1.2.2), the most striking and well-characterised of these is tobacco smoking. Furthermore, 
exposure to other toxins including silica dust (Stolt et al., 2005) and urban airborne pollutants 
(Jung et al., 2017) have also been linked to an increase risk of RA. 
Various lifestyle and dietary factors have also been associated with the development and 
persistence of RA. Several studies suggest a protective role for a Mediterranean diet (Forsyth 
et al., 2017), perhaps due to higher levels of monounsaturated fatty acids (Matsumoto et al., 
2018) which may be protective against the development of RA (de Pablo et al., 2018). 
Furthermore, modest alcohol intake has been shown to protect against the onset of RA in 
several case-control studies (Scott et al., 2013b). Obesity has been associated with an 
increased risk of RA in several studies (Lu et al., 2014; Ljung and Rantapaa-Dahlqvist, 2016; 
Turesson et al., 2016). 
Recent years have witnessed increasing interest in the role of human microflora in the 
pathogenesis of autoimmune disease, not least inflammatory arthritides such as RA. The huge 
number of microbes that colonise mucosal sites such as the oral cavity, intestines and lungs, 
together with their interactions with host immunity, provide a rich source of environmental 
modulators of the immune system (Clemente et al., 2018). Proof-of-concept studies with mice 
reared in germ-free environments have demonstrated the importance of specific elements of 
the murine gut microbiome – for example, segmented filamentous bacteria – in the 
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development of experimental arthritis (Wu et al., 2010). In humans, increased prevalence of 
Prevotella copri has been observed in faecal samples from patients with RA (Scher et al., 
2013), and P.copri-derived peptides can drive Th1 responses in vitro by peripheral blood 
mononuclear cells of RA patients (Pianta et al., 2017). Although still in its infancy, study of 
the diverse variation in the human microbiome seems likely to yield further insights to 
specific triggers and novel therapeutic avenues for the treatment of RA. Indeed, microbiome 
alterations may conceivably play a role in the mechanistic effects of many if not all of the 
dietary and lifestyle factors mentioned above (Clemente et al., 2018).  
 
1.2.8 Summary 
Although the exact mechanisms by which autoimmunity is initiated and maintained in RA 
remain uncertain, several key players, including both immune and joint stromal factors, are 
known to be important. At the heart of the disease lies the CD4+ T cell, which is firmly 
implicated in RA pathogenesis by evidence from human genetic and epigenetic studies. 
Autoimmunity is detectable in RA patients many years before the onset of clinical disease, 
and is a dynamic and fluid process that is different both between individual patients and even 
within the same patient over time. In this respect, RA is perhaps best conceptualised as a 
clinical syndrome which encompasses multiple distinct immune pathologies under a unifying 
phenotypical umbrella, in which the CD4+ T cell likely plays a crucial orchestrating role. 
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1.3  Treatment approaches in rheumatoid arthritis 
The past two decades have witnessed a remarkable transformation in RA prognosis, from a 
disease of inexorable joint destruction and disability to one where remission is now 
commonplace. This clinical revolution reflects the emergence of new therapies, including 
highly potent and selective biopharmaceutical agents, in tandem with paradigm shifts in 
regimens of drug initiation and dose escalation. 
In this section, I will summarise the role of DMARDs in the treatment of RA and the 
evolution of RA treatment paradigms, to provide a conceptual context in which to frame this 
Thesis. 
 
1.3.1 The “step-up” paradigm of DMARD therapy 
The gradual acceptance of DMARDs in mainstream rheumatology practice in the latter 
decades of the 20th century led to the emergence of the “step-up” paradigm of RA treatment 
(Figure 1.2). In this model, medications are sequentially introduced to control joint 
inflammation, with the trigger for escalation of DMARD therapy being poor disease control 
(Moreland et al., 2001). This treatment approach ensures that only those patients with severe 
disease receive the most costly treatment; cost in this sense defined in terms of the individual 
patient (i.e. side effect profile) and the healthcare provider (i.e. monetary cost of the 
medication).  
 
   
                      
Figure 1.2 – The “step-up” and “step-down” models of disease-modifying anti-rheumatic drug 
(DMARD) therapy in rheumatoid arthritis. Adapted from Dale et al. (2007). 
Step-up model Step-down model 
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A step-up approach to DMARD therapy does nevertheless carry significant disadvantages. 
Perhaps the most notable of these is the time taken to escalate drug therapy, thus effectively 
delaying commencement of an effective DMARD regimen for those with the most severe 
disease. Indeed, strong evidence exists to support the concept of a so-called “window of 
opportunity” for the treatment of RA, whereby substantial improvements in clinical and 
patient-reported outcomes are observed when effective DMARD therapy is introduced early 
in the evolution of the disease (Breedveld, 2011). A meta-analysis of 12 studies (1133 
patients) found that early DMARD commencement correlated with a 33% reduction (95% CI: 
50% to 16%) in long-term radiographic progression compared to those who received 
DMARDs later, even though the average delay in DMARD commencement was just 9 
months (Finckh et al., 2006). In a more recent meta-analysis of data from three observational 
early RA cohorts (2079 patients), a significant decrease in sustained DMARD-free remission 
was observed with increasing delay to DMARD initiation (hazard ratio (HR) 0.989 [95% CI 
0.983 to 0.995] per week increase in symptom duration) (van Nies et al., 2014). Nevertheless, 
the validities of both meta-analyses are weakened somewhat by heterogeneity in patient 
characteristics and DMARD regimens, and by their inclusion of observational study data. As 
suggested by Raza and Filer (2015) it is also important to consider the potential confounding 
by disease subtype in that patients with an insidious onset of symptoms, and hence delayed 
presentation and commencement of DMARDs, may have an inherently worse prognosis that 
is independent of treatment delay. Despite the limitations outlined above, the evidence that 
early intervention can improve long-term outcomes in RA is compelling and as such features 
prominently in international treatment guidelines (Singh et al., 2016; Smolen et al., 2017).  
 
1.3.2 Treatment-to-target in rheumatoid arthritis 
The improved patient outcomes observed with early DMARD therapy has led to the 
emergence of the “treat-to-target” approach, whereby DMARDs are escalated until a pre-
determined target of arthritis activity is achieved (Smolen et al., 2016b). For the majority of 
patients, this target is remission – now a realistic aim with modern DMARD therapy (Smolen 
et al., 2016b). Indeed, patient outcomes of target-based treatment approaches have been 
demonstrated to be superior to that guided by symptoms alone in many branches of medicine. 
This is perhaps most notable in the treatment of diabetes mellitus, where treatment to a target 
level of glycaemic control can significantly reduce microvascular complications of the disease 
(Fullerton et al., 2014). It is perhaps therefore not surprising that emerging evidence supports 
improved RA outcomes with a treat-to-target approach. In the landmark Tight Control for 
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Rheumatoid Arthritis (TICORA) study, 111 patients with active established RA were 
randomised to receive either conventional treatment or intensive treatment to a target DAS44 
< 2.4 by means of rapid escalation of DMARD therapy and intra-articular corticosteroid 
injection (Grigor et al., 2004). Patients in both arms were reviewed every three months, with 
disease activity assessment measured by a metrologist blinded to study arm allocation. After 
18 months, the mean fall in DAS44 was greater in the intensive treatment arm (-3.5 vs. -1.9, 
difference 1.6 [95% CI: 1.1 – 2.1, p<0.0001]) with lower rates of radiographic progression 
and no excess adverse effects (Grigor et al., 2004). Other clinical trials have found similar 
benefits for target-based treatment (Schoels et al., 2010) which have now been incorporated 
within the treat-to-target recommendations of an international task force (Smolen et al., 
2016b). 
 
1.3.3 The “step-down” paradigm of DMARD therapy 
Despite the apparent advantages of a treat-to-target model, the long half-lives of DMARDs 
ultimately result in several months before a change in DMARD therapy is reflected in a 
change in arthritis activity. The benefits of adopting a treat-to-target approach therefore 
remain limited by the constraints of a step-up model, with patients suffering from severe 
arthritis potentially taking many months to escalate to effective therapy (Dale and Porter, 
2010). It is thus apparent that an alternative approach to the treatment of RA is required if the 
therapeutic benefit of early effective DMARD therapy is to be maximised. 
One potential solution to this problem is offered by the paradigm of “step-down” DMARD 
therapy (Figure 1.2). In this model, potent combination DMARD therapy is commenced as 
early as possible in the evolution of the disease, ideally at the point of diagnosis and including 
biologic agents if necessary. Combination DMARD therapy is then continued until a 
treatment target is reached; upon achieving this, DMARD therapy is then reduced to the 
minimum level required to maintain the target (Dale et al., 2007). 
This step-down paradigm differs from the step-up model in two important regards. Firstly, 
patients are commenced on a potent combination of multiple DMARD therapies early in the 
course of their disease, precisely at the time when aggressive treatment is most likely to yield 
the best long-term outcomes. Secondly, the step-down model minimises the burden of 
DMARD therapy once the treatment target has been achieved, rather than perpetuating 
DMARD regimens indefinitely. Thus despite potentially greater adverse events and financial 
costs in the initial phase, the long-term cost-effectiveness of the step-down approach has been 
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calculated to be more favourable than alternative strategies (Tosh et al., 2011). Nevertheless, 
combination DMARD therapy is not required in all cases and methotrexate monotherapy in a 
treat-to-target approach can be equally efficacious in selected patients (Gaujoux-Viala et al., 
2014). 
In certain regards, the past decade has seen a gradual transition towards a partial step-down 
model. Early treatment with combination DMARDs is now advocated by current treatment 
guidelines, either within the first few months in the case of treatment failure (Singh et al., 
2016; Smolen et al., 2017), or even at first presentation (National Institute for Health and 
Care Excellence, 2009). Systemic and/or intra-articular glucocorticoids are also recommended 
as induction therapy in the initial stages of disease to help maximise disease control in this 
window of opportunity (Singh et al., 2016; Smolen et al., 2017). Nevertheless, routine use of 
biologic therapy within the first three months of disease diagnosis is not currently 
recommended (Smolen et al., 2017), even though some patients with severe disease will 
ultimately require them. Furthermore, although DMARD withdrawal is cautiously suggested 
in current guidelines (Smolen et al., 2017), routine DMARD tapering to compete cessation – 
at least outside of the setting of paediatric and adolescent rheumatology – remains a 
controversial area with no clear consensus opinion (Kuijper et al., 2017). 
There are major obstacles to the widespread adoption of a bona fide step-down treatment 
approach as described above. Firstly, there is a current paucity of biomarkers that, when 
measured at first presentation, can both reliably predict those patients who are destined to 
develop severe RA and who will respond to specific DMARDs (Dale and Porter, 2010). 
Recent developments in the search for such biomarkers lies outside the scope of this report 
(for a review, see Mohan and Assassi (2015)), but their current absence nonetheless remains a 
crucial barrier to the effective use of a step-down treatment model in the clinic. This is 
especially true for biologics, which are expensive and thus difficult to justify economically as 
first or even second-line therapy in the absence of such predictors of disease severity and 
treatment response. For this reason, current UK guidelines mandate trial of at least two 
conventional synthetic DMARDs before biologic therapy can be introduced (National 
Institute for Health and Care Excellence, 2009). As will be discussed later, a further problem 
with the step-down model is that there is currently no reliable method to predict the risk of 
arthritis flare upon DMARD reduction, effectively stalling any attempts to wean DMARD 
therapy in an individualised manner.  
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1.3.4  Summary 
The past few decades have witnessed a revolution in the treatment of RA, from the 
introduction of small molecular DMARDs to the impact of biologic agents and the emergence 
of treat-to-target approaches aiming for clinical remission. The importance of an early 
“therapeutic window of opportunity” has led to the intensification of DMARD regimens and 
the proposal of a new paradigm of step-down DMARD therapy. However, the adoption of a 
full-scale step-down model of DMARD therapy is limited by a paucity of biomarkers that are 
predictive of future severity of disease, response to DMARDs and risk of arthritis flare upon 
DMARD withdrawal. Current practice therefore relies heavily on a step-up approach to 
DMARD therapy, with consequent missed opportunities for better long-term outcomes. 
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1.4 Measuring RA disease activity 
Accurate and reliable measures of disease severity are central to the effective management 
and research of RA. Although a simple concept, the objective measurement of RA severity 
can be challenging to achieve in practice. Factors complicating assessment include patient 
subjectivity, the fluctuating intermittent nature of synovitis and the wide range of different 
parameters that can be measured: from patient-reported symptoms such as joint pain, through 
to musculoskeletal imaging and the laboratory measurement of blood-borne inflammatory 
markers. 
In general, there are two main groups of disease activity metrics in RA: those that directly 
measure the inflammatory response, and those that measure the clinical manifestations and 
consequences of joint inflammation. This latter group can be further differentiated into 
physician-observed and patient-experienced measures, although in practice there is overlap 
between them (Figure 1.3). In this chapter, I will summarise the key available methods of 
measuring disease activity in RA as relevant to the latter chapters of this Thesis. 
 
1.4.1 Composite clinical scores of disease activity 
Composite clinical scores are popular methods of RA disease activity assessment that bring 
together complementary measures such as painful and swollen joint counts, global assessment 
scores and laboratory measures of inflammation (Table 1.5). One of the earliest examples is 
the Disease Activity Score (DAS), a composite clinical scoring system incorporating pain and 
swelling in 44 joints, a patient global assessment score and ESR (van der Heijde et al., 1990). 
Whilst the DAS provided an objective measurement of disease activity, it included joints that 
are challenging to examine clinically such as in the feet. In response to this problem, an 
abbreviated version of the DAS including 28 joints was developed and became known as the 
DAS28-ESR (Prevoo et al., 1995). Although the DAS28-ESR has been criticised for 
underestimating disease activity in those with predominant foot involvement (Bakker et al., 
2012), its ease of use and reproducibility have led widespread adoption within both research 
and clinical settings. Indeed, DAS28-ESR forms the basis of the EULAR criteria of RA 
treatment response (van Gestel et al., 1996) and is central to guidelines published by the 
National Institute for Health and Care Excellence (NICE) which govern eligibility for 
biologic therapy in the UK (National Institute for Health and Care Excellence, 2007). More 
recently, the DAS28 has been further modified by the use of CRP (Fransen et al., 2003), 
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considered by many to be a more specific and sensitive marker of inflammation in RA 
compared to the traditional ESR method (van Riel, 2014). However, DAS28-CRP can 
underestimate disease activity when used with DAS28-ESR thresholds, and alternative 
slightly lower thresholds for DAS28-CRP have been recently proposed to compensate for this 
(Fleischmann et al., 2015; Fleischmann et al., 2017). 
Recent years have seen the development of further composite scoring systems such as the 
Simple Disease Activity Index (SDAI) (Smolen et al., 2003) and Clinical Disease Activity 
Index (CDAI) (Aletaha et al., 2005), both notable for their inclusion of an additional 
physician global assessment parameter. It has been argued that SDAI provides a more 
reproducible measure of RA activity by placing more emphasis on objective measures such as 
 
  
Figure 1.3 – Overview of current measures of disease activity in rheumatoid arthritis. The 
precise extent to which measures are directly reflective of synovitis burden versus clinician-
observed and/or patient experienced phenomena is contentious, and is discussed further in this 
section. MRI: magnetic resonance imaging; PROM: patient-reported outcome measure; QoL: 
quality of life; SJC: swollen joint count; TJC: tender joint count; US: ultrasound; VAS: visual 
analogue scale. 
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Table 1.5 – Various composite clinical disease activity scores for measuring disease activity in RA, adapted from Klarenbeek et al. (2011a). Note that 
use of DAS28-ESR thresholds for DAS28-CRP assessment has been shown to underestimate disease activity. Shown in italics are alternative DAS28-
CRP score thresholds validated against DAS28-ESR, as proposed by Fleischmann et al. (2015)* and Fleischmann et al. (2017)†. CDAI: clinical 
disease activity index; CRP: C-reactive protein; DAS: disease activity score; ESR: erythrocyte sedimentation rate; RAI: Ritchie articular index; SDAI: 
simple disease activity index; SJC: swollen joint count; TJC: tender joint count; VAS: visual analogue score (on a 0-10cm or 0-100mm scale). 
 
Activity 
Score 
Formula Remission Low disease activity 
Moderate disease 
activity 
High disease 
activity 
DAS 
0.53938√(RAI) + 0.06465(SJC44) + 0.330ln(ESR) + 
0.00722(VASpatient[mm]) 
<1.6 1.6 ≤ score ≤ 2.4 2.4 < score ≤ 3.7 > 3.7 
DAS28-ESR 
0.56√(TJC28) + 0.28√(SJC28) + 0.70ln(ESR) + 
0.014(VASpatient[mm]) 
< 2.6 2.6 ≤ score ≤ 3.2 3.2 < score ≤ 5.1 > 5.1 
DAS28-CRP 
0.56√(TJC28) + 0.28√(SJC28) + 0.36ln(CRP[mg/L]+1) + 
0.014(VASpatient[mm]) + 0.96 
< 2.6 
< 2.4 * 
2.6 ≤ score ≤ 3.2 
2.4 ≤ score ≤ 2.9 * 
3.2 < score ≤ 5.1 
2.9 < score ≤ 4.6 † 
> 5.1 
> 4.6 † 
SDAI 
TJC28 + SJC28 + VASphysician [cm] + VASpatient [cm] + 
CRP [mg/dL] 
≤ 3.3 3.3 < score ≤ 11 11 < score ≤ 26 > 26 
CDAI TJC28 + SJC28 + VASphysician [cm] + VASpatient [cm] ≤ 2.8 2.8 < score ≤ 10 10 < score ≤ 22 > 22 
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joint swelling and less emphasis on subjective measures such as patient global assessment in 
comparison to DAS28. 
 
1.4.2  Patient-reported outcome measures 
Recent years have witnessed a surge of interest in patient-reported outcome measures 
(PROMs) in RA. The development of PROMs such as the Rheumatoid Arthritis Disease 
Activity Index (RADAI) (Stucki et al., 1995) and the routine assessment of patient index data 
3 (RAPID3) score (Pincus et al., 2008) provide validated methods of disease activity 
assessment without the requirement for physician assessment or laboratory tests. Furthermore, 
PROMs can also provide a measure of systemic symptoms such as fatigue and joint stiffness, 
which are not included in standard composite disease scores despite being frequently cited by 
patients as the most disabling aspects of the disease. However, whilst PROMs correlate well 
with composite clinical disease activity indices in active disease, their use as treatment targets 
remains controversial. Indeed, the RAPID3 score tends to correlate less robustly with 
composite clinical disease indices at remission levels (Kim et al., 2014a), particularly in the 
absence of a swollen joint assessment (Castrejon et al., 2013). Nevertheless, a study of 705 
outpatients by Rintelen et al. (2013) found that although the sensitivity of RADAI-5 for 
identifying patients who satisfied SDAI remission was low (60%, 95% CI 53-68%) the 
specificity was impressively high (92%, 95% CI 89-94%). Furthermore, both RAPID3 and 
RADAI-5 have been demonstrated as successful tools for patient-administered screening of 
arthritis flares (Bossert et al., 2012), which is arguably a more feasible clinical role compared 
to use as definitions of remission for treatment targets. Indeed, a PROM specifically designed 
for detection of RA flare – the flare in rheumatoid arthritis (FLARE-RA) questionnaire – has 
recently been validated against clinical measures of disease activity for patient self-
assessment of disease flare, which could be employed between clinic visits (Fautrel et al., 
2017). 
 
1.4.3 Disability and quality of life scoring systems 
As with other chronic diseases, RA can have a profound effect upon physical function and 
quality of life. Questionnaire-based assessment methods can quantify physical disability and 
quality of life, many of which have been validated in RA (Table 1.6).  
  
28 
 
Table 1.6 – Selection of instruments that have been validated for the assessment of disability 
and quality of life in patients with rheumatoid arthritis. Adapted from Maska et al. (2011). 
Instrument Purpose Timeframe 
Health Assessment Questionnaire 
Disability Index (HAQ-DI) 
Assesses physical function via impact on daily 
activities (41 items) 
Past week 
Modified Health Assessment 
Questionnaire (MHAQ) 
Abbreviated version of HAQ-DI (8 items) Past 3 months 
Multidimensional Health Assessment 
Questionnaire (MDHAQ) 
 MHAQ plus two additional items regarding 
walking and sports/recreation activity (10 items).  
Past week 
Health Assessment Questionnaire II 
(HAQ-II) 
Assesses physical function via impact on daily 
activities (10 items) 
Past week 
Improved Health Assessment 
Questionnaire (Improved HAQ) 
Shortened alternative to HAQ-DI (24 items) Present 
Rheumatoid Arthritis Quality of Life 
(RAQoL) 
Assesses quality of life and activities of daily 
living (30 items) 
Past week 
EuroQol EQ-5D 
Assesses QoL and physical function across five 
domains (5 items) 
Present 
36-item Short Form Survey (SF-36) 
Assesses QoL and physical function across eight 
domains (36 items) 
Mostly 4 weeks 
(single general 
question for 
past year) 
 
A major limitation with the use of such questionnaires in assessing disease activity in RA is 
that in established disease it can be difficult to separate disability secondary to permanent 
joint damage from disability secondary to reversible joint inflammation, or indeed disability 
secondary to another comorbid disease. Furthermore, capturing the impact that RA has on 
physical function and quality of life from such a ‘snapshot’ assessment is challenging given 
the highly fluctuating nature of disease activity in RA. Nevertheless, disability and quality of 
life assessments can provide complementary measures of disease impact in longitudinal 
research studies, and in the economic evaluation of therapeutic interventions. 
 
1.4.4 The role of imaging in measuring RA disease activity 
1.4.4.a Plain radiographs 
For several decades, the gold standard approach to using imaging to assess disease activity in 
RA was to measure the accumulation of erosive joint damage on serial plan radiographs of the 
hands and feet. Plain radiographs provide an objective measure of the consequences of active 
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synovitis and hence remain widely used in clinical practice and as an outcome measure in 
clinical trials. Nevertheless, plain radiographs are limited by their inability to directly 
visualise synovitis and hence provide a necessarily retrospective measure of disease activity. 
A further limitation is that peri-articular structures such as tendons and ligaments are not 
identified by plain radiographs, and hence inflammation in these important areas can be easily 
overlooked. Finally and perhaps most importantly, the irreversible nature of joint erosions 
makes assessment of erosive progression unacceptable in the modern era where prevention of 
joint damage is a key treatment aim. 
 
1.4.4.b Magnetic resonance imaging (MRI) 
The advent of magnetic resonance imaging (MRI) has revolutionised musculoskeletal 
radiology through an ability to visualise both bone and the surrounding non-calcified joint 
structures. Furthermore, MRI can visualise the consequences of active arthritis including bone 
oedema and synovitis (McGonagle and Tan, 2008). It is now well-established that bone 
marrow oedema and synovitis visualised on MRI imaging correlate closely with future 
radiographic joint erosions (Ostergaard and Moller-Bisgaard, 2014). Thus, MRI can be used 
to detect early reversible signs of joint inflammation before irreversible joint damage occurs – 
indeed, MRI abnormalities can even precede the onset of clinical arthritis by several months 
(van Steenbergen et al., 2016). Nevertheless, MRI carries significant limitations including the 
cost and size of scanning machinery, the need for specialist musculoskeletal radiologists to 
interpret scan images and the occasional need to administer intravenous gadolinium contrast 
agents (Tan et al., 2012). Furthermore, the strong magnetic field precludes the use of MRI in 
patients with metallic foreign bodies such as many implantable cardiac defibrillators (Tan et 
al., 2012). Taken in combination, these limitations place a restriction upon the widespread use 
of MRI in current rheumatology practice. 
  
1.4.4.c Musculoskeletal ultrasound 
Ultrasound (US) imaging relies upon ultra-high frequency sound waves and their reflection at 
the interfaces between tissues of different acoustic density to create a so-called “B-mode” 
greyscale visualisation of tissue structures (Hoskins et al., 2010). Furthermore, by exploiting 
the Doppler shift of sound waves reflected from moving structures, the “power Doppler” US 
modality provides a direct visualisation of blood flow (Schmidt, 2004). Through this 
combination of greyscale and power Doppler imaging, it is possible to visualise both joint 
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erosions and active synovitis, the latter in the form of synovial thickening and 
hypervascularity. Furthermore, periarticular structures such as tendons and ligaments can also 
visualised together with the joint in real-time dynamic imaging. Such strengths, combined 
with the relatively low cost of equipment and the ability to record and interpret images at the 
bedside, make US an attractive imaging modality for a fluctuating disease such as RA (Grassi 
et al., 2004). 
Although not necessitated by current ACR classification criteria, musculoskeletal US plays an 
increasingly important role in the diagnosis and management of RA beyond clinical 
assessment (D'Agostino et al., 2016b). This is particularly true for increased synovial 
vascularity visualised as power Doppler (PD) signal, the finding of which is widely regarded 
as signifying active synovitis (Fukae et al., 2014). Indeed, the presence of PD has been shown 
to outperform clinical features of joint inflammation such as tender joint count in predicting 
future radiographic progression (Cheung et al., 2016). 
The presence of PD correlates with histological measures of synovitis in synovial tissue 
(Takase et al., 2012; Andersen et al., 2014b; Abe et al., 2016), and has been shown to 
correlate with the presence of Th17 cells in synovial fluid (Gullick et al., 2010). Increased 
colour Doppler flow has also been shown to correlate with the production of the pro-
inflammatory chemokine monocyte chemoattractant protein 1 (MCP-1) in ex vivo culture of 
synovial biopsy tissue (Andersen et al., 2014a). The presence of PD occurs early in the course 
of disease, and in the setting of undifferentiated inflammatory arthritis can add discriminatory 
diagnostic value for RA beyond standard clinical assessment alone, especially in seronegative 
patients (Freeston et al., 2010; Nam et al., 2016). Ultrasound parameters, in particular PD, are 
highly responsive to changes in disease activity (Naredo et al., 2007) and have been shown to 
improve within as little as one week after initiation of biologic DMARD therapy (D'Agostino 
et al., 2016c). Furthermore, the presence of PD has been shown to portend a poor prognosis in 
terms of both future radiographic progression and risk of arthritis flare, even in those patients 
who achieve clinical remission (Han et al., 2016b). This raises the question of whether treat-
to-target approaches based on US synovitis yields superior outcomes compared to clinical 
assessment and remains an area of current active research (Wakefield et al., 2012). 
Despite its advantages, US nevertheless has several limitations; of particular note, the 
variation in technique and subjectivity of image interpretation can lead to substantial inter-
operator variability (Tan et al., 2012). In addition, the increasing fidelity of modern US 
equipment brings increasing difficulty in ascribing diagnostic and prognostic significance to 
low-grade US synovitis. In study of 207 healthy individuals who underwent a 32-joint US 
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scan, 182/187 (97%) had at least one abnormal finding: 95 (46%) had synovial effusion alone 
(usually at the great toe), 79 (42%) had greyscale synovial hypertrophy (GS), and 8 (4%) had 
PD (Padovano et al., 2016). In a recent case-control study using a 10-joint US protocol, 127 
healthy individuals were age- and sex-matched to 127 patients from an early arthritis cohort 
of patients with RA or undifferentiated arthritis of diagnosis duration < 6 months (Millot et 
al., 2011). Although the prevalence of US findings were significantly greater (p<0.001) in 
early arthritis patients (GS: 75%, PD: 50%, erosion 36%), there were considerable numbers of 
healthy controls with US abnormalities (GS: 9%, PD: 4%, erosion: 11%), albeit to a lesser 
degree than the study by Padovano et al. (2016) perhaps reflecting the fewer number of joints 
scanned. Nonetheless, the magnitude of GS in RA joints has been shown to negatively 
correlate with years since last clinical episode of joint inflammation, suggesting that GS may 
be a useful indicator of recent inflammatory burden (Gartner et al., 2015). 
The substantial levels of US abnormalities in healthy individuals make it challenging to 
define active synovitis in terms of ultrasonographic parameters. Whilst PD is generally 
accepted to be a marker of active disease, the clinical significance of low-grade PD signal is 
contentious, particularly in the absence of GS. Whereas some authors define active synovitis 
as the presence of any level of PD in any single joint (Grassi and Filippucci, 2003), others 
adopt more stringent definitions such as PD in ≥2 joints (Dale et al., 2016), or PD in the 
presence of moderate GS (Ramirez et al., 2014). This lack of consensus surrounding the 
‘minimum-acceptable’ level of US findings that are consistent with absence of disease results 
in substantial heterogeneity between different studies and is a significant barrier to research.  
 
1.4.5 Measurement of circulating inflammatory mediators 
A further measure of RA activity is by the measurement of circulating levels of markers and 
mediators of the inflammatory response. Basic measures of inflammation including ESR and 
CRP have been in widespread clinical use for decades, and provide an objective and reliable 
measure of the degree of systemic inflammation. Unfortunately however, the limited nature of 
synovitis in RA, particularly in mild disease when inflammation can be restricted to a few 
small joints, often results in little if any detectable rise in these standard laboratory measures 
despite ongoing active disease. 
Following technological advances in the detection of cytokines and chemokines in human-
derived samples, several groups explored the association between the circulating levels of 
individual inflammatory mediators and disease activity in RA. Increased synovial and 
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circulating concentrations of many cytokines including TNF-α (Espersen et al., 1991; 
Vreugdenhil et al., 1992), IL-1β (Eastgate et al., 1988), granulocyte-macrophage colony-
stimulating factor (GM-CSF) (Xu et al., 1989), and IL-6 (Houssiau et al., 1988) have been 
demonstrated to positively correlate with arthritis activity in RA. Indeed, such observations 
provided important early insights to the immune dysregulation underlying the disease. 
However, with increasing knowledge of the dysregulation of molecular mediators of 
inflammation in RA came an appreciation of the marked heterogeneity in the dynamic 
networks of cytokine imbalance between individual RA patients (Arend, 2001). It is thus 
apparent that the measurement of a single cytokine/chemokine in isolation is limited in its 
applicability as a biomarker of disease activity that can be reliably applied across all patients 
in a clinical context. 
To address this shortcoming, attempts have been made to define composite laboratory 
biomarkers of disease activity in RA. Particularly notable in this regard is the multibiomarker 
disease activity (MBDA) score, which is commercially marketed as Vectra® DA (Crescendo 
Bioscience Inc., San Francisco, USA) (Centola et al., 2013). The MBDA score was developed 
with the aim of providing a quantitative measure of disease activity to complement composite 
clinical disease activity scores such as DAS28. Using a systematic and statistically-driven 
approach, a signature of 12 different proteins were identified and their serum concentrations 
combined to create a score from 0 to 100 that correlated with disease activity scores in 
samples from several multinational clinical trials (Centola et al., 2013). The MBDA score has 
been shown to track longitudinal changes in clinical disease activity (Hirata et al., 2013) and 
predict future radiographic progression in several studies (Markusse et al., 2014b; Hirata et 
al., 2016; Li et al., 2016). In a recent meta-analysis of three clinical studies of over 562 
patients with RA, patients with a high MBDA score had a relative risk of radiographic 
progression of 5.1 (95% CI 2.5 – 10.1, p<0.0001) compared to those with a low score; for 
comparison, the relative risk of progression was 1.6 (p = 0.01) and 1.4 for categories of CRP 
and DAS28-CRP respectively (Curtis et al., 2017). However, in a separate study MBDA did 
not predict progression to RA for 45 patients with undifferentiated arthritis (UA), though 
MBDA levels were higher in RA patients than controls (Maijer et al., 2015). Furthermore, in 
a clinical trial of abatacept versus adalimumab in RA, MBDA samples from 524 patients 
failed to show an association with clinical measures of disease activity (Fleischmann et al., 
2016). Indeed, the utility of MBDA in the management of RA beyond standard laboratory and 
clinical measures of disease activity is uncertain, has been challenged by some commentators 
(Yazici and Swearingen, 2014; Pincus et al., 2017). 
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1.4.6 Synovial joint biopsy 
A major criticism of the aforementioned approaches to disease activity assessment are that 
they are all, to varying degrees, surrogate measures of synovial inflammation. However, by 
ultrasound or arthroscopic-guided biopsy it is possible to obtain samples of synovial tissue 
directly at the site of disease (Lazarou et al., 2015). Histological analysis of synovial tissue 
can reveal the number and cellular subtype of infiltrating leukocytes and their organisation, 
thus providing additional information on the underlying immunopathological processes 
beyond solely quantifying joint inflammation (Filkova et al., 2016). Importantly, synovial 
biopsies also allow for the study of stromal cells such as synovial fibroblasts, which likely 
play a role in the initiation and perpetuation of chronic synovitis (see Introduction 1.2.6). 
Advanced next-generation and single-cell sequencing technologies allow for detailed profiling 
of gene expression and epigenetic modifications within both infiltrating leukocytes and 
stromal cells, and is an intense area of current research. 
Nevertheless, synovial biopsy has several disadvantages that have thus far limited its use in 
routine clinical practice. Although the procedure can be performed under local anaesthetic and 
is well-tolerated by patients, it is nevertheless an invasive procedure which requires additional 
resources and staff training to deliver on a wide scale (Lazarou et al., 2015).  Furthermore, the 
precise relationship between measures of synovial pathobiology and disease prognosis and 
treatment response remain to be fully elucidated. Technical challenges also exist, not least 
surrounding the range of joints amenable to biopsy and the targeting of biopsy to actively-
inflamed synovial regions (Filkova et al., 2016). Nevertheless, synovial biopsy does hold 
promise as a potential measure of disease activity that may in the future be used to help guide 
diagnosis, stratify patients for therapy, and assess the effectiveness of treatment (Orr et al., 
2017). 
 
1.4.7 Summary 
The measurement of disease activity in RA is not simply a pedantic exercise, but is crucial 
both in the clinic to assess response to therapy, and in the research and development of novel 
therapies. Nevertheless, the many varied manifestations of RA pose substantial challenges to 
the accurate and precise measurement of the activity of the disease. As is evident from the 
discussion above, no single measure of disease activity can adequately encompass all of the 
diverse domains of RA. Disease activity is thus best assessed by a combination of 
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complementary measures, which needs to be tailored to the specific clinical or research 
situation in which they are employed. 
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1.5 Defining Remission in Rheumatoid Arthritis 
With the advent of modern DMARD therapy, the past two decades have witnessed a 
remarkable paradigm shift in the treatment of RA. Whereas previously the treatment aim was 
to retard joint damage, current treatment guidelines advocate treating to a target of disease 
remission – a target that is now achievable for many patients. 
In this subsection, I will explore the various approaches to define RA remission in clinical 
practice, the frequency with which disease remission can be achieved, and the concept of 
remission ‘depth’. 
 
1.5.1 Clinical definitions of RA remission 
Following the widespread introduction of DMARDs in the latter part of the 20th century, there 
was growing interest in the concept of “remission” as a therapeutic target in RA. In a seminal 
paper, Pinals et al. (1981) defined complete remission in RA as “the total absence of all 
articular and extra-articular inflammation and immunologic activity related to RA”. The 
authors proposed clinical criteria that were adopted by the ACR as a working definition of RA 
remission (Table 1.7). However, very few patients were able to achieve these remission 
criteria in practice, and the inclusion of a time criterion demanded that remission could only 
be defined in retrospect; the criteria were thus of limited use in guiding treatment or 
prospective research studies (van Tuyl et al., 2009). 
With evidence emerging from clinical trials of the prognostic value of composite clinical 
scores, attention focussed on redefining RA remission in terms of disease activity. For 
example, DAS28-ESR < 2.6 can be defined as remission based upon correlation with the 1981 
preliminary ACR remission criteria (Fransen et al., 2004). However, disease activity 
thresholds defined by DAS28-ESR do not directly translate to the now widely used DAS28-
CRP (see Introduction 1.4.1), and a lower remission threshold of DAS28-CRP<2.4 has been 
proposed (Fleischmann et al., 2015). 
Nevertheless, although high DAS28 scores correlate well with poor outcomes, it became 
apparent that both ESR- and CRP-based DAS28 remission correlates rather poorly with both 
absence of joint pain and swelling (Makinen et al., 2005) and future progression of joint 
damage (Aletaha and Smolen, 2011). In 2011, the ACR and EULAR published joint 
remission criteria in an attempt to develop a definition of remission in RA that is “stringent 
but achievable” (Felson et al., 2011). The ACR/EULAR 2011 criteria were developed through 
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Table 1.7  – The 1981 American College of Rheumatology preliminary criteria for clinical 
remission in rheumatoid arthritis. ESR, erythrocyte sedimentation rate. Reproduced with 
permission from Pinals et al. (1981). Copyright © 1981 American College of Rheumatology.  
At least five of the following criteria must be fulfilled for at least 2 
consecutive months: 
1. Duration of early morning stiffness not exceeding 15 minutes 
2. No fatigue 
3. No joint pain (by history) 
4. No joint tenderness or pain on motion 
5. No soft tissue swelling in joints or tendon sheaths 
6. ESR less than 30mm/hr for a female or 20mm/hr for a male 
 
consensus expert opinion, and validated through their ability to predict favourable 
radiological outcomes using data from prospective clinical trials. Incorporated within the 
2011 ACR/EULAR remission criteria are both a Boolean definition and an index definition 
based on SDAI score (Table 1.8).It was acknowledged that the exclusion of foot and ankle 
joints from the remission criteria has potential to limit its specificity, though in a validation 
exercise it was demonstrated that patients with active synovitis in these areas typically failed 
to meet the other remission criteria (Felson et al., 2011).  
Low rates of radiological progression and favourable long-term functional outcomes in 
patients achieving ACR/EULAR remission have now been demonstrated by several 
independent groups (Klarenbeek et al., 2011a; Sakellariou et al., 2013). Furthermore, cross-
sectional studies have demonstrated that swollen and tender joint counts are on average lower 
when remission is defined using ACR/EULAR criteria versus DAS28 (Kuriya et al., 2012; 
Thiele et al., 2013). Nevertheless, the ACR/EULAR remission definition has been criticised 
by many authors for placing an overly strict threshold on the VASpatient, which can be affected 
by osteoarthritis and other comorbidities, such that it may lack sensitivity for remission when 
used in clinical practice (Kuriya et al., 2012; Masri et al., 2012; Studenic et al., 2012; 
Vermeer et al., 2012; Svensson et al., 2013; Thiele et al., 2013; Baker et al., 2017). For 
example, a cross-sectional analysis of 6864 RA patients found that non-RA factors, such as 
male gender and the presence of degenerative spinal disease, were significantly associated 
with failure to achieve ACR/EULAR remission despite satisfying DAS28-ESR remission 
(Thiele et al., 2013). Furthermore, the effect of non-RA factors upon patient VAS may be 
disproportionately greater in patients with lowest disease activity; for example, a prospective 
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Table 1.8 – The American College of Rheumatology (ACR) / European League Against 
Rheumatism (EULAR) 2011 remission criteria for rheumatoid arthritis. Reproduced from 
Annals of the Rheumatic Diseases, Felson et al., volume 70, pages 404-413, copyright 2011, 
with permission from BMJ Publishing Group Ltd. 
Boolean definition 
At any time point, patient must satisfy all of the following:  
Tender joint count ≤ 1 
Swollen joint count ≤ 1 
C reactive protein ≤ 1mg/dL (10mg/L) 
Patient global assessment ≤ 1 (on a 0-10 scale)  
Index definition 
At any time point, patient must have a Simplified Disease 
Activity Index score of ≤3.3 
 
longitudinal study of 260 RA patients demonstrated that patient VAS is positively associated 
with older age and health distress, though only in patients with a DAS < 4.2 (Ward et al., 
2017). Indeed, even in the original ACR/EULAR publication consensus opinion suggested a 
higher mean patient VAS of < 2.2 as a remission threshold if all other parameters were 
consistent with remission (Felson et al., 2011). 
In the original publication of the ACR/EULAR remission criteria, future radiographic 
progression was less frequently observed in those who satisfied ACR/EULAR Boolean 
remission (23%) and SDAI remission (23%) versus DAS28-ESR remission (40%) at baseline, 
which the authors present as evidence for the superiority the ACR/EULAR remission 
definitions (Felson et al., 2011). Indeed, this is mirrored in a prospective cohort study of 535 
RA patients, which demonstrated radiographic progression after 2 years in 20%, 24% and 
30% of patients who were in remission at baseline as defined by ACR/EULAR Boolean, 
SDAI and DAS28-CRP<2.6 remission respectively (Lillegraven et al., 2012). Despite the 
apparent enhanced specificity of ACR/EULAR remission to identify those patients who do 
not develop radiographic progression, it is nevertheless troubling that approximately 20-25% 
of patients can develop future joint damage despite satisfying ACR/EULAR remission at 
baseline. Whilst one could argue that this reflects an inherent instability of remission in RA, 
Lillegraven et al. (2012) even observed radiographic progression in 7/41 (17%) of patients 
who satisfied ACR/EULAR Boolean remission on two or more occasions, suggesting that 
joint damage can accumulate despite sustained clinical remission.  
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1.5.2 The role of imaging in defining RA remission 
The progression of joint damage despite fulfilment of clinical remission criteria suggests the 
presence of substantial levels of subclinical synovitis that, although asymptomatic, can 
nevertheless have an adverse impact on long-term outcomes (Brown et al., 2008). This has led 
many commentators to suggest that imaging to detect subclinical synovitis should be 
incorporated within definitions of remission in RA (Haavardsholm et al., 2012; Wakefield et 
al., 2012). 
 
1.5.2.a Ultrasound abnormalities persist despite clinical remission 
Ultrasonographic evidence of synovial pathology in the form of power Doppler (PD) and/or 
greyscale synovial hypertrophy (GS) persists in patients with RA in clinical remission 
regardless of how clinical remission is defined. In a cross-sectional study of 107 patients 
receiving DMARDs for RA (Brown et al., 2006), synovitis was similarly detectable in 
patients who satisfied DAS28-ESR remission (GS: 84%, PD: 51%) and those who satisfied 
1981 ACR remission (GS: 81%, PD: 55%). Indeed, a similar study by the same group showed 
that newer remission criteria were similarly insensitive to the presence of PD, which was 
present in 65/128 (51%), 15/29 (52%) and 34/74 (46%) of patients satisfying DAS28-ESR, 
ACR/EULAR Boolean and SDAI remission respectively (Saleem et al., 2011). In a recent 
meta-analysis of 19 studies including 1369 RA patients in clinical remission, Nguyen et al. 
(2014) demonstrated an overall prevalence of combined GS/PD positivity of 44%, which was 
comparable across different clinical remission criteria (Figure 1.4). The prevalence of GS 
alone and combined GS/PD positivity was greater in patients with longstanding RA > 2 years 
duration (GS: 87% vs 64%, GS/PD: 45% vs 34%, p<0.001), perhaps reflecting the chronicity 
of synovitis in these patients (Nguyen et al., 2014).  
Despite the high prevalence of US abnormalities in RA remission, there is some evidence to 
suggest a degree of correlation, albeit modest, between low clinical disease activity scores and 
the absence of PD. In a cross-sectional study of 97 RA patients in clinical remission, a 
significantly lower prevalence of PD in a 42-joint US examination was observed in those in 
SDAI remission (though not in DAS28 remission); nevertheless, SDAI remission had only 
modest predictive value for the absence of PD (likelihood ratio 2.24, 95% CI 1.25 – 4.01) 
(Balsa et al., 2010). In a further study, absence of PD in the MCP joints and wrists was 
associated with absence of MCP/wrist joint swelling (OR 6.60, p=0.0039), SDAI remission 
(OR 5.06, p=0.045) and low functional disability defined as Steinbrocker stage I or II  
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Figure 1.4 - Prevalence of ultrasound findings by different clinical definitions of remission in 
a meta-analysis by Nguyen et al. (2014). DASr: disease activity score (DAS) remission; 
DAS28r: either DAS28-ESR or DAS28-CRP remission; SDAI: simple disease activity index 
remission; ACRr: American College of Rheumatology 1981 ACR remission criteria; 
ACR/EULAR: ACR/European League Against Rheumatism (EULAR) Boolean remission 
criteria. Reproduced from Nguyen et al, ‘Prevalence of ultrasound-detected residual synovitis 
and risk of relapse and structural progression in rheumatoid arthritis patients in clinical 
remission: a systematic review and meta-analysis’, Rheumatology, 2014, volume 53, issue 11, 
pages 2110-8, by permission of Oxford University Press on behalf of the British Society for 
Rheumatology.  
 
(OR 9.23, p=0.0049) (Nemoto et al., 2014). Indeed, the combination of all three of these 
criteria had 100% predictive value for the absence of PD (Nemoto et al., 2014), though no 
data has been published regarding replication in an independent cohort. In another study of 
126 RA patients in clinical remission, lower DAS28-ESR scores (DAS28-ESR≤1.98 vs 
1.98<DAS28-ESR≤2.6) were associated with lower GS positivity (44.7% vs. 78%, p<0.01) 
and PD positivity (32.9% vs. 72%, P<0.01), although the prevalence of PD even in the lowest 
disease activity score group remains substantial (Geng et al., 2016). Nevertheless, the 
presence of GS and PD in healthy controls makes it difficult to confidently ascribe clinically 
relevant thresholds for low-grade ultrasonographic findings (see Introduction 1.4.4.c). 
 
1.5.2.b In RA clinical remission, the presence of PD is associated with active synovitis 
Mounting evidence suggests that the presence of PD indicates ongoing subclinical synovitis, 
even in those patients who have satisfied clinical remission criteria. A small study of RA 
patients in SDAI remission for ≥ 6 months showed that PD was present in the hands/MCPJs 
of 17/29 (59%) patients, with a significant correlation between presence of PD and bone 
erosions when analysed at the level of both the joint (p<0.001) and patient (p=0.032) 
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(Kawashiri et al., 2014). However, no correlation was observed between the presence of PD 
and the levels of CRP, ESR or angiogenic biomarkers (Kawashiri et al., 2014). In contrast, a 
study of 55 patients in DAS28-ESR remission for ≥ 6 months showed that ‘active synovitis on 
US’ (defined as GS≥2 and PD≥1) was significantly positively correlated with both clinical 
disease activity scores (DAS28 and SDAI) (Ramirez et al., 2014). Furthermore, higher levels 
of circulating angiogenic biomarkers were observed in the active synovitis group, including 
amongst others vascular endothelial factor-D (VEGF-D), matrix metallopeptidase-2 (MMP-2) 
and basic fibroblast growth factor (bFGF) (Ramirez et al., 2014). 
Further studies suggest a link between the presence of PD in clinical remission and persistent 
subclinical inflammation in synovial biopsies. Ramirez et al. (2015) obtained synovial 
biopsies from 20 RA patients in remission (DAS28-ESR<2.6 for ≥ 6 months) with PD, and 
compared them to synovial tissue from 22 patients with clinically active RA and 10 non-
inflammatory controls. Immunohistochemistry revealed less vascularity, bFGF and CXCL12 
for PD-positive RA remission compared with active RA, though these were all significantly 
greater than non-inflammatory controls (Ramirez et al., 2015). 8/20 (40%) of RA remission 
patients lost clinical remission over the 12 months following biopsy; these patients had 
significantly more synovial B cells and mast cells compared to those who maintained 
remission (Ramirez et al., 2015). 
In another biopsy study, knee synovium was compared between 25 PD-negative RA patients 
in clinical remission (DAS<1.6 for ≥ 6 months), 10 PD-negative RA patients with low disease 
activity (LDA: 1.6<DAS<2.4 for ≥ 6 months), and 50 PD-positive DMARD-naïve RA 
patients with moderate/high disease activity (mean DAS28 = 5.00) (Alivernini et al., 2017). 
Both remission and LDA patients were receiving concurrent methotrexate and anti-TNFα 
therapy. Immunohistochemistry showed significantly less staining for CD68, CD20, CD3, 
CD31 and collagen deposition for PD-negative remission patients versus the PD-positive 
moderate/high disease activity group; furthermore, these levels were comparable for the 
remission vs. PD-negative LDA groups (Alivernini et al., 2017). The authors therefore 
suggest that, compared with DAS, the absence of PD may be a better predictor of the absence 
of histological synovitis. However, the lack of a PD-positive remission group, and the 
influence of DMARD therapy upon ultrasonographic and histological measures, make it 
difficult to interpret these results further. 
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1.5.2.c In RA remission, the presence of PD is a poor prognostic factor 
Emerging data from longitudinal studies demonstrate that PD is likely to be a negative 
prognostic factor in the setting of RA clinical remission. In a recent systematic review and 
meta-analysis, Han et al. (2016b) examined the prognostic value of baseline US abnormalities 
in terms of predicting the risk of future arthritis flare and radiographic progression across 13 
longitudinal studies of RA patients in clinical remission with follow-up durations ranging 
from 3 to 24 months (Brown et al., 2008; Scire et al., 2009; Saleem et al., 2010; Peluso et al., 
2011; Raffeiner et al., 2011; Foltz et al., 2012; Saleem et al., 2012; Yoshimi et al., 2013; 
Geng et al., 2014; Iwamoto et al., 2014; Ogishima et al., 2014; Ramírez García et al., 2014; 
van der Ven et al., 2014). This meta-analysis demonstrated that the presence of PD was 
significantly associated with risk of future arthritis flare (odds ratio (OR) 4.52, 95% CI 2.61-
7.84, P<0.00001) and future bone erosions both at the patient level (OR 12.80, 95% CI 1.29 – 
126.81, p=0.03) and at the joint level (OR 11.85, 95% CI 5.01 – 28.03, p<0.00001) (Han et 
al., 2016b). There was substantial heterogeneity between the included studies, but subgroup 
analyses did not show any significant differences in duration of remission, disease duration 
and DMARD therapy (Han et al., 2016b). The studies with a follow-up period of less than 1 
year showed a stronger association of PD with arthritis flare (OR 19.98 vs. 3.41), suggesting 
that inclusion of studies with a short duration of follow-up did not bias towards a lower risk of 
flare (Han et al., 2016b). Furthermore, the presence of GS was also associated with risk of 
future arthritis flare (OR 3.69, 95% CI 1.71 – 7.93, p<0.0008), though the authors comment 
that this may be a reflection of the interaction between GS and PD positivity (Han et al., 
2016b). Following publication of this meta-analysis, a further longitudinal study of 126 RA 
patients in clinical remission have also demonstrated a significant association between PD 
positivity and arthritis flare (Geng et al., 2016). Furthermore, a recent study of 472 RA 
patients in clinical remission demonstrated that the presence of PD tenosynovitis was 
significantly associated with risk of future patient-reported flare (OR 1.95, 95% CI 1.17 – 
3.26), though not with radiographic erosion (Bellis et al., 2016). 
 
1.5.2.d Assessment of subclinical synovitis by MRI 
A key advantage of MRI over US imaging is that the former can visualise bone marrow 
oedema (BME), which is believed to precede bone erosion, and thus has potential to be a 
more sensitive marker of subclinical synovitis.  Several studies support a strong association 
between BME and future radiographic progression in patients with active RA (Ostergaard and 
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Moller-Bisgaard, 2014). Fewer studies have examined the role of MRI imaging in clinical 
remission, though persistent subclinical synovitis and BME appear to be common in this 
setting. In a prospective study of 56 early RA patients who had achieved sustained (≥6 
months) clinical remission, MRI of the dominant hand revealed substantial levels of 
subclinical inflammation (94.6% synovitis, 46.4% BME and 58.9% tenosynovitis) (Lisbona et 
al., 2014). No significant differences in MRI parameters were found at baseline (i.e. prior to 
the initiation of DMARD therapy) between patients who developed new bone erosions versus 
those who did not; however, BME scores at 12 months were greater for those patients who 
had developed new erosions (4.8 ± 5.6 vs. 1.4 ± 2.6, p=0.03) (Lisbona et al., 2014). A further 
hand MRI study by the same group found that a trend towards a lower prevalence of BME in 
patients who satisfied SDAI or ACR/EULAR Boolean remission compared to those in 
DAS28-ESR remission (DAS28-ESR remission: 64/119 [53.8%]; SDAI remission (86 
patients): 42/86 [48.8%]; Boolean remission: 40/82 [48.8%]), though this failed to reach 
statistical significance (Lisbona et al., 2016). 
Furthermore, emerging data from recent studies suggest that MRI-detected inflammation may 
be predictive of erosive progression. In a prospective MRI study of 85 patients with RA in 
remission/LDA (DAS28-CRP<3.2), synovitis and BME were seen at baseline in 87% and 
23% respectively, and baseline BME was independently associated with radiographic 
progression at 12 months (OR 1.25, 95% CI 1.09 – 1.43, p=0.0013) (Gandjbakhch et al., 
2011). In a further multi-centre study by the same research group of 254 patients with RA in 
remission/LDA, multivariate analysis showed a significant association between baseline BME 
score >5 and radiographic progression after 6 or 12 months follow-up – an effect which was 
limited to RhF positive patients (entire cohort: OR 2.42 [95% CI 1.24 – 4.72]; RhF+: OR 4.41 
[95% CI 1.72 – 11.35]; RhF-: OR 1.09 [95% CI 0.40 – 2.80]) (Gandjbakhch et al., 2014). 
However, in another prospective study of 85 RA patients in remission or LDA (DAS<2.4), 
multivariate analysis failed to show a significant association between BME or synovitis on 
MRI and either arthritis relapse or radiographic progression, whereas PD on ultrasound 
imaging was significantly associated with both events (Foltz et al., 2012). 
 
1.5.2.e Defining an optimal imaging protocol for the detection of subclinical synovitis 
The selection of an optimal joint set for imaging studies in RA remission is a balance between 
ensuring detection of subclinical synovitis where present, versus the cost of increased time, 
resources and training required to scan a large number of joints. 
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The optimal number and distribution of joints to include when assessing for US synovitis is 
uncertain and contentious (Ohrndorf et al., 2013). There are a wide array of different 
musculoskeletal US routines in the published literature, ranging from comprehensive 78-joint 
scans (Hammer et al., 2010) through to focussed scans of the dominant hand only (Saleem et 
al., 2011). Nevertheless, it is important to note is that increasing number of joints scanned 
does not necessarily increase the yield of clinically relevant information. In the meta-analysis 
discussed previously, Nguyen et al. (2014) analysed US data from 1369 patients in clinical 
remission and found the proportion of patients with at least one joint abnormality, particularly 
PD, showed very little variation between studies using different scan protocols (Figure 1.5). 
Indeed, the US7 scan protocol proposed by Backhaus et al. (2009), which includes 7 joints in 
the dominant hand and foot, has been shown to offer comparable results to an extensive yet 
laborious 78-joint US scan (Hammer and Kvien, 2011) and a 12-joint US scan (Leng et al., 
2016). Similarly, a study of 47 patients with RA in clinical remission (DAS28-ESR<2.6) 
found that the presence of PD on both a 44-joint scan and a reduced 12-joint set were 
predictive of arthritis flare at 6 months with overlapping confidence intervals (44-joint: OR 
8.21, 95% CI 1.49 – 45.1, p=0.016; 12-joints: 5.82, 95% CI 1.07 – 31.61, p=0.041) (Janta et 
al., 2016).  
 
 
Figure 1.5 – Prevalence of findings by different ultrasound routines in a meta-analysis of 
studies of RA patients in clinical remission by Nguyen et al. (2014). Reproduced from 
Nguyen et al, ‘Prevalence of ultrasound-detected residual synovitis and risk of relapse and 
structural progression in rheumatoid arthritis patients in clinical remission: a systematic 
review and meta-analysis’, Rheumatology, 2014, volume 53, issue 11, pages 2110-8, by 
permission of Oxford University Press on behalf of the British Society for Rheumatology. 
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Recently, the Outcome Measures in Rheumatology-Ultrasound (OMERACT-US) Task Force 
proposed a EULAR-endorsed standardised scoring system for PD scoring known as the 
Global OMERACT-EULAR Synovitis Score (GLOESS). The GLOESS consists of the sum 
of PD scores across a standardised full set of 22 joints, or reduced set of 9 joints (Naredo et 
al., 2011). However, in a validation study by the OMERACT-US group of 89 RA patients 
starting abatacept, change in GLOESS over 24 weeks follow-up failed to show a significant 
correlation between change in DAS28 or DAS28-defined outcomes after 24 weeks of follow-
up, thus calling in to question the validity of GLOESS as a measure of treatment response 
(D'Agostino et al., 2016a). An independent group analysed data from standardised US of 36 
joints and 4 tendons in a cohort of 439 RA patients, and proposed two candidate reduced joint 
sets (7 joints/2 tendons, and 9 joints/2 tendons) that retained 78-85% of data in unilateral 
scans (Aga et al., 2016). These joint sets remain to be validated in an independent cohort. 
Whilst debate continues within the US imaging community regarding an optimal joint set, 
interest has grown in the use of whole-body MRI for the detection of subclinical synovitis in 
RA remission. In a feasibility study of 20 patients with active RA, a whole-body contrast-
enhanced MRI protocol was developed to assess inflammation at 76 peripheral joints, 30 
entheses and the spine (Axelsen et al., 2014). Readability was ≥70% for most peripheral 
joints, although hand distal interphalangeal joints (DIPJs) and feet PIPJs/DIPJs were more 
difficult to assess (Axelsen et al., 2014). Nevertheless, the requirement for a 60 minute scan 
using a 3 Tesla MRI machine are likely to be substantial barriers to its current widespread and 
routine use in clinical practice, though this may improve with future technological advances. 
 
1.5.2.f Limitations of imaging in the assessment of RA remission 
Despite the apparent prognostic value of modern imaging techniques in detecting subclinical 
synovitis in RA remission, there remain substantial barriers in the application of this to 
routine clinical practice.  As discussed above, uncertainty surrounding the optimal number of 
joints to scan in the setting of remission leads to substantial heterogeneity between studies, 
making direct comparisons difficult. There are also technical and pragmatic limitations to 
both ultrasound and MRI modalities, as discussed in Introduction 1.4.4. 
Despite these limitations, enthusiasm in the research community remains high for the future 
translation of imaging-defined remission as a target of disease treatment. Indeed, the 
development of ultrasound-defined targets of disease control is the central focus of the 
ongoing ‘Targeted Ultrasound Initiative’, an international collaborative research group 
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(Wakefield et al., 2012). However, recent results from the Targeting Synovitis in Early 
Rheumatoid Arthritis (TaSER) study challenge this treatment paradigm (Dale et al., 2016). In 
this open-label prospective study, 111 patients with newly diagnosed RA were randomised to 
treatment strategies targeting either DAS28-ESR<3.2 (control arm) or a combined DAS28-
ESR/US construct (intervention arm). In the control arm, DMARD therapy was escalated if 
DAS28-ESR≥3.2. In the intervention arm, treatment was escalated if: DAS28-ESR>5.1, 
3.2<DAS28-ESR≤5.1 plus ≥2 swollen joints, or DAS28-ESR≤5.1 plus PD in ≥2 joints. 
DMARD escalation was performed according to the same schedule in both arms (oral 
methotrexate followed by: triple therapy with oral methotrexate, triple therapy with 
subcutaneous methotrexate, and triple therapy with etanercept). After 18 months, patients in 
the intervention arm received significantly more intensive DMARD therapy, though with no 
significant benefits in terms of change in DAS-44, change in the area under DAS-44 curve or 
MRI measures (bone erosion or BME). More patients achieved DAS44 remission in the 
intervention arm though only at the 18 month time point (43% vs 66%, p=0.03), and no 
difference in achievement of ACR/Boolean remission was observed. Whilst it is possible that 
statistically significant differences in clinical endpoints may only become apparent after 
several years of follow-up, the authors argue that these are unlikely to be clinically significant 
nor justify the greater burden of DMARD therapy and expenditure of time and resources for 
US scanning in the intervention group (Dale et al., 2016). 
These observations are further corroborated by results from the ARCTIC study (Aiming for 
Remission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a 
Clinical TIght Control regimen) (Haavardsholm et al., 2016). In this randomised controlled  
trial (RCT), 238 patients with newly diagnosed RA were randomised in a 1:1 ratio to 
conventional management (target of clinical remission defined as DAS44<2.6 and no swollen 
joints) or a ‘tight control’ (target of clinical remission plus absence of PD on 32-joint 
ultrasound scan). The primary endpoint was the proportion of patients who achieved a 
combination of clinical remission, no swollen joints and no radiographic progression after 16-
24 months. Prescription of combination csDMARDs and bDMARDs was greater in the tight-
control versus conventional therapy arms, though occurrence of adverse events was 
comparable. Despite this however, no significant difference was observed in the primary 
endpoint between the two groups (21/112 (19%) versus 16/118 (22%) patients in the 
conventional vs. tight-control groups respectively, p=0.54).  
In summary, whereas current evidence suggests that the presence of PD is a poor prognostic 
factor even in the setting of clinical remission, it would appear that targeting treatment 
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approaches towards ultrasound-defined remission does not afford significant clinical benefits. 
Research in the area remains ongoing, including an ongoing study exploring a treat-to-target 
strategy in early RA defined by the absence of BME on MRI imaging (Moller-Bisgaard et al., 
2015). However, at present there is a lack of data to support the routine use of imaging to 
define treatment targets in RA. 
 
1.5.3 The concept of ‘depth’ of remission in RA 
The concept of disease remission in RA is largely borrowed from the field of oncology, where 
remission is defined in terms of duration of cancer-free survival with a period (often 5 years) 
defined as disease ‘cure’. Disease relapse in this setting is relatively easy to define, being a 
recurrence of the original malignancy, with a relatively clear binary distinction between 
relapse and cure. Extrapolating this concept to the setting of a chronic autoimmune disease 
such as RA poses several challenges, not least a reconciliation with the stochastic nature of 
arthritis flares and the variety of different measures of disease activity. 
Addressing this issue, Schett et al. (2016) propose a hierarchical ‘shell model’ of remission in 
RA encompassing three related yet distinct remission states: clinical, imaging/serological, and 
immunological remissions (Figure 1.6). In this model, clinical remission is conceptualised as 
an absence, or virtual absence, of clinical symptoms and signs of active arthritis such that 
there is no or very minimal impact upon physical function and quality of life. Within this 
clinical remission group exists a proportion of patients who have subclinical inflammation, 
which the authors propose could be detected by either imaging and/or sensitive serological 
analysis. Patients who have no detectable subclinical inflammation are defined as being in 
imaging/serological remission, though a proportion of these could still be expected to have a 
future episode of disease activity owing to an underlying persistent immune dysregulation. 
Only those patients who have regained a state of immunological tolerance are said to have 
achieved immunological remission, which Schett et al. (2016) propose could be assessed by 
RhF and ACPA status. This hierarchical model of RA remission is attractive in that it 
acknowledges the distinction between different levels of remission in a pragmatic clinical 
approach. However, it could be argued that the distinction between imaging/serological and 
immunological remission is rather arbitrarily defined by the sensitivity of currently available 
technologies to measure disease activity. 
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Figure 1.6 – The ‘shell model’ of RA remission, as proposed by Schett et al. (2016). Distinct 
hierarchical levels of remission can be conceptualised by the absence of clinical, imaging, 
serological and immunological measures of synovitis. Reproduced from Annals of the 
Rheumatic Diseases, Schett et al, volume 75, pages 1428-37, copyright 2016, with permission 
from BMJ Publishing Group Ltd. 
 
An alternative conceptualisation of RA remission is to consider an ‘iceberg model’, whereby 
remission is considered in terms of a continuous spectrum of disease activity (Figure 1.7). In 
this model, disease activity can be visible clinically as symptoms or joint destruction, or 
invisible as subclinical immune dysregulation. The threshold at which this immune 
dysregulation manifests in clinically significant disease varies between individuals, and can 
be modified by DMARD therapy and, potentially, by environmental insults such as 
concurrent infection or smoking. Assessment of the extent of immune dysregulation becomes 
increasingly difficult with increasing depth below the clinical threshold, as available 
knowledge and technologies are stretched to their current limits. It is conceivable that with 
greater depth of RA remission comes improved long-term prognosis and potential for 
DMARD de-escalation, as will be discussed in the next subchapter. 
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Figure 1.7 – The ‘iceberg model’ of RA remission. Autoimmune processes (represented by 
the grey triangle) can manifest as clinical disease or may be invisible as subclinical synovitis 
and immune dysregulation. The threshold (red) above which disease is manifest varies 
between individual patients, and can be influenced by DMARD therapy and environmental 
factors. With increasing depth of remission comes greater difficulty in detecting and 
measuring immune dysregulation (purple), which is limited by available technology and 
knowledge. 
 
1.5.4 Summary 
Advances in modern DMARD therapy have made disease remission an achievable target for 
many patients with RA. Nevertheless, the varied and often subjective nature of RA 
symptomatology, together with the stochastic nature of arthritis flares, pose significant 
challenges in defining clinically meaningful thresholds of disease activity that are consistent 
with remission. Current international consensus guidelines define remission solely in terms of 
clinical composite scores, and do demonstrate prognostic value in predicting risk of 
radiographic progression and arthritis flare. Nevertheless, strict thresholds on patient global 
assessment scores can disproportionally preclude patients with comorbidities such as 
osteoarthritis (OA), and even patients who satisfy the most stringent of clinical remission 
criteria still can develop further radiographic joint damage. Indeed, modern imaging 
modalities including US and MRI demonstrate substantial levels of subclinical inflammation 
across all definitions of clinical remission. Imaging measures of subclinical synovitis are 
  
49 
 
associated with histological and biochemical measures of inflammation, as well as risk of 
future arthritis flare and radiographic progression. However, imaging abnormalities are 
relatively common in healthy individuals and there is uncertainty surrounding the acceptable 
levels of imaging abnormalities that are consistent with stable remission. 
Indeed, rather than viewing remission as a binary state, it may be more realistic to consider 
remission in terms of a continuous spectrum of subclinical disease activity, which can be 
assessed by  clinical, imaging and immunopathological means. Stratification by depth of 
remission could thus help separate patients at high risk of arthritis flare and progression for 
whom close surveillance is warranted, versus those at low risk for whom DMARD tapering 
and withdrawal could be considered – a conjectural though nonetheless intriguing concept. 
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1.6 DMARD-free remission in RA 
The introduction of modern DMARD therapy and its initiation earlier in the clinical course of 
disease have enabled an increasing proportion of patients to achieve disease remission. As 
noted previously, this has led to the suggestion of a ‘step-down’ paradigm of drug therapy, 
whereby DMARDs are tapered when clinical remission has been achieved (discussed in 
Introduction 1.3.3). This step-down approach raises the tantalising concept of drug-free 
remission (DFR) – a state whereby disease activity could be so low as to permit complete 
DMARD withdrawal without subsequent arthritis flare or progression. In this section, I will 
attempt to answer three important questions surrounding sustained DFR in RA based upon 
evidence from the current published literature, namely: 
1. Can drug-free remission in RA be achieved? 
2. What are the benefits and risks of DMARD withdrawal? 
3. What is the optimal strategy for DMARD withdrawal? 
 
1.6.1 Can drug-free remission in RA be achieved? 
DFR in RA is more than a simple theoretical concept and its existence is well documented 
(van den Broek et al., 2011; Scott et al., 2013a). There have been many studies exploring the 
potential to taper biologic DMARD therapy once remission is achieved. However, the 
majority of these studies do not involve complete DMARD cessation and hence are less 
relevant to this discussion. In this subsection, I will focus exclusively upon evidence from 
clinical studies addressing complete DFR in RA. 
 
1.6.1.a Evidence from observational cohort studies 
Clinical remission is a frequent outcome of modern DMARD therapy in RA. In a large meta-
analysis, Ma et al. (2010) explored the prevalence of clinical remission in 17 observational 
studies (4762 patients) and 20 RCTs (4290 patients). Within the observational studies, 
average prevalence of DAS-defined remission (DAS≤1.6 or DAS28-ESR≤2.6) in patients 
receiving DMARD therapy was 33% (9 studies). Within the RCTs, DAS-defined remission 
was observed in 26% with DMARD monotherapy and 42% with combination DMARDs (13 
studies). Indeed, current studies suggest that increasing proportion of patients have achieved 
clinical remission with DMARD therapy over recent years. For example, an analysis of data 
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from a Norwegian early arthritis cohort of 2573 patients showed significant improvements in 
the rates of clinical remission by all measures from 2000 to 2010 (Figure 1.8), an effect which 
the authors attributed to earlier initiation of more aggressive DMARD therapy (Aga et al., 
2015).  
With remission rates approaching 50% in modern practice, some longitudinal cohorts now 
include data on patients who have achieved remission and successfully discontinued 
DMARDs, providing observational data on the prevalence of DFR in authentic clinical 
settings. Van der Woude et al. (2009) examined the prevalence of DFR in two large RA 
cohorts: the British Early Rheumatoid Arthritis Study (ERAS) and Dutch Leiden Early 
Arthritis Clinic (LEAC). All patients had received non-biologic DMARDs, with DFR defined 
as no joint swelling and a clinical impression of remission in the absence of DMARD 
treatment. Substantial rates of DFR were observed in 15% (68/454 patients) and 9.4% (84/895 
patients) in the LEAC and ERAS cohorts respectively (van der Woude et al., 2009). 
A more recent study of the LEAC cohort explored the prevalence of DFR in patients 
diagnosed with RA between 1993 and 2011 (Ajeganova et al., 2016). Sustained DFR was 
defined as the absence of synovitis on clinical examination until the end of study follow-up 
and for at least 1 year after DMARD cessation, and was achieved by 155/1007 (15.4%) of 
patients. Functional ability in the sustained DFR group, as measured by the HAQ, was 
commensurate with the general population (median HAQ 0.13, IQR 0.63). 
 
 
Figure 1.8 – Response and remission rates after six months of methotrexate monotherapy by 
year of treatment initiation. Reproduced from Annals of the Rheumatic Diseases, Aga et al., 
volume 74, pages 381-88, copyright 2010, with permission from BMJ Publishing Group Ltd. 
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Long-term outcomes after 15 years of follow-up were explored in a smaller cohort of RA 
patients recruited between 1986 and 1989 in Finland (Tiippana-Kinnunen et al., 2010). Of the 
70 patients studied, 11 (16%) had permanently discontinued DMARD therapy, of which 9 
(13% of total) satisfied the 1981 ACR remission criteria. Good long-term outcomes were 
observed in patients who were able to discontinue DMARDs with a lower rate of radiological 
progression and similar disability scores compared with those patients who continued 
DMARD therapy. 
 
1.6.1.b Evidence from clinical trials of DMARD cessation in established RA 
Longitudinal cohort data provide clear evidence of the existence of DFR, with approximately 
10-15% of patients achieving this status. Nevertheless, the observational and uncontrolled 
nature of these studies make it difficult to draw firm conclusions as to the risk of arthritis flare 
attributable to DMARD cessation. There have been several clinical trials exploring the 
complete cessation of DMARD therapy in RA remission, many of which have been published 
in the last 5 years (Table 1.9). However, the majority of these studies assess DFR as a 
secondary or post-hoc outcome measure. Furthermore, the wide range of different DMARD 
treatment regimens and inconsistent definitions of remission makes comparison difficult. In 
the only published meta-analysis on the topic, O'Mahony et al. (2010) identified six 
randomised controlled trials (RCTs) of complete DMARD withdrawal incorporating a total of 
503 patients (De Silva and Hazleman, 1981; Ahern et al., 1984; Van der Leeden et al., 1986; 
Kremer et al., 1987; Gotzsche et al., 1996; ten Wolde et al., 1996). Pooled data from the 
RCTs showed a relative risk of flare or deterioration in RA with continued DMARD therapy 
versus treatment withdrawal of 0.31 (95% CI 0.16 to 0.57, p<0.001). Nevertheless, trials in 
the setting of early rheumatoid arthritis were excluded from this meta-analysis, and the 
included trials were published between 1981 and 1996 and hence all included historical 
DMARDs such as penicillamine and gold, which are now rarely used in modern 
rheumatology practice. Furthermore, several of the trials studied DMARD withdrawal in 
patients who were not in clinical remission. 
One RCT included within the meta-analysis is noteworthy for its size and extended duration 
of follow-up. In this multi-centre study (ten Wolde et al., 1996), 285 patients with established 
RA were randomised to continue their current DMARD monotherapy or switch to placebo in 
a double-blind design. All patients satisfied a remission definition at baseline adapted from 
the 1981 ACR remission criteria, and their progress was reviewed for 1 year. The cumulative
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Table 1.9 – Summary of studies of disease-modifying anti-rheumatic drug (DMARD) withdrawal in rheumatoid arthritis that have investigated complete DMARD-
free remission. Studies highlighted in bold investigated DMARD-free remission as the primary outcome. Where glucocorticoids were permitted, these were 
withdrawn at time of DMARD withdrawal unless otherwise stated. ABT, abatacept; ACR, American College of Rheumatology; ADA: adalimumab; CIC, 
ciclosporin; CRP, C-reactive protein; DAS, disease activity score, EMS, early morning stiffness; ESR, erythrocyte sedimentation rate; ETN, etanercept; HCQ, 
hydroxychloroquine; IA, intra-articular;  IM: intra-muscular; IQR, inter-quartile range; MTX, methotrexate; NTSJ, no tender or swollen joints; PBO, placebo; RAI: 
Ritchie articular index; SDAI, Simple Disease Activity Index; SFZ: sulfasalazine; SJC, swollen joint count; TNFα: tumour necrosis factor alpha; TOC, tocilizumab. 
Notes: a: 2.6 < DAS28-ESR < 3.2 at ≤2 visits during the remission period was permitted; b: study also included further 122 patients with undifferentiated 
inflammatory arthritis (data not shown); c: 160 patients were recruited to the initial study, of which 139 completed the 5 year extension; d: DMARD-free remission 
maintained for 3 and 6 months in 11 and 7 patients respectively (data limited by incomplete follow-up); e: 94% of enrolled patients satisfied 2010 ACR/EULAR RA 
classification criteria. Adapted from Tanaka and Hirata (2014). 
Study DMARDs 
Number 
of 
patients 
Disease 
activity at 
enrolment 
Disease 
duration Intervention 
Remission 
definition 
Number of 
patients 
entering 
DMARD 
withdrawal 
phase 
Proportion 
maintaining 
remission after 
DMARD 
withdrawal 
Duration of 
follow-up 
Ahern et al. 
(1984) D-penicillamine 38 
NTSJ for > 
6 months 
Mean 11.6 
years since 
diagnosis 
Treatment continuation or 
PBO, randomised, single-
blind 
NTSJ 19 
4/19 (21%)  PBO 
arm 
(vs. 17/19 (89%) 
continuation arm) 
12 months 
after 
DMARD 
withdrawal 
Bijlsma et al. 
(2016) 
 
U-Act-Early 
study 
MTX, TOC, 
HCQ, TNFα 
inhibitor 
317 
Mean 
DAS28-
ESR 5.2 
Mean 
symptom 
duration 26 
days 
Randomised, double-blind: 
TOC+MTX, TOC+PBO, 
MTX+PBO. Escalation to HCQ 
& TNFα inhibitor if remission 
not achieved. DMARD 
withdrawal once sustained 
remission achieved. 
DAS28-ESR 
< 2.6 and 
SJC≤4 for 
≥24 weeks a 
265 
77/265 (29%), of 
which: 
37 TOC+MTX 
28 TOC+PBO 
12 MTX+PBO 
2 years after 
enrolment 
El Miedany 
et al. (2016) 
Various 
biological and 
non-biological 
157 
DAS28-
ESR < 2.6 
for > 6 
months 
Disease 
duration ≥ 18 
months 
Randomised, open label: 
Arm 1: half dose bDMARDs 
Arm 2:Half dose bDMARDs 
and csDMARDs 
Arm 3: Stop bDMARDs, half 
dose csDMARDs 
Arm 4: Stop bDMARDs and 
csDMARDs 
Arm 5: Continue all DMARDs 
DAS28-ESR 
< 3.2 
157 
 
(of which 
31 had 
complete 
DMARD 
cessation) 
1: 13/31 (42%) 
2: 19/32 (59%) 
3: 21/31 (68%) 
4: 24/31 (77%) 
5: 2/32 (6%) 
12 months 
after 
DMARD 
withdrawal 
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Table 9.1 (continued) 
Study DMARDs 
Number 
of 
patients 
Disease 
activity at 
enrolment 
Disease 
duration Intervention 
Remission 
definition 
Number of 
patients 
entering 
DMARD 
withdrawal 
phase 
Proportion 
maintaining 
remission after 
DMARD 
withdrawal 
Duration of 
follow-up 
Emery et al. 
(2014) 
 
PRIZE study 
ETN, MTX, 
maintenance 
prednisolone 
permitted until 
week 26. 
306 
DAS28-
ESR 5.8 
mean 
Mean 
symptom 
duration 6 
months 
All patients open label 
ETN+MTX for 1 year. Those in 
remission (n=193) entered 
randomised, double-blind 
phase: ETN+MTX, MTX+PBO 
or PBO+PBO for 39 weeks. 
Those with DAS28-ESR≤3.2 
entered DMARD withdrawal. 
DAS28-ESR 
< 2.6 
131 
 
(of which 
110 in 
remission) 
28/50 (56%) 
ETN+MTX 
19/35 (54%) 
MTX+PBO 
15/25 (60%) 
PBO+PBO 
65 months 
after 
enrolment 
(total 
DMARD-free 
time varied 
between arms) 
Emery et al. 
(2015) 
 
AVERT study 
ABT, MTX, 
maintenance 
prednisolone 
permitted in 
first year 
351 
Mean 
DAS28-
CRP 5.4 
Mean 
symptom 
duration 0.56 
years 
Randomised, double-blind. 
ABT, MTX or ABT+MTX, 
DMARDs withdrawn after 12 
months if DAS28-CRP<3.2. 
DAS28-CRP 
< 2.6 
223 
 
(of which 
176 in 
remission) 
14/50 (28%) ABT 
18/73 (25%) 
ABT+MTX 
9/53 (17%)  MTX 
6 months after 
DMARD 
withdrawal 
Haschka et 
al. (2016) 
 
RETRO 
study 
Various 
biological & 
non-biological, 
prednisolone 
≤5mg/day 
110 
DAS28-
ESR < 2.6 
for >6 
months 
Median 5 
years since 
diagnosis 
Randomised, open-label. 3 
arms: DMARD continuation; 
50% reduction; 50% 
reduction for 6 months then 
complete DMARD 
withdrawal.  
DAS28-ESR 
< 2.6 
63 
 
(of which 
27 had 
complete 
DMARD 
cessation) 
13/27 (48% ) 
withdrawal arm 
(versus 22/36 
(61%) reduction 
arm and 36/38 
(84%) 
continuation arm) 
12 months 
after 
enrolment 
Heimans et 
al. (2016) 
 
IMPROVED 
study 
MTX, HCQ, 
SFZ, ADA, 
prednisolone. 
 
479b Mean 
DAS44 3.3 
Symptom 
duration 18 
weeks 
(median) 
Open-label. MTX + 
prednisolone for first 4 months. 
If remission not achieved, then 
randomised to 
MTX+HCQ+SFZ+prednisolone 
or MTX+ADA. 
DMARD withdrawal once 
remission achieved. 
DAS44 < 1.6 Not stated 
Not stated 
[89/479 (19%) of 
total recruited 
achieved DMARD-
free remission] 
2 years after 
study 
enrolment 
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Table 9.1 (continued) 
Study DMARDs 
Number 
of 
patients 
Disease 
activity at 
enrolment 
Disease 
duration Intervention 
Remission 
definition 
Number of 
patients 
entering 
DMARD 
withdrawal 
phase 
Proportion 
maintaining 
remission after 
DMARD 
withdrawal 
Duration of 
follow-up 
Hetland et al. 
(2010) 
 
CIMESTRA 
study 
MTX, CIC, 
HCQ, SFZ, IA 
corticosteroids 
139c 
Median 
DAS28-
ESR 5.26 
Symptom 
duration < 6 
months 
Randomised to CIC +/- MTX 
with later addition of HCQ (see 
text). DMARD withdrawal if 
remission for ≥12 months 
1981 ACR 
remission 
criteria 
Not stated 
Not stated 
[17% of total 
recruited achieved 
DMARD-free 
remission] 
5 years after 
study 
enrolment 
Huizinga et 
al. (2015) 
 
ACT-RAY 
study 
 
TOC +/- MTX, 
other non-
biologic 
DMARDs and 
corticosteroids 
553 
Mean 
DAS28-
ESR 6.34 
Mean 8.2 
years since 
diagnosis 
0-6m: TOC+MTX or TOC-
PBO, double blind. 6-12m: 
Addition of other DMARDs if 
required, open label. 12m:  
DMARD withdrawal  
DAS28-ESR 
< 2.6 Not stated 
Not stated 
[28/472 (6%) 
remaining in study 
after 12 months 
achieved DMARD-
free remission at 2 
years] 
2 years after 
study 
enrolment 
Kita et al. 
(2012) Various 13 
SDAI 20.2 
mean 
Mean 
symptom 
duration 14 
weeks 
DMARD withdrawal at 1 
year, open-label 
SDAI ≤ 3.3 
and ≥ 66% 
improvement 
in MRI bone 
marrow 
oedema 
5 3/5 (60%) 
12 months 
after 
DMARD 
withdrawal 
Klarenbeek et 
al. (2011b) 
 
BeSt study 
Various 508 DAS44 4.4 mean 
Median 23-26 
weeks 
symptom 
duration 
Randomised to open-label 
DMARD arms (see text). 
DMARD withdrawal if 
remission achieved for 6 
months 
 
DAS44 < 1.6 Not stated 
Not stated 
[115/508 (23%) 
achieved DMARD-
free remission, of 
which 59/115 
(51%) maintained 
remission at 5 year 
time-point] 
5 years after 
study 
enrolment  
 
[median (IQR) 
duration of 
remission of 
23(15-25) 
months] 
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Table 9.1 (continued) 
Study DMARDs 
Number 
of 
patients 
Disease 
activity at 
enrolment 
Disease 
duration Intervention 
Remission 
definition 
Number of 
patients 
entering 
DMARD 
withdrawal 
phase 
Proportion 
maintaining 
remission after 
DMARD 
withdrawal 
Duration of 
follow-up 
Kuijper et al. 
(2016) 
 
tREACH 
study 
MTX, SFZ, 
HCQ, ETN, 
ADA, ABT, 
glucocorticoids 
281 Mean 
DAS44 3.35 
Mean 24 
weeks 
symptom 
duration 
Open label. Randomised to 
MTX+oral prednisolone or 
MTX+SFZ+HCQ+oral/IM 
steroid. Later escalation to 
biologic therapy if remission 
not achieved. Withdrawal of 
DMARDs if remission 
sustained over ≥3 months. 
DAS44<1.6 141 34/141 (24%) d 2 years after enrolment 
Nam et al. 
(2014) 
 
EMPIRE 
study 
MTX +/- ETN 110e 
DAS28-
CRP 4.14 
mean 
Median 
symptom 
duration 6–8 
months 
Randomised to MTX+ETN or 
MTX+PBO, ETN withdrawn 
after 1 year or 26 weeks of 
remission, MTX withdrawn 12 
weeks later if in remission. 
NTSJ 110 4/110 (3.6%) 78 weeks after 
enrolment 
Nishimoto et 
al. (2014a) 
 
DREAM 
study 
TOC +/- 
glucocorticoids 187 
DAS28-
ESR ≤ 3.2 
Median 7.8 
years since 
diagnosis 
Open-label TOC cessation, 
glucocorticoids remained 
unaltered 
DAS28-ESR 
< 2.6 187 17/187 (9%) 
12 months 
after DMARD 
cessation 
ten Wolde et 
al. (1996) 
Various non-
biological 285 
Modified 
1981 ACR 
remission 
for > 1 year 
Median 9 
years since 
diagnosis 
Randomised, double-blind. 
Treatment continuation or 
PBO,  
Absence of 
flare, defined 
as: SJC ≥ 3 
and 2/3 of 
RAI > 9, 
EMS > 45 
min or raised 
ESR 
285 
90/143 (63%) PBO 
arm 
(vs. 112/142 (79%) 
in continuation 
arm) 
12 months 
after 
DMARD 
cessation 
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incidence of arthritis flare was 38% in the placebo arm versus 22% for DMARD continuation, 
giving a relative risk of arthritis flare upon DMARD withdrawal in a multivariate analysis of 
2.6 (95% CI 1.4 to 4.6). In an extension to the study, those patients whose arthritis flared were 
reviewed for a further 12 months after recommencement of DMARD therapy (ten Wolde et 
al., 1997). Of the 51 patients included in this analysis, 24/51 (47%) demonstrated at least an 
ACR20 response by 3 months after DMARD recommencement, and at 12 months disease 
activity was judged to be in remission, mild or moderate/severe categories in 18 (35%), 22 
(43%) and 11 (22%) patients respectively. Again, it is noteworthy that many of the DMARDs 
used were either antiquated or prescribed at low doses (e.g. 7.5mg/week methotrexate) 
compared to current clinical practice. The true efficacy of re-introduction of modern regimens 
DMARD therapy is therefore likely to be greater than that reported in this study. 
In a publication of interim results from the RETRO1 study (Haschka et al., 2016), 101 
patients with established RA of median 5 years duration and DAS28-ESR < 2.6 were 
randomised to either continue DMARD therapy, reduce DMARDs to 50% dose, or reduce to 
50% for 6 months then stop. Patients in the study took a range of different biologic and non-
biologic DMARDs at baseline, including corticosteroids. At 12 months, 67/101 (66%) 
patients remained in DAS28-ESR remission; significantly more patients maintained remission 
in the continuation arm (36/38 [84%]) versus the reduction (22/36 [61%], p=0.036) and 
complete DMARD cessation (13/27 [48%], p=0.003) arms. The majority of arthritis flares in 
the reduction and cessation arms occurred in the first 6 months after entry to the study. 
In another recent study (El Miedany et al., 2016), 157 patients with established RA (disease 
duration ≥ 18 months) and in clinical remission (DAS28-ESR<2.6 for > 6 months) were 
randomised to 5 arms: DMARD continuation; half-dose biologic DMARDs (bDMARDs); 
half dose bDMARDs and conventional synthetic DMARDs (csDMARDs); stop bDMARDs 
and half-dose csDMARDs; and stop all DMARDs. A range of DMARDs were permitted, 
though oral corticosteroid therapy was not allowed in the 12 months prior to study inclusion. 
All patients were reviewed monthly for one year with a clinical and 40-joint ultrasound scan 
assessments at each visit. Arthritis flare was defined as DAS28-ESR>3.2. Overall, 78/157 
(50%) remained in DFR at 12 months, though proportionally more patients flared in arms that 
involved bDMARD cessation (Table 1.9).  
                                                            
1 For the purposes of readability, study acronyms are not expanded in this chapter, but are 
listed in full in the abbreviations section at the beginning of this Thesis. 
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The recently published ACT-RAY study explored DFR, albeit as a secondary outcome in a 
rather complicated study design (Huizinga et al., 2015). This trial recruited 553 patients with 
established RA resistant to methotrexate monotherapy. Patients were randomised to receive 
tocilizumab with either methotrexate or placebo in a double-blinded manner. After 6 months, 
open label non-biologic DMARDs could be added if required to control disease activity. After 
1 year, DMARD therapy was tapered to complete cessation in patients achieving a DAS28-
ESR < 2.6. Overall, 28/472 (6%) of patients remaining in the study at 1 year had achieved 
DFR at the 2 year time-point. 
In the DREAM study (Nishimoto et al., 2014a), 187 patients were recruited with RA of 
median duration 7.8 years, receiving tocilizumab monotherapy for a median of 4 years and 
with a DAS28-ESR ≤ 3.2. Patients did not receive any other concomitant DMARDs, though 
of note a third were taking low-dose glucocorticoids throughout the study. Tocilizumab was 
discontinued at enrolment and 17/187 (9%) achieved DFR (DAS28-ESR < 2.6) at 1 year after 
tocilizumab cessation. 
 
1.6.1.c Evidence from clinical trials in the setting of early RA 
There have been many clinical trials exploring the relative efficacy of different regimens of 
DMARDs in the setting of early RA, of which some have explored DFR as a secondary 
outcome measure. The largest and most comprehensive of these studies is the Dutch 
Behandal-Strategieën (BeSt) study, a multicentre open-label RCT (Goekoop-Ruiterman et al., 
2005). In this study, 508 patients with RA of symptom duration < 2 years and a median of 2 
weeks since diagnosis were randomised to four different treatment arms comprising: 
sequential DMARD monotherapy; step-up combination therapy; initial combination therapy 
with prednisolone; and initial combination therapy with infliximab. Importantly, DMARDs 
were tapered to complete cessation in all groups for patients who achieved DAS remission 
(DAS≤ 1.6) for at least 6 months. In a 5 year analysis, 115/508 (23%) achieved drug-free 
remission, of which 59/115 (51%) remained in sustained DFR at the 5 year follow-up point 
with a median (IQR) duration of remission of 23 (15-25) months (Klarenbeek et al., 2011b). 
The rates of sustained remission were comparable across all four treatment arms with no 
statistically significant difference in this small post-hoc analysis. Patients whose arthritis 
flared were restarted on DMARD therapy, with 25/53 (47%) and 39/53 (74%) patients 
regaining remission at 3 and 6 months after DMARD recommencement respectively. Of the 
remaining patients, 11/53 (21%) achieved low-disease activity (DAS ≤ 2.4); only one patient 
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failed to achieve at least low disease activity at 6 months, with an additional 2 patients lost to 
follow-up. Importantly, no significant radiographic progression was observed in those patients 
who experienced a flare of arthritis versus those who remained in DFR, in part attributable to 
the close monitoring and rapid recommencement of DMARDs upon arthritis flare 
(Klarenbeek et al., 2011b). 
In the CIMESTRA study (Hetland et al., 2006), 160 patients with RA of less than 6 months 
duration were treated with intra-articular steroid injections and randomised to receive either 
methotrexate/ciclosporin or methotrexate/placebo, with the later withdrawal of 
ciclosporin/placebo and addition of hydroxychloroquine. If patients then achieved 1981 ACR 
remission for at least 12 months, then DMARD therapy was gradually tapered to complete 
cessation. In a 5-year analysis of 139 patients, DFR was achieved in 19% and 14% of patients 
in the methotrexate/ciclosporin and methotrexate/placebo arms respectively, with no 
significant difference between arms (Hetland et al., 2010).  
In the PRIZE study (Emery et al., 2014), 306 patients with early-onset RA of mean 6 months 
symptom duration were treated with open-label 50mg etanercept and methotrexate for 1 year. 
The 193 patients who achieved DAS28-ESR < 2.6 were then randomised to receive 25mg 
etanercept plus methotrexate (ETN+MTX), methotrexate plus placebo (MTX+PBO), or 
double placebo (PBO+PBO). After 39 weeks, the 131 patients with DAS28-ESR ≤ 3.2 (of 
which 110 had DAS28-ESR<2.6) then had all drugs withdrawn and were reviewed for a 
further 26 weeks. The proportion of patients achieving sustained DAS28 remission at 39 
weeks was significantly different between groups: 40/63 (63%), 26/65 (40%) and 15/65 
(23%) in the ETN+MTX, MTX+PBO and PBO+PBO arms respectively (p=0.009 for 
ETN+MTX vs. MTX+PBO, p<0.001 for ETN+MTX vs. PBO+PBO). The proportion of 
patients achieving DAS28 point remission at 65 weeks (i.e. after DMARD withdrawal) were 
28/63 (44%), 19/65 (29%) and 15/65 (23%) in the ETN+MTX, MTX+PBO and PBO+PBO 
arms respectively (p=0.02 for ETN+MTX vs. PBO+PBO, other comparisons not statistically 
significant). In terms of the 110 patients who were in DAS28-ESR remission at the start of the 
DMARD withdrawal period, remission at week 65 was achieved by 28/50 (56%), 19/35 
(54%) and 15/25 (60%) of patients in the ETN+MTX, MTX+PBO and PBO+PBO arms 
respectively (p values not presented in paper). Importantly, the total biologic-free follow-up 
period was much longer in the placebo arms compared to the etanercept plus methotrexate 
arm. Thus, whilst this study does highlight the high rate of arthritis flare upon etanercept 
cession, it is difficult to directly compare the groups with regards to the optimal strategy for 
etanercept withdrawal. 
  
60 
 
In the EMPIRE study (Nam et al., 2014), 110 patients with inflammatory arthritis of median 
symptom duration approximately 7 months (of which 94% satisfied 2010 ACR/EULAR RA 
classification criteria) were randomized to either methotrexate plus etanercept or methotrexate 
plus placebo in a double-blinded fashion. Etanercept or placebo was stopped after 1 year or 
when patients achieved remission for 26 weeks, defined as no tender or swollen joints in a 44 
joint count. Methotrexate was then withdrawn 12 weeks later if patients maintained remission. 
At 78 weeks after enrolment, 4/110 (3.6%) had achieved drug-free remission. Of note, the 
strict definition of remission used in this study, and the withdrawal of etanercept regardless of 
disease activity, may have resulted in a lower rate of observed DFR. 
In the tREACH study (Kuijper et al., 2016), 281 DMARD-naïve patients with early RA 
(mean symptom duration 24 weeks) were randomised to treatment with methotrexate 
monotherapy or triple therapy (methotrexate, sulfasalazine and hydroxychloroquine). Short 
course bridging glucocorticoid therapy was used in both groups at baseline, and if DAS>2.4 
after initial therapy then treatment was escalated to methotrexate plus anti-TNFα biologic. If 
sustained remission was achieved (DAS<1.6 for ≥3 months), then DMARDs were tapered in 
a standardised protocol to complete cessation if remission maintained. After 2 years of 
follow-up, 159/281 (57%) patients achieved sustained remission with no significant 
difference between initial methotrexate monotherapy vs. triple therapy groups. Of 141 
patients who entered DMARD withdrawal phase, DFR was achieved in 34/141 (24%). DFR 
was sustained for 3 and 6 months in 11 and 7 patients respectively, although this was partly 
limited by incomplete follow-up data in many patients (Kuijper et al., 2016). 
1.6.1.d Evidence from trials of DMARD therapy in very early RA 
With strong evidence to support an early therapeutic window of opportunity in RA, there has 
been increasing interest in the treatment of very early stages of disease, with the rationale that 
a brief course of DMARDs may allow for complete resolution of arthritis. Recent studies have 
explored the possibility of DMARD treatment in patients with undifferentiated arthritis or 
even in pre-symptomatic individuals with the aim of preventing progression to RA – a rather 
distinct concept to DFR in RA that will not be discussed further here. Nevertheless, several 
studies in patients with a very early diagnosis of RA do shed light on the potential for DFR if 
therapy is initiated in the very early phase of disease. 
In the U-Act-Early study (Bijlsma et al., 2016), 317 DMARD-naïve patients with a median 
symptom duration of 26 days were randomised to receive tocilizumab and methotrexate 
(TOC+MTX), tocilizumab plus placebo (TOC+PBO), or methotrexate plus placebo 
  
61 
 
(MTX+PBO) in a double-blind trial design. Patients were then reviewed at monthly intervals 
for 104 weeks, with standardised escalation of DMARD therapy (including later use of 
tocilizumab in the MTX+PBO arm, and anti-TNFα biologics in all arms) if remission was not 
achieved. The primary endpoint was sustained remission, defined as DAS28-ESR < 2.6 and ≤ 
4 swollen joints for ≥ 24 weeks (though 2.6<DAS28-ESR<3.2 on ≤2 visits during this period 
was allowed). Overall, 265/317 (84%) patients achieved sustained remission; significantly 
more patients achieved sustained remission on their initial DMARD regimen in the 
tocilizumab arms (relative risk (RR) 2.00, 95% CI 1.59 – 2.51, P<0.0001 for TOC+MTX vs, 
MTX+PBO; RR 1.86, 1.48 – 2.32, p<0.0001 for TOC+PBO vs. MTX+PBO). Patients who 
achieved sustained remission had gradual tapering of their DMARDs to eventual cessation if 
remission maintained, with 77/265 (29%) achieving DFR for ≥ 12 weeks. In a post-hoc 
analysis, the proportion of patients achieving DFR was significantly greater in those who 
initially received tocilizumab: 37/106 (35%), 28/103 (27%) and 12/108 (11%) patients 
achieved DFR in the MTX+TOC, TOC+PBO and MTX+PBO arms respectively (p<0.0001 
for TOC+MTX vs. MTX+PBO, and p=0.0037 for TOC+PBO vs. MTX+PBO). This study 
therefore suggests that early initiation of biologic therapy in a step-down treatment paradigm 
may be beneficial in facilitating future drug-free remission. Although the minimum duration 
of sustained DFR defined in this study was quite short (12 weeks), an observational 3-year 
extension to explore longer-term outcomes is currently in progress (U-Act-After study, 
NCT01918267). 
In a Japanese study, 13 patients with a diagnosis of RA satisfying 2010 ACR/EULAR RA 
classification criteria with a mean symptom duration of 13 weeks were treated with a range of 
non-biologic DMARDs including methotrexate, sulfasalazine, tacrolimus and glucocorticoids 
(Kita et al., 2012). All patients were seropositive for either RhF and/or ACPA, and exhibited 
peri-articular bone oedema on hand MRI. After 1 year of treatment, DMARD therapy was 
stopped in patients who achieved remission, defined as an SDAI ≤ 3.3 and an improvement of 
≥ 66% in bone oedema on MRI. Five patients discontinued DMARD therapy, of which three 
maintained DFR at 12 months – one patient restarted DMARD therapy after arthritis flare and 
one patient was lost to follow-up. No worsening of bone marrow oedema was observed in the 
three patients who maintained DFR.  
In the IMPROVED study (Heimans et al., 2016), 479 patients with RA and 122 patients with 
undifferentiated inflammatory arthritis (UA) (overall median symptom duration of 18 weeks) 
were treated with methotrexate and prednisolone. Patients in early remission (DAS < 1.6) at 4 
months tapered prednisolone and DMARDs to cessation whilst remission was maintained. 
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Those who did not achieve remission at four months were randomised to methotrexate plus 
adalimumab or triple therapy (methotrexate, hydroxychloroquine, sulfasalazine and low dose 
prednisolone). DMARDs were tapered and stopped in the randomisation arms if remission 
was achieved. At 2 years after enrolment, significantly more UA patients achieved drug-free 
remission compared to RA patients (41/112 (34%) of UA patients vs. 89/479 (19%) of RA 
patients, p<0.001). Furthermore, those patients who achieved early remission on methotrexate 
monotherapy were significantly more likely to achieve drug-free remission that those who 
required combination DMARDs (111/387 (29%) in early remission vs. 13/161 (8%) in 
combination DMARD arms achieved drug-free remission after 2 years, p value not stated in 
paper), though further analysis of RA vs. UA patients in this subset was not provided. 
In the PROMPT study (van Aken et al., 2014), 110 patients were recruited with ‘UA’, defined 
as fulfilment of the 1958 ACR classification criteria for probable RA (Ropes et al., 1958) and 
the absence of fulfilment of the 1987 ACR RA diagnostic criteria. Patients were randomised 
to receive methotrexate or placebo, with the aim of identifying whether methotrexate could 
prevent progression of UA to RA. After 12 months, methotrexate was withdrawn in those 
patients who had not developed RA according to the 1987 criteria. In retrospect however, 
many of the patients recruited were found to fulfil the subsequently published 2010 
ACR/EULAR RA diagnostic criteria, and hence this study provides some data concerning the 
efficacy and withdrawal of methotrexate in very early RA. Of the 110 patients recruited, 43 
satisfied 2010 ACR/EULAR RA diagnostic criteria at baseline, of which 5/19 (26%) and 6/24 
(25%) achieved DFR (DAS≤1.6) after 5 years follow-up in the methotrexate and placebo 
arms respectively. Due to the design of the study, methotrexate was not withdrawn in those 
patients who satisfied 1987 RA diagnostic criteria even if remission had been achieved; DFR 
rates may thus have been higher than that observed if drug tapering had also been employed 
in this group. Nevertheless, the comparable rates of DFR in methotrexate vs. placebo arms 
suggest that a substantial proportion of patients with early disease who satisfy 2010 
ACR/EULAR RA diagnostic criteria can experience spontaneous remission. The authors 
propose that this may represent the natural history of early RA, or perhaps reflect a lack of 
specificity in the diagnostic criteria (van Aken et al., 2014). 
The large multinational placebo-controlled AVERT study has explored the use of abatacept to 
induce drug-free remission in very early RA (Emery et al., 2015). In this study, 351 patients 
with RA of mean symptom duration 0.56 years were randomised to receive abatacept plus 
methotrexate, abatacept monotherapy or methotrexate monotherapy. Glucocorticoids were 
permitted in the first year. Drug therapy was withdrawn after 12 months in the 223 patients 
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who achieved a good response (DAS28-CRP<3.2). Of the 176 patients who had a DAS28-
CRP < 2.6 at DMARD withdrawal, remission was sustained for 6 months in 18/73 (25%), 
14/50 (28%) and 9/53 (17%) of patients in the abatacept plus methotrexate, abatacept 
monotherapy and methotrexate monotherapy arms respectively, although the statistical 
significance of the differences between treatment arms in this sub-analysis was not presented. 
Furthermore, no significant increase in bone marrow oedema, synovitis or erosions on 
unilateral hand and wrist MRI were observed in a post-hoc analysis of those patients who 
remained in remission following DMARD cessation (Peterfy et al., 2016). 
 
1.6.2 What are the benefits and risks of DMARD withdrawal? 
Tapering and withdrawal of DMARDs in RA remission clearly has the potential to afford 
many benefits, for both individual patients and the wider healthcare system. One obvious 
benefit is a reduced risk of medication-related adverse effects, which range from relatively 
trivial (though nevertheless intrusive) reversible side effects such as nausea to potentially life-
threatening serious effects such as irreversible organ damage. Whereas some of these serious 
adverse effects are idiosyncratic such as methotrexate-induced pneumonitis (Saravanan and 
Kelly, 2004), some exhibit a dose-response relationship such as the correlation between 
lifetime methotrexate exposure and liver toxicity (Whiting-O'Keefe et al., 1991). It is thus 
apparent that a sustained period without DMARD therapy, even if ultimately this therapy is 
restarted in the future, has the potential to afford long-term benefits. This is analogous to the 
now widely practised concept of drug holidays in bisphosphonate treatment for osteoporosis, 
in order to reduce the risk of medication-induced side effects (Adler et al., 2016). 
One particular adverse effect that is common to all DMARD therapy is an increased risk of 
infection. In a meta-analysis of seven clinical trials (732 patients) of methotrexate vs. placebo 
in RA (Lopez-Olivo et al., 2014), infection was more likely in those patients who received 
methotrexate (RR 1.3, 95% CI 1.0 – 1.6). Infection risk is generally greater with bDMARDs 
compared to their synthetic counterparts; a recent systematic review including 15 clinical 
trials demonstrated hazard ratios ranging from 1.0 to 1.8 for serious infections in bDMARD 
vs. csDMARD groups (Ramiro et al., 2017). Although population-level risks of infection 
usually drop with increasing duration of DMARD therapy owing to healthy survivor bias (i.e. 
early drop-out of those susceptible to infection) (Fautrel and den Broeder, 2015), it is still 
conceivable that infections could be reduced by DMARD tapering in those established on 
therapy. However, this theory is yet to be tested in a prospective trial setting, 
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In addition to reducing the risk of medication side effects, DMARD withdrawal may also 
afford economic benefits by reducing the financial costs of unnecessary treatment. This is 
particularly notable for bDMARDs, whose cost often runs in to tens of thousands of pounds 
per year per patient. Even a partial reduction in bDMARD dose can lead to considerable 
savings, as has recently been demonstrated by the DRESS study (van Herwaarden et al., 
2015). In this randomised open-label non-inferiority study, 180 patients treated with 
adalimumab or etanercept were randomised (2:1) to either taper or continue their bDMARD 
therapy. bDMARD tapering was non-inferior to bDMARD continuation, with a mean cost 
saving of €12 280 per patient per year (Kievit et al., 2016). Impact on quality of life was 
minimal, with a substantial saving of €390,493 per quality-adjusted life year (QALY) lost 
(Kievit et al., 2016). 
The medication costs of csDMARDs are substantially lower than bDMARDs, with an 
estimated annual cost of £300 versus £10,000 per patient respectively (National Audit Office, 
2009). Nevertheless, given the relatively high prevalence of RA, csDMARD withdrawal in 
even a fraction of patients could be expected to yield substantial cost savings. For example, in 
the UK an estimated 580,000 adults are living with RA (National Audit Office, 2009); 
csDMARD withdrawal in only 10% could thus be expected to save £1.74 million per year. 
Furthermore, the use of csDMARDs carries further substantial financial costs in terms of the 
monitoring systems that are required for their safe prescription. Potential adverse effects such 
as hepatitis and bone marrow suppression mandate regular blood monitoring at monthly or 
two-monthly intervals for the vast majority of csDMARDs (Ledingham et al., 2017), and is 
estimated to cost the NHS £17 million per year for RA patients alone (National Audit Office, 
2009).  
In addition to the clear benefits of reduced medication-related adverse effects and financial 
savings, it has also been shown that RA patients value several less tangible though 
nevertheless important benefits of DMARD withdrawal. During my previous MRes degree, I 
performed a qualitative study of 13 patients with established RA in clinical remission or low 
disease activity (Baker et al., 2015). Patients considered DMARD withdrawal in the context 
of their normal life, with issues such as the inconvenience of blood monitoring and even the 
physical act of taking medication viewed as significant barriers to a normal lifestyle. To these 
patients, DMARD withdrawal offered a potential mechanism by which to restore a degree of 
normality to their lives, which had otherwise been disrupted by living with a chronic illness 
such as RA (Baker et al., 2015). Similar positive benefits of DMARD withdrawal were also 
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identified in a qualitative study of 20 RA patients, including hope, happiness and relief when 
considering DMARD cessation (Markusse et al., 2014a).  
The obvious disadvantage to DMARD withdrawal is the risk of arthritis flare, which, as 
discussed earlier, lies approximately in the region of 50%. The stochastic nature of RA flare 
creates further uncertainty for any patient considering DMARD withdrawal. Aside from pain 
and stiffness, the onset of flare can also herald a loss of function that can have important 
consequences for the patient. For example, patients vulnerable to loss of function by virtue of 
manual employment or through caring for others are less likely to consider DMARD 
withdrawal (Baker et al., 2015). 
A further concern is that arthritis activity may be subsequently more difficult to control, even 
if DMARD therapy is restarted. Only a handful of studies explore the long-term outcomes of 
patients who flare following DMARD withdrawal, though the small amount of published data 
is largely reassuring.  Studies of complete or partial DMARD withdrawal have demonstrated 
that the vast majority of patients who experienced an arthritis flare regained remission by 6 
months after resumption of their previous DMARD therapy (Table 1.10). A handful of studies 
of partial or complete DMARD withdrawal have also assessed radiographic progression, with 
the majority demonstrating no significant progression of joint erosions in those patients who 
experienced an arthritis flare versus those who remained in sustained remission (Table 1.11). 
It thus appears that swift reintroduction of DMARDs at the point of flare leads to a restoration 
of clinical remission in the majority of patients, with minimal risk of joint damage during the 
flare period – however, evidence from long-term follow-up studies are limited. 
 
1.6.3 What is the optimal strategy for DMARD withdrawal? 
Increasing evidence supports the feasibility and safety of DMARD withdrawal in RA 
remission, and recommendations to support consideration of the approach are included in 
national and international guidelines of RA management (Table 1.12). However, there 
currently remains very little evidence to inform the optimal strategy of DMARD withdrawal, 
not least due to a lack of consistency in DMARD withdrawal strategies employed in the 
published literature. Consequently, current guideline recommendations are based on 
consensus opinion only and largely defer to the discretion of the managing clinician. Indeed, 
where ACR guidelines recommend against complete DMARD cessation in RA remission, it is 
nonetheless acknowledged that this is based on clinical experience alone and that the available 
evidence is of very low quality (Singh et al., 2016). 
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There are a range of possible questions to consider when designing a strategy of DMARD 
withdrawal (Table 1.13), the answers to which remain uncertain. A hierarchy of DMARD 
withdrawal has recently been proposed which recommends initial discontinuation of 
glucocorticoids, followed by bDMARDs and finally csDMARDs (Smolen et al., 2017). This 
recommendation is based on consensus opinion and influenced by long-term medication side-
effect profiles (hence the prioritisation of glucocorticoid withdrawal), the high financial cost 
of biologic agents, and concern surrounding the potential formation of neutralising anti-drug 
antibodies in bDMARD monotherapy. Whether the strategy of initial bDMARD tapering is 
superior to initial csDMARD tapering is the subject of two currently recruiting RCTs: the 
REMINDRA study (NCT02935387), and the TARA study (van der Ven et al., 2014). 
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Table 1.10 – Summary of prospective studies of RA remission incorporating cessation of at least one DMARD and that include data regarding rates of return to 
clinical remission following resumption of DMARDs in those patients who experienced an arthritis flare. Studies highlighted in bold incorporated tapering strategies 
that culminated in complete DMARD cessation in at least one study arm. ABT: abatacept; ADA: adalimumab; CRP: C-reactive protein; ESR: erythrocyte 
sedimentation rate; ETN: etanercept; HCQ: hydroxychloroquine; LDA: low disease activity; MTX: methotrexate; PBO: placebo; SFZ: sulfasalazine; TNF: tumour 
necrosis factor; TOC: tocilizumab. *: exact number restarting ADA not stated in manuscript. Adapted from Kuijper et al. (2015) and Verhoef et al. (2017). 
 
Study Intervention 
Patients restarting 
previous 
DMARDs after 
arthritis flare 
Outcome following DMARD resumption 
Ahern et al. (1984) D-penicillamine 15 13 (87%) regained clinical remission after 4 months 
Brocq et al. (2009) 
TNF-inhibitor discontinuation 
(csDMARDs and 
glucocorticoids<5mg/day 
continued) 
15 All patients regained remission (DAS28-ESR<2.6) within 20 
weeks (mean 5.6 weeks) 
Chatzidionysiou et al. 
(2016) 
ADMIRE study 
ADA cessation (csDMARDs and 
glucocorticoids continued) 9 
9/9 regained remission (DAS28-ESR<2.6) by 1 year after 
enrolment (8/9 within 12 weeks) 
El Miedany et al. (2016) Various biologic and non-biologic DMARDs 79 
All patients regained remission (DAS28-ESR<2.6) within 4 
months. 
Ghiti Moghadam et al. 
(2016) 
POET study 
Randomisation to anti-TNF 
bDMARD continuation or 
discontinuation. (csDMARDs and 
glucocorticoids continued) 
195 
After 6 months: 
132 (68%) regained remission (DAS28-ESR<2.6) after median 14 
weeks 
33 (17%) achieved LDA (2.6≤DAS28-ESR<3.2) after median 12 
weeks 
Inui et al. (2014) 
RESUME study 
ETN discontinuation 
(csDMARDs continued) 13 
All patients regained LDA (DAS28-ESR<3.2) after mean 3.7 
months. 
Klarenbeek et al. 
(2011b) 
BeSt study 
Various biologic and non-
biologic DMARDs 53 
After 6 months: 
39 (74%) regained remission (DAS<1.6) 
11 (21%) achieved LDA (1.6≤DAS≤2.4) 
Kuijper et al. (2016) 
tREACH study 
MTX, SFZ, HCQ, ETN, ADA, 
ABT, glucocorticoids 45 
By Kaplan-Meir analysis: 
65% (95% CI: 50-79%) regained remission after 6 months 
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Table 1.10 (continued) 
Study Intervention 
Patients restarting 
previous 
DMARDs after 
arthritis flare 
Outcome following DMARD resumption 
Nishimoto et al. (2014b) 
RESTORE study TOC 157 
After 3 months: 
139 (89%) regained remission (DAS28-ESR<2.6) 
Smolen et al. (2015) 
CERTAIN study 
Certolizumab pegol cessation 
(csDMARDs and glucocorticoids 
continued) 
10 10/10 (100%) achieved CDAI-defined LDA/remission (CDAI) after 28 weeks 
Tanaka et al. (2015) 
HONOR study ADA cessation (MTX continued) c. 15* 
90% regained LDA (DAS28-ESR<3.2) within 6 months, all 
patients regained LDA by 9 months. 
ten Wolde et al. (1997) Various csDMARDs 51 
After 12 months, by physician global assessment: 
18 (35%) regained clinical remission 
22 (43%) regained mild disease activity 
van Vollenhoven et al. 
(2016) 
DOSERA study 
Randomisation to continue ETN, 
half-dose ETN, or PBO 
(csDMARDs and glucocorticoids 
continued) 
35 
After 35 weeks: 
19/20 (95%) in PBO arm and 13/15 (87%) in half-dose ETN arm 
achieved LDA/remission after median 3.9 and 5.9 weeks 
respectively 
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Table 1.11– Summary of studies of DMARD withdrawal that report rates of radiographic progression in those patients who experienced an arthritis 
flare. Studies highlighted in bold using tapering strategies that culminated in complete DMARD cessation in at least one study arm. ABT: abatacept; 
ADA: adalimumab; CRP: C-reactive protein; DFR: drug-free remission; ESR: erythrocyte sedimentation rate; ETN: etanercept; IFX: infliximab; LDA: 
low disease activity; ΔmTSS: change in modified total Sharp score; MTX: methotrexate; NS: not stated; PBO: placebo. *: DMARD tapering initiated 
in patients with low disease activity rather than remission. *data from exploratory analysis of subset of 115 patients who achieved DMARD-free 
remission. Adapted from Kuijper et al. (2015) and Verhoef et al. (2017). 
 
Study Intervention 
Proportion patients flared after 
DMARD withdrawal 
(flare definition) 
Radiographic progression 
Chatzidionysiou et al. (2016) 
ADMIRE study 
Randomisation to continued 
ADA+MTX (A) or MTX 
monotherapy (B) 
A: 2/16 (13%) 
B: 13/15 (87%) 
No significant progression after 28 
weeks between study arms 
Emery et al. (2014) 
PRIZE study 
Randomisation to continued ETN 
+ MTX (A), PBO + MTX (B) or 
PBO + PBO (C) 
A: 23/63 (37%) 
B: 39/65 (60%) 
C: 50/65 (23%) 
(DAS28-ESR>2.6 at week 24 or 
29) 
No significant progression after 
≤39 weeks (mean ΔmTSS, A: 0.1, 
B: 0, C :0.4. p=0.79, 0.48 & 0.34 
for A vs. B, A vs. C and B vs. C 
respectively) 
Fautrel et al. (2016) 
STRASS study 
Randomisation to continued 
ETN/ADA (A) or progressive 
spacing to eventual discontinuation 
(B) (csDMARDs and 
glucocorticoids condtinued) 
49/64 (77%) 
(DAS28-ESR>2.6) 
No significant progression in A vs. 
B after 18 months (median ΔmTSS 0 
vs. 0, p=0.7) 
Klarenbeek et al. (2011b) 
BeSt study 
Tapering followed by complete 
cessation of DMARDs when 
DAS44<1.6 (various) 
53/115 (46%) ** 
(DAS44≥1.6) 
No significant progression in flare 
vs. DFR groups after 1 year 
(median ΔmTSS 0 vs. 0, p=0.44) 
Smolen et al. (2013) 
PRESERVE study 
Randomisation to continued ETN 
(A), 50% dose ETN (B) or placebo 
(C) (MTX continued) 
190 
(DAS28-ESR>3.2) 
Minimal but statistically significant 
progression in C vs. A after 1 year 
(ΔmTSS 0.6 vs. -0.06, p=0.03) 
Smolen et al. (2014) 
OPTIMA study 
Randomisation to continued ADA 
(A) or placebo (B) 
(MTX continued) 
28 
(DAS28-CRP≥3.2) 
Non-significant trend towards 
progression in B vs. A after 18 
months (ΔmTSS ≥0.5: 89% vs. 81%, 
p=0.06) 
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Table 1.11 (continued) 
Study Intervention 
Proportion patients flared after 
DMARD withdrawal 
(flare definition) 
Radiographic progression 
Takeuchi et al. (2015) 
Non-randomised withdrawal of ABT 
if DAS28-CRP<3.2 (csDMARDs 
and glucocorticoids continued) 
12 
(DAS28-CRP>2.7 at 2 consecutive 
visits) 
No significant progression in ABT 
cessation versus continuation groups 
after 1 year (ΔmTSS 0.80 vs. 0.32, 
p=0.37) 
Tanaka et al. (2010) 
RRR study 
Discontinuation of IFX (MTX & 
glucocorticoids continued) 
56/102 (55%) 
(DAS28-ESR≥3.2) 
No significant progression in flare 
vs. sustained LDA after 1 year 
(median ΔmTSS 1.5 vs. 0, p=0.11) 
Tanaka et al. (2015) 
HONOR study 
Discontinuation of ADA 
(csDMARDs & glucocorticoids 
continued) 
20/52 (38%) 
(DAS28-ESR≥3.2 at 1 year) 
Statistically significant progression 
in both LDA and flare patients at 1 
year (mean ΔmTSS 0.59, [p=0.02] 
and 1.59 [p=0.04] in remission vs 
flare respectively) 
van Herwaarden et al. (2015) 
DRESS study 
Randomisation to continued 
ADA/ETN (A) or progressive 
spacing to eventual discontinuation 
(B) (csDMARDs and 
glucocorticoids continued) 
14/119 (12%) 
(rise in DAS28-CRP>1.2, or rise 
>0.6 and DAS28-CRP≥3.2) 
Minimal but statistically significant 
progression in A vs. B after 18 
months (mean ΔmTSS 0.75 vs. 0.15, 
p<0.05) 
Yamanaka et al. (2016) 
ENCOURAGE study 
Randomisation to ETN continuation 
(A) or ETN discontinuation (B) 
(csDMARDs +/- glucocorticoids 
continued) 
A: 4/32 (13%) 
B: 13/28 (46%)  
(DAS28-ESR≥2.6) 
No significant progression in A vs. 
B after 1 year (mean ΔmTSS 0.3 vs. 
0.7, p>0.05) 
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Table 1.12 – Recommendations regarding DMARD withdrawal in current national and international RA clinical management guidelines. 
Organisation Year Recommendation 
National Institute for Health and Care Excellence 
(National Institute for Health and Care Excellence, 
2009) 
2009 
(updated 
2015) 
“In people with established RA whose disease is stable, cautiously reduce dosages of 
disease-modifying or biological drugs. Return promptly to disease-controlling dosages 
at the first sign of a flare.” 
Scottish Intercollegiate Guidelines Network 
(Scottish Intercollegiate Guidelines Network, 2011) 2011 
“Where parallel or step-down strategies are employed, DMARDs should be carefully 
and slowly withdrawn in patients who are in remission.” 
European League Against Rheumatism 
(Smolen et al., 2017) 2016 
“If a patient is in persistent remission after having tapered GC, one can consider 
tapering bDMARDs, especially if this treatment is combined with a csDMARD.” 
“If a patient is in persistent remission, tapering the csDMARD could be considered.” 
American College of Rheumatology 
(Singh et al., 2016) 2015 
“If the patient is in remission: taper DMARD therapy, taper TNFi, non-TNF biologic, 
or tofacitinib” 
“If the patient’s disease is in remission, do not discontinue all RA therapies” 
Canadian Rheumatology Association 
(Bykerk et al., 2012) 2011 
“If a patient achieves sustained remission after discontinuation of NSAID and 
glucocorticoids, a reduction in traditional and biologic DMARD can be attempted with 
caution as a shared decision between the patient and physician.” 
Table 1.13 – Summary of the key considerations when designing a strategy of DMARD withdrawal. 
Consideration Issues 
Eligibility criteria for withdrawal 
Which clinical remission criteria to use? 
How long should a patient be in remission before attempting DMARD withdrawal? 
Should imaging measures of synovitis be included? 
Are there any biomarkers that can stratify patients by risk of arthritis flare? 
Hierarchal order of withdrawal In what order should combination DMARD therapy be withdrawn? 
Rate of withdrawal Should DMARDs be stopped abruptly or gradually tapered? If gradually tapered, what is the optimum speed of DMARD withdrawal? 
Monitoring during withdrawal period 
How frequently should patients be monitored during DMARD withdrawal? 
What form should such monitoring take? (e.g. patient-reported measures, clinician assessment, blood 
sampling, musculoskeletal imaging) 
Criteria for DMARD resumption Given the unpredictable nature of RA disease activity and its imprecise measurement, how tolerant should the clinician be to small increases in disease activity during and after the withdrawal period? 
  
72 
 
1.6.4 Summary 
 
Evidence from observational cohorts and interventional trials suggest that DFR can be 
achieved in approximately 10 to 25% of all patients with RA. The majority of studies to-date 
have recruited patients with active disease at baseline, and hence the overall prevalence of 
DFR in these studies is a function of both the induction of remission and, if remission is 
achieved, the maintenance of remission after DMARD withdrawal. When focussing 
exclusively on those patients who have already achieved remission with DMARD therapy, 
limited data suggest that up to half may maintain this state for at least one year after drug 
cessation. It appears that those patients who experience an arthritis flare do not display 
significant radiological progression and generally have an excellent response to 
recommencement of DMARD therapy if required, although long-term follow-up data is 
limited. Rates of arthritis flare may be greater upon biologic DMARD cessation compared 
with non-biologic DMARDs, although higher drug-free remission rates may be achieved with 
the use of DMARDs at an early disease stage. Nevertheless, comparison between studies is 
very difficult owing to a wide array of different DMARD regimens, inconsistent definitions of 
remission and different protocols of DMARD withdrawal. 
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1.7 Predicting drug-free remission in RA 
The proportion of patients who can both achieve and maintain DFR is small, and the risk of 
arthritis flare following DMARD withdrawal is considerable. This has led some authors to 
recommend against the cessation of DMARDs in RA remission (O'Mahony et al., 2010). 
Such recommendations may be sagacious when applied to whole populations, but neglect the 
compelling evidence that some individual patients are able to achieve sustained DFR. Indeed, 
reliable biomarkers that are able to predict DFR at an individual patient level would 
revolutionise the approach to step-down therapy in RA (Isaacs, 2010). Such biomarkers 
would ideally need to be measurable before the cessation of DMARD therapy to be a useful 
and effective guide to treatment in the clinic. 
In this section, I will summarise the current available evidence for biomarkers of DFR in 
studies of DMARD withdrawal. For simplicity, discussion is divided between clinical, 
imaging and laboratory biomarkers – however, in practice, these categories are unlikely to be 
mutually exclusive and considerable interaction between individual parameters is to be 
expected. Finally, I will explore the potential immunological mechanisms that may be 
permissive of DFR, and the extent to which this may inform the search for biomarkers to 
measure such processes. 
 
1.7.1 Clinical biomarkers of DFR 
Several recurring themes are emerging from studies of DMARD withdrawal that point 
towards clinical characteristics that may be helpful in predicting DFR (Table 1.14). In the 
previously mentioned observational study of ERAS and LEAC cohorts (van der Woude et al., 
2009), a multivariate Cox-regression analysis identified several baseline clinical factors that 
were independently associated with DFR. Many of these factors, although statistically 
significant, carried little predictive value. However, four factors were strongly associated with 
reduced levels of DFR: RhF positivity, the presence of ACPA, HLA-SE positivity and a 
protracted symptom onset (van der Woude et al., 2009). 
The rapidity and intensity of initial DMARD therapy is also likely to be an important factor 
influencing the likelihood of a patient achieving DFR. Evidence to suggest this comes from a 
later analysis of the LEAC cohort in which DFR rates were compared between patients 
treated in different decades in a Cox-regression model adjusted for baseline swollen joint 
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Table 1.14 – Baseline biomarkers predictive of flare or drug-free remission in studies of complete or partial DMARD withdrawal in RA remission. Studies 
highlighted in bold using tapering strategies that culminated in complete DMARD cessation in at least one study arm. See text and Table 1.9 for further details 
regarding study design. ACPA, anti-citrullinated peptide antibody; GS: greyscale; HAQ, Health Assessment Questionnaire; HLA, human leukocyte antigen; HR, 
hazard ratio; MTX, methotrexate; OR, odds ratio; PCS, prospective cohort study; PD: power Doppler; RAI, Ritchie articular index; RCT, randomised controlled 
trial; RhF, rheumatoid factor; RR, relative risk; SFZ, sulfasalazine. mTSS: modified total Sharp score. *: effect size not stated in manuscript. 
 
Study Type Baseline predictors of flare after DMARD withdrawal Effect in multivariate analysis (95% CI) 
El Miedany et al. (2016) Egyptian RCT 157 patients ACPA+ ORflare 5.35 – 8.64 (dependent on study arm) 
Fautrel et al. (2016) 
STRASS study 
French RCT 
137 patients 
Baseline HAQ 
RhF+ 
HRflare 2.07 (1.23 – 3.49) 
HRflare 1.99 (1.03 – 3.83) 
Ghiti Moghadam et al. (2016) 
POET study 
Dutch RCT 
817 patients 
Baseline DAS28 
Disease duration > 10 years 
GS>1 and/or PDS>0 on ultrasound 
HRflare 1.39 (1.21 – 1.60) 
HRflare 1.29 (1.03 – 1.61) 
HRflare 1.69 (1.11 – 2.53) 
Haschka et al. (2016) 
RETRO study 
German RCT 
110 patients ACPA + ORflare 5.2 (1.1-24.9, p=0.038) 
Iwamoto et al. (2014) Japanese PCS 
42 patients 
Total ultrasound GS score 
Total ultrasound PDS score 
p = 0.005* (univariate) 
p = 0.002* (univariate) 
(Kawashiri et al., 2017) 
Japanese retrospective 
cohort 
40 patients 
Joint erosions on ultrasound ORflare 8.35 (1.78 – 53.2, p=0.006) 
Klarenbeek et al. (2011b) 
BeSt study 
Dutch RCT 
508 patients 
ACPA+ 
High mean DAS-44 prior to 
remission 
Baseline HAQ 
SFZ vs. MTX as last DMARD 
ORflare 7.5 (2.9-19.4) 
ORflare 4.7 (1.5-15.2) 
ORflare 0.41 (0.19-0.88) 
ORflare 3.5 (1.5-15.2) 
Kuijper et al. (2016) 
tREACH study 
Dutch RCT 
281 patients 
Female sex 
Paid employment 
Baseline DAS-44 
ORremission 0.352 (p=0.01) 
ORremission 0.404 (p=0.03) 
ORremission 0.0587 (p=0.022) 
Naredo et al. (2015) Spanish PCS 77 patients Total ultrasound PDS score ORflare 29.92 (6.81 – 131.40, p < 0.0005) 
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Table 1.14 (continued) 
Study Type Baseline predictors of flare after DMARD withdrawal Effect in multivariate analysis (95% CI) 
Tanaka et al. (2010) 
RRR study 
Japanese RCT 
114 patients 
Disease duration 
RhF titre 
p = 0.0019* 
p = 0.0128* 
Tanaka et al. (2015) 
HONOR study 
Japanese RCT 
75 patients 
Baseline DAS28-4ESR 
 ORremission 0.143 (0.029 –  0.143, p = 0.0174) 
ten Wolde et al. (1996) 
Dutch RCT 
285 patients 
RhF+ 
High DMARD dose 
Painless swollen joints 
RRflare 1.9 (1.0-3.6) 
RRflare 2.3 (1.3-4.2) 
RRflare 1.8 (1.0-3.3) 
van der Woude et al. (2009) 
Observational 
 
Dutch LEAC cohort 
(454 patients) 
 
British ERAS cohort 
(895 patients) 
LEAC cohort: 
ACPA+ 
 
ERAS cohort: 
Long symptom duration (months) 
Acute onset (protective against flare) 
High RAI score 
High modified HAQ score 
RhF+ 
HLA-SE+ 
 
HRremission 0.09 (0.04-0.20, p<0.001) 
 
 
HRremission 0.94 (0.89-0.99, p=0.029) 
HRremission 2.03 (1.15-3.59, p=0.015) 
HRremission 0.92 (0.88-0.97, p=0.001) 
HRremission 0.66 (0.44-0.99, p=0.044) 
HRremission 0.28 (0.16-0.49, p<0.001) 
HRremission 0.44 (0.26-0.73, P=0.002) 
van Vollenhoven et al. (2016) 
DOSERA study 
Swedish RCT 
73 patients 
Patient pain VAS 
mTSS radiographic erosion score 
ORflare 1.08 (1.01 – 1.15, p=0.018) 
ORflare 1.05 (1.02 – 1.09, p = 0.005) 
Yamanaka et al. (2016) 
ENCOURAGE study 
Japanese RCT 
222 patients Lower baseline SDAI p = 0.015* 
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count, inflammatory markers and autoantibody status. In this analysis, rates of DFR were 
significantly greater in those patients who received target-driven intensive DMARD therapy 
versus initial low-dose DMARD monotherapy (HR for DFR 3.72 [95% CI: 1.60 to 8.62] 
versus 1.13 [0.48 to 2.64], p < 0.001) (Ajeganova et al., 2016). Nevertheless, part of this 
difference may be attributable to the increased availability of newer DMARDs and biologic 
agents in the intensive DMARD group.  
Only a handful of interventional studies of DMARD cessation have investigated predictors of 
DFR, and mainly as exploratory post-hoc analyses (Table 1.14). High DMARD dose, high 
mean DAS and greater disability scores prior to remission were predictive of flare upon 
DMARD-withdrawal (Klarenbeek et al., 2011b), suggesting that patients with historically 
active disease are less likely to remain in remission following DMARD cessation. This is 
perhaps unsurprising given the well-established correlation between early disease activity and 
long-term outcomes. This is further supported by exploratory analyses of several studies that 
suggest at least a trend towards higher rates of sustained DFR with earlier instigation of 
biologic therapy, including tocilizumab (Bijlsma et al., 2016), etanercept (Emery et al., 2014) 
and abatacept (Emery et al., 2015). 
 
1.7.2 Imaging biomarkers of sustained remission 
Musculoskeletal imaging, in particular musculoskeletal US, may be another potentially useful 
biomarker in predicting DFR. As has already been discussed, there is now increasing evidence 
to show that the presence of PD in patients in remission on DMARD therapy can predict 
future radiographic erosions and arthritis flare (see Introduction 1.5.2.b-c). Nevertheless, there 
remains a paucity of evidence as to whether the absence of imaging measures of subclinical 
synovitis offers a more favourable prognosis to those patients in remission wishing to 
withdraw from DMARD therapy. 
Only a single published study exists that explores the value of ultrasound parameters in 
predicting arthritis flare following complete DMARD cessation. In this rather complex study, 
157 patients with RA in remission (DAS28-ESR < 2.6) were randomised to one of 5 arms, 
including: treatment continuation; 50% bDMARD dose; 50% bDMARD and 50% 
csDMARD; bDMARD cessation and 50% csDMARDs; and cessation of both bDMARDs and 
csDMARDs (El Miedany et al., 2016). No significant difference was found between those 
who remained in remission and those who experienced an arthritis flare in relation to either 
PD or GS in 40 joints at baseline, either across the study as a whole or in individual treatment 
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arms. No data was presented regarding the predictive utility of ultrasound-detected erosions in 
this study (El Miedany et al., 2016). 
Several studies have explored the role of ultrasound in predicting which patients with RA in 
remission can safely taper or stop bDMARDs. Baseline csDMARDs were invariably 
continued in these studies and hence they address a different scenario to complete DMARD 
cessation; nevertheless, such studies can still offer insights in to the role of ultrasound in the 
measurement of subclinical synovitis in RA remission. In a recent Japanese study (Iwamoto et 
al., 2014), 42 patients with established RA of mean 8.2 years duration and a DAS28-ESR < 
2.6 were withdrawn from various different biologic therapies. The doses of concurrent non-
biological DMARDs including low-dose oral corticosteroids were not changed. After 6 
months, 23 (55%) patients remained in remission; the levels of both PD and GS synovitis in 
40 joints at baseline were significantly lower in the sustained remission group versus those 
whose arthritis flared. GS and PD synovitis were strongly correlated, though a multivariate 
analysis to identify their individual association with sustained remission was not possible in 
this small study (Iwamoto et al., 2014). 
In a similar study (Naredo et al., 2015), 77 patients with established RA of mean 13.1 years 
duration and DAS28-ESR < 2.6 underwent tapering (though not complete withdrawal) of 
biologic therapy. Synthetic DMARDs and low-dose prednisolone (≤5mg/day) were permitted 
and not changed during the study. Arthritis flare occurred in 35 (45%) of patients, and 
multivariate analysis showed that the presence of PD was independently associated with risk 
of flare (OR 29.92, 95% CI 6.81 – 131.4, p<0.0005). 
In the POET study (Ghiti Moghadam et al., 2016), 871 patients with established RA in low 
disease activity (DAS28-ESR<3.2) and receiving anti-TNFα agents for ≥1 year were 
randomised 2:1 to stop or continue their biologic therapy. A 20-joint US scan was performed 
at baseline, with a positive scan defined as GS>1 and/or PD>0 at any joint; flare of arthritis 
was defined as DAS28>3.2 and >0.6 greater than at baseline. An interim analysis of 12-month 
follow-up data in 251 patients who stopped biologic therapy showed a statistically significant 
though modest association between a positive US scan and arthritis flare after biologic 
withdrawal (HR 1.69, 95% CI 1.11 – 2.53, p<0.05) (Lamers-Karnebeek et al., 2016). 
Although it could be expected that PD may outperform GS in this setting, an analysis of the 
predictive value of PD independent of GS was not presented in this preliminary report. 
In contrast, a study of anti-TNF withdrawal in 47 patients with established RA in DAS28-
ESR remission found no significant correlation between baseline levels of PD or GS synovitis 
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and arthritis flare at 2 years of follow-up (Saleem et al., 2010). Of note, this study used a 
limited US assessment of 11 joints in the dominant hand and wrist compared with the studies 
by Iwamoto et al. (2014) and Naredo et al. (2015). 
Whereas a signal of increased flare following DMARD withdrawal is starting to emerge for 
PD, the prognostic value of GS is far more uncertain. In a study by Alivernini et al. (2016), 42 
patients with established RA (mean 10.9 years duration) in sustained clinical remission 
(DAS<1.6 on 3 visits over 9 months) and no PD on a 16-joint US scan had tapering and 
withdrawal of TNFα inhibitors. Twenty-nine patients completely stopped their biologic, of 
which 16 experienced a flare (defined as rise in DAS >1.2). Baseline mean synovial thickness 
was significantly greater at the 2nd and 5th metatarsophalangeal joints in those patients who 
subsequently flared, though the absolute differences were small (<0.3mm) between groups in 
this univariate analysis without multiple test correction (Alivernini et al., 2016). 
In an observational study, Kawashiri et al. (2017) followed 40 patients in low disease activity 
(DAS28-ESR<3.2) with a total PD score ≤ 1 on 22 joint-scan who discontinued bDMARD 
therapy. No significant association between baseline GS and arthritis flare was observed, 
although the presence of ultrasound-detected erosions was a significant poor prognostic 
marker (ORflare 8.35, 95% CI 1.78-53.2, p = 0.006). This is in keeping with the results of the 
DOSERA study (van Vollenhoven et al., 2016), which found a statistically significant though 
modest association between baseline modified total Sharp radiographic erosion score (mTSS) 
and arthritis flare following dose reduction and cessation of etanercept (ORflare 1.05, 95% CI 
1.02 – 1.09, p=0.005). 
Given the high sensitivity of MRI in the detection of subclinical synovitis and bone marrow 
oedema, this imaging modality has the potential to be a useful prognostic tool in the setting of 
DMARD withdrawal – however, this remains a largely under-researched area. This was 
explored in a sub-analysis of 55 patients in the RETRO study (dOliveira et al., 2016); despite 
MRI abnormalities in over half of patients, baseline MRI scores did not significantly differ 
between groups (median RAMRIS score 9 vs. 8 in flare vs. remission groups respectively, 
p=0.27). 
In summary, current evidence suggests that the presence of ultrasound-detected PD is likely to 
portend a greater risk of flare following predominantly biologic DMARD cessation. In 
contrast, there is insufficient evidence to assess the prognostic value of GS in this setting. In 
particular, a lack of consensus on fundamental parameters such as the number of joints to scan 
and thresholds of GS and PD consistent with remission, results in considerable differences in 
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ultrasound methodology making comparison between studies difficult. MRI does not suffer 
from the same methodological uncertainties as US, though limited data suggest that its 
prognostic value in the setting of DMARD withdrawal may be limited. More research in this 
area is needed before firm conclusions can be drawn as to the optimal use of US in guiding 
DMARD withdrawal (D'Agostino et al., 2016b). 
 
1.7.3 Laboratory biomarkers of DFR 
As noted above, seropositivity for either RhF or ACPA was associated with lower rates of 
DFR in several studies (Table 1.13), mirroring data from observational cohorts. In particular, 
the aforementioned RETRO study is notable for its detailed analysis of serological predictors 
of DFR. In this study, ACPA positivity was significantly associated with risk of arthritis flare 
following DMARD withdrawal (ORflare 5.2, 95% CI 1.1-24.9, p=0.038). Further testing for 
autoantibodies against a panel of 10 different citrullinated, carbamylated and acetylated 
proteins demonstrated a significant increase in risk of flare with increasing numbers of 
autoantibodies (18%, 34% and 55% risk of flare with 0-1, 2-5 and >5 autoantibodies 
respectively, p=0.011) (Figueiredo et al., 2017). The authors suggest that a broader specificity 
of autoantibodies may reflect a greater dysregulation of the immune system, which could 
explain the greater risk of flare observed in these patients (Figueiredo et al., 2017). 
Levels of circulating pro-inflammatory cytokines may also play a role in predicting which 
patients can successfully achieve DFR – one commercially available method of measuring 
such cytokines is the MBDA assay (see Introduction 1.4.5). In the RETRO study, MBDA 
score was an independent predictor of flare following DMARD withdrawal (OR 8.5, 95% CI 
2.0-36.4, p=0.004) (Rech et al., 2016). Furthermore, MBDA score interacted with the 
presence of ACPA to predict flare following DMARD withdrawal (MBDA-/ACPA-: 13%, 
MBDA-/ACPA+: 32%, MBDA+/ACPA-: 33%, MBDA+/ACPA+: 76% risk of flare, 
p=0.0001 for double negative vs. double positive) (Rech et al., 2016). These results therefore 
suggest the presence of subclinical inflammation in some patients, which may drive arthritis 
relapse upon DMARD withdrawal. This concept is further supported by the DREAM study 
(Nishimoto et al., 2014a), in which low levels of serum IL-6 prior to withdrawal of 
tocilizumab were predictive of DFR – though this may simply be a surrogate marker of 
efficacy of this anti-IL-6 biologic agent. 
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Combining clinical, imaging and laboratory biomarkers of remission across a variety of 
disparate studies is challenging. A recent attempt to synthesise biomarkers of successful 
bDMARD tapering and withdrawal was complicated by extensive heterogeneity between 
different studies (Tweehuysen et al., 2017). Although a meta-analysis was not possible, a 
systematic review and qualitative analysis was performed including results from 15 
independent patient cohorts. 17 and 33 biomarkers were included in the settings of bDMARD 
tapering and cessation respectively. However, only three biomarkers were identified as 
consistent predictors of sustained remission, namely: high adalimumab trough level, low 
baseline mTSS score and short symptom duration. In particular, the authors commented that 
reporting bias in the studies was a major limitation in confidently excluding non-predictive 
biomarkers in the final analysis (Tweehuysen et al., 2017). 
 
1.7.4 What are the biological mechanisms permissive for DMARD-free remission? 
The state of DMARD-free remission may reflect distinct immunological phenotypes. One 
possibility is that DMARD-free remission represents the natural progression of RA in certain 
individuals, with a “burn-out” of active inflammation secondary to a loss of inflammatory 
drive. The observation that the rates of DMARD-free remission remain relatively constant 
across different DMARD regimes has been cited by some authors as anecdotal evidence to 
support the hypothesis that DMARD-free remission is a part of the natural history of RA 
(Scott et al., 2013a). If this is the case, then the state of DMARD-free remission may 
permitted by a lack of pro-inflammatory mediators. Evidence that potentially supports this 
view lies with the so-called “inflammation-related cell” (IRC) – a hyper-responsive subset of 
CD4+ T cells (CD45RBhighCD45RA+CD45ROlowCD62L- ) that are postulated to contribute to 
a systemic chronic inflammatory state, and have been observed in both RA (Ponchel et al., 
2002) and ACPA+ ‘pre-RA’ individuals (Hunt et al., 2016). It has been shown that lower 
levels of circulating IRCs correlates with lower risk of flare in patients with RA in remission 
receiving DMARD therapy (Burgoyne et al., 2008) and also with lower risk of flare upon 
withdrawal of anti-TNF treatment (Saleem et al., 2010). Nevertheless, these observations 
remain to be confirmed in the setting of DMARD-free remission and by independent research 
groups. 
An alternative hypothesis is that patients who achieve DMARD-free remission do so by virtue 
of an active pro-tolerogenic mechanism that shifts the immune system balance from 
autoimmunity back to self-tolerance. If this is the case, then elucidation of this mechanism 
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could provide novel insights in to potential new avenues of therapy for RA. Indeed, evidence 
does exist to support a dysregulation of regulatory T cell populations in RA, which may 
contribute to the pathogenesis and perpetuation of the disease (Sempere-Ortells et al., 2009). 
Furthermore, the number of circulating Tregs (defined as CD4+CD25highCD127low/-) have been 
shown to be low in patients with active RA compared to healthy controls, whereas Treg 
numbers in patients in clinical remission are comparable to that observed in healthy 
individuals (Kawashiri et al., 2011). Similarly, the number of Tregs (defined as 
CD4+CD25highFoxP3+CD62L+) were increased in patients able to achieve sustained remission 
following anti-TNF withdrawal (Saleem et al., 2010). However, Tregs are notoriously difficult 
to distinguish from activated T cells without functional assays to confirm a regulatory 
phenotype, and the observed correlations with remission do not prove a causal link with 
disease pathogenesis. Nevertheless, such observations do provide some evidence to suggest 
that active pro-tolerogenic mechanisms such as Tregs may play a role in the maintenance of 
DMARD-free remission. 
Valuable insights in to the mechanisms permissive for DMARD-free remission may also be 
gained from the study of immunosuppressive drug withdrawal in other conditions. 
Particularly relevant in this regard is the field of solid organ transplantation, where powerful 
immunosuppression is required to prevent allograft rejection. Sometimes this 
immunosuppression is stopped, either because of patient non-concordance or due to a life-
threatening complication such as lymphoproliferative disease. The usual outcome of this is 
allograft rejection, but on rare occasions such patients demonstrate continued graft survival in 
the complete absence of immunosuppression despite a fully functional immune system – a 
phenomenon termed “operational tolerance” (Monaco, 2004). Several international 
collaborative studies have identified peripheral blood gene expression signatures unique to 
operational tolerance in renal (Brouard et al., 2007; Sagoo et al., 2010; Baron et al., 2015) 
and liver (Martinez-Llordella et al., 2008; Li et al., 2012a) transplant recipients. Furthermore, 
a prospective clinical trial of immunosuppressant withdrawal in liver transplant recipients 
with stable allograft function has identified similar gene expression profiles unique to those 
patients who achieve operational tolerance (Bohne et al., 2012). Intriguingly, distinct patterns 
of gene expression are seen in operational tolerance to different organ grafts; a signature 
enriched for B-cell genes is seen in operational tolerance to renal grafts whereas genes 
involved in natural killer cell function and iron homeostasis are seen in tolerant liver 
transplant recipients (Lozano et al., 2011). This raises the possibility of multiple pathways to 
tolerance – in other words, the pathway to immune tolerance may be dictated by the original 
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immunological insult and/or by different mechanisms of immune homeostasis between 
different individuals and disease states (Massart et al., 2017). 
 
1.7.5 Summary 
Unequivocal evidence demonstrates that DMARD-free remission in RA can be achieved, 
albeit in a small proportion of patients. Historically, the number of patients achieving disease 
remission was so small that the possibility of DMARD withdrawal was rarely encountered. 
However, an increasing proportion of patients are now able to achieve sustained remission 
with early DMARD initiation in modern treat-to-target regimens. Therefore, the conundrum 
of how to balance risks versus benefits of continued DMARD therapy versus medication 
withdrawal in such cases is increasingly encountered in clinical practice. Biomarkers that are 
predictive of sustained DMARD-free remission are crucial to guide effective step-down 
therapy, although very few studies have explored this area and fewer still investigate DFR as 
a primary outcome. Furthermore, the vast majority focus on bDMARD and neglect 
csDMARD withdrawal, thus disregarding biologic-naïve patients who have successfully 
achieved sustained remission by the treat-to-target paradigm. 
Seropositivity for ACPA or RhF have both consistently been associated with lower rates of 
DMARD-free remission across multiple studies. Other clinical parameters, novel blood-borne 
biomarkers and musculoskeletal imaging may all potentially be useful in guiding DMARD 
withdrawal, although evidence is lacking and where present is often contradictory. DMARD-
free remission may represent a lack of inflammatory drive or the net effect of active pro-
tolerogenic mechanisms, the further characterisation of which may lead to novel avenues of 
future therapy. Further research in this area is urgently needed if the concept of step-down 
DMARD therapy is to become a clinical reality. 
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Chapter 2. Objectives 
 
In the preceding Introduction, I discuss the evidence to support two key assertions, namely: 
1. Approximately half of patients with RA who achieve clinical remission with DMARD 
therapy can expect to achieve sustained drug-free remission (DFR) following DMARD 
withdrawal 
2. There is a lack of reliable biomarkers that, when measured prior to DMARD 
withdrawal, can predict which patients can achieve DFR. 
 
To address this unmet clinical need, the primary objective of this study is: 
Primary Objective: To identify baseline biomarkers prior to DMARD withdrawal that 
are predictive of DFR in RA, including: 
a. Clinical features 
b. Ultrasound features 
c. Differential gene expression in CD4+ T cells isolated from peripheral blood 
by next-generation RNA sequencing 
d. Differential cytokine levels in peripheral blood 
 
In order to satisfy this objective, this study takes the form of a prospective longitudinal 
interventional clinical trial of DMARD withdrawal in patients with RA in clinical and 
ultrasound remission  - the Biomarkers of Remission in Rheumatoid Arthritis (BioRRA) 
Study (defined and justified further in the Methods chapter). In the process of conducting this 
study, I thus also address two secondary objectives: 
Secondary Objective 1: To assess the correlation between ultrasound measures of joint 
inflammation and clinical measures of disease activity in the setting of RA remission 
Secondary Objective 2: To assess the longitudinal changes in circulating 
cytokines/chemokines, and peripheral CD4+ T cell transcriptomic profile, in order to 
gain insight in to the immunological events underlying sustained DFR and RA flare. 
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A specific focus of this project will be the exploration of global gene expression within CD4+ 
T cells as a potential biomarker of DFR. A whole-genome approach was chosen based on the 
aforementioned success of peripheral blood microarray analysis in identifying biomarkers of 
operational tolerance to solid organ grafts (see Introduction 1.7.4). The decision to focus upon 
the transcriptome of CD4+ T cells is based upon the central importance of this cell in both the 
pathogenesis of RA (see Introduction 1.2.3) as well as the potential immunological 
mechanisms underlying sustained remission in the disease (see Introduction 1.7.4). 
Furthermore, by analysing gene expression exclusively within the CD4+ T cell subset I aim to 
minimise non-specific variations in gene expression that could otherwise mask a remission 
biomarker signature in whole blood. Finally, the feasibility of high purity isolation of CD4+ T 
cells from peripheral blood samples and subsequent transcriptomic analysis has been 
demonstrated by previous work in the Newcastle University Musculoskeletal Research 
Group, which has identified the presence of a 12-gene signature in peripheral CD4+ T cells 
that can predict future progression from undifferentiated arthritis to RA (Pratt et al., 2012). 
Nevertheless, it is recognised that by restricting gene analysis solely to the CD4+ T cell subset 
there is a risk that potential biomarkers in other peripheral blood cells may be overlooked. To 
address this, additional samples will also be taken at study visits including whole blood 
samples for potential future transcriptomic analysis and peripheral blood mononuclear cells 
(PBMCs) for potential future flow cytometry analysis. Whilst not necessarily forming part of 
the aims of this study, the collection of these additional samples will provide opportunity for 
alternative future biomarker analyses and hence maximise the yield of data from this unique 
patient cohort. 
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Chapter 3. Methods  
 
In this chapter, I present the methods used during the course of this PhD project. First, I 
summarise the key considerations in the design and conduct of the Biomarkers of Remission 
in Rheumatoid Arthritis (BioRRA) Study, together with the methods of ultrasound 
examination. Amendments to the study design are then discussed and justified. A detailed 
account of the laboratory procedures for sample handling and processing is described, 
followed by the methods of statistical analysis. Finally, the ethical and governance 
arrangements for oversight of the study are presented. 
 
3.1 Inclusion and exclusion criteria 
The inclusion, exclusion and DMARD-cessation criteria for the Biomarkers of Remission in 
Rheumatoid Arthritis (BioRRA) Study are summarised in Table 3.1.  
 
3.1.1 Justification of inclusion criteria 
Patients were only recruited if they had a clinical diagnosis of RA made at least 1 year prior to 
the baseline study visit. A duration of 12 months from diagnosis was mandated to permit a 
degree of certainty on the clinical diagnosis. Furthermore, after consultation with local 
rheumatologists, it was deemed unlikely that DMARD tapering would be considered in 
clinical practice at an earlier time point. The inclusion criteria did not require a formal 
diagnosis of RA according to published diagnostic criteria, because such formal assessment 
on behalf of the referring clinician was considered a possible disincentive to patient referral. 
Furthermore, clinical notes were not available to the research team at the baseline study visit 
for patients referred from centres outside of Newcastle. Thus, medical notes review by the 
research team (for the purposes of diagnostic criteria assessment) prior to study enrolment 
would have posed a substantial barrier to patient recruitment. A pragmatic compromise was 
thus reached whereby patients could only be enrolled to the study if they had a clinical 
diagnosis of RA, with fulfilment of diagnostic criteria assessed retrospectively by the research 
team after study enrolment (see Methods 3.6.3). 
Clearly, it was necessary for patients to be both in clinical remission and willing to 
discontinue DMARD therapy before they could be enrolled in the study. However, it was felt 
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Table 3.1 – Inclusion, exclusion and DMARD cessation criteria for the BioRRA study. 
Patients who met the inclusion and exclusion criteria were enrolled for the baseline visit, but 
only those patients who met the DMARD-cessation criteria stopped DMARDs and continued 
in study follow-up. *: ACR/EULAR Boolean remission was initially used as the clinical 
remission definition, though this was subsequently changed to DAS28-CRP < 2.4 (see 
Methods 3.2). 
Inclusion 
criteria 
1. Clinical diagnosis of rheumatoid arthritis made by consultant 
rheumatologist at least 12 months previously 
2. Current single or combination use of methotrexate, sulfasalazine 
and/or hydroxychloroquine 
3. Arthritis currently in remission, as judged clinically by referring 
healthcare professional 
4. Willing to consider DMARD withdrawal 
Exclusion 
criteria 
1. Use of biologic therapy within the past 6 months 
2. Received steroids within past 3 months (enteral, parenteral or 
intra-articular) 
3. Use of any DMARD other than methotrexate, sulfasalazine or 
hydroxychloroquine within the past 6 months (or past 12 months 
for leflunomide) 
4. Current pregnancy, or pregnancy planned within next 6 months 
5. Current participation within another clinical trial 
6. Inability to provide informed consent 
DMARD-
cessation 
criteria 
1. Clinical remission, defined as DAS28-CRP < 2.4 * 
2. Absence of power Doppler signal on 7-joint ultrasound scan 
 
that mandating a predetermined level of disease activity could have been a disincentive to 
patient referral, and thus judgement on this was deferred to the referring clinician for the 
purposes of study recruitment. 
 
3.1.2 Justification of exclusion criteria 
 
Patients who were receiving or who had recently received biologic therapy were excluded 
from the study for several reasons. First, there was concern that patients who were receiving 
bDMARDs would, by therapeutic indication, have more aggressive underlying disease and 
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thus be at higher risk of arthritis flare following DMARD cessation. Indeed, in comparison to 
csDMARD cessation, substantially higher rates of arthritis flare have been observed in some 
of the published studies of bDMARD withdrawal (see Introduction 1.6). Second, there was 
concern that arthritis flare would be more difficult to control in such patients, owing to both a 
more aggressive underlying disease pathophysiology and the potential for anti-drug antibody 
formation during the DMARD-free period. Third, there was a desire to minimise 
heterogeneity between individual patients at enrolment, and the potent selective nature of 
bDMARDs could have potentially skewed or masked any generic biomarkers of DFR. For 
example, the anti-IL-6R agent tocilizumab could be expected to mask any IL-6-related 
signatures in cytokine measurements and/or CD4+ T cell transcriptional profile, as well as 
potentially influencing disease activity assessment by spurious suppression of CRP levels. 
Fourth, observations from qualitative interviews as part of my MRes project (Baker et al., 
2015) and from patient-public engagement suggested that patients who were currently 
receiving bDMARDs were generally not inclined to consider DMARD withdrawal. Finally, 
regulatory issues surrounding the prescription of bDMARDs in the NHS had the theoretical 
potential to make it difficult to restart bDMARD therapy in those patients who experienced an 
arthritis flare either during or after their participation in the study. 
Only patients receiving methotrexate, sulfasalazine and/or hydroxychloroquine were 
permitted to enter the study, reflecting a balance between reducing baseline patient 
heterogeneity whilst maintaining sufficiently flexible eligibility criteria for the purposes of 
study recruitment. A longer exclusion period applied to previous use of leflunomide, 
reflecting the prolonged half-life of this drug secondary to entero-hepatic recirculation. 
Patients who had received recent systemic glucocorticoids were excluded, as this was felt 
likely to interfere with sensitivity of ultrasound assessment and the detection of a remission 
biomarker signature. Routes of local glucocorticoid delivery – including topical, inhaled and 
intra-nasal – were permitted as the effect on systemic immunity was deemed negligible. 
Patients who were, or were planning to become, pregnant were excluded as it was expected 
that the physiological changes that occur in pregnancy would likely influence any putative 
biomarker signature. Furthermore, the significant effect of pregnancy on RA activity could be 
expected to alter the balance between sustained remission and flare in pregnant participants. 
Participation in another clinical trial was grounds for exclusion from the study on the basis 
that DMARD cessation could potentially influence the outcomes of such studies. 
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3.2 Remission criteria 
In the original BioRRA study design, the 2011 ACR/EULAR remission criteria were used to 
define clinical remission. However, after the first 3 months of recruitment it became apparent 
that several patients recorded visual analogue scores (VAS) of just over 10/100, and were thus 
failing to achieve remission despite the absence of any tender or swollen joints, the absence of 
PD synovitis and undetectable CRP levels. This observation has been replicated by other 
groups, with the suggestion that an overly-strict VAS threshold results in sub-optimal 
specificity of the ACR/EULAR 2011 remission criteria when applied to clinical practice – see 
Introduction 1.5.1 and discussed further by Kuriya et al. (2012); Masri et al. (2012); Studenic 
et al. (2012); Vermeer et al. (2012); Svensson et al. (2013); Thiele et al. (2013); Baker et al. 
(2017). A pragmatic decision was therefore made to change the clinical remission definition 
to the composite scoring system of DAS28-CRP, which is extensively used in current clinical 
practice (Box 3.1). The use of CRP was preferred owing to its greater specificity for 
inflammation than compared with ESR, which can be affected by non-inflammatory factors 
such as age, gender, red blood cell morphology and hyperglobulinaemia (Ward, 2004). A 
threshold of DAS28-CRP < 2.4 was used as the definition of clinical remission – this is lower 
than the remission threshold for DAS28-ESR (<2.6) and is in line with recently published 
data that recommends this lower remission threshold (Fleischmann et al., 2015). Values of 
CRP below the detectable threshold of the local clinical laboratory (<5mg/L) were recorded 
as zero for the purposes of DAS28-CRP calculation. 
Within the design of the study, it was acknowledged that circumstances may arise where 
DAS28-CRP ≥ 2.4 in the absence of active arthritis – for example, during systemic infection 
causing a rise in CRP, or after trauma causing local joint pain/swelling. In these 
circumstances, clinician discretion to overlook a single DAS28-CRP ≥ 2.4 measurement was 
permitted only if there was a clear alternative explanation, with the requirement that a further 
Box 3.1 – The final clinical remission definition used in the BioRRA study. CRP, C-reactive 
protein in mg/L; DAS28, disease activity score in 28 joints; SJC28, swollen joint count in 28 
joints; TJC28, tender joint count in 28 joints; VASpatient, patient visual analogue score in 
millimetres (on 0-100mm scale). 
DAS28-CRP remission 
(Fleischmann et al., 2015) 
[0.56√(TJC28) + 0.28√(SJC28) + 0.36ln(CRP+1) + 
0.014(VASpatient) + 0.96] < 2.4 
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review as performed within the following four weeks. If DAS28-CRP ≥ 2.4 at this subsequent 
visit, then the patient exited the study regardless of whether an alternative explanation was 
present, and was referred back to their rheumatology clinical team for recommencement of 
DMARD therapy. 
 
3.3 Study design and sample size estimation 
The design of the study together with sample size estimations are summarised in Figure 3.1 
Patients who satisfied both DAS28-CRP < 2.4 and an absence of PD signal on ultrasound 
assessment (see Methods 3.6) at the baseline visit were eligible for DMARD cessation. 
Further administrations of methotrexate, sulfasalazine and/or hydroxychloroquine were 
immediately stopped without tapering. Non-DMARDs, including folic acid, remain unaltered 
and non-steroidal anti-inflammatory drug (NSAID) use was permitted. Research blood tests 
including serum, plasma, peripheral blood mononuclear cells (PBMCs), CD4+ T cell isolation 
and whole blood RNA TEMPUS™ tubes (Applied Biosystems, Foster City, California, USA) 
were collected at baseline, month 3 and month 6 following DMARD cessation. An US scan 
was performed again at the month 6 visit. If a patient experienced a flare of their arthritis 
(defined as DAS28 ≥ 2.4) or if they developed PD synovitis on the month 6 scan, then they 
could receive rescue corticosteroids and were discharged from the study with their DMARD 
therapy promptly recommenced by their referring rheumatologist. Those patients who 
remained in remission at 6 months with no PD synovitis were discharged back to their 
referring rheumatologist without DMARD therapy. Patients could request additional 
appointments at any time should they believe their arthritis may be flaring. A schedule of 
events for the study is detailed in Table 3.2. 
The BioRRA study was conducted with the ethos of an exploratory study. Indeed, it was 
impossible to conduct a formal power calculation owing to the complete absence of 
information regarding the nature of a putative gene expression and/or cytokine signature of 
DMARD-free remission. In consultation with local bioinformaticians, and based upon the 
previous demonstration of an ability to detect significant differences in CD4+ gene expression 
at the 1.1 to 1.4-fold level (Pratt et al., 2012), it was estimated that a total of 60 patients would 
be required for transcriptomic analysis. This is based on the assumption of a 50% flare rate 
within 6 months of DMARD cessation (Step C, Figure 1), as was observed in previous studies 
(Klarenbeek et al., 2011b; Haschka et al., 2016).  
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Figure 3.1 – Design of the BioRRA study together with sample size estimations. Figure 
reproduced from the BioRRA study protocol (version 6). CRP, C-reactive protein; DAS, 
disease activity score; DMARD, disease-modifying anti-rheumatic drug; IA, intra-articular; 
IM, intra-muscular. 
 
It was estimated that 110 patients were needed to be recruited to the study in order to achieve 
60 patients stopping DMARD therapy. Of these 110 patients, an estimated 75% were 
expected to have a DAS28-CRP < 2.4 (Step A, Figure 3.1). This was based on data from my 
Newcastle-based MRes project, where 13/17 (76%) of patients referred to the study satisfied 
this criteria (Baker, 2014). Of those patients in clinical remission, an estimated 20% were 
anticipated to display PD signal and hence not be eligible for DMARD withdrawal (Step B, 
Figure 3.1). Finally, a 10% drop-out rate was estimated during the six-month follow-up period 
(Step D, Figure 3.1). 
During the course of conducting the study, it became apparent that no patients were being lost 
to follow-up and that substantially greater proportion of patients satisfied DAS28-CRP 
remission than previously anticipated. The overall recruitment target was therefore reduced 
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Table 3.2 – Schedule of events for the BioRRA study. Patients were able to request an 
additional review at any time if they thought they might be experiencing an arthritis flare 
between routine scheduled visits. ACPA: anti-citrullinated peptide antibody; CRP: C-reactive 
protein; ESR: erythrocyte sedimentation rate; HAQ-DI: Health assessment questionnaire 
disability index; RhF: rheumatoid factor. 
Activity Baseline Month 1 Month 3 Month 6 
Patient-
requested 
Informed consent X     
Focussed medical history X     
Blinded DAS28-CRP X     
Unblinded DAS28-CRP  X X X X 
US7 ultrasound scan X   X  
HAQ-DI X   X  
CRP X X X X X 
ESR X     
RhF X     
ACPA X     
Research bloods X1 X2 X X X2 
DMARD cessation X1     
Response to arthritis flare 
 If DAS28-CRP ≥ 2.4 at any time following 
DMARD cessation, then: 3 
1. IM steroid injection given at discretion of 
study clinician 
2. Patient exits study and is referred back to 
rheumatology clinical team for 
recommencement of DMARDs 
 
Footnotes 
1 Only if DMARD cessation criteria fulfilled at baseline.  
2 Were originally only collected if joint count and VASpatient not compatible with DAS28-
CRP remission, later amended to be collected at all visits (substantial amendment 2) 
3 A single measure of DAS28-CRP ≥ 2.4 was permitted if alternative explanation (e.g. 
concurrent infection, joint trauma) – see Methods 3.2. 
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from 110 to 90 patients, whilst maintaining the same target of 60 patients to complete the 
study following DMARD cessation. 
 
3.4 Patient recruitment 
Patients were referred to the BioRRA study from routine outpatient rheumatology clinic 
appointments by their clinician or nurse specialist. Patients were referred to the study from 
five separate rheumatology centres across the North East of England, namely: Newcastle upon 
Tyne Hospitals NHS Foundation Trust; Northumbria Healthcare NHS Foundation Trust; 
Gateshead Health NHS Foundation Trust; County Durham and Darlington NHS Foundation 
Trust; and Sunderland City Hospitals NHS Foundation Trust. All study procedures were 
performed at a single research site (Newcastle). Recruitment to the study commenced on 
7/8/14 and ended on 31/10/16. Study visits were performed between 9am and 1pm where 
possible to minimise circadian variation in laboratory samples. 
 
3.5 Clinical variable assessment 
3.5.1 Prospective clinical variable assessment 
Pre-specified clinical variables were recorded prospectively at the baseline study visit, as 
listed in Table 3.3. Included in these variables is the Health Assessment Questionnaire 
Disability Index (HAQ-DI), a self-completed questionnaire (Appendix A) that quantifies 
physical disability that has been extensively validated in the setting of RA and other chronic 
diseases (Bruce and Fries, 2003). 
 
3.5.2 Retrospective clinical variable assessment 
 
Data were obtained for a range of pre-specified variables, as listed in Table 3.4. This data was 
obtained both by patient interview at baseline visit, and from clinical notes review. Historical 
clinical records were available for all patients and were assessed by a single reviewer (KB). It 
was acknowledged that the most reliable source of information might differ depending on the 
variable of interest. A systematic methodology of recording clinical variables was therefore 
implemented (Table 3.4).  
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Table 3.3 – Baseline clinical variables recorded prospectively in the BioRRA study. CRP: C-
reactive protein; ESR: erythrocyte sedimentation rate; RhF: rheumatoid factor; ACPA: anti-
citrullinated peptide antibody; HAQ-DI:  
Baseline variable Data type 
Age Continuous 
Sex Binary 
28 tender joint count Discrete 
28 swollen joint count Discrete 
Patient arthritis visual analogue score (range 0-100) Continuous 
ESR Continuous 
CRP Continuous 
RhF positive Binary 
ACPA positive Binary 
DAS28-CRP Continuous 
DAS28-ESR Continuous 
Fulfilment of ACR/EULAR Boolean remission Binary 
HAQ-DI (range 0 – 3) Continuous 
Patient global health score (range 0-100) Continuous 
Patient pain score (range 0-100) Continuous 
 
Data regarding smoking and alcohol history were frequently missing or out-dated in the 
medical notes, and hence patient-reported values for these variables at the baseline visit were 
recorded. Although glucocorticoid prescription for RA was recorded in the medical notes, 
systemic glucocorticoid use for other indications (e.g. asthma, chronic obstructive pulmonary 
disease etc.) was frequently not recorded in hospital records. It was therefore decided to 
record the shortest of either the value recorded in the medical notes or that reported by the 
patient at baseline. Values of all other retrospective clinical variables were recorded as per the 
value stated in the medical notes. 
 
3.5.3 Assessment of RA classification criteria 
As previously discussed, it was not practically possible to formally assess fulfilment of 
classification criteria at the point of patient recruitment to the study owing to a lack of 
availability of clinical notes access for patients referent from external hospital sites. Patients  
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Table 3.4 – Baseline clinical variables recorded retrospectively in the BioRRA study. 
Variable Data type Data source 
Year of RA diagnosis Continuous Medical notes 
Months from symptom onset 
to first rheumatology clinic 
review 
Continuous Medical notes 
Months from first 
rheumatology clinic review 
to commencement of first 
DMARD 
Continuous Medical notes 
Months since last change in 
DMARD therapy (dose 
and/or drug) 
Continuous Medical notes 
Months since last 
glucocorticoid 
Continuous 
Most recent of either 
medical notes or patient 
interview 
Smoking status 
Categorical 
(current/previous/never) 
Patient interview 
Weekly alcohol unit intake Continuous Patient interview 
Methotrexate use 
Categorical 
(current/previous/never) 
Medical notes 
Sulfasalazine use 
Categorical 
(current/previous/never) 
Medical notes 
Hydroxychloroquine use 
Categorical 
(current/previous/never) 
Medical notes 
Other previous DMARDs Free text Medical notes 
 
were therefore recruited on the grounds of a clinical diagnosis of RA made by a consultant 
rheumatologist, with satisfaction of formal classification criteria assessed retrospectively after 
patient recruitment. 
Fulfilment of both 1987 ARC (Arnett et al., 1988) and 2010 ACR/EULAR classification 
criteria for RA (see Introduction 1.1.5, Tables 1.3 – 1.4) were assessed for all patients by 
medical notes review, to account for those diagnosed before and after publication of the 2010 
criteria. Both the clinic letters and original hand-written clinical notes were reviewed by the 
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same researcher (KB) for all patients. Where there was ambiguity as to the extent of joint 
involvement for the 2010 classification criteria assessment, the most conservative value was 
recorded - for example, if a clinic entry states that ‘the MCP joints were swollen’, then a value 
of 2 was recorded for the joint count. In cases where there was no documentation of a 
classification parameter (e.g. duration of morning stiffness), this parameter was treated as 
absent for the purposes of classification assessment. 
 
3.6 Musculoskeletal ultrasonography 
The emerging role of musculoskeletal US in predicting long-term outcomes in RA holds 
promise for its use in predicting DMARD-free remission. It was felt important not to 
withdraw DMARDs from patients with PD synovitis on US, given the emerging evidence of 
its potential value in predicting future flare and radiographic progression in the context of 
active disease (see Introduction 1.4.4.c) and RA remission (see Introduction 1.5.2). The US7 
protocol of Backhaus (Backhaus et al., 2009) was used in this study as it is externally 
validated, realistic to perform within a 20 minute timeframe and has been shown to yield 
comparable results to more laborious 78-joint scans (Hammer and Kvien, 2011). Furthermore, 
in my previous MRes thesis I demonstrated good levels of both intra and inter-observer 
agreement in PD and GS synovitis scores in scans performed by myself according to the US7 
protocol, and rescored in a blinded fashion by a rheumatology consultant experienced in 
musculoskeletal ultrasound (Baker, 2014). 
All US scans were performed using the same machine (Xario XG Diagnostic Ultrasound 
System model SSA-680A, Toshiba Medical Systems Corporation, Otawara, Tochigi 
Prefecture, Japan) by the same operator (KB) who is trained in the use of musculoskeletal US. 
All scans were performed in the same darkened room using the same linear mixed array 
transducer (part number PLT-1204BT). B-mode frequency was fixed at 12MHz for all scans, 
and B-mode gain was individually set to a level providing optimal contrast between soft 
tissue, tendons and bony surfaces. Power Doppler images were acquired at a Doppler 
frequency of 5.3MHz for all scans, with Doppler gain individually set to the maximum level 
possible without cortical bone artefact. It was not possible to alter the pulse-repetition 
frequency (PRF) on this ultrasound machine, which automatically adjusts PRF according to 
the default musculoskeletal settings as calibrated by a Toshiba ultrasound technical 
representative. 
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A minimum of 30 still images were recorded per scan, corresponding to the individual views 
of the seven joints of the US7 protocol: the dominant wrist; 2nd and 3rd metacarpophalangeal 
joints; 2nd and 3rd proximal interphalangeal joints; and 2nd and 5th metatarsophalangeal joints 
(Figure 3.2 and Appendix B).  The level of GS at each joint, and the levels of PD at each joint 
and tendon complex, were scored using the semi-quantitative scales as per the approach of 
Scheel et al. (2005) and Szkudlarek et al. (2003) respectively (Table 3.5 and Figure 3.3). 
Tendon-associated GS and joint erosions were scored as either present (1) or absent (0). Low-
level PD signal is often difficult to interpret at the wrist, owing to small blood vessels that 
traverse the joint. For pragmatic purposes, minor vessel-related Doppler signal at the wrist 
was not scored as power Doppler signal so long as all of the following criteria were satisfied: 
a) Only a single vessel was present, and 
b) The origin of the vessel could be easily visualised as arising from a vessel superficial 
to the tendons of extensor digitorum, and 
c) No further branching of the vessel occurred below deep to the tendons of extensor 
digitorum 
d) The vessel did not traverse any areas of any level of greyscale change. 
 
Such an approach is in keeping with representative images from a published atlas of 
musculoskeletal ultrasonographic scoring for use in clinical research (Hammer et al., 2011). 
 
Table 3.5 – Scoring systems used to grade GS and PD change in the BioRRA study. 
Greyscale (GS) Grading 
Scheel et al. (2005) 
Power Doppler (PD) Grading 
Szkudlarek et al. (2003) 
0 = absent 0 = absent 
1 = mild (small hypoechoic line) 1 = single vessel signal 
2 = moderate (hypoechoic area within joint 
capsule to level of joint) 
2 = confluent vessel signals in <50% of 
joint/tendon area 
3 = severe (joint capsule markedly 
distended) 
3 = confluent vessel signals in >50% of 
joint/tendon area 
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Figure 3.2 – The images obtained in the US7 scan protocol. Reproduced with permission from 
Backhaus et al. (2009). Copyright © 2009 by the American College of Rheumatology. 
 
 
Figure 3.3 – Representative ultrasound images from the BioRRA study demonstrating semi-
quantitative scoring of greyscale (GS) and power Doppler (PD) at the dorsal view of the wrist, 
as agreed by both ultrasound assessors. No instances of grade 3 GS or PD at the dorsal view 
of the wrist were recorded. 
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Individual summed scores across all 7 joints were calculated for each patient to obtain total 
scores for joint GS (possible range 0 – 27), joint PD (possible range 0 – 39), tendon GS 
(possible range 0 – 7), tendon PD (possible range 0 – 21), and joint erosions (possible range 0 
– 14). 
Baseline DAS28-CRP assessments were performed by a research nurse, thus blinding the 
ultrasound operator (KB) to the DAS28-CRP score at baseline to maintain the objectivity of 
the baseline ultrasound assessments. All scan images were scored at the time of image 
acquisition by KB. The ultrasound images were later reviewed by KB and a second observer 
(BT), blinded to the original ultrasound images and disease activity scores, in order to 
calculate the intra- and inter-rater agreement respectively (see Methods 3.10.1). 
 
3.7 Study amendments 
A number of amendments were made to the study protocol and documentation to respond to 
unanticipated issues as they arose. All amendments received research ethics committee 
approval (see Methods 3.11) before they were implemented (Table 3.6). 
There were three substantial amendments made to the protocol during the recruitment period. 
The first substantial amendment was to change the remission criteria from ACR/EULAR 
Boolean remission to DAS28-CRP<2.4, as is further discussed in Methods 3.2. Consequently, 
a greater proportion of patients were eligible for DMARD cessation and the recruitment target 
was reduced (from 170 to 110 patients). 
During study design it had been anticipated that the majority of patients would experience an 
arthritis flare between 3 and 6 months of follow-up, and collection of research bloods had not 
been planned at the month one visit to reduce financial expenditure. However, during the 
conduct of the study it became apparent that most flare events occurred before 12 weeks of 
follow-up, and thus before the subsequently scheduled routine research blood sampling at 
month three. The second substantial amendment therefore allowed the collection of research 
blood samples at month one for the purposes of longitudinal analysis. 
The original study protocol specified that microarray technology would be used for the 
analysis of differential gene expression. However, in the three years that elapsed between the 
start of study design and the end of recruitment, microarray technology became obsolete and 
was discontinued by the manufacturer (Illumina). It was therefore decided to use next-
generation RNAseq technology, and the third substantial amendment was necessary to effect  
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Table 3.6– Amendments to study protocol and documentation during the course of patient 
recruitment. 
Amendment 
Date of ethical 
committee 
approval 
Purpose 
Minor amendment 1 2/10/14 
• Correction to error in order of events in 
baseline visit 
• Update of contact telephone numbers on 
clinician information forms 
Minor amendment 2 10/10/14 • Correction to error in version number on front cover of protocol 
Substantial amendment 1 22/12/14 
• Change remission criteria from 
ACR/EULAR Boolean to DAS28-
CRP<2.4 (see Methods 3.2) 
• Reduce recruitment target from 170 to 110 
• Explicitly seek consent to reproduce 
anonymised ultrasound images 
Minor amendment 3 23/12/14 
• To allow patients who were previously 
ineligible for DMARD withdrawal owing 
to failure to meet ACR/EULAR Boolean 
remission (i.e. prior to substantial 
amendment 1) to be re-recruited to the 
study should they so wish. 
Substantial amendment 2 23/7/15 
• Collection of  research blood samples from 
patients in remission at month one visit 
• Update to clinician information sheets to 
reflect change to DAS28-CRP remission 
criterion 
Substantial amendment 3 23/8/16 
• Change from microarray to RNAseq 
technology for analysis of differential gene 
expression 
• Reduction of recruitment target from 110 
to 90 patients 
• Minor changes to protocol wording to 
explicitly state that serum samples may be 
sent to external parties for processing 
where possible (already included in patient 
consent form) 
 
this change. Furthermore, higher-than-anticipated rates of eligibility for DMARD-cessation 
allowed a further reduction in recruitment target from 110 to 90 patients (see Methods 3.4). 
 
3.8 Healthy control participants 
In order to provide a control group for subsequent transcriptomic analyses, four healthy 
participants were recruited. Each participant donated blood at four time points to mirror those 
of the patient participants – i.e. baseline, month 1, month 3 and month 6. Healthy participants 
donated blood between 9am and 1pm where possible to minimise circadian variation in 
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laboratory samples. Blood was left to stand at room temperature to mimic the equivalent 
period of transit for patient samples, before being processed for CD4 T cell extraction and 
subsequent downstream RNA/DNA applications using identical protocols to those of the 
patient participants. 
 
3.9 Laboratory procedures 
The reagents and equipment used in the laboratory procedures together with manufacturer and 
catalogue number details are listed in Appendix C. All procedures were performed at room 
temperature using aseptic technique in a positive-pressure laminar flow tissue culture hood 
unless otherwise stated. 
 
3.9.1 CD4+ T cell Isolation 
CD4+ T cells were isolated from 27ml of whole blood drawn into three 9ml 
ethylenediaminetetraacetic acid (EDTA) tubes following the protocol of Pratt (2011). Briefly, 
monocytes were first depleted by the use of an anti-CD34 antibody (Rosettesep® human 
monocyte depletion cocktail) that crosslinks monocytes to erythrocytes forming 
immunorosettes, which were separated by centrifugation after the addition of the erythrocyte 
aggregation agent HetaSep®. The supernatant was then collected and the remaining CD4+ T 
cells were positively selected by automated anti-CD4 antibody-based magnetic isolation 
(Easisep® whole blood CD4+ selection kit and Robosep® automated cell separator). By the 
prior removal of CD4lo expressing monocytes this extraction method is able to obtain CD4+ T 
cell purities of over 98%, compared to approximately 90% for single step column-based 
immunoprecipitation methods (Pratt et al., 2012). After cell counting (Section 3.9.6), 2 x 105 
cells were transferred to a single well of a 96-well V-bottom plate for flow cytometry 
processing (Methods 3.9.7). 
 
3.9.2 CD4+ T cell lysis 
Purified CD4+ T cell isolates were transferred to 30ml universal tube and washed by addition 
of cold (4°C) calcium- and magnesium-free Hanks balanced salt solution (HBSS) + 1% foetal 
calf serum (FCS) to a total volume of 25ml. The tube was then centrifuged at 400g for 7 
minutes at 4°C, after which the supernatant was removed by aspiration using a vacuum-driven 
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glass pipette. In an RNase-free open workbench area, the pellet was then resuspended in cold 
(4°C) Qiagen Buffer RLT Plus + 1% β-mercaptoethanol dependent on the number of T cells 
to be lysed; if <5 million cells then 350µL of Buffer/ β-mercaptoethanol was added, whereas 
if ≥5 million cells then 600µL of Buffer/β-mercaptoethanol was added (in line with the 
manufacturer’s protocol). The suspension was thoroughly mixed by pipetting and vortexing 
before transfer to a QIA-shredder column. Lysis of the T cells was completed by 
centrifugation of the column at 13,000g for 2 minutes, and the lysate was then stored 
at -80°C. 
 
3.9.3 Peripheral blood mononuclear cell isolation 
PBMCs were isolated from 18ml of whole blood drawn into two 9ml EDTA tubes. The blood 
was diluted in HBSS + 2mM EDTA to a total volume of 40ml. The diluted blood was then 
split to two 20ml volumes that were layered by slow pipetting above 15ml of Lymphoprep® 
within a 50ml centrifuge tube. The layered tubes were then centrifuged at 895g for 30 minutes 
with minimal acceleration and deceleration speeds to maintain layering of the sample. After 
centrifugation, PBMCs were removed from the interface layer using a Pasteur pipette and 
transferred to a fresh 50ml centrifuge tube. The PBMCs were then immediately washed in 
cold (4°C) HBSS + 1% FCS to a total volume of 50ml, and centrifuged at 600g for 7 minutes 
at 4°C to remove any residual Lymphoprep®. The supernatant was discarded, and the pellet 
resuspended in 50ml of cold (4°C) HBSS + 1% FCS before centrifuging at 250g for 7 minutes 
at 4°C to remove any platelets. The supernatant was discarded, and the pellet resuspended in 
7ml of cold (4°C) HBSS + 1% FCS and strained through a 70µm nylon filter to a new 50ml 
centrifuge tube(to exclude clumped cells), which was kept on ice for immediate cell counting. 
After cell counting, 2 x 105 cells were transferred to a well of a 96-well V-bottom plate and 
stored at 4°C for flow cytometry analysis (Methods 3.9.7). The remaining volume was 
centrifuged at 400g for 7 minutes at 4°C, and the supernatant discarded. The pellet was then 
resuspended in freezing medium (90% FCS + 10% dimethyl sulphoxide [DMSO]) and 
transferred to cryovials such that each aliquot contained no less than 5 million cells. The 
cryovials were then frozen at -80°C in a polystyrene foam box before transfer to long-term 
Biobank storage at -150°C. 
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3.9.4 Plasma separation 
Blood drawn in to a single 9ml EDTA tube was centrifuged at 1,800g for 12 minutes. The 
supernatant (i.e. plasma) was then carefully removed using a Pasteur pipette and transferred to 
a 30ml universal tube. Plasma proteases were then inhibited by the addition of one cOmplete 
mini protease cocktail inhibitor tablet, which was dissolved within the sample. The resultant 
volume was then divided to 1ml aliquots, which were frozen at -80°C for future analysis. 
 
3.9.5 Serum separation 
Blood drawn in to a single 8ml serum separator clot activator tube was centrifuged at 1,800g 
for 12 minutes. The supernatant (i.e. serum) was then carefully removed by pipetting and 
divided to 1ml aliquots, which were frozen at -80°C for future analysis. 
 
3.9.6 Cell counting 
PBMCs and CD4+ T cells were counted within 10µL of diluted sample placed underneath a 
cover slip mounted upon a Bürker haemocytometer chamber. The number of cells within 25 
squares was then manually counted using a light microscope. The total number of cells 
present in the sample was calculated as per Formula 3.1. 
Formula 3.1 – calculation of cell number by Bürker haemocytometer chamber counting. 
Total cells = [volume (ml)] x [dilution factor] x [number of cells in 25 squares] x 104 
 
3.9.7 CD4+ purity check by flow cytometry 
Unfixed samples of PBMCs and CD4+ T cells stored in 96-well V-bottom plates at 4°C were 
stained and analysed by flow cytometry within 18 hours of sample isolation. Firstly, the plate 
was centrifuged at 400g for 3 minutes and the supernatant removed by flicking. Cells were 
then resuspended in 50µL of flow cytometry antibody mixture by thorough pipetting and 
incubated in the dark for 30 minutes at 4°C. After this, 100µL of flow cytometry buffer was 
added to each well and the plate then centrifuged at 400g for 3 minutes. After removal of the 
supernatant by flicking, the stained cells were then resuspended in 150µL of flow cytometry 
buffer and the plate centrifuged at 400g for 3 minutes. After removal of the supernatant by 
flicking, the cells were resuspended in 200µL of flow cytometry buffer and transferred to 
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individual cytometry tubes. Flow cytometry data was recorded using a FACSCanto-II 
cytometer and FACSDiva software (Becton Dickinson Biosciences, San Jose, California, 
USA). Analysis of flow cytometry data was performed using FlowJo software (FlowJo LLC 
Data Analysis Software, Ashland, Oregon, USA). PBMC samples were first gated on side-
scatter area (SSC-A) and width (SSC-W) to identify singlets, which were then gated on SSC-
A and forward-scatter area (FSC-A) to exclude debris. The resulting population was then 
gated on compensated CD3 and compensated CD4 to identify CD3+CD4+ T cells, SSC-A and 
compensated CD14 to identify CD14+ monocytes, and SSC-A and compensated CD19 to 
identify CD19+ B-cells. These gates were then applied to the CD4+ T cell isolate matched to 
the individual patient where available to assess purity (Figure 3.4). 
 
3.9.8 TEMPUS™ tube storage 
Blood was drawn into TEMPUS™ tubes (3ml blood per tube) and stored at -80°C for future 
analysis. 
 
 
Figure 3.4 – Gating strategy for analysis of CD4+ T cell purity by flow cytometry. FSC-A: 
forward-scatter area; SSC-A: side-scatter area; SSC-W: side-scatter width. 
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3.9.9 CD4+ T cell RNA extraction 
Frozen CD4+ T cell lysates (see Methods 3.9.2) were thawed at room temperature in an 
RNase-free open workbench area. Thawed lysates were mixed by pipetting and transferred to 
RNase-free conical-bottom 2ml microcentrifuge tubes. In order to remove residual magnetic 
nanoparticles remaining from the CD4+ T cell isolation procedure, the lysates were 
centrifuged at maximum speed (13000 rpm) for 2 minutes. The supernatant was then carefully 
removed using a P1000 pipette (taking care not to disturb the pellet of magnetic nanoparticles 
at the bottom of the tube) and transferred to a Qiagen AllPrep DNA Mini spin column placed 
within a 2ml collection tube. The sample was then centrifuged at maximum speed (13000 
rpm) for 30 seconds, following which the column was placed in a new 2ml collection tube 
and stored at 4°C for processing (see Methods 3.9.10) after completion of the RNA extraction 
protocol below. 
The collection tube containing the flow-through from the DNA column was then processed 
according to the manufacturer’s instructions, including on-column DNase digestion and all 
steps designated as ‘optional’ according to the manufacturer’s instructions. Final purified 
RNA was eluted from the RNeasy Mini spin column using a volume of RNase-free water 
determined by total number of CD4+ T cells present in the initial sample (see Methods 3.8.6) 
as follows: 30μL for <5 x 106 cells, or 40μL for ≥5 x 106 cells. The amount of RNA present in 
each sample was then quantified using a NanoDrop™ ND1000 ultraviolet (UV) 
spectrophotometer (Thermo Fisher Scientific), with 2μg of each sample (or the total sample if 
<2μg) stored at -80°C for RNA sequencing processing (see Methods 3.9.11). Any remaining 
RNA solution was divided in to 1μg aliquots and stored at -80°C for potential future analysis. 
 
3.9.10 CD4+ T cell DNA extraction 
Immediately following completion of the RNA extraction protocol, the DNA Mini spin 
column (see Methods 3.9.5) was processed according to the manufacturer’s instructions. Final 
purified DNA was eluted from the DNA Mini spin column using 200μL of Buffer EB. The 
amount of DNA present in each sample was then quantified using a NanoDrop™ ND1000 
UV spectrophotometer (Thermo Fisher Scientific). The samples were then divided to three 
equal aliquots (66.3μL volume) and stored at -80°C for potential future analysis. 
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3.9.11 Next-generation RNA sequencing (RNAseq) 
The laboratory processing detailed in this section 3.9.11 was performed by Raf Hussain and 
Jonathan Coxhead at the Newcastle University Core Genomics Facility. 
The quantitiy and estimated RNA integrity (RINe) of RNA samples was measured by gel 
electrophoresis using a Tapestation™ 4200 machine (Agilent). Following quantification, 
1.5μg of total RNA per sample was used for RNAseq processing; where total RNA < 1.5μg, 
the entire sample was used.  Total RNA was processed using the TruSeq™ Stranded mRNA 
Library Prep Kit (Illumina), according to the ‘High Sample Protocol’ section of the 
manufacturer's instructions. First, messenger RNA (mRNA) was enriched from the purified 
total RNA by poly-A selection using poly-T oligo attached magnetic beads in two rounds of 
purification. Enriched mRNA was then fragmented by heating with magnesium cations, and 
then incubated with reverse transcriptase to synthesise first strand cDNA for each sample. 
This step was performed in the presence of Actinomycin D to prevent DNA-dependent 
synthesis of a second strand.  The mRNA was then degraded with RNase and second strand 
cDNA was then synthesised by incubation with DNA Polymerase I. Double-stranded cDNA 
was then isolated using solid phase reversible immobilisation (SPRI) paramagnetic beads 
(Agencourt™ AMPure™ XP beads, Beckman Coulter Genomics), after which the 3’ ends 
were adenylated to facilitate sequencing adaptor binding.  The Illumina sequencing adaptors 
contained three key functional elements: an amplification element required for amplification 
of the cDNA by polymerase chain reaction, a sequencing element required for the sequencing 
reaction, and a unique index element to allow identification of each individual patient sample. 
cDNA that had successfully ligated with adaptors was selectively amplified by polymerase 
chain reaction. Amplified cDNA was then diluted to equimolar concentrations and pooled 
before sequencing. 
RNA sequencing was performed using an Illumina NextSeq™ 500 in high-output mode. This 
configuration delivered 400 million reads over 75 cycles for 40 samples loaded across 4 lanes 
per flow cell. Sequencing was performed in batches across 4 separate flow cell sequencing 
runs. Samples were allocated to sequencing batches such that computational correction for 
any batch-to-batch variation at the level of either the RNA extraction (6 batches) or RNA 
sequencing (4 batches) could be achieved, according to a predetermined experimental design 
using the duplicate correlation command of the ‘limma’ Bioconductor/R package (v3.32.5) 
(Ritchie et al., 2015). This sequencing batch allocation was performed by Andrew Skelton, 
Experimental Scientific Officer, Bioinformatics Support Unit, Newcastle University. Using 
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this approach, it was possible to sequence all 136 CD4+ T cell samples to a depth of 10 
million reads per sample, with 75bp single-end reads. 
 
3.9.12 Multiplex cytokine/chemokine electrochemiluminescence assays 
Previously separated serum samples stored at -80°C (see Methods 3.8.5) were thawed at 
37°C, mixed by vortexing and then centrifuged for 2 minutes at maximum speed (13000 rpm) 
to separate any contaminating debris. Serum was then transferred to 96-well V-PLEX™ 
plates (MesoScale Discovery) and processed according to the manufacturer’s instructions. 
The volumes of sample loaded per well, together with the fold dilution and dilution method 
for each plate is detailed in Table 3.7, as specified by the manufacturer. The assays included 
on each plate are detailed in Table 3.8. 
Owing to their large number, samples were processed across pairs of each plate type. Each 
pair of plates was processed on the same day to minimise variation between plates for each set 
of analytes. Although V-PLEX™ plates are specifically designed and certified to have 
minimal variation in assay performance between separate plates of the same lot number, 
additional steps were taken to minimise any potential for plate-to-plate variation to affect data 
analysis. First, for each plate pair, all baseline samples were included together on the same 
individual plate. This allowed for comparison of baseline samples between patients 
independent of any effect of plate-to-plate variation. Secondly, it was ensured that all samples 
from each individual patient were included together on the same individual plate. This  
Table 3.7 – Volume, fold dilution and dilution method for samples according to V-PLEX™ 
plate. 
V-PLEX™ plate 
Sample 
volume (μL) 
Fold 
dilution 
Dilution method 
Cytokine panel 1 (human) 25 2 In-plate 
Chemokine panel 1 
(human) 
12.5 4 In-plate 
Proinflammatory panel 1 
(human) 
25 2 In-plate 
Th17 panel 1 (human) 12.5 4 In-plate 
Vascular injury panel 2 
(human) 
10 1000 
Three serial 10-fold dilutions 
prior to addition to plate 
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allowed for comparison between study time points at the level of each individual patient 
independent of any effect of plate-to-plate variation in absolute quantification. 
Following processing, plates were immediately analysed by electrochemiluminescence (ECL) 
using a MESO™ QuickPlex SQ120 (Meso Scale Diagnostics, LLC.) according to 
Table 3.8 – Cytokine and chemokine assays by V-PLEX™ plate type. CCL: C-C motif 
chemokine ligand; CXCL: C-X-C motif chemokine ligand; GM-CSF: granulocyte-
macrophage colony-stimulating factor; hsCRP: high-sensitivity C-reactive protein; ICAM: 
intercellular adhesion molecule;  IFN: interferon; IL: interleukin; MCP: monocyte 
chemoattractant protein; MDC: macrophage-derived chemokine; MIP: macrophage inhibitory 
protein; IP-10: interferon-γ induced protein 10kDa; SAA: serum amyloid A; TARC: thymus 
and activation-regulated chemokine; TNF: tumour necrosis factor; VCAM: vascular cell 
adhesion molecule; VEGF: vascular endothelial growth factor. 
V-PLEX™ plate Assays 
Cytokine panel 1 (human) 
GM-CSF 
IL-1α 
IL-5 
IL-7 
IL-12/23 p40 subunit 
IL-15 
IL-16 
IL-17A 
TNF-β 
VEGF-A 
Chemokine panel 1 (human) 
Eotaxin (CCL11) 
MIP-1β (CCL4) 
Eotaxin-3 (CCL26) 
TARC (CCL17) 
IP-10 (CXCL10) 
MIP-1α (CCL3) 
IL-8(HA) 
MCP-1 (CCL2) 
MDC (CCL22) 
MCP-4 (CCL13) 
Proinflammatory panel 1 (human) 
IFN-γ 
IL-1β 
IL-2 
IL-4 
IL-6 
IL-8 
IL-10 
IL-12p70 subunit 
IL-13 
TNF-α 
Th17 panel 1 (human) 
IL-17A 
IL-21 
IL-22 
IL-23 
IL-27 
IL-31 
MIP-3α (CCL20) 
Vascular injury panel 2 (human) 
SAA 
hsCRP 
VCAM-1 
ICAM-1 
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themanufacturer’s instructions. Signal – concentration curves based on serial dilutions of a 
known supplied standard were generated for each assay to calculate the concentration of 
analytes in each sample using the Discovery Workbench™ software version 4.0 (Meso Scale 
Diagnostics, LLC.). For each assay, the upper limit of detection (ULOD) for was defined as 
the concentration of the highest calibrator, and the lower limit of detection (LLOD) was 
defined as 2.5 x standard deviation above the lowest calibrator concentration. Analytes with 
an ECL signal corresponding to a calculated concentration above the ULOD were assigned a 
calculated concentration equal to the ULOD. Analytes with an ECL signal corresponding to 
calculated concentration below the LLOD were assigned a calculated concentration equal to 
the LLOD. Where a sample was duplicated on the same plate (for internal quality control 
purposes), the mean calculated concentration value was used for analysis. 
Owing to time constraints imposed by the PhD programme, MSD plates were processed 
before the final clinical study visit, though after recruitment had closed. Therefore, whilst all 
baseline samples were processed, there were some longitudinal follow-up samples for patients 
who remained under follow-up in the study at the time of plate processing which were not 
available for analysis. 
 
3.10 Data analysis 
Two general approaches to analysing data in this study were possible, dependent on the 
outcome measure of interest. One approach was to categorise patients by flare status – i.e. a 
binary outcome of ‘flare’ vs. ‘remission’ for each patient upon their completion of the study. 
A major drawback of this intuitive approach was that it makes no distinction between those 
patients who flared early versus those who flared at a later time point following DMARD 
cessation, and thus did not make full use of the richness of the available study dataset. 
Nevertheless, it allowed standard statistical tests to be performed (e.g. comparison of means 
using parametric tests), which form the basis of many of the well-optimised analysis pipelines 
that have been developed for application in computationally-intensive large datasets such as 
those generated by next-generation RNAseq. For this reason, the core analyses in the RNAseq 
results chapter were based on analyses that dichotomised patients by flare as a binary outcome 
measure. 
An alternative approach to data analysis was to use time-to-flare as the outcome measure. In 
this approach, it was possible to use more powerful survival analysis approaches such as Cox 
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regression, which are able to account for differences in the time between DMARD cessation 
and onset of flare. In this approach, patients who remain in remission at the end of the study 
were treated as being censored at the time of their final study visit. Owing to its superior 
statistical power in this setting, the majority of analyses of non-transcriptomic data were 
performed using this survival-based approach. 
 
3.10.1 Analysis of clinical, ultrasound and cytokine data 
Analysis of clinical, ultrasound and cytokine data was performed in the R environment, 
version 3.3.2  (R Core Team, 2016), with additional packages installed as listed in Table 3.9. 
Table 3.9 – Additional R packages used for data analysis. 
Package name Package version Citation 
biomaRt 2.32.1 Durinck et al. (2009) 
checkmate 1.8.2 Lang (2016) 
dplyr 0.7.2 Wickham et al. (2017) 
forestplot 1.7 Gordon and Lumley (2017) 
futile.logger 1.4.3 Rowe (2016) 
ggpubr 0.1.2 Kassambara (2017) 
ggplot2 2.2.1 Wickham (2009) 
irr 0.84 Gamer et al. (2012) 
limma 3.32.5 Ritchie et al. (2015) 
lpSolve 5.6.13 Berkelaar (2015) 
magrittr 1.5 Bache and Wickham (2014) 
MASS 7.3-47 Venables and Ripley (2002) 
ordinal 6-28 Christensen (2015) 
pls 2.6-0 Bjørn-Helge et al. (2016) 
pROC 1.10.0 Robin et al. (2011) 
rmcorr 0.1.0 Bakdash and Marusich (2017) 
survival 2.41-3 Therneau (2015) 
survminer 0.3.1 Kassambara and Kosinski (2017) 
tximport 1.4.0 Soneson et al. (2015) 
VennDiagram 1.6.17 Chen (2016) 
 
  
110 
 
Analyses of all three types of data (clinical, ultrasound and cytokine) was performed 
according to the structure detailed below. All Cox regression models used Breslow 
approximation for handling of tied survival times (Therneau, 2015). 
1. The quality of data was assessed, and where necessary, low quality data was excluded. 
2. The distributions of data were summarised by descriptive statistics and, for continuous 
data, were visualised by standard methods including boxplots, Q-Q plots and 
histograms. 
3. Where the distributions of data were skewed, appropriate transformations of data 
groups was performed (e.g. natural logarithmic transformation). 
4. The association of each individual variable at baseline with time-to-flare was assessed 
by univariate Cox regression using the ‘survival’ package. 
5. Baseline variables were selected based on their univariate p-value to be taken forward 
to a multivariate Cox regression model. For clinical, ultrasound and cytokine data, an 
elevated significance threshold (p<0.2) was used in order to reduce the risk of type II 
error at this preliminary stage, in keeping with established precedent (Dales and Ury, 
1978; Mickey and Greenland, 1989). In comparison, a more stringent significance 
threshold (p<0.001) was utilised for RNAseq univariate analysis (see Methods 3.10.2) 
in reflection of the several log-fold greater number of variables analysed. 
6. Backward stepwise variable selection based on the Akaike information criterion (AIC) 
using the ‘stepAIC’ function of the ‘MASS’ package was used to create a stepwise 
multivariate Cox regression model. The regression coefficient (equivalent to the 
natural logarithm of the hazard ratio) and its corresponding 95% confidence interval 
for each variable was visualised in a forest plot format using the package ‘forestplot’ 
(and its dependent packages ‘checkmate’ and ‘magrittr’). 
7.  Patients were dichotomised by the levels of variables measured at baseline. In the 
case of binary variables, patients were dichotomised simply by presence or absence of 
the variable at baseline. For continuous variables, thresholds were determined by 
receiver operating characteristic (ROC) analysis (using the ‘pROC’ package). For each 
continuous variable, two optimum thresholds were set to maximise negative predictive 
value (NPV) and positive predictive value (PPV) for flare, corresponding to biomarker 
thresholds for remission and flare respectively. Confidence intervals for these metrics 
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and the area under the ROC curve (ROCAUC) were calculated by bootstrapping (2000 
replicates) and the DeLong procedure (DeLong et al., 1988) respectively. 
8. Variables that were significantly associated with time-to-flare in the stepwise 
multivariate Cox regression model at the p<0.05 threshold were then combined in 
composite scores, weighted by their respective coefficients in multivariate Cox 
regression analysis. 
9. Survival curves were compared between the dichotomised groups (using the 
‘survminer’, and its dependent ‘ggpubr’ and ‘ggplot2’, packages) by the log-rank test 
as a measure of their utility in predicting time-to-flare after DMARD cessation. 
10. Finally, where data allowed, the relationship between longitudinal changes in 
variables at the individual patient level and time-to-flare were explored.  
A key assumption of Cox regression is that that the hazard function for each stratum of the 
dataset is proportional over time – in other words, the proportional change in hazard 
attributable to a given variable must be constant across all time points. In a seminal paper, 
Schoenfeld defined residuals of the proportional hazards model that, if proportionality of 
hazards is true, show no significant correlation with time (Schoenfeld, 1982). Following this 
approach, proportionality of hazards was tested for each individual variable in univariate and 
stepwise multivariate Cox regression models by plotting scaled Schoenfeld residuals against 
time, and fitting a smoothed spline curve with four degrees of freedom using the survival 
package (Therneau, 2015). Proportionality of hazards was assumed if no significant 
association at the 0.05 threshold was observed between scaled Schoenfeld residuals versus 
time. 
The Akaike information criterion (AIC) was used to drive stepwise backwards selection of 
variables in the multivariate Cox regression models. The AIC is a well-established method of 
nested model selection, which penalises goodness of model fit by the number of variables 
contained within the model (Bozdogan, 1987). The best model, displaying the optimum 
balance between predictive utility and number of variables, is distinguished the lowest AIC 
score. In backwards stepwise selection, a set of reduced models is created by dropping each of 
variables in turn from the starting model. The model with the lowest AIC is then taken 
forward to the next round of variable selection, and the process repeated until no further 
reduction in AIC is possible – the model with the lowest AIC in the final step is accepted as 
the final stepwise model. Stepwise backwards variable selection of Cox regression models 
based on AIC has been previously described in analyses of differential gene expression in 
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cancer studies, using both microarray technology (Wozniak et al., 2013) and next-generation 
sequencing data (Falco et al., 2016; Fan and Liu, 2016). 
Additional analyses were performed for the ultrasound data. Cohen’s kappa statistic (Jacob, 
1960) was used to quantify intra- and inter-rater agreement in ultrasound image scoring. This 
technique allows for adjustment of agreement in scoring that would be expected by chance 
alone, and thus has substantial advantage over simple measures of agreement such as 
percentage agreement. It is also better suited to analysis of categorical data, as opposed to 
intra-class correlation which is arguably better suited to analysis of continuous data 
(Mandrekar, 2011). Cohen’s kappa was calculated for scores of each individual ultrasound 
image both with and without linear weighting using the ‘irr’ package (and its dependent 
‘lpSolve’ package) – linear weighting was used to account for the ordinal nature of the 
ultrasound scores. The strength of agreement measured by the kappa statistic was interpreted 
as per the approach of Landis and Kock (1977), summarised in Table 3.10. For assessment of 
inter-rater agreement, scores recorded by the observers at the time of image review were 
compared rather than with those recorded at the time of image acquisition, to allow for 
minimisation of any differences in image visualisation on the ultrasound machine screen 
versus computer display.  
Although the total ultrasound scores were made more continuous by virtue of summation, 
they were nevertheless derived from the individual ordinal ultrasound scores. Therefore, in 
order to appropriately acknowledge the ordinal derivation of these data, ordinal logistic 
regression was performed to assess the correlation between clinical and ultrasound parameters 
at baseline using the ‘ordinal’ package. 
Table 3.10 – Interpretation of Cohen’s kappa according to Landis and Kock (1977). 
Cohen’s kappa value Strength of agreement 
<0 Poor 
0.00 – 0.20 Slight 
0.21 – 0.40 Fair 
0.41 – 0.60 Moderate 
0.61 – 0.80 Substantial 
0.81 – 1.00 Almost perfect 
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3.10.2 Analysis of next-generation RNAseq data 
Computer programming scripts, bioinformatics analysis and figure generation for all RNAseq 
data (with the exception of multivariate Cox regression and ROC analysis) were performed by 
Andrew Skelton, Experimental Scientific Officer, Bioinformatics Support Unit, Newcastle 
University. I am grateful to Andrew for his help in the writing of the methods for this section 
3.10.2. 
The quality of raw RNA sequencing data within each individual FASTQ file was assessed 
using the FastQC tool (v0.11.5) (Andrews, 2016). Quality metrics measured for each sample 
included number of sequences, sequencing length distribution, Phred score distribution by 
sequence position, percentage GC content, and percentage adaptor sequence contamination. 
Graphical visualisations of quality metrics were produced using the MultiQC tool (v0.7) 
(Ewels et al., 2016). Correlation between laboratory sample processing time and RINe 
measurements was analysed using the ‘rmcorr’ package, accounting for clustering effect of 
repeated measurements at the individual patient level. 
Transcript abundance was estimated from the raw FASTQ files using Kallisto software 
(v0.43.0) (Bray et al., 2016) ran in single-end mode, and using an index based on Gencode 
v24 transcript sequences (Harrow et al., 2012). Read counts were imported to R (v3.4.1) 
using the ‘tximport’ package, removing genes with mean read count of <60. The ‘dplyr’ 
package was used to aid data manipulation. Gene annotation using the Ensembl GRCh38 
assembly (Yates et al., 2016) was performed using the ‘biomaRt’ package. Read counts were 
normalised using trimmed mean of M-values normalisation (TMM), and were then 
logarithmically transformed to log counts per million (logCPM) using the variance modelling 
at the observational level (voom) approach described by Law et al. (2014). This 
transformation effectively renders the data to be similar to the output of microarray platforms, 
thus allowing for well-established and validated microarray packages to be utilised (Law et 
al., 2014). 
Differential gene expression (DGE) between binary contrast groups was analysed within a 
linear model using the ‘limma’ package, applying correction for RNA sequencing batch and 
CD4+ T cell purity. For longitudinal analyses, the ‘duplicateCorrelation()’ function of the 
‘limma’ package was used to account for pairing of patient samples. Statistical significance of 
DGE was assessed using the moderated t-test with empirical Bayes moderation, with false-
discovery rate correction according to approach of Benjamini and Hochberg (1995). DGE 
which exceeded a 1.5 fold-change threshold at a corrected p value of <0.05 was considered as 
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significant. Exploratory analyses were performed using a relaxed significance threshold 
(unadjusted p<0.001). 
The association between baseline gene expression and time-to-flare was analysed by 
univariate Cox regression across all genes using the ‘survival’ package. Genes which were 
significantly (unadjusted p<0.001) associated with time-to-flare were then advanced to 
multivariate Cox regression and ROC analysis following the procedure detailed in Methods 
3.10.1 (steps 6 – 8). Volcano plots were generated using the ‘ggplot2’ package. Venn 
diagrams were produced using the ‘VennDiagram’ package, and its dependent package 
‘futile.logger’. 
 
3.11 Ethical approval and study governance 
The study was approved by an NHS Health Research Authority (HRA) Research Ethics 
Committee (REC) and received NHS Research & Development approval before recruitment 
of the first participant (REC reference 14/NE/1042). The study was registered online at 
clinicaltrials.gov (NCT02219347). Professor John Isaacs was the Chief Investigator for the 
study, and the Newcastle upon Tyne Hospitals NHS Foundation Trust acted as study Sponsor. 
A Trial Steering Committee comprising of BioRRA investigators and researchers from 
outside the study team met at least once every six months during the active recruitment period 
to review study progress, with reports made available to the study Sponsor, NHS REC and the 
Wellcome Trust (as study funder). Healthy participants were recruited as part of an approved 
project within the Newcastle Academic Health Partners Bioresource (NAHBP), under the 
ethical approval of Newcastle University. All patients and healthy participants provided 
written informed consent before participation in the study, which was conducted in 
accordance with the Declaration of Helsinki (World Medical Association, 2013).  
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Chapter 4. Results 1 – Clinical data 
 
4.1 Introduction 
Rheumatoid arthritis was historically a disease with only limited treatment options, with 
irreversible joint destruction and disability an inevitable consequence for many patients. In 
contrast, the past two decades have witnessed remarkable therapeutic advances in terms of 
both novel drugs and improved treatment paradigms, including early combination DMARDs 
and the treat-to-target approach (see Introduction 1.3). Such has been the success of these 
strategies that remission is now a realistic treatment target for the majority of patients. This 
changing face of RA in modern clinical practice poses a novel and increasingly encountered 
dilemma – when is it appropriate to withdraw DMARDs in RA remission? 
Such a question is clearly important, not least because of the significant side effects of 
DMARD therapy, and the expense and inconvenience of regular safety monitoring. The 
concept of DMARD withdrawal and cessation has been explored by several recent studies, 
with encouraging results. Of the handful of studies that have addressed complete drug-free 
remission in RA as a primary outcome, it appears that approximately half of patients can 
achieve this status following DMARD cessation (see Introduction 1.6). However, the majority 
of studies have explored only partial DMARD withdrawal, usually in the form of bDMARD 
tapering and cessation, and often as secondary or exploratory endpoints. Evidence 
surrounding the potential for biomarkers that can predict DFR in patients with established RA 
controlled with csDMARD therapy is thus lacking (see Introduction 1.7), and is the primary 
focus of this study. 
In this results chapter I focus on the clinical aspects of the BioRRA study. The primary aim of 
this work was to identify baseline clinical variables that are predictive of sustained DFR 
versus flare following DMARD cessation. First, general clinical aspects of the study, 
including patient recruitment, cohort demographics, and clinical outcomes are presented. 
Clinical variables identified a priori at the study design stage are then compared between flare 
and remission groups, and their association with time-to-flare analysed by Cox regression. 
Finally, I present a composite clinical score and assess its utility in predicting flare versus 
DFR within the study population. 
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The structure of the remainder of this results chapter is as follows: 
4.2 Study procedures 
4.3 Quality control 
4.4 Descriptive analysis 
4.5 Comparison of clinical variables between flare versus remission groups  
4.6 Survival analysis 
4.7 Composite clinical biomarker score 
4.8 Long-term clinical outcomes 
4.9 Discussion 
4.10 Summary 
 
4.2 Study procedures 
4.2.1 Patient recruitment 
A total of 78 patients attended a baseline study visit. Of these, 3 patients did not meet the 
eligibility criteria and were not recruited: one was enrolled in another long-term clinical trial, 
and 2 patients were taking leflunomide. A further patient did not receive the patient 
information sheet prior to their baseline visit - as the ethical approval of the study mandated 
that all patients receive the information sheet at least a day in advance of their baseline visit, 
this patient was provided with an information sheet and their baseline visit rescheduled. 
Unfortunately, the patient did not attend this rescheduled appointment, and despite multiple 
attempts could not be contacted before the closure of the study recruitment period and hence 
was not enrolled in the study. A further patient had received systemic glucocorticoids within 3 
months of their baseline visit – in this case, their baseline visit was rescheduled to a later date 
and they were subsequently successfully enrolled. 
Of the 74 patients who were enrolled in the study, 30 (41%) patients did not meet the criteria 
for DMARD cessation. 19/74 (26%) patients failed DMARD cessation criteria owing only to 
the presence of PD signal on baseline ultrasound scan, 4/74 (9%) failed solely due to DAS28-
CRP≥2.4, and 3 (4%) failed owing to both DAS28-CRP≥2.4 and PD signal on ultrasound. A 
further 5 patients, who were recruited prior to the protocol amendment to change the 
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remission criteria to DAS28-CRP<2.4 (see Methods 3.2), satisfied DAS28-CRP remission but 
did not satisfy ACR/EULAR Boolean remission and hence did not stop DMARD therapy in 
accordance with the protocol version in force at the time. Following the protocol amendment, 
ethical approval was granted to offer these patients a further study appointment using the 
amended remission criteria – only one patient accepted this offer, and they were subsequently 
eligible for DMARD cessation. 
 
4.2.2 Patient outcomes 
Of the 44 patients who stopped DMARDs, 21 patients maintained DAS28-CRP remission for 
the 6 months of study follow-up. One of these patients had synovitis of both ankles and a 5th 
MTP joint at review 176 days after DMARD cessation, demonstrated both by clinical and 
ultrasonographic examination. Despite clearly exhibiting objective evidence of active disease, 
their DAS28-CRP score (which does not include assessment of the ankles or feet) was within 
the remission range (1.58). Nevertheless, the patient was deemed to have experienced an 
arthritis flare, received an intramuscular steroid injection and was referred back to their 
rheumatology team for recommencement of DMARD therapy. This did not constitute a 
breach of the study protocol, which permits recommencement of DMARDs in those patients 
with PD signal at the month 6 ultrasound scan. A further 3 patients had grade 1/3 PD signal at 
the wrist on their month 6 ultrasound scan, but no clinical synovitis, and maintained DAS28-
CRP remission. As ultrasound findings do not form part of the clinical remission criteria, 
these patients were classified as maintaining clinical remission for the purposes of data 
analysis. 
A DAS28-CRP score ≥ 2.4 was recorded for 22 patients during the follow-up period, who 
were classified as having experienced an arthritis flare. An additional patient was reviewed 69 
days after DMARD withdrawal before the first substantial protocol amendment – although 
this patient had a DAS28-CRP score within the remission range (1.46), they did not satisfy 
ACR/EULAR Boolean remission. Thus, according to the study protocol in force at the time 
they were treated as having experienced an arthritis flare, and were referred back to their 
rheumatology team for recommencement of DMARD therapy. Therefore, had this visit 
occurred after implementation of the first substantial amendment, this patient would in effect 
have been lost to further follow-up. Nevertheless, the remainder of all patients successfully 
completed the follow-up period. 
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In summary, of the 44 patients who discontinued DMARD therapy, 23 (52%) were classified 
as experiencing an arthritis flare, 20 (45%) maintained DFR and 1 (2%) was effectively lost to 
follow-up (Figure 4.1). In order to maintain consistency in data analysis, two separate 
approaches have been implemented to account for this latter patient dependent on the outcome 
measure of interest. For analyses where the outcome is binary (i.e. flare vs. remission), the 
patient has been excluded as it is unclear whether they would have maintained DAS28-CRP 
remission to the end of the 6 month study period. For analyses where the outcome is time-to-
flare, the patient has been analysed as being censored in remission after 69 days follow-up. 
 
4.2.3 Adverse events 
Arthritis flare was recorded as an adverse event in 24 patients (i.e. including the patient who 
was classified as flare prior to the first substantial amendment). Routine influenza and 
pneumococcal vaccination during study follow-up were also recorded as adverse events (11 
events, 10 patients) to allow for subsequent identification during longitudinal data analysis. A 
further 66 adverse events were recorded, none of which were judged to be a consequence of 
DMARD cessation (Table 4.1). There were no serious adverse events. 
 
Figure 4.1 – Flow diagram showing patient recruitment and outcomes. 
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Table 4.1 – Adverse events occurring in the study.  
Category Adverse Event Number of Events 
Infection 
Nasopharyngitis 12 
Pneumonia 2 
Skin infection 2 
Influenza-like illness 1 
Herpes zoster 1 
Oral herpes 1 
Urinary tract infection 1 
Respiratory 
Breathlessness 2 
Incidental finding of asbestos-related pleural plaque 1 
Nasal polyposis 1 
Metabolic Hypercholesterolaemia 3 Increase in diabetes mellitus medications 1 
Circulatory Outpatient coronary imaging 2 Increase in ischaemic heart disease medications 1 
Musculoskeletal 
Arthritis flare 24 
Elbow epicondylitis 2 
Muscle cramp 1 
Lower back pain 1 
Myalgia & lethargy following intravenous bisphosphonate 1 
Pain around knee replacement 1 
Sialadenitis 1 
Skin 
Actinic keratosis 3 
Basal cell carcinoma 2 
Dry skin 1 
Itch 1 
Gastrointestinal 
Diarrhoea 2 
Abdominal pain 2 
Irritable bowel syndrome 1 
Inguinal hernia 1 
Routine elective screening colonoscopy 1 
Fatty liver change on ultrasound 1 
Ophthalmological 
Red/dry eyes 2 
Elective phacoemulsification 2 
Elective ocular punctoplasty 1 
Other 
Influenza vaccination 10 
Fall 5 
Pneumococcal vaccination 1 
Dental extraction 1 
Fatigue 1 
Hay fever 1 
 
Of note, one patient was treated with a 7-day course of oral prednisolone for nasal polyposis 
at 5 months after DMARD cessation. This patient subsequently maintained DFR at their 
month six follow-up visit. This was annotated on the study database to allow for subsequent 
identification during longitudinal data analysis. 
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4.3 Quality control 
4.3.1 Study visits 
 
A total of 184 study visits were conducted, the timings of which are detailed in Table 4.2 
All visits were performed according to the study protocol with no protocol deviations. Two 
patients were unable to attend their month 3 visit owing to personal/family commitments – 
both of these patients subsequently attended their month 6 visit as scheduled. 
 
4.3.2 Missing data 
4.3.2.a Prospectively recorded clinical data 
ESR measurements were not available for 3 patients at baseline owing to insufficient blood 
sample (2 patients) and failure by clinical laboratory to perform test (1 patient). These values 
were left missing in the final dataset, with exclusion of these records as necessary in analyses 
based on ESR values. Aside from this, prospectively recorded clinical data were otherwise 
complete for all other variables. 
 
4.3.2.b Retrospectively recorded clinical data 
Medical notes were available for all patients and the quality of documentation was generally 
excellent. Symptom duration before first rheumatology review was not documented in three 
medical records. For two cases the patient-recollected value was recorded as a substitute – 
however, one patient could not recollect their symptom duration and this value was left 
Table 4.2– Number of study visits. 
Timing of visit Number 
Baseline 74 
Month 1 42 
Month 3 26 
Month 6 23 
Unscheduled (patient-requested) 19 
Total 184 
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 missing in the final dataset. Similarly, time from first rheumatology review to 
commencement of first DMARD was not recorded in two medical records. Both of these 
patients could not recall this duration, and hence these two values were left as missing in the 
final dataset. 
Aside from the above, retrospectively recorded clinical data were otherwise complete for all 
other variables. 
 
4.4 Descriptive analysis 
4.4.1 Patient demographics 
Demographic details of the patients who stopped DMARD therapy are listed in Table 4.3. 
Demographics of all 74 patients who were recruited to the study are listed in Appendix D.  
Overall, the 44 patients who stopped DMARDs are largely representative of an established 
RA outpatient population, with a median of 5.5 years since diagnosis. Half of patients were 
women, slightly less than the expected 2.5:1 female:male ratio for RA. An extended period of 
stable disease control prior to study enrolment was suggested by the prolonged time since 
both last DMARD change and last steroid use (median 22.5 and 30 months respectively). 
Three-quarters of patients were seropositive for either RhF or ACPA in keeping with the 
expected proportion in RA. A similar proportion of patients had ultrasonographic evidence of 
erosions on the baseline ultrasound scan, in keeping with what would be expected clinically 
for an established RA cohort. All patients who stopped DMARDs satisfied the 2010 
ACR/EULAR RA diagnostic criteria, and all patients who stopped DMARDs were 
Caucasian. 
Systemic markers of inflammation were generally low at baseline– of note, one patient did 
have a significantly raised ESR (77mm/hr) though this was secondary to comorbid polyclonal 
hypergammaglobulinaemia as part of secondary Sjögren’s syndrome, and both their CRP and 
DAS28-CRP were low (<5mg/L and 1.07 respectively). A further patient had an elevated 
ESR of 44 leading to an elevated DAS28-ESR (3.23) at baseline, though this patient satisfied 
both DAS28-CRP and ACR/EULAR Boolean remission. Two thirds of patients fulfilled 
Boolean remission – reasons for failure to achieve Boolean remission were: VASpatient 
>10/100 (11 patients), two swollen joints (3 patients) and CRP>10mg/L (1 patient). Of the 11 
patients who had a VASpatient>10/100, the median (range) score was 21 (13-35).  
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Table 4.3 – Demographics of the patients who stopped DMARD therapy. HCQ: 
hydroxychloroquine; MTX: methotrexate; SJC: swollen joint count; SFZ: sulfasalazine; TJC: 
tender joint count. 
Demographic Value 
Number of patients stopped DMARDs 44 
Satisfied 2010 ACR/EULAR RA diagnostic criteria: n(%) 44 (100%) 
Age: median (IQR) [range] 66.5 (54.5 – 71.3) [35 – 82] 
Female: n(%) 23 (52%) 
Years since RA diagnosis: median (IQR) [range] 5.5 (3 – 11) [1 – 40] 
Symptom duration in months prior to first rheumatology 
review: median (IQR) [range] 5 (2 – 8.5) [1 – 60] 
Months from first rheumatology review to starting first 
DMARD: median (IQR) [range] 1 (0 – 3) [0 – 210] 
Months since last steroid: median (IQR) [range] 30 (12 – 46.5) [0 – 95] 
Months since last change in DMARDs: median (IQR) 
[range] 22.5 (12 – 48.5) [2 – 132] 
Current smoker: n (%) 5 (11%) 
Previous smoker: n (%) 21 (48%) 
Never smoker: n(%) 18 (41%) 
Weekly alcohol unit intake: median (IQR) [range] 5 (0 – 10.3) [0 – 50] 
Total DMARDs since diagnosis: median [range] 2 [1 – 4] 
Current MTX monotherapy: n(%) 23 (52%) 
Current SFZ monotherapy: n(%) 4 (9%) 
Current HCQ monotherapy: n(%) 1 (2%) 
Current MTX+SFZ: n(%) 5 (11%) 
Current MTX+HCQ: n(%) 8 (18%) 
Current SFZ+HCQ: n(%) 1 (2%) 
Current MTX+SFZ+HCQ: n(%) 2 (5%) 
RhF positive: n(%) 25 (57%) 
ACPA positive: n(%) 24 (55%) 
RhF or ACPA positive: n(%) 32 (73%) 
RhF and ACPA positive: n(%) 17 (39%) 
Baseline 28 SJC: median (IQR) [range] 0 (0 – 0) [0 – 2] 
Baseline 28 TJC: median (IQR) [range] 0 (0 – 0) [0 – 2] 
Baseline patient VAS (mm): median (IQR) [range] 3 (1 – 10) [0 – 35] 
Baseline CRP in mg/L: median (IQR) [range] 0 (0 – 0) [0 – 13] 
Baseline ESR in mm/hr: median (IQR) [range] 9 (2 – 15) [1 – 77] 
Baseline DAS28-CRP: median (IQR) [range] 1.07 (0.99 – 1.63) [0.96 – 2.34] 
Baseline DAS28-ESR: median (IQR) [range] 1.66 (0.71 – 2.38) [0.48 – 3.23] 
ACR/EULAR Boolean remission: n(%) 29 (66%) 
Presence of joint erosion on baseline 7-joint ultrasound 
scan: n(%) 29 (70%) 
 
Current methotrexate use was common in those patients who went on to discontinue 
DMARDs, reflecting the popularity of this medication in current rheumatology practice. Half 
of patients were taking methotrexate monotherapy, with methotrexate forming part of 
combination DMARD therapy in a further 15 (34%) patients. Only 6 (14%) of patients were 
not taking methotrexate at the time of DMARD cessation – of these patients, 3 had been 
prescribed methotrexate previously. 
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4.4.2 Distribution of arthritis flare events 
Of the 44 patients who stopped DMARDs, 23 (52%) experienced an arthritis flare (defined as 
DAS28-CRP ≥ 2.4) in the 6 months following DMARD cessation. The median (IQR) time to 
flare was 48 (31.5 – 86.5) days, and ranged from 16 – 187 days (Figure 4.2). The median 
flare-free survival was 176 days (95% confidence interval: lower limit 83 days, upper limit 
undefined) (Figure 4.3). 
The median (IQR) DAS28-CRP value at the time of flare was 3.12 (2.62 – 3.94), and ranged 
from 1.58 – 4.51 (Figure 4.4). Note that one patient was classified as experiencing a flare with 
a DAS28-CRP value of 1.58 owing to the presence of synovitis in the ankles and feet (see 
Results 4.2.2) – removing this patient gave a DAS28-CRP range of 2.45 – 4.51 at the time of 
flare. 
 
 
Figure 4.2 – Distribution of flare events by weeks after DMARD cessation. 
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Figure 4.3 – Kaplan-Meier plot of flare-free survival for all patients who stopped DMARDs. 
Shaded region depicts 95% confidence interval of survival estimate. 
 
Figure 4.4 – Distribution of DAS28-CRP score at the time of flare. 
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4.5 Comparison of clinical variables between flare versus remission groups 
Patients who stopped DMARDs were stratified by subsequent flare status (n=43), and the 
statistical significance of differences in values of baseline clinical parameters between flare 
vs. remission groups was assessed by univariate binary logistic regression (Table 4.4).   
 
The 13 variables with a univariate p-value<0.2 were then entered in a multivariate binary 
logistic regression model with backwards stepwise variable selection based on the Akaike 
information criterion (AIC). After 7 rounds of selection, 6 variables remained in the final 
stepwise multivariate binary logistic regression model (Table 4.5). Three variables were 
significantly (p<0.05) associated with increased occurrence of arthritis flare following 
DMARD cessation, namely: failure to satisfy ACR/EULAR Boolean remission at baseline, 
current methotrexate therapy and shorter time since last change in DMARD therapy, though  
the effect size of the latter was negligible (Figure 4.5). 
 
4.6 Survival analysis 
The association between baseline clinical variables and time to flare following DMARD 
cessation was analysed by univariate Cox regression for all 44 patients who stopped 
DMARDs (Table 4.6). Proportionality of hazards was assessed for each univariate variable by 
correlation of scaled Schoenfeld residuals with transformed flare-free survival time (see 
Methods 3.10.1). No significant departure from proportional hazards was observed for any of 
the variables. 
The 15 variables with a univariate p value < 0.2 were then entered simultaneously in a 
multivariate Cox regression model. Stepwise backward selection based on AIC was then 
performed using the same variables to fit a stepwise Cox regression model. After 6 rounds of 
selection, 9 variables remained in this stepwise model (Table 4.7).  
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Table 4.4 – Association of clinical variables with arthritis flare following DMARD cessation 
by univariate binary logistic regression. For continuous variables, logistic regression 
coefficients (B) and odds ratios (OR) are calculated for a 1 unit change in that variable. HCQ: 
hydroxychloroquine; MTX: methotrexate; SFZ: sulfasalazine. 
Variable 
Value in 
flare 
group 
(n = 23) 
Value in 
remission 
group 
(n = 20) 
B ORflare 95% CI ORflare 
Univariate 
p-value 
Median current number of 
DMARDs 
1 1 1.272 3.57 1.00 – 12.64 0.049 
Median months since last 
change in DMARDs 
20 41.5 -0.022 0.98 0.96 – 1.00 0.052 
Median cumulative number 
of DMARDs since diagnosis 
2 1.5 0.716 2.05 0.98 – 4.28 0.057 
Proportion ACR/EULAR 
Boolean remission 
0.52 0.8 -1.299 0.27 0.07 – 1.07 0.063 
Proportion both RhF and 
ACPA positive 
0.52 0.25 1.186 3.27 0.89 – 12.03 0.074 
Proportion current MTX  0.96 0.75 1.992 7.33 0.78 – 69.24 0.082 
Median baseline patient 
VAS (mm) 
5 3 0.066 1.07 0.99 – 1.15 0.086 
Proportion male 0.61 0.35 1.061 2.89 0.83 – 10.01 0.094 
Proportion current HCQ 0.35 0.15 1.106 3.02 0.68 – 13.51 0.148 
Median baseline 28 TJC 0 0 -0.982 0.37 0.10 – 1.45 0.156 
Median months since last 
steroid 
24 40.5 -0.019 0.98 0.96 – 1.01 0.173 
Proportion RhF positive 0.65 0.45 0.829 2.29 0.67 – 7.84 0.186 
Proportion ACPA positive 0.65 0.45 0.829 2.29 0.67 – 7.84 0.186 
Proportion ever smoker 0.52 0.7 -0.760 0.47 0.13 – 1.65 0.236 
Median symptom duration in 
months prior to first 
rheumatology review 
6.5 4.5 0.045 1.05 0.97 – 1.13 0.264 
Proportion baseline DAS28-
ESR remission 
0.90 0.80 0.930 2.53 0.41 – 15.8 0.319 
Proportion either RhF or 
ACPA positive 
0.78 0.65 0.662 1.94 0.50 – 7-49 0.337 
Median weekly alcohol unit 
intake 
6 5 0.031 1.03 0.96 – 1.11 0.398 
Median months from first 
rheumatology review to 
starting first DMARD 
1 1 0.074 1.08 0.90 – 1.29 0.409 
Median years since diagnosis 6 5.5 0.028 1.03 0.95 – 1.11 0.467 
Median age (years) 69 64 0.017 1.02 0.96 – 1.07 0.524 
Proportion current smoker 0.09 0.15 -0.617 0.54 0.08 – 3.61 0.525 
Median baseline HAQ-DI 
score 
0 0.125 -0.356 0.70 0.23 – 2.12 0.528 
Median baseline ESR 
(mm/hr)  
9 6 0.009 1.01 0.97 – 1.05 0.673 
Median baseline 28 SJC 0 0 0.169 1.18 0.43 – 3.25 0.742 
Proportion current SFZ  0.26 0.3 -0.194 0.82 0.22 – 3.13 0.776 
Median baseline CRP 
(mg/L) 
<5 <5 0.024 1.02 0.83 – 1.26 0.822 
Median baseline DAS28-
ESR 
1.66 1.54 -0.024 0.98 0.48 – 1.98 0.946 
Median baseline DAS28-
CRP 
1.35 1 -0.006 0.99 0.25 – 3.97 0.993 
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Table 4.5 - Association of clinical variables with occurrence of arthritis flare following 
DMARD cessation, using a backwards stepwise multivariate binary logistic regression model. 
For continuous variables, logistic regression coefficients (B) and odds ratios (OR) are 
calculated for a 1 unit change in that variable. 
Variable B ORflare 95% CI ORflare Multivariate p 
Baseline ACR/EULAR Boolean 
remission 
-5.011 0.01 0.007 – 0.32 0.011 
Months since last change in 
DMARDs 
-0.055 0.95 0.90 – 0.99 0.019 
Current methotrexate 2.841 17.13 1.27 – 231.10 0.032 
ACPA positive 1.964 7.13 0.91 – 56.07 0.062 
Baseline 28 TJC -1.722 0.18 0.02 – 1.46 0.108 
RhF positive 1.572 4.82 0.70 – 33.27 0.111 
 
Figure 4.5 – Association of baseline clinical variables with occurrence of flare following 
DMARD cessation within a stepwise multivariate binary logistic regression model. OR: odds 
ratio. DMARD change: months since last change in DMARD therapy. 
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Table 4.6 – Association of clinical variables with occurrence of arthritis flare following 
DMARD cessation by univariate Cox regression. For continuous variables, hazard ratios (HR) 
and the Cox regression coefficients (B) are presented for a 1 unit change in that variable. P 
values calculated by the Wald test. HCQ: hydroxychloroquine; MTX: methotrexate; SFZ: 
sulfasalazine. 
Variable B HRflare 95% CI HRflare Univariate p-value 
Double seropositive 0.982 2.67 1.17 – 6.09 0.019 
Symptom duration prior to first 
rheumatology review (months) 
0.036 1.04 1.00 – 1.07 0.032 
Current number of DMARDs 0.704 2.02 1.06 – 3.86 0.033 
Cumulative number of DMARDs since 
diagnosis 
0.401 1.49 0.98 – 2.27 0.060 
Months since last change in DMARD 
therapy 
-0.015 0.98 0.97 – 1.00 0.067 
Male sex 0.763 2.14 0.93 – 4.96 0.075 
ACPA positive 0.752 2.12 0.90 – 5.01 0.087 
Current hydroxychloroquine 0.752 2.12 0.89 – 5.04 0.089 
Baseline ACR/EULAR Boolean 
remission 
-0.692 0.50 0.22 – 1.14 0.098 
Baseline VASpatient 0.032 1.03 0.99 – 1.07 0.100 
RhF positive 0.698 2.01 0.85 – 4.77 0.113 
Months from first rheumatology review 
to starting first DMARD 
0.007 1.01 1.00 – 1.02 0.141 
Current methotrexate 1.422 4.14 0.56 – 30.84 0.165 
Weekly alcohol unit intake 0.033 1.03 0.99 – 1.08 0.167 
Disease duration (years) 0.034 1.03 0.99 – 1.09 0.172 
Baseline 28 TJC -0.700 0.50 0.16 – 1.53 0.222 
Either RhF or ACPA positive 0.612 1.84 0.68 – 4.99 0.229 
Months since last steroid -0.011 0.99 0.97 – 1.01 0.252 
Ever smoker -0.405 0.67 0.29 – 1.52 0.334 
Baseline DAS28-ESR remission 0.579 1.79 0.42 – 7.67 0.436 
Baseline CRP (mg/L) 0.055 1.06 0.92 – 1.21 0.440 
Baseline HAQ-DI -0.295 0.74 0.32 – 1.74 0.495 
Baseline ESR (mm/hr) 0.009 1.01 0.98 – 1.04 0.526 
Age (years) 0.011 1.01 0.97 – 1.05 0.569 
Current smoker -0.314 0.73 0.17 – 3.12 0.671 
Current sulfasalazine -0.109 0.90 0.35 – 2.28 0.819 
Baseline DAS28-CRP 0.080 1.08 0.45 – 2.60 0.858 
Baseline 28 SJC 0.049 1.05 0.54 – 2.02 0.885 
Baseline DAS28-ESR 0.019 1.02 0.63 – 1.64 0.938 
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Table 4.7 - Association of clinical variables with occurrence of arthritis flare following 
DMARD cessation, using a backwards stepwise multivariate Cox regression model. For 
continuous variables, hazard ratios and the Cox regression coefficients (B) are presented for a 
1 unit change in that variable. P values calculated by the Wald test. 
Variable B HRflare 95% CI p value 
Months from first rheumatology 
review to starting first DMARD 
0.034 1.03 1.01 – 1.06 0.008 
RhF positive 1.629 5.10 1.48 – 17.6 0.010 
ACPA positive 1.589 4.90 1.36 – 17.7 0.015 
Baseline ACR/EULAR Boolean 
remission 
-1.126 0.32 0.12 – 0.90 0.031 
Current methotrexate 2.435 11.41 1.25 – 104 0.031 
Months since last change in DMARD 
therapy 
-0.025 0.98 0.95 – 1.00 0.034 
Disease duration (years) -0.127 0.88 0.76 – 1.02 0.092 
Male sex 0.975 2.65 0.80 – 8.73 0.109 
Symptom duration prior to first 
rheumatology review (months) 
0.042 1.04 0.98 – 1.11 0.158 
 
Proportionality of hazards was again assessed for each variable in the final stepwise 
multivariate Cox regression model. A significant departure from proportional hazards was 
observed only for current methotrexate use (p = 0.04), though this was only notable for a 
single outlier with no discernible trend in the remainder of the data (Figure 4.6). The global 
Schoenfeld test was non-significant (p = 0.49), indicating proportionality of hazards for the 
model as a whole. 
Four variables were associated with shorter time-to-flare at the 5% significance level, namely: 
ACPA positivity, RhF positivity, current methotrexate and time from diagnosis to 
commencement of first DMARD. In contrast, fulfilment of ACR/EULAR Boolean remission 
criteria and time since last change in DMARD therapy were associated with a longer time-to-
flare (Figure 4.7). 
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Figure 4.6 – Correlation of scaled Schoenfeld residuals ( Beta(t) ) against Kaplan-Meier-
transformed flare-free survival time for current methotrexate in the stepwise multivariate Cox 
regression model. Dashed lines indicate ± 2 standard errors of the smoothed spline fit with 4 
degrees of freedom (solid line). Discounting the single outlier, there does not appear to be any 
observable correlation between the scaled residuals and survival time. 
 
 
Figure 4.7 - Association of baseline clinical variables with occurrence of flare following 
DMARD cessation within a stepwise multivariate Cox regression model. HR: hazard ratio. 
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The study cohort was dichotomised by presence of these four variables, and the statistical 
significance of differences in survival distributions between groups compared by the log-rank 
test. Presence of RhF or ACPA was associated with a shorter time-to-flare (Figure 4.8 and 
Figure 4.9) – the difference in survival distribution was marginally greater for double 
seropositivity (p = 0.048, Figure 4.10). The survival distributions for presence or absence of 
baseline ACR/EULAR Boolean remission were comparable for the first 3 months – beyond 
this point, the rate of flare in those patients who satisfied Boolean remission plateaued, 
whereas those who failed to satisfy Boolean remission at baseline continued to experience a 
constant ongoing rate of flare. However, the difference in overall survival distributions failed 
to meet statistical significance (Figure 4.11). All but one of the patients not taking 
methotrexate at baseline maintained remission to the end of the follow-up period, though the 
statistical significance of the difference in survival distribution was low owing to the small 
sample size (n=6) (Figure 4.12). 
 
 
Figure 4.8 – Kaplan-Meier plot of DMARD-free survival time stratified by presence (red) or 
absence (blue) of rheumatoid factor. Significance of difference between survival curves was 
assessed by the log-rank test. 
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Figure 4.9 – Kaplan-Meier plot of DMARD-free survival time stratified by presence (red) or 
absence (blue) of ACPA. Significance of difference between survival curves was assessed by 
the log-rank test. 
 
 
Figure 4.10 – Kaplan-Meier plot of DMARD-free survival time stratified by double 
seropositivity (red) or double seronegativity (blue) of RhF and ACPA. Significance of 
difference between survival curves was assessed by the log-rank test. 
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Figure 4.11 – Kaplan-Meier plot of DMARD-free survival time stratified by failure (red) or 
satisfaction (blue) of ACR/EULAR Boolean remission at baseline. Significance of difference 
between survival curves was assessed by the log-rank test. 
 
 
Figure 4.12 – Kaplan-Meier plot of DMARD-free survival time stratified by current use (red) 
or non-use (blue) of methotrexate at baseline. Significance of difference between survival 
curves was assessed by the log-rank test. 
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For the continuous variables, thresholds were determined by receiver operating characteristic 
(ROC) analysis. For time since last change in DMARD therapy, two optimum thresholds 
were set to maximise negative and positive predictive values for flare, corresponding to 
biomarker thresholds for the prediction of remission and flare respectively (Figure 4.13A). 
Patients with a time since last change in DMARD therapy greater than the ‘remission 
threshold’ (i.e. 43 months) had a significantly longer time-to-flare than those below this level 
(log-rank p = 0.014) (Figure 4.13B). In contrast, the distribution of flares in patients with a 
time since last DMARD change shorter than the ‘flare threshold’ (i.e. 13 months) only 
differed from the remainder of the study population towards the end of the follow-up period, 
with no significant difference between overall survival distributions (p = 0.14) (Figure 
4.13C). Time from first rheumatology review to commencement of first DMARD was a 
relatively poor predictor of outcome during the six months of study follow-up (Figure 4.14). 
 
         
Figure 4.13 – A: Receiver operating characteristic (ROC) curve for sensitivity and specificity for flare, as 
predicted by time since last change in DMARD therapy. Crosses indicate the remission (43 months) and flare 
(13 months) thresholds. B: Kaplan-Meier plot of DMARD-free survival stratified by time since last change in 
DMARD therapy of >43 months (blue) or ≤43 months (red). C: Kaplan-Meier plot of DMARD-free survival 
stratified by time since last change in DMARD therapy of >13 months (blue) or ≤13 months (red). P-values 
calculated by log-rank test. 
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Figure 4.14 – A: Receiver operating characteristic (ROC) curve for sensitivity and specificity 
for flare, as predicted by time from first rheumatology review to commencement of first 
DMARD. The cross indicates the 3.1 month threshold. B: Kaplan-Meier plot of DMARD-free 
survival stratified by DMARD commencement time of >3.1 months (red) or ≤3.1 months 
(blue). P-value calculated by log-rank test.   
 
4.7 Composite clinical biomarker score 
Values of the six variables that were significantly (p<0.05) associated with time-to-flare at in 
the multivariate stepwise Cox regression model were multiplied by their respective 
coefficients in the model and then summed to create composite scores. The predictive value of 
all 63 possible combinations of these variables to predict flare and remission following 
DMARD cessation was then compared by area under the receiver-operating characteristic 
curve (ROCAUC). The ten composite scores with the highest ROCAUC are listed in Table 4.8 
(for a full listing, see Appendix E). 
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Table 4.8 - The top ten clinical composite scores ranked by ROCAUC. Variables included 
within each score are indicated in green, and those excluded are indicated in red. 
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      0.833 
      0.805 
      0.798 
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      0.786 
      0.782 
      0.777 
 
Optimal performance was observed for a four-variable composite score incorporating ACPA 
positivity, ACR/EULAR Boolean remission, time since last change in DMARD therapy, and 
current use of methotrexate (Formula 4.1). The composite clinical score performed well its 
ability to discriminate flare versus remission following DMARD cessation, with a total area 
under the ROC curve (ROCAUC) of 0.85 (95% CI 0.73 – 0.97) (Figure 4.15). Optimal 
thresholds were determined to maximise detection of flare (1.82) and remission (0.51) (Figure 
4.15). Both thresholds performed well in the study population, with a positive predictive value 
(PPV) of 0.90 (95% CI 0.78 – 1.00) for the flare threshold, and a negative predictive value 
(NPV) of 0.87 (95% CI 0.69 – 1.00) for the remission threshold (Table 4.9). 
 
Formula 4.1 – Composite clinical biomarker score. Values for binary variables, as indicated 
by the square brackets, are only added to the equation if the variable is present. 
Clinical score = 0.654[ACPA positive] + 1.130[current methotrexate] - 0.521[ACR/EULAR 
Boolean remission] - 0.012(months since last DMARD change) 
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Table 4.9 – Predictive utility of the clinical composite clinical score in predicting flare 
following DMARD cessation, with a positive test defined by either flare or remission 
thresholds. NPV: negative predictive value; PPV: positive predictive value. 
Positive test threshold Sensitivity Specificity PPV NPV 
Flare 
(>1.82) 
0.78 
(0.61 – 0.91) 
0.90 
(0.75 – 1.00) 
0.90 
(0.78 – 1.00) 
0.78 
(0.67 – 0.91) 
Remission 
(>0.51) 
0.91 
(0.78 – 1.00) 
0.60 
(0.40 – 0.80) 
0.72 
(0.62 – 0.85) 
0.87 
(0.69 – 1.00) 
 
 
             
Figure 4.15 - A: Receiver operating characteristic (ROC) curve for sensitivity and specificity 
for flare, as predicted the composite clinical score. B: Kaplan-Meier plot of DMARD-free 
survival stratified by composite clinical score >1.82 (red) versus ≤ 1.82 (blue). C: Kaplan-
Meier plot of DMARD-free survival composite clinical score >0.51 (red) or ≤0.51 (blue). P-
values calculated by log-rank test. 
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4.8 Long-term clinical outcomes 
The medical records of patients who participated in the BioRRA study were reviewed 5 to 6 
months after the end of study recruitment. Formal measures of disease activity were 
frequently not recorded, and hence sustained remission was pragmatically defined as 
satisfaction of all three of: clinical impression of remission by the assessing clinician, no 
escalation of DMARD therapy, and no use of systemic glucocorticoids. Drug-free remission 
was defined as satisfying the above sustained remission definition in the absence of 
DMARDs. 
 
4.8.1 Outcomes following arthritis flare 
Follow-up data was available for 20 of the 23 patients who experienced an arthritis flare and 
restarted DMARD therapy. Of these patients, 15 (75%) were documented to have regained 
remission following study discharge. The infrequent nature of outpatient clinic attendances 
prohibited the analysis of time to regain remission in this group. Of these 15 patients, 10 had 
follow-up data extending beyond 6 months after study discharge, all of whom maintained 
remission, suggesting that remission status was stable once re-achieved. 
Five patients failed to re-achieve remission following study discharge. Of note, 4 of these 
patients elected to restart DMARDs at a lower dose than was prescribed at baseline. Follow-
up data was limited to 1 month following study discharge in the remaining patient. 
 
4.8.2 Outcomes following sustained DFR 
Follow-up data was available for 12 of the 20 patients who maintained DFR during the six-
month study period. Of these, 9/12 (75%) maintained DFR after a median (range) of 5 (2 – 
22) months of follow-up. 
Of the three patients who failed to maintain DFR following discharge from the study: 
1. One patient elected to restart DMARDs at the end of the study period (clinical 
remission, grade 1/3 PD at wrist on ultrasound) and subsequently remained in clinical 
remission after 13 months of follow-up. 
2. One patient received an IM steroid for a possible arthritis flare one month after study 
discharge, though was not clinically reviewed at the time. This patient subsequently 
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remained in clinical remission without DMARDs or further steroids after 9 months of 
follow-up. 
3. One patient restarted DMARDs one month after study discharge following clinician-
observed arthritis flare, though at a lower dose than that prescribed at entry to the 
study. After 19 months of follow-up, this patient was yet to re-achieve remission 
though remained on a lower dose of DMARDs than at study enrolment. 
 
4.9 Discussion 
4.9.1 Occurrence and timing of arthritis flare 
In this study, 23/44 (52%) patients experienced an arthritis flare during the six-month follow-
up period. Although few studies have explored complete DMARD cessation in the setting of 
established RA (reviewed in Introduction 1.6), the occurrence of flare in these studies was 
broadly similar. In the RETRO study, randomisation to complete cessation of a variety of 
biological (bDMARD) and conventional synthetic DMARDs (csDMARDs) was associated 
with arthritis flare (DAS28-ESR > 2.6) in 14/27 (52%) patients by six months after complete 
DMARD withdrawal (Haschka et al., 2016). In the placebo-controlled RCT conducted by ten 
Wolde et al. (1996), cessation of csDMARDs (many of which are now considered historical) 
was associated with a clinical definition of arthritis flare in 53/143 (37%) patients after 12 
months follow-up. In the BeST study, arthritis flare (DAS44 > 1.6) was observed in 56 (49%) 
of 115 patients who tapered DMARDs to complete cessation (Klarenbeek et al., 2011b). 
The apparently consistent proportion of patients who maintain drug-free remission following 
DMARD cessation in this and other studies is even more remarkable given the range of 
different definitions of flare and heterogeneity in DMARDs studied. Indeed, this has been 
cited by some as circumstantial evidence of a possible inherent biological characteristic of 
RA, whereby drug-free remission represents a final end-point in the natural history of the 
disease for a small subset of patients (Scott et al., 2013a). 
Alternative explanations are conceivable; for example, the consistent rate of flare observed in 
the published studies above may represent a common failure of clinical definitions of 
remission to identify patients with low-level subclinical synovitis. Nevertheless, a similar rate 
of flare is observed in this study, despite the mandatory absence of power Doppler signal on a 
7-joint ultrasound scan as a prerequisite for DMARD cessation. Although synovitis may have 
been present in joints outside the scan protocol, one would expect that the exclusion of 19 
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patients on the grounds of PD-positivity alone should have resulted in a lower rate of flare in 
BioRRA in comparison to the above published studies if, indeed, the sole explanation for flare 
was persistent low-grade synovitis at baseline. This raises the possibility that the low-grade 
PD signal observed may not have been indicative of active synovitis (discussed further in 
Chapter 5). Nevertheless, direct comparison between this and other studies is difficult owing 
to heterogeneity in patient demographics, baseline DMARD therapy and methodology of 
DMARD withdrawal. 
In this study, the median (IQR) time-to-flare was 48 (31.5 – 86.5) days after DMARD 
cessation, which was shorter than that observed in other studies. For example, ten Wolde et 
al. (1996) observed flare at a mean (sd) of 24 (16) weeks after DMARD cessation, whereas 
arthritis flare occurred at a median (IQR) of 5 (2 – 16) months after achievement of complete 
DMARD cessation in the BeST study (Klarenbeek et al., 2011b). In the RETRO study, 
patients who completely stopped mediation first tapered DMARDs to 50% dose for 6 months, 
with the majority of flares occurring towards the end of this six-month tapering phase 
(Haschka et al., 2016). Indeed, during the design of the BioRRA study it was anticipated that 
most flare events would occur in the final 3 months of follow-up; the fact that the opposite 
occurred was unexpected.  
The reason that arthritis flares occurred sooner in my study in comparison to others is not 
immediately apparent. Assessment of disease activity in my study was performed only 
slightly more frequently during the six month follow-up period than in the RETRO study (one 
more visit), and less frequently than by ten Wolde et al. (1996) (one less visit). It is thus 
unlikely that frequency of assessment would have substantially affected the detection of flare 
events. Another explanation is that my study included a greater proportion of patients with 
subclinical active synovitis – however, as discussed above, this would seem counterintuitive 
given the use of musculoskeletal ultrasound. Alternatively, patients recruited to my study may 
have had a more severe or unstable RA phenotype, which more readily transitioned to flare 
following DMARD cessation. However, a difference in clinical disease phenotype is not 
suggested by the broadly equivalent prevalence of RhF positivity in my study (57%) as 
compared to ten Wolde et al. (1996) (66%) and in the DMARD-discontinuation arm of the 
RETRO study (67%). In addition, the prevalence of ACPA positivity was similar in both my 
study (55%) and the DMARD discontinuation arm of the RETRO study (63%). Furthermore, 
the long time since last steroid use or change in DMARD therapy (median 30 and 22.5 
months respectively) in my study would suggest an extended period of excellent, as opposed 
to unstable, disease control. 
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One possible explanation for the earlier occurrence of arthritis flare is an excessively stringent 
flare definition. In my study, a single DAS28-CRP ≥ 2.4 measurement at any point during the 
follow-up period was sufficient for categorisation of arthritis flare and exit from the study. 
This decision was driven by concern at the study design phase that patients may experience 
severe arthritis flares, and hence a desire for early intervention to prevent this. However, 8/23 
(35%) of patients who experienced an arthritis flare exited the study with a DAS28-CRP score 
< 2.9, which arguably may have settled back to remission levels with time in a subset of 
patients. Indeed, an alternative flare definition may have been more appropriate to account for 
this borderline group – for example, either i) DAS28-CRP ≥ 2.9, or ii) 2.4≥DAS28-CRP > 2.9 
on two occasions 7 days apart. Similar leniency for such borderline patients has been 
permitted in the flare definitions of other DMARD withdrawal studies; for example, the U-
Act-Early study permitted ≤2 visits with 2.6≤DAS28-ESR<3.2 within its sustained remission 
definition (Bijlsma et al., 2016). Nevertheless, such definitions would risk losing specificity 
for drug-free remission, which was the primary focus of this study. Indeed, the robust 
inflammatory signatures seen in longitudinal cytokine and gene expression analyses – as 
discussed in Chapters 6 and 7 – corroborate an active inflammatory state at the time of flare 
within the flare patient group. 
 
4.9.2 Recovery from arthritis flare 
One concern when designing this study was that arthritis flare may prove difficult to control, 
even after recommencement of DMARDs. It was therefore reassuring to observe that clinical 
remission was regained for the majority (15/20) of patients for whom outcome data was 
available following study discharge. Furthermore, 10 of these 15 patients had follow-up data 
extending beyond 6 months after study discharge, suggesting that remission was stable once 
re-achieved. Importantly, 4/5 of the patients who failed to regain remission elected to restart 
DMARDs at a lower dose than that prescribed at baseline, and the remaining patient had no 
follow-up data beyond just one month after study discharge. It would thus appear that robust 
disease remission is relatively easily regained, provided prompt administration of DMARDs 
at the time of flare and at the original dose, with additional intramuscular glucocorticoid as 
required. Longer-term outcome data is required, but these provisional findings are in keeping 
with the generally high rates of restoration of remission following arthritis flare that have 
been observed in other DMARD tapering and withdrawal studies (see Introduction 1.6). 
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4.9.3 Stability of drug-free remission 
A weakness of this study is the short six-month duration of follow-up, which was an 
unavoidable consequence of the limited study resources and time available within this PhD 
Fellowship. It is thus entirely conceivable that patients who exited the study in drug-free 
remission (DFR) may have experienced an arthritis flare in the immediate few months 
following study discharge. Long-term outcome data for this group was limited, partly owing 
to the infrequent outpatient reviews of patients in clinical remission, which are often 
conducted at yearly intervals. Nevertheless, follow-up data was available for 12/20 patients 
who maintained DFR for the duration of the study, of which 9/12 maintained DFR after a 
median (range) of 5 (2 – 22) months of follow-up after study discharge. Again, longer-term 
outcome data is required, though this data is clearly encouraging and is in keeping with the 
long-duration of DFR (median follow-up of 23 months) that was observed in the BeST study 
(Klarenbeek et al., 2011b). 
 
4.9.4 Baseline predictors of drug-free remission 
Of the six variables significantly associated with time-to-flare in the multivariate stepwise 
Cox regression model, four had discriminatory value in a composite score for predicting flare 
and remission in the six months after DMARD cessation. ACPA and RhF positivity were 
predictive of increased likelihood of flare; and ACR/EULAR Boolean remission and months 
since last DMARD change were predictive of increased likelihood of remission. 
 
4.9.4.a Autoantibody status 
There is in general a dearth of evidence surrounding biomarkers of drug-free remission in RA. 
Nevertheless, data is emerging from a small number of recent studies that suggests 
autoantibody status is predictive of flare following DMARD cessation. RhF positivity has 
been consistently associated with an increased risk of arthritis flare in three independent 
prospective DMARD withdrawal studies (ten Wolde et al., 1996; Tanaka et al., 2010; Fautrel 
et al., 2016). Indeed, RhF positivity was associated with an approximately 2 – 4 times 
increase in risk of arthritis flare in multivariate analysis in these studies (see Introduction 1.7), 
similar to the multivariate HRflare of 5.10 (95% CI 1.48 – 17.6) presented herein. Similarly, 
ACPA positivity has been associated with an approximately 5 – 10 times increased risk of 
arthritis flare in three independent prospective studies (Klarenbeek et al., 2011b; El Miedany 
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et al., 2016; Haschka et al., 2016), which again is in keeping with the stepwise multivariate 
HRflare of 4.90 (95% CI 1.36 – 17.67) observed in my study. Both ACPA and RhF positivity 
are well-established prognosticators of poor outcome in RA, identifying a subset of patients 
who are at greater risk of joint erosions and extra-articular manifestations of the disease. It is 
entirely conceivable that patients with more aggressive disease, as defined by autoantibody 
positivity, are at greater risk of relapse following DMARD cessation. Compelling evidence 
now links seropositive RA with a breakdown of tolerance to citrullinated peptide 
autoantigens, likely generated by environmental insults in the lung and other mucosal sites 
(see Introduction 1.2.2). If DMARDs provide a pharmacological brake to such processes, it is 
thus conceivable that latent autoimmunity could be unleashed following DMARD cessation in 
the presence of continued exposure to citrullinated autoantigens. Indeed, the very presence of 
circulating autoantibodies confirms the presence of autoreactive B/plasma cells (and likely 
CD4+ T cells), which could be the effectors in such a process. Longitudinal analysis of the 
circulating autoantibody repertoire in the approach to arthritis flare may shed further light on 
this topic and would be a possible extension to this current work. 
 
4.9.4.b Time since last DMARD change 
The inverse association between time since last DMARD change and risk of arthritis flare 
observed in this study does have face validity, given that this is a surrogate measure of recent 
stability of arthritis control. Due to the design of my ‘real-world’ study of patients with 
established RA, it was not possible to formally assess disease activity in the period before 
study enrolment. Such an assessment was however possible in the BeST study, in which 
DMARD-naïve patients were recruited, received treatment in a prospective clinical trial 
setting, and then discontinued DMARDs once remission was achieved. In the BeST study, 
higher mean disease activity (DAS-44) in the period before DMARD cessation was indeed 
predictive of an increased risk of flare (ORflare 4.7, 95% CI 1.5 – 15.2). Owing to different 
measures of disease stability and different methods of statistical analysis, it is not possible to 
directly compare this finding to the results of my study. Nevertheless, these data do suggest 
that period of stable remission prior to DMARD cessation is important in increasing the 
chance of successful DMARD withdrawal. Whether this reflects a necessary period of 
immune homeostasis – perhaps permissive for a pro-tolerogenic modulation of immunity 
mediated by mechanisms such as epigenetic modification – or is simply indicative of a less 
severe clinical phenotype, remains to be determined. 
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4.9.4.c Current methotrexate use 
Current use of methotrexate was significantly associated with increased flare in the six 
months following DMARD cessation in my study, albeit with a wide confidence interval 
(HRflare 11.41, 95% CI 1.25 – 104.47, p = 0.031). This finding does not appear to have been 
replicated in the published literature, and indeed is contradicted by the BeST study that found 
a lower rate of flare in those patients who discontinued methotrexate versus sulfasalazine 
(Klarenbeek et al., 2011b). When interpreting this result, it is prudent to note that only 6/44 
(14%) patients in my study were not receiving methotrexate at baseline, only one of whom 
experienced an arthritis flare. Despite its statistical significance in the multivariate Cox 
analysis of clinical variables, it is thus possible that non-use of methotrexate was confounded 
by another unmeasured variable. Furthermore, given the popularity of methotrexate as a first-
line DMARD in current clinical practice, it is likely that patients who were not receiving 
methotrexate at baseline were fundamentally different from their counterparts, for example in 
terms of comorbidities or disease activity. Taken together, there is reasonable grounds to 
suspect that the observed effect of current methotrexate use in this study could be artefactual – 
further study with a larger independent cohort is required to confirm this. 
 
4.9.4.d ACR/EULAR Boolean remission 
A notable finding of this study is that fulfilment of ACR/EULAR Boolean remission at 
baseline is associated with a 3-fold lower risk of arthritis flare in the six months following 
DMARD cessation. Given the relatively new introduction of this remission definition, data 
surrounding its utility in the prediction of DFR following DMARD cessation remains scarce. 
The only study to have previously addressed this issue is the RETRO study, which 
demonstrated only a non-significant trend towards lower flare rate in those satisfying 
ACR/EULAR Boolean remission (ORflare 0.673, 95% CI 0.211 – 2.144, p = 0.503) (Haschka 
et al., 2016).  
The precise properties of ACR/EULAR Boolean remission that confer its predictive value in 
this study remain open to question. Any of the individual components that constitute 
ACR/EULAR Boolean remission failed to demonstrate a significant association with time-to-
flare in the multivariate analysis, suggesting that it is the combination of variables within the 
definition that is of importance. Although not designed specifically for clinical use, a major 
limitation of the use of ACR/EULAR Boolean remission in clinical practice lies in its 
stringent VASpatient ≤ 10/100 threshold (see Introduction 1.5.1). Indeed, 10/74 (15%) of 
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patients recruited to my study satisfied DAS28-CRP remission at baseline yet failed to 
achieve ACR/EULAR remission solely on grounds of VASpatient alone (median 22/100, range 
12 – 34). A modified Boolean remission criteria incorporating a higher VASpatient threshold 
(for example ≤20/100) may have greater specificity for flare without losing sensitivity. Such 
analysis is however not possible using my small dataset, and would be of interest in future 
larger cohorts.  
 
4.10 Summary 
A similar proportion of patients experienced an arthritis flare in my study (44/23, 52%) 
compared to other published studies. However, arthritis flares occurred after an unexpectedly 
short duration following DMARD cessation in my study compared to others, for reasons that 
are not readily apparent. Rapid resumption of DMARD therapy at the same dose as baseline, 
with supplementary intramuscular steroid depot injection, was sufficient to quickly restore 
clinical remission in the vast majority of patients. Many patients who maintained DFR for the 
duration of study follow-up remained in remission beyond the end of the study, though further 
long-term follow-up data is required. 
Autoantibody status (ACPA and RhF positivity) predicted flare following DMARD cessation, 
corroborating the observations of other studies. Current methotrexate use was also positively 
associated with flare, though there is uncertainty surrounding the validity of this finding. In 
contrast, longer time since last DMARD change and ACR/EULAR Boolean remission were 
both negatively associated with flare, suggesting a robust and stable clinical remission 
phenotype at baseline in those patients who subsequently achieved sustained drug-free 
remission. 
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Chapter 5. Results 2 – Ultrasound data 
 
5.1 Introduction 
Musculoskeletal ultrasound provides a semi-quantitative measure of disease activity that is 
complementary to clinical and laboratory assessments (see Introduction 1.4). By direct 
visualisation of synovial thickening and increased vascularity, US imaging can be used both 
to corroborate clinical findings and to detect subclinical synovitis. However, there remains 
considerable uncertainty surrounding the optimum number of joints to scan, and the 
acceptable threshold of ultrasonographic parameters that constitute clinically relevant 
synovial pathology in the absence of symptoms of disease (see Introduction 1.5). 
Furthermore, the potential role of ultrasound as a treatment target in RA has been challenged 
by negative results from recent large treat-to-ultrasound-target clinical trials (see Introduction 
1.5). Despite these limitations, US imaging is a unique non-invasive modality by which 
subclinical disease activity can be assessed, and thus is ideally placed to serve as a potential 
biomarker of DFR in RA. However, virtually no studies have explored the predictive utility of 
musculoskeletal ultrasound in the setting of DMARD-cessation (see Introduction 1.7). 
In this chapter, I outline the ultrasound data of the BioRRA study. I first describe the quality 
of ultrasound image acquisition and scoring, followed by a descriptive analysis of differences 
between ultrasound parameters at baseline between flare and remission groups, and 
longitudinal change from baseline to month six. I then explore the association of ultrasound 
parameters with both baseline clinical variables and time-to-flare following DMARD 
cessation.  
The structure of the remainder of this chapter is as follows: 
5.2 Quality control 
5.3 Descriptive analysis: 
5.4 Association between clinical and ultrasound parameters in RA remission 
5.5 Survival analysis 
5.6 Discussion 
5.7 Summary 
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5.2 Quality control 
A total of 97 seven-joint US7 ultrasound scans (see Methods 3.6) comprising 3089 images 
were recorded. Ultrasound scans were performed at baseline for all 74 patients who were 
enrolled in the study, and for all 23 patients who attended a month 6 appointment. The median 
(IQR) time taken to perform the scans was 21 (19 – 23) minutes, ranging from 14 – 35 
minutes. 
Ultrasound scores recorded at the time of image acquisition were compared with scores 
recorded at subsequent image re-grading by the same ultrasound operator (KB) to calculate 
the intra-rater agreement. Intra-rater agreement in ultrasound scores was high, as measured by 
Cohen’s kappa statistic (see Methods 3.10.1). The strength of agreement was greater when 
linear weighting was employed, indicating that the majority of disagreements were small in 
magnitude (Table 5.1). Weaker agreement was observed for tendon greyscale (GS) change, 
owing in part to fewer observed events as each individual disagreement contributed 
proportionately more to the Kappa statistic in comparison to, for example, joint GS scores. 
The overall kappa value for intra-rater agreement was 0.73, which compares favourably to the 
value of 0.64 observed in the original US7 publication (Backhaus et al., 2009).  
Inter-rater agreement was assessed by comparison of ultrasound scores recorded at the time of 
image review between the original ultrasound operator (KB) and a second blinded observer 
(BT). Inter-rater agreement was, as expected, lower than intra-rater agreement in ultrasound 
scores, though generally followed a comparable profile. Both intra- and inter-rater agreement 
compares favourably with those observed by the authors of the original US7 scan publication 
(Table 5.2) (Backhaus et al., 2009).  
 
5.3 Descriptive analysis 
5.3.1 Prevalence of ultrasound-detected abnormalities at baseline 
The prevalence of ultrasonographic findings at baseline is detailed in Table 5.3. As per the 
design of the study, no patient with any degree of PD signal was permitted to stop DMARDs. 
All patients had GS change recorded in at least one joint, reflecting a high prevalence of GS 
change in this established RA cohort. 
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Table 5.1 – Intra- and inter-rater agreement in ultrasound scores, as assessed by Cohen’s 
kappa statistic. Kappa scores are listed with and without linear weighting. Number of events 
was calculated as the number of images containing any degree of the specified ultrasound 
finding as recorded in the original ultrasound score. For binary parameters (i.e. tendon GS and 
erosions), weighted kappa scores are identical to their unweighted counterparts and are 
omitted here for clarity. 
Intra-rater agreement Inter-rater agreement 
Parameter 
Number 
of scores 
Number 
of events 
Unweighted 
κ 
Weighted 
κ 
Unweighted 
κ 
Weighted 
κ 
Joint GS 864 356 0.62 0.69 0.46 0.56 
Joint PD 1248 40 0.92 0.95 0.74 0.79 
Tendon GS 672 45 0.45  0.37  
Tendon PD 672 4 1.00 1.00 0.57 0.77 
Erosions 1344 181 0.79  0.71  
Total 4800 626 0.73 0.77 0.62 0.68 
Table 5.2 – Comparison of inter-rater agreement in ultrasound scans between this study and 
the original US7 publication by (Backhaus et al., 2009). κ: unweighted Cohen’s kappa 
statistic. 
Inter-rater unweighted κ 
Parameter BioRRA Backhaus 
Joint GS 0.46 0.55 
Joint PD 0.74 0.67 
Erosions 0.71 0.56 
Table 5.3 – Prevalence and distribution of scoring of ultrasonographic findings at baseline. 
Parameter All patients (n = 74) 
Patients who stopped 
DMARDs (n = 44) 
Proportion with joint GS: n(%) 74 (100) 44 (100) 
Proportion with joint PD n(%) 21 (28) 0 (0) 
Proportion with tendon GS: n(%) 31 (42) 21 (48) 
Proportion with tendon PD: n(%) 2 (3%) 0 (0) 
Proportion with erosions: n(%) 51 (69) 29 (66) 
Total joint GS score: median (IQR) [range] 5 (3 – 6) [1 – 10] 5 (3 – 6) [1 – 8] 
Total joint PD score: median (IQR) [range] 0 (0 – 1) [0 – 7] n/a 
Total tendon GS score: median (IQR) [range] 0 (0 – 1) [0 – 3] 0 (0 – 1) [0 – 2] 
Total tendon PD score: median (IQR) [range] 0 (0 – 0) [0 – 5] n/a 
Total erosion score: median (IQR) [range] 0 (0 – 3) [0 – 10] 2 (0 – 3) [0 – 8] 
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The baseline distribution of total joint GS, tendon GS and erosion scores by flare status in 
those patients who stopped DMARDs is depicted in Figures 5.1 – 5.3. No significant 
differences were observed in the distributions of total baseline ultrasound scores between the 
two groups (p = 0.27, p = 0.67, and p = 0.28 for joint GS, tendon GS and erosion total scores 
respectively by Mann-Whitney U test). Analysis at the individual joint level also failed to 
demonstrate any significant differences between flare and remission groups (p = 0.76, p = 
0.26, and p = 0.45 for number of joints with GS≥1, GS≥2, and erosive change respectively).   
 
    
 
     
Figure 5.1 – Distribution by flare status of total joint GS score (A), number of joints with 
GS≥1 (B), and number of joints with GS≥2 (C) at baseline in patients who stopped DMARDs 
(p value calculated by Mann-Whitney U test). 
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Figure 5.2 – Distribution by flare status of total tendon GS score at baseline in patients who 
stopped DMARDs (p value calculated by Mann-Whitney U test). 
 
          
Figure 5.3 – Distribution by flare status of total erosion score (A), and number of joints with 
erosive change (B) at baseline in patients who stopped DMARDs (p value calculated by 
Mann-Whitney U test). 
 
5.3.2 Longitudinal change in ultrasound scores  
The distributions of total ultrasound scores at baseline and month six visits in the 20 patients 
who maintained DFR for the duration of study follow-up are summarised in Table 5.4. 
Tendon PD was not observed in any of these patients on the month 6 scans. No significant 
differences were observed in the distributions of total ultrasound scores between baseline and 
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month 6 scans (p > 0.999, p = 0.174, p = 0.402, and p = 0.098 for joint GS, joint PD, tendon 
GS and erosion total scores respectively by paired Wilcoxon signed rank sum test) (Figure 
5.4).  
Of the 23 patients who experienced a flare during study follow-up, only 3 attended a month 
six appointment and thus had a repeat ultrasound scan. All three patients had developed grade 
1/3 PD in a single joint at month 6, and 2/3 demonstrated increased joint GS compared to 
baseline (Figure 5.5A). There was no change in tendon GS score and no patient had tendon 
PD signal. There was no increase in total erosion score compared to baseline (Figure 5.5B). 
The small sample size prohibited statistical analysis in this group. 
 
        
       
Figure 5.4 – Distribution of total joint GS scores (A), total joint PD scores (B), total tendon 
GS scores (C), and total joint erosion scores (D) at baseline and month 6 for patients who 
maintained DFR (p value calculated by paired Wilcoxon signed rank sum test). 
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Table 5.4 – Distribution of ultrasound scores at baseline and month six visits for the 20 
patients who maintained DMARD-free remission for the duration of the study. PD (joint or 
tendon) was not observed at baseline by virtue of the study design, and none of the patients 
had tendon PD at month 6. 
Parameter Baseline visit Month 6 visit 
Total joint GS score: median (IQR) [range] 4.5 (2.7 – 6) [1 – 8] 5 (3 – 6) [2 – 8] 
Total joint PD score: median (IQR) [range] n/a 0 (0 – 0) [0 – 2] 
Total tendon GS score: median (IQR) [range] 0 (0 – 1) [0 – 2] 0 (0 – 0.3) [0 – 2] 
Total tendon PD score: median (IQR) [range] n/a n/a 
Total erosion score: median (IQR) [range] 1.5 (0 – 2.3) [0 – 5] 1 (0 – 2) [0 – 3] 
 
         
Figure 5.5 – Change in total joint GS score (A), and total erosion score (B) for the three 
patients who experienced an arthritis flare and had an ultrasound scan at six months. Each line 
represents the trajectory of an individual patient. 
 
5.4 Association between clinical and ultrasound parameters in RA remission 
The association between baseline clinical and ultrasound parameters was explored by 
multivariate ordinal logistic regression. Clinical parameters that were felt likely to correlate 
with ultrasound measures were selected, namely: sex, age, disease duration, smoking history, 
alcohol intake, RhF and ACPA positivity, ACR/EULAR Boolean remission, baseline HAQ-
DI score, ESR and the individual components of the DAS28-CRP score. Patients who either 
had a baseline DAS28-CRP ≥ 2.4 (n = 7) or who had failed to meet either 1987 or 2010 RA 
diagnostic criteria (n=1) were excluded, leaving 66 patients with RA in clinical remission for 
  
153 
 
analysis. Regression was performed separately with each individual ultrasound parameter as 
the dependent variable (Appendix F); however, there were insufficient occurrences of tendon 
PD signal to allow for its statistical analysis.  
Seven variable-score associations were statistically significant at the unadjusted p<0.05 level: 
male sex and ESR versus joint GS score; disease duration, tender joint count and ESR versus 
erosion score; and swollen joint count and alcohol intake versus tendon GS. (Figure 5.6).  The 
largest effect was observed for male sex, which was associated with increased total joint GS 
score (ORGS 5.04, 95% CI 1.47 – 17.26, p = 0.010). Higher ESR was also associated with 
higher joint GS score, though the effect size was small and of borderline significance (ORGS 
1.05 per year of disease, 95% CI 1.00 – 1.09, p = 0.038). Joint erosion was positively 
associated with disease duration (ORerosion 1.16, 95% CI 1.06 – 1.27, p = 0.002) though was 
negatively associated with tender joint count (ORerosion 0.17, 95% CI 0.05 – 0.56, p = 0.004) 
and ESR (ORerosion 0.92, 95% CI 0.85 – 0.99, p = 0.022). For tendon GS, swollen joint count 
showed a positive association (ORtendon.GS 5.37, 95% CI 1.46 – 19.72, p = 0.011) and alcohol 
intake showed a borderline negative association (ORtendon.GS 0.88, 95% CI 0.77 – 1.00, p = 
0.044). All other variables failed to show a significant association with any of the ultrasound 
scores at the unadjusted 5% significance level. 
To take account of multiple testing, p values were corrected according to the Benjamini-
Hochberg procedure. After multiple test correction, only two associations remained 
significant, namely disease duration versus erosions (corrected p = 0.024) and tender joint 
count versus erosions (p = 0.025). 
 
5.5 Survival analysis 
The association between baseline ultrasound parameters (joint GS, tendon GS and erosions) 
and time-to-flare was analysed by Cox regression for all 44 patients who stopped DMARD 
therapy. Patients with higher total joint GS and erosion scores at baseline tended towards a 
shorter time-to-flare, though this was not statistically significant in either univariate or 
multivariate analysis (Table 5.5, Table 5.6 and Figure 5.7).  
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Figure 5.6 – Association between clinical and ultrasound parameters at baseline in a 
multivariate ordinal logistic regression model. OR: odds ratio. * = unadjusted p < 0.05, ** = 
Benjamini-Hochberg corrected p < 0.05) 
Table 5.5 – Association of baseline ultrasound parameters with time-to-flare following 
DMARD cessation by univariate Cox regression. 
Variable HRflare 95% CI 
Univariate p-
value 
Total joint GS score 1.14 0.93 – 1.40 0.216 
Total tendon GS score 1.01 0.52 – 1.97 0.980 
Total erosion score 1.17 0.96 – 1.43 0.114 
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Table 5.6 – Association of baseline ultrasound parameters with time-to-flare following 
DMARD cessation by multivariate Cox regression. 
Variable HRflare 95% CI 
Multivariate 
p-value 
Total joint GS score 1.15 0.93 – 1.43 0.208 
Total tendon GS score 1.00 0.49 – 2.07 0.995 
Total erosion score 1.18 0.96 – 1.44 0.109 
 
 
 
Figure 5.7 – Association between baseline ultrasound parameters and time-to-flare following 
DMARD cessation in a multivariate Cox regression model. 
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5.6 Discussion 
5.6.1 Power Doppler 
The primary focus of this study was to identify biomarkers of drug-free remission in RA. As 
such, it was considered advantageous to ensure as far as possible that all patients who were 
recruited to the study were genuinely in remission with no demonstrable evidence of 
synovitis. With this in mind, a decision was made during the design of the study not to 
withdraw DMARDs from patients with any grade of PD signal on a 7-joint musculoskeletal 
ultrasound scan. In doing so, it was acknowledged that low-level non-specific PD signal 
unrelated to RA activity might preclude DMARD cessation in otherwise eligible patients. 
Indeed, PD positivity has been observed in approximately 5% of healthy individuals (Millot et 
al., 2011; Padovano et al., 2016). Nevertheless, data emerging at the time of study design that 
supported a prognostic role of PD signal in predicting future flare (Saleem et al., 2012) and 
joint erosion (Foltz et al., 2012), combined with evidence of a correlation between PD-
positivity and increased circulating angiogenic biomarkers (Ramirez et al., 2014), was 
deemed sufficiently strong evidence to support the need for exclusion of PD-positive patients 
in this study. 
Several criteria were specified for the definition of PD-positivity at the wrist in order to 
minimise the unnecessary exclusion of patients from DMARD withdrawal. These pragmatic 
criteria allowed for the inclusion of patients with single vessel PD signal, provided its origin 
could be easily traced, there was no branching within the joint space, and there was no 
surrounding greyscale change (see Methods 3.6). Despite these modifications, 19/30 (63%) of 
the patients who were excluded from DMARD withdrawal did so on the grounds of PD 
positivity alone, of which 7 had a single measurement of grade 1/3 PD signal at the wrist 
only. 
Following the design of this study, several studies of biologic withdrawal in RA have 
identified PD signal as a predictor of arthritis relapse (Iwamoto et al., 2014; Naredo et al., 
2015; Lamers-Karnebeek et al., 2016). However, other studies have raised questions as to the 
value of ultrasound in the management of RA, with two recent large prospective trials 
(ARCTIC and TaSER) both failing to demonstrate a benefit of treat-to-ultrasound-target 
strategies over clinical targets alone (Dale et al., 2016; Haavardsholm et al., 2016). These 
findings have led to a recent shift away from a focus on ultrasound-defined treatment targets 
(Caporali and Smolen, 2018), though further research is needed. Given the current lack of 
clarity surrounding the role of ultrasound in the management of RA, hindsight suggests that 
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excluding patients with positive PD signal may have been a weakness in study design, both 
limiting recruitment and precluding assessment of its predictive utility in this setting. 
Nevertheless, analysis of the utility of other ultrasound parameters was possible, including 
greyscale hypertrophy at both joints and tendons, and joint bony erosions.  
 
5.6.2 Baseline predictors of drug-free remission 
Joint greyscale hypertrophy, joint erosions, and tendon greyscale change were explored for 
their utility in predicting DFR following DMARD cessation. Total scores for all three 
measures, as well as counts at the individual joint level, all failed to show a significant 
association with time-to-flare in univariate Cox regression analysis. 
Few studies that have explored the predictive value of ultrasound in the setting of DMARD 
withdrawal, the results of which are often contradictory with wide confidence intervals, 
particularly for GS and erosion measures. In a study of bDMARD tapering in 77 patients in 
remission (Naredo et al., 2015), total GS score in 12 joints was a significant predictor of flare 
at 12 months in univariate analysis (p=0.028), though not at 6 months (p=0.370) and not in 
the full 42-joint set (p = 0.187 at 12 months). In another study of 42 RA patients in remission 
discontinuing biologic therapy, both total GS and PD scores were significant univariate 
predictors of flare (p < 0.01), though a multivariate analysis was not performed (Iwamoto et 
al., 2014). In a retrospective study of 40 patients discontinuing bDMARD therapy (Kawashiri 
et al., 2017), bone erosion on ultrasound was the only significant predictor of flare in a 
multivariate analysis (ORflare 8.35, 95% CI 1.78 – 53.2, p = 0.006). Finally, in a prospective 
study of csDMARD and bDMARD withdrawal, baseline ultrasound parameters demonstrated 
no utility for prediction or flare or drug-free remission (El Miedany et al., 2016).  
When comparing these results to those of my study, it is important to remember that the 
setting of the majority of these trials is very different, with a focus largely upon bDMARD 
withdrawal (with continued csDMARDs) and not complete DMARD cessation. It is thus 
conceivable that the patients within these studies have a more aggressive disease phenotype 
that may respond differently to the challenge of DMARD withdrawal. The results of my study 
therefore add useful data to the field and suggest, within the confines of limited sample size, 
that ultrasound-defined GS hypertrophy and erosions have limited role in the prediction of 
DFR following complete DMARD cessation. 
  
158 
 
5.6.3 Association of baseline ultrasound and clinical parameters 
The association between baseline clinical and ultrasound parameters was explored for all 66 
patients who both satisfied DAS28-CRP remission at baseline and who satisfied either 1987 
or 2010 RA diagnostic criteria at baseline. After multiple test correction, two clinical 
variables demonstrated a significant association with joint erosions at baseline: disease 
duration (ORerosion 1.16, 95% CI 1.06 – 1.27, adjusted p = 0.024), and baseline tender joint 
count (ORerosion 0.17, 95% CI 0.05 – 0.56, p = 0.025). 
The positive association between disease duration and erosions is expected, given that patients 
who have had RA for a longer period of time are likely to have been exposed to a longer 
cumulative duration of active synovitis. Furthermore, those with longer disease duration are 
likely to have ben diagnosed at a time when intensive early DMARD therapy was not 
standard-of-care for RA, and thus may have been more at risk of developing erosions in the 
early phases of the disease. The observation that patients with higher tender joint counts had 
less erosions is however unexpected, and perhaps suggests joint pain unrelated to RA activity 
in these patients – such as comorbid osteoarthritis for example. Intriguingly, Cheung et al. 
(2016) also observed a negative correlation between joint tenderness and future radiographic 
progression in RA patients starting anti-TNF therapy, though only in the absence of 
ultrasound-defined synovitis. Whether these observations reflect a distinct subset of ‘high 
pain, low erosion’ patients remains to be determined. 
Few studies have examined the correlation between clinical and ultrasound measures of 
remission. In a cross-sectional study of 94 patients with RA, Peluso et al. (2011) found that 
early disease was associated with greater odds of combined GS and PD negativity (OR 7.6, 
95% CI 2.3 – 25.8), in keeping with the non-significant trend towards higher GS with longer 
disease duration in my study. In contrast to my study, Peluso et al. (2011) demonstrated a 
positive association between ACR/EULAR Boolean remission and combined GS/PD 
negativity. However, in a cross-sectional analysis of 128 patients with RA in remission 
(DAS28-ESR < 2.6), Saleem et al. (2011) found no significant association of ACR/EULAR 
Boolean remission, CRP or tender joint count with either total GS nor total PD scores, in 
keeping with the negative findings of my study.  
In summary, there was little correlation between clinical variables and ultrasound measures at 
baseline in those patients in clinical remission after application of multiple-test correction, 
notably including the key measure of PD positivity. If low-grade PD does indeed reflect 
clinically significant active synovitis despite clinical remission – as suggested by 
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histopathological studies (Alivernini et al., 2017)  – this would suggest that ultrasound 
assessment is necessary in addition to clinical assessment in order to detect subclinical 
inflammation prior to contemplating DMARD cessation. Nevertheless, the negative results of 
recent treat-to-ultrasound target initiatives, such as the ARCTIC and TaSER studies, suggest 
that such low-level PD signal may perhaps not be of clinical significance in the setting of 
clinical remission. This issue cannot be addressed further with the data from this study – 
further research in an independent cohort is required to validate these observations as well as 
address the significance of low-level PD in the setting of DMARD cessation.  
 
5.6.4 Longitudinal ultrasound data 
Ultrasound scans were repeated at month six, thus allowing for assessment of longitudinal 
change in those patients who maintained DFR. No significant change was seen in any of the 
ultrasound parameters between baseline and month six, demonstrating that maintenance of 
clinical remission was mirrored by a lack of accumulation of further ultrasound abnormalities. 
Three patients who experienced a flare at the month six appointment also had a second scan – 
this revealed an increase in joint PD and joint GS scores in 3/3 and 2/3 patients respectively, 
in keeping with the clinical flare phenotype. However, no increase in joint erosion score was 
apparent, suggesting no accumulation of joint damage during the study period in these 
patients, at least within the 7-joint set of the US7 scan protocol. 
Although intra- and inter-rater reliability were good, a potential issue arose with the 
sensitivity to change of erosion score. For the 20 patients who maintained DFR, there was a 
non-significant trend towards a reduced joint erosion score at month six compared to baseline. 
Although it has been reported that erosions can resolve with time in some RA patients if their 
disease is controlled (Sharp et al., 2003), this is unlikely to have occurred in the short duration 
of this study. In reality, the apparent reduction in erosion score more likely relates to issues 
surrounding the reproducibility of repeated ultrasound measures of joint erosion. The same 
effect was observed in those patients who experienced a flare at month six – for example, the 
total erosion score reduced from 3 to 0 for one patient. There are several possible explanations 
for these observations. Owing to the relatively advanced age of the cohort, it was sometimes 
difficult to discriminate osteoarthritic change from joint erosions, which may have led to 
misclassification in some patients. Furthermore, it is recognised that additional topographic 
features such as the anatomical joint neck and vascular bone channels can also be erroneously 
classified as erosions by ultrasound imaging (Kawashiri et al., 2017). It would thus seem that 
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structures previously defined as erosions at baseline were either not seen or not classified as 
erosions on the repeat scan, perhaps due to differences in probe orientation. Alternatively, 
given the month six scans were performed unblinded to previous disease activity scores, 
unconscious bias by the ultrasound operator may have influenced the month six scan results. 
A more robust approach would have been to enlist an ultrasound operator who was blinded to 
both previous disease activity and study visit number; however, this was not possible given 
the limited study resources. Alternatively, joint erosions could have been assessed by plain 
radiographs at baseline and month six and interpreted by a blinded radiologist – however, it is 
unlikely that erosions large enough to be visible on plain radiographs would have developed 
over the short duration of the study. Nevertheless, it is important to emphasise that analysis of 
longitudinal change in imaging measures was not an aim of this study. To address this issue 
adequately, further research is required using more sensitive imaging modalities such as MRI, 
thus allowing visualisation of bone marrow oedema which would likely be the most sensitive 
to change over the six-month follow-up period.  
 
5.7 Summary 
In summary, this study provides no evidence to support a role for ultrasound-defined erosions 
and GS hypertrophy in the prediction of outcome following DMARD cessation in RA 
remission. Longitudinal observations serve to both corroborate a robust remission phenotype 
in those patients who maintained DFR, and confirm an increase in ultrasonographic measures 
of joint inflammation in the three patients who experienced an arthritis flare at month six. 
Furthermore, ultrasound measures were largely independent of clinical parameters, in keeping 
with the opinions of others that ultrasound assesses complementary though distinct aspects of 
disease activity compared to clinical assessment alone. Whether or not the detection of 
subclinical PD signal is important in guiding DMARD cessation cannot be addressed by the 
data from this study, and represents an important area of future research. 
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Chapter 6. Results 3 – Cytokine and Chemokine Data 
 
6.1 Introduction 
The measurement of circulating chemokines and cytokines provides an attractive approach to 
the development of biomarkers of DFR in RA. Suitable biological samples (serum or plasma) 
can be obtained with simple venepuncture, and require only a single centrifugation step before 
suitable for long-term freezer storage. Furthermore, many laboratory assays for the sensitive 
and specific detection of a wide range of human cytokines are already in widespread research 
and clinical use. A robust serum-based circulating cytokine/chemokine biomarker of DFR 
would thus be ideally placed for translation to a high-throughput assay suitable for use in 
clinical practice. 
Surprisingly little research has been conducted to date that explores circulating serum 
predictors of DFR in RA beyond acute-phase markers. One notable exception is the 
multibiomarker disease activity (MBDA) score, a composite biomarker of 12 
cytokines/chemokines that has shown potential in predicting DFR in a single study of 
DMARD cessation (see Introduction 1.7.3). Nevertheless, available tools such as the MBDA 
assay have been developed for the measurement of disease activity, and not specifically for 
the prediction of DFR. It is thus possible that such measures could overlook more nuanced 
mediators that are not directly involved in the acute phase response, but nonetheless play 
crucial roles maintaining the balance between sustained DFR and arthritis flare. 
In this chapter, I present analysis of the cytokine and chemokine data of the BioRRA study. 
The specific aim of this work was to develop a cytokine/chemokine biomarker that, when 
measured immediately prior to DMARD cessation, could differentiate those patients who 
subsequently developed arthritis flare versus those who remained in sustained DFR. A 
secondary aim of these analyses was to explore the longitudinal change in circulating 
cytokine/chemokine profile in both flare and remission groups, thus providing insights to the 
underlying immunobiology of flare and DFR. 
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The structure of the remainder of this results chapter is as follows: 
6.2  Quality control 
6.3  Baseline predictors of drug-free remission and flare 
6.4  Longitudinal analysis 
6.5  Discussion 
6.6  Summary 
 
6.2 Quality control 
In this study, commercially available multiplex electrochemiluminescence assays (MesoScale 
Discovery) were used for the detection of 39 chemokines and cytokines (see Methods 3.9.12). 
These kits benefit from both a highly specific antibody-based capture mechanism, together 
with robust quality control mechanisms to ensure reliable assay performance. 
 
6.2.1 Sample collection 
Serum was not collected for one patient at baseline due to difficult venous access – thus of the 
44 patients who stopped DMARDs, baseline samples from 43 patients were available for 
analysis. Prior to the second substantial protocol amendment, serum was not collected at the 
month one visit for patients who satisfied remission criteria (see Methods 3.7). Consequently, 
serum was available for 29/42 month one visits and for 15/19 patient-requested unscheduled 
visits. Serum was collected for all month 3 and month 6 visits. Owing to time constraints, 
some of the MSD plates were processed before the final clinical study visit. Therefore, 
samples from later time points for patients who were still under follow-up within the study at 
the time of plate processing were not available for inclusion within the analysis (Table 6.1). 
Serum was available at the time of flare for 22/23 patients who experienced an arthritis flare – 
serum was not collected for the remaining patient as failure to achieve remission criteria was 
only apparent after the CRP result was available. 
Time from blood draw to centrifugation was recorded for 133/136 serum samples collected, 
with a median value of 50 (IQR: 43 – 87, range: 30 – 210) minutes (Figure 6.1). 
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Table 6.1 – Collection of serum samples by study visit for patients who stopped DMARDs. 
Visit type 
Number of 
visits 
Number of 
serum 
samples: 
n(% visits) 
Number of 
samples processed 
on chemokine, 
cytokine and 
proinflammatory 
plates: 
n (% visits) 
Number of 
samples 
processed on 
Th17 and 
vascular plates: 
n (% visits) 
Baseline 44 43 (98) 43 (98) 43 (98) 
Month one 42 29 (69) 29 (69) 29 (69) 
Month three 26 26 (100) 22 (85) 26 (100) 
Month six 23 23 (100) 16 (70) 23 (100) 
Unscheduled 19 15 (79) 15 (79) 15 (79) 
Total 154 136 (88) 125 (81) 136 (88) 
 
 
     
Figure 6.1 – Distribution of timed lengths between blood draw and serum centrifugation. 
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6.2.2 Calibrator coefficient of variation 
Seven manufacturer-supplied calibrator solutions containing known concentrations of 
analytes were prepared by serial dilution for each plate. This allowed calculation of the 
percentage coefficient of variation (%CV) of calculated concentration for each calibrator on 
each plate (Appendix G). The manufacturer states that the %CV is typically less than 20% for 
repeat measurements. Over the 10 individual plates there were 656 pairs of calibrator 
measurements, of which %CV>20 in 60 (9%) of measurement pairs. Of these measurement 
pairs, 37/60 (62%) were within the three lowest concentration calibrators. 
 
6.2.3 Limits of detection 
A total of 6324 assay measurements (excluding calibrators and blanks) were recorded over the 
10 plates. Upper and lower limits of detection (ULOD and LLOD respectively) were 
calculated for each assay as previously described (see Methods 3.9.12). No samples exceeded 
the ULOD, whereas 3391 (54%) had a calculated concentration below the LLOD. Samples 
where the calculated concentration fell below the LLOD were assigned a calculated 
concentration equal to the LLOD for each respective assay. 
Two IL-8 assays were included with differing ranges of detection: a standard IL-8 assay and 
an alternative IL-8 assay (IL-8 (HA)) with a higher detection range. Concentration 
measurements frequently fell below the limits of detection for the IL-8(HA) assay, and thus 
results from the standard IL-8 assay were used for analysis. Similarly, two IL-17A assays 
were included based on different isotypes of detection antibody. A greater proportion of 
assays fell below the LLOD for the IL-17A assay on the Th17 panel plates in comparison to 
the IL-17A assay on the cytokine panel plates, and thus the former was excluded from 
analysis. 
For analyses based solely on baseline samples, 13 assays where <20% of measurements were 
below the LLOD were excluded (Figure 6.2). For longitudinal analysis of flare patients, six 
assays where all measurements were below the LLOD at both baseline and time of flare were 
excluded. For longitudinal analysis of remission patients, eight assays where all 
measurements were below the LLOD at both baseline and month six visit were excluded. The 
assays included within each analysis following the above quality control steps are summarised 
in Table 6.2. 
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Figure 6.2 – Proportion baseline samples where calculated concentration was above the assay-
specific LLOD. Assays which fell below the 20% threshold (red line) were excluded from 
analysis. 
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Table 6.2 – Inclusion of assays by type of analysis. 
Inclusion of assay by analysis type 
MSD plate Assay Baseline (all patients) 
Baseline to 
flare visit 
(flare 
patients) 
Baseline to month six 
visit (remission 
patients) 
Cytokine panel 1 
(human) 
GM-CSF    
IL-12/IL-
23p40 
subunit 
   
IL-15    
IL-16    
IL-17A    
IL-1α    
IL-5    
IL-7    
TNF-β    
VEGF    
Chemokine panel 
1 (human) 
Eotaxin    
Eotaxin-3    
IL-8(HA)    
IP-10    
MCP-1    
MCP-4    
MDC    
MIP-1α    
MIP-1β    
TARC    
Proinflammatory 
panel 1 (human) 
IFN-γ    
IL-10    
IL-12p70 
subunit    
IL-13    
IL-1β    
IL-2    
IL-4    
IL-6    
IL-8    
TNF-α    
Th17 panel 1 
(human) 
IL-17A    
IL-21    
IL-22    
IL-23    
IL-27    
MIP-3α    
IL-31    
Vascular injury 
panel 2 (human) 
CRP    
ICAM-1    
SAA    
VCAM-1    
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6.2.4 Logarithmic data transformation 
The distribution of calculated concentrations for each assay was typically positively skewed. 
To create a more even distribution of data, the natural logarithm of each analyte concentration 
measurement was calculated before further data analysis. A constant value (+ 1) was added to 
each analyte concentration before logarithmic transformation to allow for zero values. An 
illustrative effect of this logarithmic transformation is depicted in Figure 6.3. 
6.2.5 Plate equilibration 
It was not possible to analyse all serum samples together on the same plate, as the total 
number of samples (136) exceeded the number of available wells (80) on a single plate. It was 
therefore necessary to process samples across pairs of each type of MSD plate. Each pair of 
plates was processed on the same day to minimise variation. Furthermore, all baseline 
samples were run together on the same plate within each plate pair, thus permitting analysis of 
baseline samples without any effect of plate-to-plate variation. 
By replicating baseline samples where space allowed, it was attempted to keep all samples 
from the same participant together on the same single plate for the purposes of longitudinal 
analysis – however, this was not possible in all cases. Despite the manufacturer’s claims of 
excellent reproducibility of assay performance between plates of identical lots, it was deemed 
necessary to apply a data equilibration procedure to minimise any potential effect upon 
 
 
Figure 6.3 – Normal quantile-quantile (Q-Q) plot for baseline CRP concentration before (A) 
and after (B) natural logarithmic transformation. 
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longitudinal analyses. First, the relationship between the concentrations of each individual 
analyte for duplicated samples (i.e. present on both plates within a pair) was modelled by 
linear regression as detailed in Formula 6.1. 
Formula 6.1 – linear regression equation for plate equilibration procedure 
Plate2 concentration = m * (plate1 concentration) + c 
 
The regression formula was then applied to each individual concentration measurement for 
each assay within each plate2, thus equilibrating plate2 with plate1 measurements in each plate 
pair. Regression coefficients and constants for each assay are listed in Appendix H. Finally, to 
avoid any bias introduced by differing LLODs between plate pairs, the highest LLOD of 
either plate within each pair was applied for the purposes of longitudinal data analyses. Where 
a sample had been analysed on both plates, the sample measurement on the same plate as the 
majority of other samples for that patient was used for analysis to reduce further any bias 
introduced by plate-to-plate variation.  
There were 11 assays where only two or fewer samples measured above the LLOD on both 
plates – these assays were thus excluded from plate equilibration, namely: GM-CSF, IL-1α, 
TNFβ, IL-12p70, IL-13, IL-1β, IL-2, IL-4, IL-21, IL-23 and IL-31. In addition, MIP1α 
concentration demonstrated a poor correlation between plates and was also excluded. Plate 
equilibration was not performed for these samples, but rather only concentrations from a 
single plate (i.e. excluding values from the other plate) at the level of each patient were used 
for analysis. 
 
6.3 Baseline predictors of drug-free remission and flare 
6.3.1 Baseline survival analysis 
The association between baseline cytokine/chemokine levels and time-to-flare following 
DMARD cessation were analysed by univariate Cox regression (Table 6.3) for all 26 assays 
that passed quality control checks (see Results 6.1.3). Proportionality of hazards was observed 
for all variables with the exception of ln(ICAM1+1). There was no statistical association 
between ln(ICAM1+1) and flare by univariate Cox regression (p = 0.95). To confirm that this 
lack of association was not a spurious effect of poor survival modelling, the relationship  
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Table 6.3 – Association between the circulating concentration of cytokines/chemokines at 
baseline and time-to-flare following DMARD cessation, analysed by univariate Cox 
regression. Hazard ratios are calculated for a 1-unit change in log-transformed 
cytokine/chemokine concentration. B: Cox regression coefficient. P values calculated by the 
Wald test. 
Variable B HRflare HRflare 95% CI Univariate p value 
ln(MCP1+1) 2.212 9.13 1.97 – 42.32 0.005 
ln(CRP+1) 0.426 1.53 1.02 – 2.31 0.042 
ln(Eotaxin+1) 1.386 4.00 0.97 – 16.5 0.055 
ln(IL6+1) 0.730 2.08 0.97 – 4.45 0.060 
ln(TNFa+1) 1.273 3.57 0.93 – 13.7 0.063 
ln(IP10+1) 0.592 1.81 0.97 – 3.38 0.064 
ln(IL10+1) 1.737 5.68 0.65 – 49.8 0.117 
ln(IL27+1) 0.948 2.58 0.78 – 8.53 0.120 
ln(MCP4+1) 0.522 1.69 0.84 – 3.38 0.140 
ln(IL15+1) 1.572 4.82 0.56 – 41.6 0.153 
ln(Eotaxin3+1) 0.310 1.36 0.81 – 2.28 0.238 
ln(VCAM1+1) 0.654 1.92 0.55 – 6.72 0.306 
ln(IL16+1) 0.694 2.00 0.52 – 7.65 0.311 
ln(IL7+1) 0.628 1.87 0.51 – 6.84 0.342 
ln(IL22+1) -0.502 0.61 0.20 – 1.87 0.384 
ln(MIP1a+1) -0.485 0.62 0.19 – 2.04 0.427 
ln(TARC+1) 0.283 1.33 0.64 – 2.76 0.448 
ln(MIP1b+1) 0.342 1.41 0.47 – 4.17 0.538 
ln(MDC+1) -0.376 0.69 0.15 – 3.07 0.623 
ln(IL8+1) 0.171 1.19 0.55 – 2.57 0.664 
ln(IFNg+1) 0.074 1.08 0.73 – 1.59 0.712 
ln(VEGF+1) -0.043 0.96 0.46 – 1.99 0.909 
ln(MIP3a+1) 0.033 1.03 0.58 – 1.85 0.912 
ln(SAA+1) 0.017 1.02 0.66 – 1.56 0.940 
ln(ICAM1+1) 0.033 1.03 0.34 – 3.15 0.954 
ln(IL1223p40+1) 0.019 1.02 0.47 – 2.21 0.961 
 
between ln(ICAM1+1) and occurrence of flare was assessed by univariate binomial logistic 
regression, which also demonstrated a similar lack of association (ORflare 0.66, 95% CI 0.12 – 
3.72, p = 0.64). 
Following univariate modelling, the 10 variables with a univariate p-value < 0.2 were then 
entered to a multivariate Cox regression model, and stepwise backward variable selection 
based on AIC was performed. After seven rounds of selection, three variables remained in this 
stepwise model (Table 6.4 and Figure 6.4). Proportionality of hazards was confirmed for all 
three variables by the Schoenfeld residual test. 
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Figure 6.4 – Summary of the three variables included in the stepwise multivariate Cox 
regression model. 
 
The distributions of baseline ln(MCP1+1), ln(IL27+1) and ln(CRP+1) by flare status are 
summarised in Figure 6.5. Baseline MCP1 levels were significantly higher in those patients 
who experienced an arthritis flare (p=0.012, unpaired Student’s T-test). There was a trend 
towards higher baseline CRP and IL-27 in the flare group, though this was not statistically 
significant (p = 0.121 and p = 0.224 respectively). 
 
6.3.2 ROC analysis and biomarker thresholds 
Patients were dichotomised based on their baseline levels of MCP1, IL-27 and CRP using two 
thresholds determined by ROC analysis optimised for the prediction of flare and remission, as  
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Table 6.4 - Association between the circulating concentration of cytokines/chemokines at 
baseline and time-to-flare following DMARD cessation, analysed in a backward stepwise 
multivariate Cox regression model. Hazard ratios are calculated for a 1-unit change in log-
transformed cytokine/chemokine concentration. B: Cox regression coefficient. P values 
calculated by the Wald test. 
Variable B HRflare 95% CI HRflare Multivariate p 
ln(MCP1+1) 2.320 10.2 2.01 – 51.4 0.005 
ln(IL27+1) 1.464 4.32 1.17 – 16.0 0.029 
ln(CRP+1) 0.404 1.50 0.99 – 2.26 0.054 
 
 
 
    
Figure 6.5 – Distribution of log2-transformed concentrations of MCP1 (A), IL-27 (B), and 
CRP (C) at baseline in flare and remission groups. Solid line represents mean value, statistical 
significance of difference in means calculated by unpaired Student’s T-test. 
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previously discussed (Methods 3.10.1). Variables were also combined to form composite 
scores, weighted by their respective coefficients from the stepwise multivariate Cox 
regression model (Table 6.5). The ROC curves for each score are presented in Figure 6.6. 
Whereas MCP1 performed reasonably well in isolation, the discriminative value of IL-27 and 
CRP when used on their own was relatively poor. The best results were observed for 
composite measures, namely MCP1+CRP and MCP1+IL27, which performed best for the 
identification of future remission (Figure 6.7) and flare (Figure 6.8) respectively. A composite 
score encompassing all three variables did not yield any additional predictive value (Table 
6.6).  
Table 6.5 – Cytokine/chemokine composite scores ranked by ROCAUC. Variables included 
within each score are indicated in green, and those excluded are indicated in red. 
ln(MCP1+1) ln(IL27+1) ln(CRP+1) Remission threshold 
Flare 
threshold ROCAUC 
   29.31 30.54 0.757 
   23.01 24.695 0.746 
   18.17 19.29 0.725 
   5.43 5.85 0.705 
   16.15 17.45 0.664 
   13.68 14.51 0.654 
   7.13 7.69 0.613 
Table 6.6 - Predictive utility of cytokine/chemokine variables in predicting flare following 
DMARD cessation, with a positive test defined by either flare or remission thresholds. 
Optimum pairs of predictive metrics are highlighted in bold. NPV: negative predictive value; 
PPV: positive predictive value. 
Variable 
ROCAUC 
(95% CI) 
Threshold 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
MCP1+CRP 
0.73 
(0.57 – 0.88) 
Flare 
(19.29) 
0.52 
(0.30 – 0.70) 
0.84 
(0.68 – 1.00) 
0.80 
(0.63 – 1.00) 
0.59 
(0.48 – 0.72) 
Remission 
(18.17) 
1.00 
(1.00 – 1.00) 
0.37 
(0.16 – 0.58) 
0.66 
(0.59 – 0.74) 
1.00 
(1.00 – 1.00) 
MCP1+IL27 
0.75 
(0.60 – 0.89) 
Flare 
(24.695) 
0.43 
(0.26 – 0.65) 
1.00 
(1.00 – 1.00) 
1.00 
(1.00 – 1.00) 
0.59 
(0.53 – 0.70) 
Remission 
(23.01) 
0.96 
(0.87 – 1.00) 
0.32 
(0.11 – 0.53) 
0.63 
(0.56 – 0.72) 
0.88 
(0.57 – 1.00) 
MCP1+IL27+CRP 
0.76 
(0.61 – 0.90) 
Flare 
(30.54) 
0.43 
(0.22 – 0.65) 
0.95 
(0.84 – 1.00) 
0.92 
(0.71 – 1.00) 
0.58 
(0.50 – 0.69) 
Remission 
(29.31) 
0.96 
(0.87 – 1.00) 
0.37 
(0.16 – 0.58) 
0.65 
(0.58 – 0.74) 
0.89 
(0.60 – 1.00) 
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Figure 6.6 – Receiver-operating characteristic curves for cytokine/chemokine composite biomarker scores for the prediction of flare following 
DMARD cessation. A: MCP1+IL27+CRP, B: MCP1+IL27, C: MCP1+CRP, D: MCP1, E: IL27+CRP, E: CRP, F: IL27.  
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Figure 6.7 – Kaplan-Meier plot of DMARD-free survival for the study population 
dichotomised by baseline composite MCP1/CRP score using the remission threshold. All 
patients with a negative composite score maintained DFR. 
 
 
Figure 6.8 - Kaplan-Meier plot of DMARD-free survival for the study population 
dichotomised by baseline composite MCP1/IL-27 score using the flare threshold. All patients 
with a positive composite score experienced an arthritis flare. 
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6.3.3 Sensitivity analysis for time to centrifugation 
Cytokines and chemokines are known to degrade in whole blood that has been left to stand for 
a prolonged period before centrifugation (Jackman et al., 2011). To assess whether this may 
have influenced the biomarker analysis, the three variables within the composite scores (i.e. 
ln(MCP1+1), ln(IL27+1) and ln(CRP+1)), and time from blood draw to centrifugation, were 
entered to a multivariate Cox regression model. In the three visits where centrifugation delay 
was not recorded, the median centrifugation delay across all visits was imputed. No 
significant association was observed between centrifugation delay (minutes) and arthritis flare 
(HRflare 1.00, 95% CI 0.99 – 1.00, p = 0.465). Similar coefficients and statistical significance 
were observed for the three cytokine/chemokine variables as per the main analysis, 
demonstrating that their utility for predicting arthritis flare was not affected by inclusion of 
centrifugation delay within the model (Table 6.7). Proportionality of hazards was observed for 
all individual variables and the model as a whole. 
 
6.4 Longitudinal analysis 
6.4.1 Baseline to flare visit 
Cytokine and chemokine levels were compared at baseline and flare visits in the 22 patients 
who both experienced a flare and had serum available at the time of flare. The statistical 
significance of differences between log-transformed cytokine/chemokine concentrations at 
baseline and flare visits was assessed by Student’s paired T-test (Table 6.8). Four analytes 
demonstrated a >1.5 fold change in concentration at the 5% significance level after multiple-
test correction using the Benjamini-Hochberg procedure: CRP, SAA, IL-6 and IP-10 (Figure 
6.9). 
Table 6.7 – Sensitivity analysis incorporating time from blood draw to centrifugation within a 
multivariate Cox regression model. Hazard ratios are calculated for a 1-unit change in log-transformed 
cytokine/chemokine concentration, or for a 1 minute change in centrifugation delay. 
Variable B HRflare 95% CI p 
ln(MCP1+1) 2.24 9.41 1.83 – 48.42 0.007 
ln(IL27+1) 1.47 4.34 1.18 – 15.94 0.027 
ln(CRP+1) 0.37 1.45 0.97 – 2.18 0.070 
Centrifuge delay 
(minutes) 
0.00 1.00 0.99 – 1.01 0.465 
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Figure 6.9 – Volcano plot of loge(fold change) in chemokine/cytokine concentration between 
baseline versus flare visit, and associated adjusted p values (Student’s paired T-test, 
Benjamini-Hochberg) for those patients who experienced an arthritis flare. Thresholds for 
significance are shown at fold-change > 1.5 and adjusted p < 0.05. FC: fold-change. 
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Table 6.8 – Change in cytokine/chemokine concentration from baseline to flare visits in those 
patients who experienced an arthritis flare following DMARD cessation. Statistical 
significance was assessed by Student’s paired T-test, with multiple test-correction using the 
Benjamini-Hochberg procedure. FC: fold-change. 
Variable Number of sample pairs 
Mean loge(FC) from 
baseline to flare 
Unadjusted 
p value 
Adjusted   
p value 
ln(IL1223p40+1) 20 0.206 <0.001 0.008 
ln(CRP+1) 22 1.111 <0.001 0.008 
ln(VEGF+1) 20 0.239 0.001 0.014 
ln(IL6+1) 20 0.545 0.004 0.031 
ln(Eotaxin+1) 20 -0.132 0.006 0.035 
ln(SAA+1) 22 1.071 0.006 0.035 
ln(IP10+1) 20 0.447 0.010 0.043 
ln(IL15+1) 20 -0.095 0.010 0.043 
ln(MIP1α+1) 20 0.304 0.013 0.047 
ln(IL16+1) 20 0.165 0.014 0.048 
ln(IL27+1) 22 0.100 0.021 0.064 
ln(MDC+1) 20 -0.066 0.024 0.067 
ln(Eotaxin3+1) 20 0.248 0.032 0.082 
ln(ICAM1+1) 22 0.192 0.081 0.190 
ln(MIP3α+1) 22 0.204 0.108 0.238 
ln(IL1α+1) 20 0.168 0.124 0.256 
ln(VCAM1+1) 22 0.077 0.173 0.336 
ln(IL5+1) 20 0.034 0.194 0.356 
ln(TARC+1) 20 -0.076 0.219 0.381 
ln(IL17A+1) 20 0.006 0.257 0.385 
ln(IL10+1) 20 0.058 0.248 0.385 
ln(TNFα+1) 20 0.089 0.240 0.385 
ln(IL2+1) 20 -0.023 0.330 0.454 
ln(IL4+1) 20 0.008 0.330 0.454 
ln(IL13+1) 20 -0.029 0.380 0.502 
ln(IL1β+1) 20 0.007 0.485 0.615 
ln(MCP1+1) 20 -0.024 0.594 0.726 
ln(IL7+1) 20 -0.022 0.654 0.771 
ln(MCP4+1) 20 0.014 0.739 0.813 
ln(IFNγ+1) 20 -0.105 0.732 0.813 
ln(MIP1β+1) 20 -0.012 0.779 0.829 
ln(IL22+1) 22 0.019 0.810 0.835 
ln(IL8+1) 20 0.015 0.897 0.897 
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6.4.2 Baseline to month six remission visit 
Cytokine and chemokine levels were compared at baseline and month six visits in the 19 
patients who maintained DFR and had serum available at baseline and month six. The 
statistical significance of differences between log-transformed cytokine/chemokine 
concentrations at baseline and month six visits was assessed by Student’s paired T-test (Table 
6.9). No analytes exceeded a >1.5 fold change in concentration at the 5% significance level 
(Figure 6.10). 
  
Figure 6.10 - Volcano plot of loge(fold change) in chemokine/cytokine concentration between 
baseline and month six visits and associated adjusted p values (Student’s paired T-test, 
Benjamini-Hochberg) for those patients who remained in remission. Thresholds for 
significance are shown at fold-change > 1.5 and adjusted p < 0.05. FC: fold change. 
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Table 6.9 – Change in cytokine/chemokine concentration from baseline to month six visits in 
those patients who remained in remission following DMARD cessation. Statistical 
significance was assessed by Student’s paired T-test, with multiple test-correction using the 
Benjamini-Hochberg procedure.  
Assay Number of sample pairs 
Mean loge(fold 
change) from 
baseline to month 6 
Unadjusted 
p value 
Adjusted p 
value 
ln(TNFα+1) 14 0.203 0.051 0.562 
ln(MCP1+1) 14 0.088 0.064 0.562 
ln(IL15+1) 14 -0.074 0.077 0.562 
ln(IL1223p40+1) 14 0.151 0.099 0.562 
ln(MIP3α+1) 19 0.208 0.100 0.562 
ln(IP10+1) 14 0.284 0.121 0.562 
ln(TARC+1) 14 -0.077 0.127 0.562 
ln(IL1α+1) 14 -0.069 0.188 0.693 
ln(IFNγ+1) 14 0.276 0.216 0.693 
ln(IL5+1) 14 0.029 0.259 0.693 
ln(IL10+1) 14 0.019 0.260 0.693 
ln(IL7+1) 14 -0.066 0.294 0.693 
ln(IL27+1) 19 0.039 0.309 0.693 
ln(TNFβ+1) 14 0.001 0.336 0.693 
ln(IL2+1) 14 -0.013 0.336 0.693 
ln(VEGF+1) 14 0.059 0.419 0.771 
ln(VCAM1+1) 19 0.049 0.423 0.771 
ln(ICAM1+1) 19 0.057 0.534 0.803 
ln(IL16+1) 14 -0.046 0.541 0.803 
ln(SAA+1) 19 0.116 0.542 0.803 
ln(IL17A+1) 14 0.013 0.544 0.803 
ln(MIP1β+1) 14 0.022 0.598 0.843 
ln(Eotaxin3+1) 14 0.059 0.626 0.844 
ln(IL22+1) 19 0.028 0.688 0.872 
ln(MDC+1) 14 -0.017 0.704 0.872 
ln(IL6+1) 14 0.003 0.768 0.912 
ln(MCP4+1) 14 0.022 0.794 0.912 
ln(MIP1α+1) 14 -0.018 0.862 0.955 
ln(IL8+1) 14 0.010 0.929 0.988 
ln(CRP+1) 19 0.011 0.968 0.988 
ln(Eotaxin+1) 14 -0.001 0.988 0.988 
 
6.4.3 Longitudinal change in selected cytokines and chemokines 
The longitudinal change in circulating concentrations of selected cytokines and chemokines 
was explored across all study visits where serum samples were available for analysis. Owing 
to infrequent sampling, particularly within patients who flare, it was not possible to use 
formal hypothesis-testing methods such as spline analysis or multi-level modelling beyond 
comparison of baseline to final study visit (Figure 6.11). Therefore, descriptive analysis with 
the aid of longitudinal ‘spaghetti plots’ is presented herein (Figure 6.12). 
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Figure 6.11 – Longitudinal change in selected cytokines and chemokines from baseline to 
flare visit in patients who experienced an arthritis flare, and baseline to month six visit for 
patients who remained in remission following DMARD cessation. Solid line shows mean 
value, unadjusted statistical significance of difference between means calculated by paired 
Student’s t-test. 
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Figure 6.11 (continued) 
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Figure 6.12 – Longitudinal change in selected cytokines and chemokines. Each line represents an individual patient; those who experienced an arthritis flare are shown in red, 
whereas those who remained in remission are shown in grey. Spikes in CRP and SAA secondary to urinary tract infection (*) and chest infection (+) are highlighted. 
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Both CRP and SAA concentrations rose in the approach towards arthritis flare, and remained 
essentially static for patients in remission, with the exception of two remission patients who 
had a concomitant urinary tract and lower respiratory tract infections respectively at the time 
of their month 3 study visit. IL6 concentrations abruptly rose at the time of flare, and 
remained static for patients in remission, although many samples fell below the plate-merged 
LLOD. Overall, IP10 concentrations rose higher in the flare versus remission group, though 
there was greater heterogeneity in the individual patient trends. 
There was a modest overall increase in IL-27 from baseline to flare which was not observed 
in patients who remained in remission, although the individual patient trends were somewhat 
mixed. There were no clear longitudinal trends in MCP1, in contrast to its utility for 
predicting flare when measured at baseline.  
 
6.5 Discussion 
6.5.1 Baseline predictors of drug-free remission 
Studies of DMARD withdrawal in RA remission to-date have focussed largely on clinical 
parameters, and surprisingly few data have been published regarding the use of cytokines in 
the prediction of DFR. The only studies of note to have addressed this issue utilise a 12-
cytokine score known as the multi-biomarker disease activity (MBDA) score, commercially 
marketed as Vectra® DA (Crescendo Bioscience Inc., San Francisco, USA) (Centola et al., 
2013) (see Introduction 1.4.5). Of the 12 cytokines included in the MBDA score, five were 
also measured in this study: serum amyloid A (SAA), C-reactive protein (CRP), IL-6, 
vascular endothelial growth factor (VEGF) and vascular cell adhesion molecule 1 (VCAM-1).  
In a sub-analysis of 94 patients of the RETRO study, MBDA score was significantly higher (p 
= 0.0001) at baseline in patients who subsequently experienced an arthritis flare following 
DMARD tapering/cessation compared to those remaining in remission (Rech et al., 2016). 
Furthermore, the predictive value of MBDA score appeared to be multiplicative with that of 
ACPA status, such that 76% of ACPA+ patients with a high MBDA score experienced an 
arthritis flare compared with 13% of ACPA- patients with a low MBDA score (p = 0.0001). 
Of note, the statistically significant higher MBDA score in those patients who flared was a 
result of a combination of relatively small and individually non-significant elevations of 8 of 
the 12 cytokine score components, namely SAA, CRP, IL-6, matrix metalloproteinase 1 and 3 
(MMP-1 and -3), leptin, epidermal growth factor (EGF), and VEGF (Rech et al., 2016). The 
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results of the RETRO study therefore corroborate the elevated baseline CRP and IL-6 
measurements in patients who flared in my study, and corroborate the lack of predictive value 
of VCAM-1. In contrast, no predictive value was seen at baseline for SAA or VEGF in my 
study, though the levels of SAA did rise at the time of flare. 
The predictive value of the MBDA score has also been studied in the setting of bDMARD 
tapering and withdrawal, though with mixed results. In an exploratory analysis of the 439 
patients who stopped anti-TNF therapy as part of the POET study, high MBDA score was 
associated with a modest increased risk of physician-reported flare (ORflare 2.00, 95% CI 1.06 
– 3.77) (Lamers-Karnebeek et al., 2015). A description of the components of the MBDA 
score that contributed to this observation was not presented. In contrast to the above two 
studies, a sub-analysis of 171 patients from the DRESS study – an RCT of anti-TNF tapering 
and cessation in RA – found no significant association between MBDA score and future 
arthritis flare in those patients tapering anti-TNF therapy (Bouman et al., 2017). Again, a 
breakdown of individual cytokine trends was not presented by the authors of this study. 
However, neither of these studies addressed DFR as csDMARDs were continued in all 
patients. 
 
6.5.2 Monocyte chemoattractant protein 1 (MCP-1/CCL2) 
Monocyte chemoattractant protein 1 (MCP-1, also known as CCL2) is a 13kDa protein 
composed of 76 amino acids, and encoded on the long arm of chromosome 17 (Deshmane et 
al., 2009). MCP-1 is secreted by a wide range of different cell types, and has potent 
chemoattractant properties for monocytes, and also memory T cells and NK cells (Deshmane 
et al., 2009). MCP1 acts via the G-protein coupled receptor CCR2, which exists in 2 
isoforms: CCR2A and CCR2B. Upregulation of CCR2 expression has been observed in in 
several autoimmune diseases, including by myocytes and mononuclear inflammatory 
infiltrates in inflammatory myopathy (Bartoli et al., 2001), and by synovial fibroblasts in RA 
(Cho et al., 2007). Studies of single nucleotide polymorphisms (SNPs) affecting MCP-1 have 
also shed light on the potential importance of the chemokine in human autoimmunity. In a 
recent meta-analysis of 26 studies exploring the association between autoimmunity and the 
2518A/G SNP in the MCP-1 promotor, Chen et al. (2016) found a positive association of A 
vs G allele in Asian patients with RA (OR 1.616, 95% CI 1.027 – 2.542, p = 0.038) and 
European patients with Crohn’s disease (OR 1.383, 95% CI 1.142 – 1.676, p = 0.022). 
However, a converse association was observed for AA vs. AG/GG genotype in European 
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patients with lupus nephritis (OR 0.713, 95% CI 0.545 – 0.933, p = 0.014) (Chen et al., 2016). 
In contrast however, an independent though smaller meta-analysis of 14 studies found no 
significant association of the MCP-1-2518A/G SNP with susceptibility to RA, vasculitis or 
multiple sclerosis (Lee and Bae, 2016). 
MCP-1 has been implicated in the pathogenesis of RA by several studies. Higher 
concentration of MCP-1 has been observed in the synovial fluid of patients with RA versus 
non-RA controls (Chen et al., 2017), and higher CCR2 expression has been demonstrated in 
synovial fibroblasts (Cho et al., 2007) and circulating neutrophils (Talbot et al., 2015) in RA 
versus OA and healthy controls respectively. Furthermore, in a nested case-control study of 
220 women who later developed RA compared to 675 controls, Arkema et al. (2015) 
demonstrated a positive association between circulating MCP-1 concentration in the five 
years before disease onset and future risk of developing RA (OR 2.42, 95% CI 1.22 – 4.89) 
adjusted for confounding factors including smoking, alcohol intake and obesity. Finally, 
circulating MCP-1 concentration has been shown to correlate closely with DAS28-CRP score 
in an observational cohort study of 111 RA patients (Liou et al., 2013). 
In my study, MCP-1 is predictive of outcome following DMARD cessation, with low levels at 
baseline demonstrating particular discrimination for those patients who maintained DFR. This 
observation is biologically plausible - low circulating levels of MCP-1 could conceivably 
reflect lower production by stromal and immune cell mediators within the synovium, thus 
reducing recruitment of monocytes, T cells and NK cells to the joints. Interestingly, no 
significant increase in MCP-1 concentration was observed in longitudinal analysis of patients 
who experienced an arthritis flare. This observation suggests a possible modulatory effect of 
MCP-1 at baseline, as opposed to representing a surrogate measure of disease activity. 
However, whether the observed low levels of circulating MCP-1 reflect a qualitative 
difference in immune homeostasis in those patients who maintain DFR, rather than simply a 
quantitative difference in subclinical synovitis, remains open to speculation and would require 
the study of matched synovial biopsy tissue in these patients.  
 
6.5.3 Interleukin-27 
IL-27 is a relatively recently discovered member of the IL-12 family, which also includes IL-
12, IL-23 and IL-35. IL-27 is a heterodimer composed of the 34kDa glycopeptide Epstein-
Barr virus-induced gene 3 (EBI3) – which is also a component of IL-35 – together with the 
24.5 kDa polypeptide IL-27p28 (Yoshida and Hunter, 2015). IL-27 is produced primarily by 
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antigen presenting cells including dendritic cells, monocytes and macrophages (Meka et al., 
2015). The receptor for IL-27 (IL-27R) is a heterodimer of IL-27Rα and gp130, the latter of 
which also forms part of several other cytokine receptors including the receptors for IL-6 and 
IL-35 (Yoshida and Hunter, 2015). IL-27R is expressed on T and B lymphocytes, NK cells, 
mast cells and antigen-presenting cells, and signals via the Janus kinase (JAK) / signal 
transducer and activation of transcription (STAT) and p38 mitogen-activated protein kinase 
(MAPK) pathways (Meka et al., 2015). 
The role of IL-27 in the modulation of immune processes is complex, with sometimes 
contradictory effects dependent on the cell type, local cytokine milieu, and experimental 
setting or human disease in question. Initial animal studies demonstrated a pro-Th1 effect of 
IL-27 attributed to an increase in STAT1 signalling synergistic to the effects of IL-12 (Pflanz 
et al., 2002), and in human cells to lead to enhanced CD8+ T cell cytolytic activity (Schneider 
et al., 2011). However, further studies have shown the ability of IL-27 to induce type 1 
regulatory cells (Tr1) – which produce IL-10 – and suppress the differentiation of Th17 cells 
(Awasthi et al., 2007; Murugaiyan et al., 2009). As discussed by Yoshida and Hunter (2015), 
Il-27 also appears to be important in the development of a subset of regulatory T cells in mice 
that express the transcriptional factor T-bet and CXCR3, which can function to control Th1 
responses via production of IL-10 at the sites of inflammation in Toxoplasma gondii infection 
(Hall et al., 2012). Such a process is hypothesised to be important in the resolution of 
inflammation after clearance of intracellular infection, and similar IL-27-induced IL-10 
production by NK cells has also been demonstrated in murine models (Chong et al., 2015). 
Thus in different contexts, IL-27 can serve to either promote a Th1 response or promote a 
regulatory T cell phenotype. 
Several studies have highlighted a role for IL-27 in the pathogenesis of RA. An SNP in IL27 
(-924A/G) has been associated with susceptibility to RA in a Polish population (Paradowska-
Gorycka et al., 2014). Circulating (Shen et al., 2011; Lai et al., 2016) and synovial fluid 
(Tanida et al., 2011) concentrations of IL-27 are higher in RA patients versus healthy and OA 
controls respectively. When stimulated by IL-27 ex vivo, RA synovial fibroblasts can induce a 
dose-dependent increase in the production of pro-inflammatory mediators such as matrix 
metalloproteinase 1 (MMP1) (Wong et al., 2010). Furthermore, IL-27 knock-out mice show a 
reduced severity and delayed onset of disease in the proteoglycan-induced arthritis model 
(Cao et al., 2008). However, evidence also suggests a beneficial role of IL-27 in inflammatory 
arthritis dependent on the setting. In the murine collagen-induced arthritis model, exogenous 
IL-27 can reduce synovitis when administered at the time of onset of disease (Niedbala et al., 
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2008). Furthermore, high expression of IL27 (which encodes IL-27p28) in human RA 
synovial tissue has also been shown to associate with reduced ectopic lymphoid structure 
formation, mirroring an increased number of synovial Th17 cell aggregates seen in an IL-27R 
knock-out murine model (Jones et al., 2015). 
In my study, circulating levels of IL-27 at baseline were predictive of outcome following 
DMARD cessation, with high levels at baseline demonstrating particular discrimination for 
those patients who experienced an arthritis flare. Furthermore, there was a significant though 
small increase in circulating levels of IL-27 at the time of flare (mean fold change 1.07, 
unadjusted p = 0.021), though this latter observation was not robust to multiple test 
correction. Taken together, these results would imply a positive association between 
circulating IL-27 and arthritis flare in this study. This would be in keeping with the pro-Th1 
actions of IL-27 described above, though it is impossible to infer causality based on these 
data. Indeed, higher levels of IL-27 at baseline may serve to modulate the response to 
upstream perturbations of the immune response following DMARD cessation rather than play 
a causative role per se, for example by altering the signalling of other STAT-pathway 
cytokines such as IL-6. The robust increase in IL-6 observed at the time of flare in this study 
(discussed further below) lends some support to this hypothesis. Alternatively, it is even 
conceivable that high IL-27 may reflect a regulatory response to pro-inflammatory 
mechanisms, but that this regulatory response is somehow deficient in those patients who 
subsequently develop an arthritis flare. Clearly, there are many limitations of circulating 
cytokine data, leading to substantial uncertainty in how this reflects immune processes at the 
synovium. Again, synovial joint biopsies would be a vital source of corroborative data, 
though this was not feasible in this small exploratory study. 
 
6.5.4 Longitudinal cytokine data 
Although not the primary focus of this study, longitudinal observation of trends in circulating 
cytokine levels provides a tantalising insight in to the mechanisms underlying the emergence 
of RA flare. The most striking observation was that significant changes in cytokine levels 
were only observed in the flare group, whereas those patients who maintained DFR 
demonstrated very little, if any, longitudinal change in cytokine levels. This presumably 
reflects the substantial dysregulation of immunity that occurs at the time of arthritis flare, 
which is readily detected in the peripheral circulation. In contrast, the continued immune 
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homeostasis underlying those who maintain DFR is likely to generate more subtle signals, 
which may furthermore be detectable only at the individual joint level. 
The acute-phase proteins CRP and serum amyloid A (SAA) demonstrated the greatest 
increase from baseline to time of flare (mean fold change 2.16 [adjusted p = 0.008] and 2.10 
[adjusted p = 0.035] respectively). CRP is the most widely used measure of the acute phase 
response in clinical practice, and is an integral component of many disease activity scores 
including DAS28-CRP, the Simple Disease Activity Index (SDAI), and ACR/EULAR 
Boolean remission (see Introduction 1.4.1). Increased levels of SAA in inflammatory states 
are well established, and can lead to amyloidosis in cases of chronic uncontrolled 
inflammation – typically historically observed in diseases such as RA and ankylosing 
spondylitis, though now relatively rare in the era of effective modern DMARD therapy 
(Nakamura, 2011). Circulating SAA has been shown to correlate with clinical disease activity 
(Hwang et al., 2016), and can itself mediate pro-inflammatory effects via Toll-like receptor 2 
(TLR2) ligation in RA synovial fibroblasts (Connolly et al., 2016). Of note, both CRP and 
SAA are components of the aforementioned 12-cytokine MBDA score (Centola et al., 2013). 
Taken together, the observed increased concentrations of CRP and SAA at the time of flare in 
my study provide biochemical evidence of a robust systemic inflammatory response in 
patients who experienced an arthritis flare.  
Further analysis of longitudinal cytokine trends in this study yields additional insights beyond 
only an increase in acute-phase response. IL-6 concentration was higher at the time of flare 
than baseline (mean fold change 1.50, corrected p = 0.031) despite many results falling below, 
and thus being assigned the value of, the lower limit of detection for the assay. Given this 
technological limitation in assay performance, it is likely that the true difference in IL-6 
concentration between baseline and flare is actually greater than that observed. IL-6 is a  
26kDa glycoprotein known to be of central importance in the pathogenesis of a range of 
autoimmune conditions including RA, vasculitis and juvenile idiopathic arthritis (Kishimoto, 
2010). IL-6 can bind to either membrane-bound or soluble IL-6 receptor, which after signal 
transduction via gp130 signals by the JAK/STAT pathway to increase the levels of 
intracellular STAT3 (Kim et al., 2015). The effects of IL-6 are vigorously pro-inflammatory, 
including immunoglobulin production by plasma cells and the activation of osteoclasts (Kim 
et al., 2015). The observation that circulating IL-6 levels closely correlate with intracellular 
phosphorylated STAT3 in peripheral CD4+ T cells in early ACPA-negative RA further 
underscores the importance in the early pathophysiological events of the disease (Anderson et 
al., 2016). IL-6 also plays a key role in Th17 differentiation in murine T cells, though other 
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cytokines including TGF-β, IL-21 and IL-23 are also known to modulate Th17 differentiation 
in human T cells (Yang et al., 2008). Toclizumab, a monoclonal antibody that blocks the IL-6 
receptor, is now in widespread clinical use in the treatment of RA and several more IL-6 
targeting biologic therapies are in the advanced stages of clinical development (June and 
Olsen, 2016). 
The observation that IL-6 levels rise in the approach to arthritis flare in my study is in keeping 
with the well-established role of IL-6 in the pathogenesis of the disease. Additionally, co-
stimulation of Toll-like receptor 3 (TLR3) and TLR7 pathways has been observed to lead to 
transcriptional synergy of IL-6 and IL-12 in mouse macrophages, an effect mediated by 
interaction of the transcription factors Jun B, CCAAT/enhancer-binding protein beta 
(C/EBPβ) and IRF1 at the IL6 and IL12b promoters (Liu et al., 2015). This effect may be of 
relevance given the statistically significant though small increase in circulating IL-12 at the 
time of flare in my study (fold change 1.15, adjusted p < 0.008). 
Circulating concentration of the chemokine interferon-γ inducible protein 10 (IP-10, also 
known as CXCL10) was significantly higher at the time of flare (fold change 1.36, adjusted p 
= 0.043). IP-10 is a 10 kDa protein produced by a wide variety of cell types in response to 
IFN-γ (Liu et al., 2011). IP-10 signals via the CXCR3 G-protein coupled receptor, and has a 
potent chemoattractive effect for numerous immune cells including activated T lymphocytes, 
NK cells, dendritic cells and macrophages (Liu et al., 2011). IP-10 is thus thought to be a key 
player in a positive-feedback loop of recruitment of Th1 cells, which themselves secrete IFN-
γ, to the sites of inflammation (Antonelli et al., 2014). Circulating concentrations of IP-10 are 
higher in RA patients versus healthy controls and correlate with disease activity (Kuan et al., 
2010; Pandya et al., 2017). Furthermore, blockade of IP-10 can reduce both synovial 
inflammatory cell infiltrate and bone erosions in the murine collagen-induced arthritis model 
(Kwak et al., 2008), and IP-10 knock-out mice are resistant to collagen antibody-induced 
arthritis (Lee et al., 2017). 
The observation of higher circulating levels of IP-10 at the time of flare in my study would 
therefore be in keeping with an active flare phenotype where activated lymphocytes are 
recruited to the inflamed synovium. Furthermore, the postulated role of IP-10 in amplifying 
the recruitment of Th1 cells may be of significance given the increased levels of the pro-Th1 
cytokine IL-12 at the time of flare. 
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6.6 Summary 
In summary, circulating concentrations of IL-27, MCP1 and CRP at baseline were predictive 
of flare and remission following DMARD cessation. Longitudinal analysis demonstrated 
increased levels of acute phase reactants (CRP and SAA) at the time of flare, together with the 
pro-Th17 cytokine IL-6, and the pro-Th1 mediators IL-12 and IP-10. Taken together, one can 
hypothesise a potent pro-inflammatory cytokine and chemokine milieu at the time of arthritis 
flare, characterised potentially by dysregulated Th17 and Th1 responses. 
There are several limitations to these cytokine data, most notably the lack of corroborative 
synovial tissue in which to validate the peripheral cytokine findings. Without such tissue, it is 
impossible to confirm how these findings relate to the pathophysiological processes occurring 
in the joint. These difficulties are most pronounced where mediators are known to have 
pleiotropic effects – for example, it is unclear whether the increased IL-27 concentration 
observed at baseline in the flare population represents a pro-Th1 state, or reflects an activated 
yet defective Tr1-like regulatory response in these patients. A further limitation was 
encountered with the assay technology – 13/39 analytes had >80% of measurements below 
the lower limit of detection at baseline and were thus excluded from the analysis. This 
included several key mediators of interest, including GM-CSF, IL-17A, IL-2 and IL-12. In 
longitudinal analysis, measurements falling below the LLOD were assigned the value of the 
LLOD for that assay. This conservative approach is likely to have artificially reduced the 
magnitude of observed increases in cytokine concentrations, such as that observed for IL-6 for 
example. Nevertheless, the electrochemiluminescence assays used in this study represent the 
most sensitive and specific method of multiplex cytokine measurement possible given the 
financial and equipment resources available. Finally, the exploratory nature of this study 
necessitated analysis of a broad range of cytokines and chemokines. Multiple significance test 
correction was employed to limit the rate of type I error, though could have resulted in 
significant associations being overlooked. Validation of these cytokine findings with a 
reduced variable set focussed on key mediators (e.g. CRP, SAA, MCP1, IL-27, IP-10, and IL-
6) in a larger cohort of patients with more frequent sampling is necessary to address these 
concerns. 
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Chapter 7. Results 4 – CD4+ T cell RNAseq data 
 
7.1 Introduction 
The results discussed in the first two results chapters of this Thesis relate to data gained by 
clinical and ultrasound measurements. Although distinct in their nature, these parameters all 
share the common characteristic of being global measures of disease phenotype and/or 
activity, rather than a measure of disease-specific processes per se. In Chapter 6, I described 
circulating cytokine data may reflect trends in underlying immune processes, albeit still at a 
systemic level. Conceivably, measuring parameters within a cellular compartment of the 
immune system of particular relevance to disease pathogenesis may hold additional promise 
in the identification of disease-specific biomarkers. 
RA is undeniably a heterogeneous disease that involves many different cellular and humoral 
pathogenic pathways. Nevertheless, as outlined in Introduction 1.2, compelling evidence 
supports a key role for CD4+ T cells in the pathogenesis of the disease. Circulating CD4+ T 
cells therefore provide a potential compartment that is both important in RA pathobiology as 
well as easily obtainable without the need for invasive sample collection procedures. In 
previous work by the Newcastle University Musculoskeletal Research Group, a protocol was 
developed to isolate CD4+ T cells from whole blood with a high cell yield and purity (Pratt, 
2011). Furthermore, microarray analysis of genome-wide gene expression in CD4+ T cells 
isolated by this method identified a 12-gene signature, which had prognostic utility in 
predicting which patients with undifferentiated inflammatory arthritis subsequently 
progressed to a diagnosis of RA (Pratt et al., 2012). Therefore, robust data support both the 
feasibility of gene expression analysis in highly purified CD4+ T cells and the utility of this 
data in biomarker identification. Transcriptional profiling of circulating CD4+ T cells 
therefore represents a logical target upon which to focus efforts to identify a cell-specific 
biomarker of drug-free remission. Furthermore, the increased transcriptome coverage, 
specificity and sensitivity of modern next-generation sequencing techniques offer unparalleled 
opportunities to study this in greater detail than previously possible using microarray 
platforms. 
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In this results chapter I present analysis of CD4+ T cell gene expression data as generated by 
next-generation RNA sequencing. The aims of this chapter are: 
1. To demonstrate the feasibility of CD4+ T cell isolation from whole blood, RNA 
extraction from these cells, and RNA sequencing to a high quality. 
2. To use gene expression data to create a biomarker signature which, when applied to 
baseline samples, has predictive utility in discriminating patients who flare versus 
those who remain in remission following DMARD cessation. 
3. To explore differential gene expression both at baseline between contrast groups, and 
longitudinally at an individual patient level, in order to gain insights in to the 
immunological mechanisms underlying DFR and arthritis flare. 
 
 The structure of the remainder of this results chapter is as follows: 
7.2 Quality control 
7.3 Baseline analyses 
7.4 Longitudinal analyses 
7.5  Comparison between contrast groups 
7.6 Predictive biomarker analyses 
7.7 Discussion 
7.8 Summary 
 
7.2 Quality control 
7.2.1 Sample collection 
7.2.1.a Patient samples 
CD4+ T cell samples were available at all baseline, month three and month six study visits. 
Prior to the second substantial protocol amendment, blood was not collected at the month one 
visit for patients who satisfied remission criteria. Consequently, CD4+ T cell samples were 
available for 26/42 month one visits and for 14/19 patient-requested unscheduled visits. 
Owing to time constraints, RNA extraction and sequencing was performed before the final 
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clinical study visit. Therefore, samples from later time points for patients who were still under 
follow-up within the study at the time of sample processing were not available for inclusion 
within the analysis (Table 7.1). In total, CD4+ T cell RNA was available for sequencing for 
120/154 (78%) of study visits. CD4+ T cell RNA was available for sequencing at the time of 
flare for 18/23 (78%) patients who experienced an arthritis flare, and was available at month 
six for 15/20 (75%) patients who maintained drug-free remission. 
Time from blood draw to start of CD4+ T cell processing, and time from start of T cell 
processing to freezing of T cell lysate, were recorded for 117/120 of the sequenced patient 
samples (Figure 7.1A). The median (IQR, range) time from blood draw to start of processing 
was 95 (80-150, 40-368) minutes. The median (IQR, range) time from start of processing to 
freezing of lysate was 242 (217-285, 166-333) minutes. 
The number of cells in every T cell isolate was recorded to calculate the cell yield, with a 
median (IQR, range) value of 2.3 x 105 cells per ml whole blood (1.8 – 3.2, 0.5 – 7.2) (Figure 
7.1B). The purity of every CD4+ T cell isolate was confirmed by flow-cytometric analysis as 
described in Methods 3.9.7 (Figure 7.1C). The median (IQR, range) percentage of CD3+CD4+ 
cells in patient T cell isolates  was 98.9 (98.3 – 99.3, 95.3-99.8). The percentage of 
contaminating monocytes and B-cells, defined as CD14+ or CD19+ respectively, were 
generally low and are summarised in Figure 7.1D. To account for small variations in CD4+ T 
cell purity, the percentage of CD3+CD4+ cells was included as a covariate in gene expression 
models together with sequencing batch. 
Table 7.1 – Collection and sequencing of CD4+ T cell samples by study visit for patients who 
stopped DMARDs. 
Visit type Number of visits 
Number of CD4+ 
samples:  
n(% visits) 
Number of CD4+ T 
cell samples 
sequenced: n(% 
visits) 
Baseline 44 44 (100) 44 (100) 
Month one 42 26 (62) 26 (62) 
Month three 26 26 (100) 21 (81) 
Month six 23 23 (100) 16 (70) 
Unscheduled 19 14 (74) 13 (68) 
Total    154 133 (86) 120 (78) 
 
  
194 
 
Figure 7.1 – Quality control data for sequenced patient CD4+ T cell isolates: time delays (A), 
cellular yield (B), percentage of CD3+CD4+ cells (C), and percentage of contaminating cells 
positive for CD14 (monocytes) and CD19 (B cells) (D). ‘Blood draw time’: time from 
venepuncture to start of laboratory processing; ‘Processing time’: time from start of 
laboratory processing to freezing of T cell lysate. 
         
 
       
 
7.2.1.b Healthy controls 
Four healthy volunteers were recruited to donate blood as a control arm for comparison with 
the study population. The volunteers were aged 50 years (male), 40 years (male), 31 years 
(female) and 31 years (female) at the time of first donation. Sampling was performed at four 
time points (baseline, month 1, month 3 and month 6) from all participants giving 16 healthy 
CD4+ T cell samples in total. Blood was drawn where possible between 9am-1pm and left to 
stand before processing to mimic the collection and transport of the patient samples. Time 
from blood draw to start of CD4+ T cell processing, and time from start of T cell processing to 
freezing of T cell lysate, were recorded for all samples. The median (IQR, range) time from 
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blood draw to start of processing was 67 (56-90, 28-198) minutes. The median (IQR, range) 
time from start of processing to freezing of lysate was 254 (231 – 305, 170 – 333) minutes. 
There was no significant difference in mean blood draw or processing times between healthy 
controls and patients (p = 0.141 and p = 0.538 respectively, Mann-Whitney U test) (Figure 
7.2A). 
The median (IQR, range) cell yield for healthy control T cell isolates was 3.1 (2.3 – 3.7, 1.2 – 
5.0) x105 cells per ml whole blood. The mean cellular yield was not significantly different 
between healthy controls and patients (p = 0.267, Mann-Whitney U test) (Figure 7.2B). The 
median (IQR, range) percentage of CD3+CD4+ cells in healthy control T cell isolates was 98.1 
(97.6 – 98.9, 96.8-99.2). The mean percentage CD3+CD4+ cells was not significantly 
   
     
Figure 7.2 – Comparison of quality control data between sequenced patient samples and 
hea;thy controls: mean blood draw and mean processing times (A), mean cell yield (B), mean 
percentage CD3+CD4+ (C) and mean percentage contaminating cells positive for  CD14 
(monocytes) and CD19 (B cells) (D). P values calculated by Mann-Whitney U test. 
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different between healthy controls and patients (p = 0.156, Mann-Whitney U test) (Figure 
7.2C). The percentage of contaminating monocytes and B-cells, defined as CD14+ or CD19+ 
respectively, are summarised in Figure 7.2D. Significantly greater mean CD19+ 
contamination was seen for healthy controls versus patients (p = 0.022). The explanation for 
this is not immediately apparent. Where data was available, the mean yield of CD19+ cells in 
parallel PBMC isolations was not significantly different between patients and healthy controls 
(p = 0.843, Mann-Whitney U test). This suggests that the higher CD19+ contamination in 
healthy T cell isolates was not due to a greater number of CD19+ cells healthy control versus 
patient blood – however, an absolute CD19+ cell count in whole blood, as opposed to the 
CD19+ cell yield following density centrifugation, would be required to confirm this. 
One participant had a mild upper respiratory tract infection at the time of the month one 
sample, and another had mild hay fever (not requiring any treatment) at the month three time 
point. Data from these two individuals, at the relevant time-point in each case, were excluded 
after read count normalisation and before differential gene expression analysis. 
 
7.2.3 RNA yield and integrity 
The quantity and quality of RNA in each T cell lysate was measured by gel electrophoresis 
using a Tapestation™ 4200 machine (Agilent) (Figure 7.3). The median (IQR, range) RNA 
yield was 870 (660 – 884, 277 – 2275) ng per million cells lysed. (Figure 7.4A). Prior to 
sequencing, the 28S/18S ribosomal RNA (rRNA) ratio and estimated RNA integrity number 
(RINe) were calculated for each sample. Lower RINe and 28S/18S ratios suggest RNA 
degradation; the RNAseq platform manufacturer (Illumina) recommends a RINe > 8 and a 
28S/18S rRNA ratio > 2.0 for high quality RNAseq analysis. The median (IQR, range) RINe 
was 9.4 (9.2 – 9.6, 8.1 – 10.0) (Figure 7.4B). The median (IQR, range) 28S/18S rRNA ratio 
was 2.6 (2.5 – 2.7, 2.1 – 2.9) (Figure 7.4C). There was no correlation between RINe and total 
time from venepuncture to freezing of T cell lysate (repeated measures R2 = -0.023, p = 
0.833), suggesting that the RNA integrity was not affected by laboratory processing time 
during the T cell isolation procedure (Figure 7.4D). There was no significant difference in 
mean RINe between patients and healthy controls (p = 0.104, Mann-Whitney U test). 
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Figure 7.3 – Assessment of RNA integrity. A. Gel electrophoresis of a representative set of 
RNA samples as visualised using a Tapestation™ 4200 machine. The ladder was loaded in 
lane A1, and patient samples loaded in the remaining lanes. Arrows in the sample lanes 
highlight the lower marker, 18S and 28S bands. B. Electropherogram for sample B1 showing 
the lower marker, 18S and 28S peaks. RINe: estimated RNA integrity number; nt: nucleotide. 
Images copyright Agilent Technologies Inc. 2015, reproduced with permission. 
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Figure 7.4 – Quality control of sequenced RNA samples. CD4+ T cell lysates RNA yield (A), 
estimated RNA integrity number (RINe) (B), 28S/18S ribosomal RNA (rRNA) ratio (C), and 
correlation between RINe and time from venepuncture to freezing of T cell lysate (D). Lines 
represent individual patient linear regression lines, and R2/p-values refer to overall correlation 
accounting for repeated measures. 
 
7.2.4 Sequencing quality 
 
The quality of RNA sequencing data was assessed as described in Methods 3.10.2. Samples 
were sequenced to a mean (range) depth of 12.3 (9.2 – 18.4) reads per sample (Figure 7.5A). 
Sequencing read length was tightly clustered around the expected 75bp (Figure 7.5B), and no 
samples were found with adaptor contamination >0.1%. Quality of the sequencing was 
excellent with a mean Phred score >30 across all read positions (Figure 7.5C) and no read 
trimming was necessary. 
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Figure 7.5 – Quality control of RNA sequencing. A: Number of sequences of each patient 
sample RNA library. B: Distribution of mean number of reads by RNA sequence length. Read 
count range for each sequence length is shown in grey. C: Distribution of mean Phred score 
by sequence position across all samples. Phred score range at each sequence position is shown 
in grey. 
 
 
7.3 Baseline analyses 
All analyses were performed with adjustment for RNA sequencing batch and sample CD4+ T 
cell purity (see Methods 3.10.2). Change in gene expression was considered significant if 
there was >1.5 fold-difference in expression between groups at the 0.05 significance level 
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according to the moderated t-test, after false-discovery rate (FDR) correction using the 
Benjamini-Hochberg procedure. Where changes in gene expression failed to meet statistical 
significance, unadjusted p-values were used as in a secondary exploratory analysis with a post 
hoc significance threshold of p < 0.001. Computer programming scripts, bioinformatics 
analysis and figure generation for all RNAseq data (with the exception of multivariate Cox 
regression and ROC analysis) were performed by Andrew Skelton, Experimental Scientific 
Officer, Bioinformatics Support Unit, Newcastle University. 
 
7.3.1 Flare versus remission 
The comparison of CD4+ T cell gene expression at baseline between patients who experienced 
a flare versus those who remained in DFR following DMARD cessation was the primary 
analysis for this study. Substantial variation in gene expression between flare and remission 
groups by log-fold change values was evident, but none of these differences reached statistical 
significance after FDR adjustment (Figure 7.6A). 
An exploratory analysis was performed without FDR correction, which identified 11 genes 
that were differentially expressed with an unadjusted p-value < 0.001 (Figure 7.6B and Table 
7.2). Pathway analysis was performed with functional gene annotation using Ingenuity™ 
Pathway Analysis (IPA™) software (Qiagen, Redwood City, USA). Log fold-change of all 
118 genes that demonstrated differential expression with an unadjusted p-value threshold of 
<0.01 were analysed. The top identified network contained the functions “cell cycle, cell 
death and survival, and inflammatory response”, for which 11/35 were up-regulated and 1/35 
down-regulated in flare versus remission patients. Nevertheless, visualisation of this network 
did not identify any clear edges between the differentially expressed nodes (Figure 7.8).  
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Figure 7.6 – Volcano plots showing baseline differential gene expression in circulating CD4+ 
T cells between patients who subsequently experienced an arthritis flare versus those who 
remained in drug-free remission following DMARD cessation. Plots are shown with (A: 
FDR-corrected p-value < 0.05) and without (B: unadjusted p < 0.001) multiple test correction. 
Horizontal lines represent log-fold change (log2FC) > 1.5. 
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Table 7.2 – Differential expression of genes at baseline between flare and remission groups, using an unadjusted significance threshold of p<0.001. 
Positive log-fold change indicates higher expression in the flare group, whereas negative log-fold change indicates higher expression in the remission 
group.  FC: fold-change; HGNC: HUGO gene nomenclature committee; lincRNA: long intergenic non-coding RNA. 
 
Ensembl gene ID Log2 FC 
Average 
expression t 
Unadjusted 
p value 
HGNC 
symbol Description 
ENSG00000102362 0.97 -1.229 3.907 0.000156 SYTL4 synaptotagmin like 4 
ENSG00000213296 -1.01 -3.627 -3.855 0.000188 
 
(known processed pseudogene) 
ENSG00000247033 1.74 -2.527 3.769 0.000257 
 
(novel antisense) 
ENSG00000255330 1.09 2.602 3.766 0.00026 SOGA3 suppressor of glucose, autophagy associated (SOGA) family member 3 
ENSG00000221957 1.93 -3.008 3.726 0.0003 KIR2DS4 killer cell immunoglobulin like receptor, two Ig domains and 
short cytoplasmic tail 4 
ENSG00000260876 1.10 -3.327 3.629 0.000421 LINC01229 long intergenic non-protein coding RNA 1229 
ENSG00000182489 -1.24 -0.281 -3.593 0.000476 XKRX XK related, X-linked 
ENSG00000164741 1.14 -2.246 3.593 0.000477 DLC1 Deleted In Liver Cancer 1 (DLC1) Rho GTPase activating protein 
ENSG00000144366 1.26 -2.506 3.590 0.000482 GULP1 engulfment adaptor PTB domain containing 1 
ENSG00000234199 1.06 -2.748 3.540 0.000573 LINC01191 long intergenic non-protein coding RNA 1191 
ENSG00000214803 -1.10 -2.297 -3.507 0.00064 
 
(known lincRNA) 
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Figure 7.7 – Visualisation of differential expression of genes within a predicted “cell cycle, 
cell death and survival, and inflammatory response” network between patients who 
experienced an arthritis flare versus those who remained in remission following DMARD 
cessation. Genes highlighted in red were up-regulated in the flare group, whereas those 
highlighted in blue were down-regulated in the flare group relative to the remission group. 
Copyright Qiagen 2017, reproduced with permission. 
 
 
7.3.2 Flare versus healthy control 
CD4+ T cell gene expression was compared between baseline samples of patients who flared 
following DMARD cessation versus healthy controls. Three genes were differentially 
expressed after FDR adjustment (Figure 7.8A), and a further 55 were differentially expressed 
using an unadjusted significance threshold of p<0.001 (Figure 7.8B). The entire 58-gene list is 
detailed in Appendix I, and the top 20 genes (by unadjusted p value) are presented in Table 
7.3. 
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Figure 7.8 - Volcano plots showing baseline differential gene expression in circulating CD4+ 
T cells between patients who subsequently experienced an arthritis flare following DMARD 
cessation versus healthy controls (HC). Plots are shown with (A: FDR-corrected p-value < 
0.05) and without (B: unadjusted p < 0.001) multiple test correction. Horizontal lines 
represent log-fold change (log2FC) > 1.5. Genes that exceeded both thresholds are highlighted 
in red. 
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Table 7.3 - Top 20 (by unadjusted p value) differentially expressed genes at baseline between flare patients and healthy controls. Positive log-fold 
change indicates higher expression in the patient group, whereas negative log-fold change indicates higher expression in the control group. FC: fold-
change; HGNC: HUGO gene nomenclature committee. * = significant after FDR adjustment (corrected p<0.05). 
Ensembl gene ID Log2 FC 
Average 
expression 
t 
Unadjusted p-
value 
HGNC symbol Description 
ENSG00000171560 2.42 -3.929 5.664 1.05E-07* FGA fibrinogen alpha chain  
ENSG00000106927 2.13 -3.961 5.116 1.21E-06* AMBP alpha-1-microglobulin/bikunin precursor  
ENSG00000171564 2.00 -4.006 4.890 3.19E-06* FGB fibrinogen beta chain  
ENSG00000163631 4.07 -2.059 4.665 8.15E-06 ALB albumin  
ENSG00000182489 -2.85 -0.281 -4.387 2.50E-05 XKRX Kell Blood Group Complex Subunit-Related, X-Linked 
ENSG00000198538 -1.30 2.898 -4.350 2.89E-05 ZNF28 zinc finger protein 28  
ENSG00000223551 1.87 -0.957 4.323 3.22E-05 TMSB4XP4 thymosin beta 4, X-linked pseudogene 4  
ENSG00000226029 0.78 2.868 4.081 8.16E-05 LINC01772 long intergenic non-protein coding RNA 1772  
ENSG00000141622 1.47 0.279 4.048 9.25E-05 RNF165 ring finger protein 165  
ENSG00000251411 2.32 -2.195 4.006 1.08E-04  (known processed pseudogene) 
ENSG00000197841 -0.93 3.455 -3.999 1.11E-04 ZNF181 zinc finger protein 181  
ENSG00000164136 1.25 2.113 3.994 1.13E-04 IL15 interleukin 15  
ENSG00000172985 -1.15 2.204 -3.993 1.13E-04 SH3RF3 SH3 domain containing ring finger 3  
ENSG00000247311 1.85 -0.006 3.983 1.18E-04  (novel antisense) 
ENSG00000112139 6.09 2.575 3.946 1.35E-04 MDGA1 
meprin, A-5 protein, and receptor protein-tyrosine phosphatase mu (MAM) 
domain containing glycosylphosphatidylinositol anchor 1  
ENSG00000088538 0.85 2.753 3.914 1.52E-04 DOCK3 dedicator of cytokinesis 3  
ENSG00000131080 1.84 -0.562 3.886 1.68E-04 EDA2R ectodysplasin A2 receptor  
ENSG00000229314 2.72 -3.203 3.879 1.73E-04 ORM1 orosomucoid 1  
ENSG00000125726 1.70 0.422 3.860 1.85E-04 CD70 CD70 molecule  
ENSG00000152242 0.60 6.523 3.837 2.01E-04 C18orf25 chromosome 18 open reading frame 25  
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7.3.3 Remission versus healthy control 
CD4+ T cell gene expression was compared between baseline samples of patients who 
remained in FDR following DMARD cessation versus healthy controls. No genes were 
differentially expressed after FDR adjustment (Figure 7.9A); 39 were differentially expressed 
using an unadjusted significance threshold of p<0.001 (Figure 7.9B). The entire gene list is 
detailed in Appendix I, and the top 20 genes (by unadjusted p-value) are presented in      Table 
7.4. 
 
 
Figure 7.9 - Volcano plots showing baseline differential gene expression in circulating CD4+ 
T cells between patients who subsequently remained in drug-free remission following 
DMARD cessation versus healthy controls (HC). Plots are shown with (A: FDR-corrected p-
value < 0.05) and without (B: unadjusted p < 0.001) multiple test correction. Horizontal lines 
represent log-fold change (log2FC) > 1.5. Genes that exceeded both thresholds are highlighted 
in red. 
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Table 7.4 - Top 20 (by unadjusted p value) differentially expressed genes at baseline between remission patients and healthy controls. Positive log-fold 
change indicates higher expression in the patient group, whereas negative log-fold change indicates higher expression in the control group.  FC: fold-
change; HGNC: HUGO gene nomenclature committee. TEC = to be experimentally confirmed. 
Ensembl gene ID Log2 FC 
Average 
expression t 
Unadjusted 
p value 
HGNC 
symbol Description 
ENSG00000106927 2.05 -3.961 4.882 3.31E-06 AMBP alpha-1-microglobulin/bikunin precursor 
ENSG00000226029 0.92 2.868 4.782 5.02E-06 LINC01772 long intergenic non-protein coding RNA 1772 
ENSG00000112139 7.13 2.575 4.595 1.09E-05 MDGA1 meprin, A-5 protein, and receptor protein-tyrosine phosphatase mu (MAM) domain containing glycosylphosphatidylinositol anchor 1 
ENSG00000247311 2.06 -0.006 4.420 2.19E-05 
 
(novel antisense) 
ENSG00000198538 -1.33 2.898 -4.418 2.21E-05 ZNF28 zinc finger protein 28 
ENSG00000163631 3.88 -2.059 4.415 2.24E-05 ALB albumin 
ENSG00000171560 1.87 -3.929 4.359 2.79E-05 FGA fibrinogen alpha chain 
ENSG00000171564 1.74 -4.006 4.238 4.48E-05 FGB fibrinogen beta chain 
ENSG00000256913 1.67 -0.059 4.165 5.94E-05 
 
(novel processed pseudogene) 
ENSG00000259657 1.54 0.037 4.124 6.92E-05 PIGHP1 phosphatidylinositol glycan anchor biosynthesis class H pseudogene 1 
ENSG00000265293 1.75 -0.842 3.969 1.24E-04 ARGFXP2 arginine-fifty homeobox pseudogene 2 
ENSG00000204380 2.30 -1.803 3.908 1.55E-04 PKP4-AS1 Plakophilin 4 - antisense RNA 1 
ENSG00000228382 2.06 -1.596 3.901 1.59E-04 ITPKB-IT1 Inositol-Trisphosphate 3-Kinase B - intronic transcript 1 
ENSG00000279148 1.92 -1.618 3.825 2.10E-04 
 
(known TEC) 
ENSG00000214081 -2.58 -3.722 -3.807 2.24E-04 CYP4F30P cytochrome P450 family 4 subfamily F member 30, pseudogene 
ENSG00000165259 2.05 -0.644 3.778 2.48E-04 HDX highly divergent homeobox 
ENSG00000251411 2.19 -2.195 3.755 2.70E-04 
 
(known processed pseudogene) 
ENSG00000154099 0.98 0.726 3.700 3.28E-04 DNAAF1 dynein axonemal assembly factor 1 
ENSG00000261487 1.58 0.395 3.660 3.77E-04 
 
(novel processed transcript) 
ENSG00000253676 1.79 -0.299 3.660 3.77E-04 TAGLN2P1 transgelin 2 pseudogene 1 
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7.4 Longitudinal analysis 
7.4.1 Flare visit versus baseline: flare patients 
CD4+ T cell gene expression was compared between time of flare and baseline for the 17 
patients who experienced an arthritis flare following DMARD cessation and where both 
baseline and flare samples were included in the RNAseq experiment. A total of 81 genes were 
differentially expressed between the two groups at an unadjusted significance level of 
p<0.001, of which 2 were robust to FDR correction (Figure 7.10). The entire list of 81 genes 
is presented in Appendix I, and the top 20 genes by p value are listed in Table 7.5. 
Log fold-change of the 284 genes that demonstrated differential expression with an 
unadjusted p-value threshold of <0.01 were analysed by Ingenuity Pathway Analysis. 
Canonical pathways were dominated by genes involved in cellular proliferation. The top 
network identified was related to “cell cycle; cellular assembly and organisation; DNA 
replication, recombination and repair” processes, with robust upregulation of 31/35 genes 
across the virtually the entire network (Figure 7.11). 
 
7.4.2 Month six versus baseline visits: remission patients 
CD4+ T cell gene expression was compared between baseline and the final month six study 
visit for the 15 patients who remained in DFR following DMARD cessation and where both 
baseline and month six samples were included in the RNAseq experiment. There was no 
significant differential expression after FDR adjustment (Figure 7.12A). Using unadjusted p 
values, 19 genes were differentially expressed at the p<0.001 significance level (Figure 
7.12B, Table 7.6). 
Ingenuity pathway analysis was performed using the 183 genes that were differentially 
expressed at an unadjusted p threshold of p<0.01between month 6 and baseline visits in the 
remission group. The top network that was identified involved genes with roles in “cancer; 
cell-to-cell signalling and interaction; and organismal injury and abnormalities”. Differential 
expression was observed in 16/35 nodes in this predicted network, the majority of which were 
down-regulated at month six verses baseline (Figure 7.13). There were however very few 
edges between differentially expressed nodes in the network. 
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Figure 7.10 - Volcano plots showing longitudinal change in gene expression between time of 
arthritis flare versus baseline for patients who experienced an arthritis flare following 
DMARD cessation. Plots are shown with (A: FDR-corrected p-value < 0.05) and without (B: 
unadjusted p < 0.001) multiple test correction. Horizontal lines represent log-fold change 
(log2FC) > 1.5. Genes that exceeded both thresholds are highlighted in red. 
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Table 7.5 – Top 20 (by unadjusted p value) differentially expressed genes between flare versus baseline visits in 17 patients who experienced an 
arthritis flare. Positive log-fold change indicates higher expression at the flare visit, whereas negative log-fold change indicates higher expression at 
baseline.  HGNC: HUGO gene nomenclature committee. * = significant after multiple test correction (p<0.05). 
 
Ensembl gene ID Log2 FC 
Average 
expression t 
Unadjusted 
p value 
HGNC 
symbol Description 
ENSG00000144354 1.05 2.811 5.489 2.79E-07 CDCA7 cell division cycle associated 7 * 
ENSG00000130164 0.79 4.180 5.105 1.47E-06 LDLR low density lipoprotein receptor * 
ENSG00000165409 1.19 -0.350 4.678 8.59E-06 TSHR thyroid stimulating hormone receptor 
ENSG00000171533 1.69 -2.505 4.641 9.98E-06 MAP6 microtubule associated protein 6 
ENSG00000137474 1.37 0.283 4.640 1.00E-05 MYO7A myosin VIIA 
ENSG00000156127 0.78 3.068 4.544 1.47E-05 BATF basic leucine zipper ATF-like transcription factor 
ENSG00000251537 1.80 -2.089 4.480 1.89E-05 
 
(known protein coding) 
ENSG00000088325 1.10 2.241 4.458 2.07E-05 TPX2 TPX2, microtubule nucleation factor 
ENSG00000156535 0.72 1.385 4.447 2.15E-05 CD109 CD109 molecule 
ENSG00000138180 1.36 0.809 4.399 2.60E-05 CEP55 centrosomal protein 55 
ENSG00000137812 0.83 1.516 4.365 2.97E-05 KNL1 kinetochore scaffold 1 
ENSG00000216819 -1.48 -3.326 -4.323 3.50E-05 TUBB2BP1 tubulin beta 2B class IIb pseudogene 1 
ENSG00000131747 1.21 3.351 4.294 3.91E-05 TOP2A topoisomerase (DNA) II alpha 
ENSG00000170312 1.02 1.016 4.293 3.91E-05 CDK1 cyclin dependent kinase 1 
ENSG00000148773 1.53 4.054 4.274 4.20E-05 MKI67 marker of proliferation Ki-67 
ENSG00000267496 -0.90 -0.920 -4.266 4.34E-05 FAM215A family with sequence similarity 215 member A (non-protein coding) 
ENSG00000263218 1.72 -3.428 4.250 4.62E-05 
 
(known antisense RNA) 
ENSG00000237649 1.14 1.173 4.230 4.98E-05 KIFC1 kinesin family member C1 
ENSG00000137804 0.91 2.575 4.201 5.56E-05 NUSAP1 nucleolar and spindle associated protein 1 
ENSG00000175063 1.59 -0.144 4.063 9.31E-05 UBE2C ubiquitin conjugating enzyme E2 C 
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Figure 7.11 – Visualisation of differential expression of genes within a predicted “cell cycle; 
cellular assembly and organisation; DNA replication, recombination and repair” network 
between baseline and flare visit samples in those patients who experienced an arthritis flare 
following DMARD cessation. Genes highlighted in red were up-regulated at the flare visit, 
whereas those highlighted in blue were down-regulated at the flare visit relative to baseline. 
Copyright Qiagen 2017, reproduced with permission. 
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Figure 7.12 - Volcano plots showing longitudinal change in gene expression between month 
six versus baseline for patients who remained in drug-free remission following DMARD 
cessation. Plots are shown with (A: FDR-corrected p-value < 0.05) and without (B: 
unadjusted p < 0.001) multiple test correction. Horizontal lines represent log-fold change 
(log2FC) > 1.5. Genes that exceeded both thresholds are highlighted in red. 
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Table 7.6– Differential expression of genes between month six versus baseline visits in 15 patients who remained in DFR, using an unadjusted 
significance threshold of p<0.001. Positive log-fold change indicates higher expression at the month six visit, whereas negative log-fold change 
indicates higher expression at baseline.  HGNC: HUGO gene nomenclature committee. 
Ensembl gene ID Log2 FC 
Average 
expression 
t 
Unadjusted 
p value 
HGNC symbol Description 
ENSG00000211677 -1.99 -0.565 -4.844 4.36E-06 IGLC2 immunoglobulin lambda constant 2 
ENSG00000240036 1.82 -2.709 4.410 2.49E-05 
 
(processed pseudogene) 
ENSG00000244357 1.44 -1.978 4.182 5.97E-05 RN7SL145P RNA, 7SL, cytoplasmic 145, pseudogene 
ENSG00000238260 1.31 -3.377 4.135 7.12E-05 
 
(known antisense RNA) 
ENSG00000254230 -1.17 -3.649 -3.817 0.000227 
 
(known antisense RNA) 
ENSG00000271153 -0.96 -4.036 -3.759 0.00028 RPL23AP88 ribosomal protein L23a pseudogene 88 
ENSG00000260896 -1.10 -2.058 -3.738 0.000301 LINC02170 long intergenic non-protein coding RNA 2170 
ENSG00000255757 -0.80 0.052 -3.643 0.000419 
 
(processed pseudogene) 
ENSG00000104067 -0.98 -1.610 -3.618 0.000457 TJP1 tight junction protein 1 
ENSG00000255045 -1.14 -2.449 -3.603 0.00048 
 
(known antisense RNA) 
ENSG00000237593 -0.85 -0.704 -3.595 0.000495 
 
(processed pseudogene) 
ENSG00000136634 -0.89 -0.556 -3.584 0.000514 IL10 interleukin 10 
ENSG00000254095 -1.01 -3.776 -3.574 0.000531 
 
(processed transcript) 
ENSG00000211895 -1.97 0.058 -3.568 0.000542 IGHA1 immunoglobulin heavy constant alpha 1 
ENSG00000101384 1.01 -0.338 3.509 0.000663 JAG1 jagged 1 
ENSG00000256651 -1.23 -2.981 -3.459 0.000782 
 
(processed pseudogene) 
ENSG00000211890 -1.81 -2.260 -3.443 0.000825 IGHA2 immunoglobulin heavy constant alpha 2 (A2m marker) 
ENSG00000224842 1.15 -3.139 3.419 0.000892 
 
(known antisense RNA) 
ENSG00000272945 1.16 -2.857 3.385 0.000999 
 
(sense intronic) 
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Figure 7.13 – Visualisation of differential expression of genes within a predicted network of 
“cell cycle; cellular assembly and organisation; DNA replication, recombination and repair” 
genes between month six and baseline visit samples in those patients who maintained drug-
free remission following DMARD cessation. Genes highlighted in red were up-regulated at 
month six, whereas those highlighted in blue were down-regulated at month six relative to 
baseline. 
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7.5 Comparison between contrast groups 
In a further exploratory analysis, genes that were differentially expressed at the unadjusted 
p<0.001 threshold in the various contrasts described above were compared (Figure 7.14). 
Very little overlap was observed in differentially expressed genes (DEGs) between contrast 
pairs, with the exception of flare vs. controls and remission vs. controls analyses, which 
shared 23 common DEGs (Table 7.7). The substantially higher number of common DEGs in 
these comparisons is to be expected, given the common comparator group of healthy controls. 
These DEGs could conceivably represent gene expression specific to RA disease processes, or 
a gene expression profile common to the effects of DMARD treatment. 
 A further single gene (XKRX - XK related, X-linked, which encodes for a Kell blood group 
antigen) was down-regulated in both flarebaseline vs. remissionbaseline (log2FC -1.24) and 
flarebaseline vs. HCbaseline (log2FC -2.85) comparisons. 
 
  
Figure 7.14 – Overlap of differentially expressed genes identified in different contrast pairs at 
the unadjusted p<0.001 significance threshold. F: flare patient; FV: flare visit; HC: healthy 
control; V6: month 6 visit; VB: baseline visit; VF: flare visit; R: remission patient. 
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Table 7.7 – Differentially expressed genes common to both flarebaseline versus healthy control (HCbaseline) and remissionbaseline versus HCbaseline analyses 
at the unadjusted p<0.001 significance threshold. Positive log2(fold change) (log2FC) indicates higher expression in patients, whereas a negative 
log2FC indicates lower expression in patients relative to healthy controls. HGNC: HUGO gene nomenclature committee. lincRNA: long intergenic 
non-coding RNA; TEC = to be experimentally confirmed. 
Ensembl gene ID log2FC flarebaseline vs HCbaseline 
log2FC remissionbaseline vs. 
HCbaseline 
HGNC 
symbol Description 
ENSG00000106927 2.13 2.05 AMBP alpha-1-microglobulin/bikunin precursor 
ENSG00000226029 0.78 0.92 LINC01772 long intergenic non-protein coding RNA 1772 
ENSG00000112139 6.09 7.13 MDGA1 MAM domain containing glycosylphosphatidylinositol anchor 1 
ENSG00000247311 1.85 2.06 
 
(antisense RNA) 
ENSG00000198538 -1.30 -1.33 ZNF28 zinc finger protein 28 
ENSG00000163631 4.07 3.88 ALB albumin 
ENSG00000171560 2.42 1.87 FGA fibrinogen alpha chain 
ENSG00000171564 2.00 1.74 FGB fibrinogen beta chain 
ENSG00000259657 1.35 1.54 PIGHP1 phosphatidylinositol glycan anchor biosynthesis class H pseudogene 1 
ENSG00000265293 1.64 1.75 ARGFXP2 arginine-fifty homeobox pseudogene 2 
ENSG00000228382 1.91 2.06 ITPKB-IT1 ITPKB intronic transcript 1 
ENSG00000279148 1.87 1.92 
 
(TEC) 
ENSG00000165259 1.94 2.05 HDX highly divergent homeobox 
ENSG00000251411 2.32 2.19 
 
(processed pseudogene) 
ENSG00000261487 1.59 1.58 
 
(processed transcript) 
ENSG00000141622 1.47 1.32 RNF165 ring finger protein 165 
ENSG00000115129 1.15 1.18 TP53I3 tumour protein p53 inducible protein 3 
ENSG00000246016 1.95 2.02 LINC01513 long intergenic non-protein coding RNA 1513 
ENSG00000159882 -0.67 -0.68 ZNF230 zinc finger protein 230 
ENSG00000272086 1.27 1.31 
 
(known LincRNA) 
ENSG00000267939 2.31 2.17 
 
(known LincRNA) 
ENSG00000273598 -1.89 -1.95 
 
(unprocessed pseudogene) 
ENSG00000229314 2.72 2.43 ORM1 orosomucoid 1 
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7.6 Predictive biomarker analyses 
7.6.1 Univariate Cox regression 
Standard bioinformatics pipelines analyse differential gene expression dependent on the 
presence or absence of a binary outcome measure. Whilst this approach benefits from many 
years of accumulated knowledge and refined computer packages, it is inherently 
underpowered in comparison to survival analysis when analysing time-to-event data. 
Therefore, in a further analysis, the association between gene expression at baseline and time-
to-flare following DMARD cessation was analysed across all sequenced genes using 
univariate Cox regression. Using this approach, 19 genes were identified that were 
significantly associated with time-to-flare by a post hoc unadjusted p-value threshold of 
<0.001 (Figure 7.15). None of the genes were robust to multiple test correction, although the 
Benjamini-Hochberg procedure appeared particularly conservative in its correction relative to 
the two-way analyses (Table 7.8). No significant departure from proportional hazards was 
observed for any of these 19 genes. 
 
 7.6.2 Multivariate Cox regression 
The 19 genes that were significantly associated with time-to-flare at unadjusted significance 
level of <0.001 by univariate Cox regression were entered in to a multivariate Cox regression 
model. Stepwise backward selection based on Akaike Information Criterion (AIC) was then 
performed in order to reduce the number of variables to a practical size for the purposes of a 
biomarker signature, where a lower AIC score indicates a better model (see Methods 3.10.1). 
After five selection steps, 14 variables remained in the preliminary backwards stepwise 
multivariate Cox model (Table 7.9), with a reduction in AIC from 86.97 to 79.42. The 13 
variables in this model with a p value < 0.2 were then taken forward to a second round of 
stepwise backward selection. Although this 13 variable model had an AIC slightly greater 
AIC (79.81) than the 14 variable model, this could be reduced further by an additional two 
selection steps. This generated a final stepwise multivariate Cox regression model with 11 
variables and an AIC (77.69) that was lower than the 14 variable model (Table 7.10). 
Proportionality of hazards was demonstrated for all variables in both the 14-variable and 11-
variable stepwise models, and for both models as a whole. 
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Figure 7.15 - Volcano plot showing baseline gene expression in circulating CD4+ T cells as 
analysed by univariate Cox regression of time-to-flare following DMARD cessation. The 
horizontal line shows the unadjusted p-value < 0.001 threshold – genes that exceeded this 
threshold are highlighted in red. B: univariate Cox regression coefficient. 
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Table 7.8 – Association between baseline gene expression and time-to-flare following DMARD cessation by univariate Cox regression, using an 
unadjusted significance threshold of p<0.001. HGNC: HUGO gene nomenclature committee. LincRNA: long intergenic non-coding RNA. P value 
calculated by the likelihood ratio test. 
 
Ensembl gene ID HRflare HRflare 95% CI B 
Unadjusted 
p-value 
Adjusted 
p-value 
HGNC 
symbol Description 
ENSG00000102362 4.30 1.93 – 9.58 1.46 2.04E-05 0.555 SYTL4 synaptotagmin like 4 
ENSG00000247033 1.84 1.33 – 2.54 0.61 4.11E-05 0.559 
 
(novel antisense) 
ENSG00000276571 0.40 0.25 – 0.65 -0.91 7.33E-05 0.615 
 
(novel antisense) 
ENSG00000204965 0.46 0.31 – 0.68 -0.78 9.04E-05 0.615 PCDHA5 protocadherin alpha 5 
ENSG00000241146 0.41 0.27 – 0.63 -0.89 1.44E-04 0.785 RPL7P41 ribosomal protein L7 pseudogene 41 
ENSG00000250030 2.63 1.58 – 4.36 0.97 2.15E-04 0.863 
 
(novel processed pseudogene) 
ENSG00000213296 0.37 0.20 – 0.66 -1.01 2.50E-04 0.863 
 
(known processed pseudogene) 
ENSG00000229619 5.30 2.05 – 13.7 1.67 2.72E-04 0.863 MBNL1-AS1 muscleblind-like protein 1 - antisense RNA 1 
ENSG00000125046 0.37 0.22 – 0.61 -0.99 2.97E-04 0.863 SSUH2 suppressor of stomatin mutant uncoordination (ssu-2) homolog (C. elegans) 
ENSG00000182489 0.53 0.38 – 0.75 -0.63 3.17E-04 0.863 XKRX Kell Blood Group Complex Subunit-Related, X-Linked 
ENSG00000144366 1.87 1.30 – 2.70 0.63 4.84E-04 1.000 GULP1 engulfment adaptor PTB domain containing 1 
ENSG00000237473 3.42 1.58 – 7.39 1.23 5.28E-04 1.000 
 
(known lincRNA) 
ENSG00000228010 0.25 0.11 – 0.56 -1.38 6.02E-04 1.000 
 
(novel antisense) 
ENSG00000250827 0.47 0.30 – 0.74 -0.76 7.86E-04 1.000 MFSD4BP1 major facilitator superfamily domain containing 4B pseudogene 1 
ENSG00000042286 10.2 2.42 – 42.6 2.32 7.94E-04 1.000 AIFM2 apoptosis inducing factor, mitochondria associated 2 
ENSG00000231305 0.24 0.11 – 0.56 -1.41 7.99E-04 1.000 
 
(known antisense) 
ENSG00000255330 2.66 1.32 – 5.36 0.98 8.33E-04 1.000 SOGA3 suppressor of glucose, autophagy associated (SOGA) family member 3 
ENSG00000227070 2.15 1.41 – 3.28 0.77 8.47E-04 1.000 
 
(novel antisense) 
ENSG00000162636 12.9 2.57 – 64.5 2.56 9.14E-04 1.000 FAM102B family with sequence similarity 102 member B 
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Table 7.9 – Association of baseline gene expression and time-to-flare following DMARD-
cessation in a preliminary 14-variable backward stepwise multivariate Cox regression model. 
B: Cox regression coefficient. P-value calculated by the Wald test. 
Ensembl gene ID B HRflare 95% CI HRflare p 
ENSG00000204965 -2.80 0.06 0.01 – 0.58 0.015 
ENSG00000241146 -1.90 0.15 0.03 – 0.71 0.017 
ENSG00000229619 4.48 88.2 2.05 – 3800 0.020 
ENSG00000228010 -7.12 0.00 0.00 – 0.59 0.034 
ENSG00000125046 -2.53 0.08 0.01 – 0.88 0.039 
ENSG00000162636 13.62 8.19x105 1.18 – 5.69x1011 0.047 
ENSG00000227070 4.11 60.64 1.03 – 3560 0.048 
ENSG00000250827 1.78 5.92 0.95 – 36.8 0.056 
ENSG00000042286 2.75 15.6 0.86 – 284 0.063 
ENSG00000247033 2.22 9.20 0.88 – 96.4 0.064 
ENSG00000276571 -1.46 0.23 0.05 – 1.17 0.076 
ENSG00000237473 1.77 5.87 0.72 – 47.9 0.098 
ENSG00000182489 0.85 2.33 0.77 – 7.06 0.133 
ENSG00000102362 -2.34 0.10 0.002 – 4.30 0.227 
 
Table 7.10 – Association of baseline gene expression and time-to-flare following DMARD-
cessation in a final 11-variable backward stepwise multivariate Cox regression model. B: Cox 
regression coefficient. P-value calculated by the Wald test. 
Ensembl gene ID B HRflare 95% CI HRflare p 
ENSG00000228010 -4.15 0.02 0.00 – 0.14 2.24E-04 
ENSG00000162636 6.97 1060 22.6 – 50000 3.88E-04 
ENSG00000227070 1.78 5.94 2.08 – 16.9 8.63E-04 
ENSG00000204965 -1.69 0.18 0.07 – 0.52 1.45E-03 
ENSG00000229619 2.93 18.7 2.90 – 121 2.08E-03 
ENSG00000247033 1.18 3.26 1.53 – 6.98 2.29E-03 
ENSG00000125046 -1.49 0.23 0.09 – 0.60 2.62E-03 
ENSG00000241146 -1.32 0.27 0.10 – 0.71 7.96E-03 
ENSG00000276571 -0.83 0.44 0.18 – 1.07 7.07E-02 
ENSG00000250827 0.71 2.04 0.89 – 4.69 9.42E-02 
ENSG00000042286 1.75 5.78 0.68 – 49.3 1.09E-01 
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7.6.3 ROC analysis 
Based on a p value threshold of <0.001, three variables were selected from this final stepwise 
multivariate model, namely: ENSG00000228010, ENSG00000162636 and 
ENSG00000227070. Candidate genes were explored for their biomarker utility either alone, 
or in combination with each other – when combined, expression values for each gene were 
weighted by the respective coefficient in the final stepwise Cox regression model. Patients 
were dichotomised for each gene score using two thresholds determined by ROC analysis 
optimised for the prediction of flare and remission, as previously discussed (Methods 3.10.1) 
(Table 7.11). 
The ROC curve for each variable, together with the survival curves for dichotomised groups 
based on flare and remission biomarker thresholds are presented in Figure 7.16. Based on 
overall AUC, it is clear to see that the composite scores provided greater predictive utility 
than any of the single gene expression variables alone. The prognostic performance of the 
composite scores are detailed further in Table 7.12.  
 
Table 7.11 – Composite scores ranked by area under the receiver operating characteristic 
curve (ROCAUC). Variables included within each score are indicated in green, and those 
excluded are indicated in red.  
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Remission 
threshold 
Flare 
threshold ROCAUC 
   59.19 60.55 0.900 
   75.86 79.4 0.854 
   39.33 41.17 0.841 
   0.18 2.69 0.820 
   19.21 19.97 0.750 
   56.38 59.1 0.743 
   -19.11 -15.96 0.685 
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Figure 7.16 – Receiver-operating characteristic curves for RNAseq composite biomarker scores for the prediction of flare following DMARD 
cessation. A: MCP1+IL27+CRP, B: MCP1+IL27, C: MCP1+CRP, D: MCP1, E: IL27+CRP, E: CRP, F: IL27. 
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Table 7.12 - Predictive utility of cytokine/chemokine variables in predicting flare following 
DMARD cessation, with a positive test defined by either flare or remission thresholds. 
Optimum pairs of predictive metrics are highlighted in bold. NPV: negative predictive value; 
PPV: positive predictive value. 
Variable 
ROCAUC 
(95% CI) 
Threshold 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
ENSG00000228010 
ENSG00000162636 
ENSG00000227070 
0.90 
(0.81 – 0.99) 
Flare 
(60.55) 
0.78 
(0.61 – 0.96) 
0.95 
(0.85 – 1.00) 
0.95 
(0.84 – 1.00) 
0.79 
(0.67 – 0.95) 
Remission 
(59.19) 
0.91 
(0.78 – 1.00) 
0.75 
(0.55 – 0.90) 
0.81 
(0.70 – 0.92) 
0.89 
(0.74 – 1.00) 
ENSG00000228010 
ENSG00000162636 
0.85 
(0.74 – 0.97) 
Flare 
(79.4) 
0.61 
(0.39 – 0.78) 
0.95 
(0.85 – 1.00) 
0.94 
(0.81 – 1.00) 
0.68 
(0.58 – 0.80) 
Remission 
(75.86) 
0.96 
(0.87 – 1.00) 
0.45 
(0.25 – 0.65) 
0.67 
(0.59 – 0.77) 
0.91 
(0.70 – 1.00) 
ENSG00000228010 
ENSG00000227070 
0.84 
(0.72 – 0.96) 
Flare 
(41.17) 
0.65 
(0.43 – 0.83) 
0.85 
(0.65 – 1.00) 
0.83 
(0.68 – 1.00) 
0.68 
(0.56 – 0.82) 
Remission 
(39.33) 
0.91 
(0.78 – 1.00) 
0.65 
(0.45 – 0.85) 
0.75 
(0.65 – 0.88) 
0.88 
(0.71 – 1.00) 
 
Overall, the 3-gene composite score performed the best for prediction of both flare and 
remission and discriminated patients with significantly different flare-free survival times 
(Formula 7.1 and Figure 7.17). 
Formula 7.1 – The 3-gene composite biomarker score, based on log-transformed gene 
expression values. 
Composite score = 6.97(ENSG00000162636) + 1.78(ENSG00000227070) 
- 4.15(ENSG00000228010) - 1.22(ACR/EULAR Boolean remission) 
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Figure 7.17 - A: Kaplan-Meier plot of DMARD-free survival stratified by 3-gene composite 
score >60.55 (red) versus ≤ 60.55 (blue). B: Kaplan-Meier plot of DMARD-free survival 
stratified by 3-gene composite score >59.19 (red) or ≤59.19 (blue). P-values calculated by 
log-rank test. 
 
7.6.4 Sensitivity analysis incorporating processing time 
During the laboratory isolation procedure, CD4+ T cells are alive until the final cell lysis step. 
The transcriptional profiles of the cells may therefore be influenced by the isolation procedure 
itself. In order to ascertain the effect of this upon the composite biomarker score, a sensitivity 
analysis was performed whereby the three genes from the final composite score were entered 
in to a multivariate Cox regression model with the addition of total time from venepuncture to 
freezing of CD4+ T cell lysate. Total processing time showed no significant association with 
time-to-flare, whereas the three genes remained strongly associated independent of processing 
time (Table 7.13). Proportionality of hazards was demonstrated for all four variables and the 
model a whole. 
Table 7.13 – Sensitivity analysis incorporating genes from the final composite biomarker 
score, together with total time from venepuncture to freezing of cell lysate, in a multivariate 
Cox regression model. B: Cox regression coefficient. 
Variable B HRflare 95% CI HRflare p 
ENSG00000162636 2.863 17.51 3.15 97.31 
ENSG00000227070 0.713 2.04 1.32 3.14 
ENSG00000228010 -1.785 0.17 0.06 0.44 
Total time -0.004 1.00 0.99 1.00 
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7.7 Discussion 
7.7.1 Baseline comparison of flare versus drug-free remission patients 
In the primary analysis of the gene expression data of this study, CD4+ T cell gene expression 
was compared at baseline between those patients who experienced an arthritis flare versus 
those who remained in DFR following DMARD cessation. Although substantial number of 
differentially expressed genes (DEGs) were observed, none of these were robust to multiple 
test correction. Using post hoc unadjusted p-value thresholds of <0.001 and <0.01, 11 and 118 
genes respectively were identified as differentially expressed at the pre-specified >1.5 fold-
change level. Pathway analysis of the all 118 DEGs identified 12 as functioning within a 
network of genes involved in cell cycle, cell death and inflammatory response processes, 
though with no connecting edges between these identified nodes. A review of the published 
literature for the 11 DEGs at the p<0.001 significance level does however yield some 
interesting observations, as detailed below. 
 
7.7.1.a Killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 4 
(KIR2DS4) 
Expression of Killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic 
tail 4 (KIR2DS4) was up-regulated in flare versus DFR (log2FC 1.93, unadjusted p = 0.0003). 
KIRs are a diverse group of transmembrane glycoproteins that belong to the immunoglobulin 
superfamily, and are expressed on NK cells and T cells (Béziat et al., 2017). Inhibitory KIRs 
tend to bind class I HLA molecules and are thought to play an important role in viral and 
tumour surveillance, whereas the ligands for the majority of stimulatory KIRs remain 
unknown (Colucci and Traherne, 2017). Akin to HLA molecules, KIRs are notable for their 
vast allelic diversity and are inherited in haplotypes with ethnic and geographical separation 
(Béziat et al., 2017). A role for KIRs in the development of autoimmune disease has been 
postulated (Kusnierczyk, 2013), particularly by CD4+CD28-KIR+ T cells in RA and vasculitis 
(Yen et al., 2001; van Bergen and Koning, 2010). Of particular relevance to the findings of 
my study, KIR2DS4 has been implicated in the pathogenesis of RA. In a case-control 
Taiwanese genotyping study of 122 RA patients and 96 healthy controls, presence of the 
KIR2DS4 gene was significantly greater in RA patients versus controls (OR 1.9, 95% CI 1.1 – 
3.4, corrected p<0.01) (Yen et al., 2006). Furthermore, in a Polish study of 312 RA patients 
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treated with methotrexate, presence of the full-length KIR2DS4 gene was associated with a 
lower chance of responding to methotrexate (OR 0.43, 95% CI 0.22 – 0.99, p = 0.033) 
(Majorczyk et al., 2014). Given the apparent association of KIR2DS4 with both the 
development of RA and its response to treatment, it is thus conceivable that the higher 
KIR2DS4 expression by CD4+ T cells observed in this study may be of functional relevance 
in the predisposition to flare following DMARD cessation. 
 
7.7.1.b Engulfment adaptor PTB domain containing 1 (GULP1) 
Expression of engulfment adaptor PTB domain containing 1 (GULP1) was up-regulated in 
flare versus DFR (log2FC 1.26, unadjusted p = 4.82 x 10-4). GULP1 is an evolutionarily 
conserved adaptor protein involved in the phagocytosis of apoptotic cells (Kinchen and 
Ravichandran, 2007). In a small study of four patients with RA and three with OA, Qingchun 
et al. (2008) analysed differential expression of apoptosis-related genes. Included within the 
eight apoptosis-related DEGs was GULP1, which was down-regulated in RA compared to 
OA synovium. Exactly how this relates to the observation of up-regulated baseline GULP1 
expression by CD4+ T cells in the flare group of my study is uncertain, though nevertheless 
may suggest a role for the protein in RA processes. GULP1 can also bind to one of the two 
NPxY motifs in the cytoplasmic domain of low-density lipoprotein receptor-related protein 
(LRP) (Su et al., 2002) – a protein with structural homology to low-density lipoprotein 
receptor (LDLR) –  that is thought to be important in various signal transduction pathways 
(Lin and Hu, 2014). This observation may be of relevance given the up-regulation of LDLR at 
the time of flare in my study (discussed further below). Nevertheless, although LDLR also 
possesses an NPxY motif in its cytoplasmic tail (Lillis et al., 2008), there are no reports of 
GULP1-LDLR interactions in the published literature. 
 
7.7.1.c Synaptotagmin like 4 (SYTL4) 
The most significantly up-regulated DEG by p-value in flare vs. DFR patients at baseline was 
Synaptotagmin like 4 (SYTL4, also known as Slp4, or granuphilin) (log2FC 0.97, unadjusted p 
value 1.56 x 10-4).  SYTL4 interacts with the protein Rab27a to reduce exocytosis of dense-
core vesicles in rat PC12 cells (Fukuda et al., 2002). Mutations in Rab27a are the underlying 
defect in the rare type 2 Griscelli syndrome, where defects in vesicle exocytosis lead to 
albinism (due to reduced melanin secretion) and immunodeficiency with haemophagocytic 
lymphohistiocytosis (Anikster et al., 2002). Although no publications relate to the role of 
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SYL4 in lymphocytes, the structurally related proteins SYTL1 and SYTL2 play a role in 
secretion of vesicles at the immunological synapse of mouse and human cytotoxic T 
lymphocytes (Holt et al., 2008). Nevertheless, the significance of up-regulated SYTL4 
expression in the global CD4+ T cell population observed in flare patients at baseline is 
difficult to interpret based on gene expression data alone, and its functional effect would 
depend upon the cellular subpopulation of interest. 
 
7.7.2 Baseline comparison of patients with healthy controls 
DEGs were compared between patients and healthy controls in exploratory analyses to 
identify disease-specific genes associated with flare and sustained DFR. A greater number of 
DEGs were observed in the flare vs. healthy (58) than the remission vs. healthy (39) 
comparisons, using a pre-specified 1.5 fold-change threshold and a post hoc unadjusted 
significance threshold of p < 0.001. Furthermore, DEGs that were robust to multiple-test 
correction were only observed in the flare vs. healthy comparison: α-fibrinogen (FGA), β-
fibrinogen (FGB), and α1-microglobulin/bikunin precursor (AMBP). These three genes, 
together with other relevant genes up-regulated at the unadjusted p<0.001 threshold in the 
flare vs. healthy analysis, are discussed below. 
 
7.7.2.a Fibrinogen 
The expression of both FGA (log2FC 2.42, adjusted p = 0.003) and FGB  (log2FC 2.00, 
adjusted p 0.029) were significantly up-regulated in flare patients vs. healthy controls at 
baseline. Fibrinogen is a large hexameric protein, consisting of two subunits each containing 
three chains: α, β and γ (Mosesson, 2005). Upon cleavage by thrombin, fibrinogen forms 
insoluble fibrin – the principle scaffolding substrate of blood clots (Mosesson, 2005). 
Fibrinogen is mainly synthesised by hepatocytes, and its expression is well-established to 
increase during times of systemic inflammation as part of the acute-phase response, especially 
in response to IL-6 (Fish and Neerman-Arbez, 2012). Nevertheless, fibrinogen is also 
expressed by other cell types. For example, human lung epithelial cells up-regulate expression 
of γ-fibrinogen in response to exogenous IL-6 in vitro (Nguyen and Simpson-Haidaris, 2000). 
Furthermore, synthesis of β-fibrinogen by circulating CD4+ T cells was observed by Alberio 
et al. (2012), who found lower expression in patients with Parkinson’s disease versus healthy 
controls. However, no reports of T-cell specific expression of fibrinogen in RA have been 
published. 
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7.7.2.b α1-microglobulin/bikunin precursor (AMBP) 
AMBP was significantly up-regulated in both flare (log2FC 2.13, unadjusted p 1.21 x 10-6) and 
DFR (log2FC 2.05, unadjusted p = 3.31 x 10-6) versus healthy controls, and was robust to 
multiple test correction in the flare group comparison (adjusted p = 0.016). AMBP is a 
precursor protein that is cleaved to form two separate secreted proteins: α1-microglobulin and 
bikunin. Bikunin (also known as ulinastatin) is a Kunitz-type serine protease inhibitor found 
in blood and urine (Fries and Blom, 2000). Bikunin has been demonstrated to show 
immunomodulatory properties, such as the inhibition of lipopolysaccharide (LPS)-induced 
release of TNFα by human PBMCs in vitro (Matsuzaki et al., 2004). Bikunin is in current 
clinical use (outside of Europe and USA) for the treatment of acute pancreatitis and severe 
sepsis (Moggia et al., 2017). α1-microglobulin (also known as protein HC) is a plasma protein 
with immunosuppressive actions in vitro, including suppression of human PBMC 
proliferation (Akerstrom and Logdberg, 1984), inhibition of human neutrophil chemotaxis 
(Mendez et al., 1986), and inhibition of IL-2 production by murine CD4+ T cell hybridomas 
(Wester et al., 1998). Although AMBP is primarily expressed in hepatocytes, animal studies 
have demonstrated expression in other tissues including pancreatic lymph nodes (Yip et al., 
2009), and renal tubular epithelium (Grewal et al., 2005). Immunohistochemical studies with 
human tissue have also demonstrated the presence of bikunin in the brain, skin, testes and 
lungs (Businaro et al., 1992). Circulating AMBP levels have also been demonstrated to 
discriminate patients with active ulcerative colitis from those with quiescent disease 
(Wasinger et al., 2016). Given the above observations, it is theoretically possible that up-
regulated AMBP expression by CD4+ T cells could play a potentially immunoregulatory role 
in the context of RA flare, albeit insufficient in flare patients. However, no published studies 
exist to demonstrate either the expression of AMBP by human CD4+ T cells or the relevance 
of such cell-specific expression in the context of inflammatory processes. 
 
7.7.2.c Interleukin-15 
CD4+ T cell expression of IL15 was greater in flare patients versus healthy controls (log2FC 
1.25, unadjusted p 1.13 x 10-4). As reviewed by Yang et al. (2015), numerous observations 
implicate IL-15 in the pathogenesis and maintenance of synovitis in RA, notably: SNPs in the 
IL15 gene are associated with rate of joint destruction in RA (Knevel et al., 2012); IL-15 
levels are elevated in in the sera (Gonzalez-Alvaro et al., 2003) and synovial fluid (McInnes 
et al., 1996) of RA patients; and circulating IL-15 levels correlate with both RhF/ACPA titres 
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and clinical disease activity (Pavkova Goldbergova et al., 2012). In mice, exogenous IL-15 
can induce a local T cell inflammatory infiltrate (McInnes et al., 1996), whereas blockade of 
the cytokine can ameliorate synovitis in experimental arthritis (Ferrari-Lacraz et al., 2004) 
and has been trialled in RA patients (Baslund et al., 2005). IL-15 has several pro-
inflammatory effects, including differentiation of Th17 and Th1 cells, stimulation of B cells 
and NK cells, and promotion of CD8+ memory T cells survival (Brincks and Woodland, 
2010; Yang et al., 2015). Nevertheless, IL-15 has also been demonstrated to have 
immunoregulatory roles in some murine models of inflammatory bowel disease (Tosiek et al., 
2016) and experimental autoimmune encephalomyelitis (Yu et al., 2014). IL-15 is expressed 
by a variety of human cell types including synovial macrophages (Thurkow et al., 1997) and 
RA synovial fibroblasts (Miranda-Carus et al., 2004), and is produced in an 
autocrine/juxtacrine manner by both CD4+ and CD8+ T cells (Miranda-Carus et al., 2005). 
Indeed, it has been observed that both peripheral and synovial T cells from patients with 
active RA express surface IL-15 and can potentiate osteoclast differentiation in co-culture 
with autologous monocytes in vitro – an effect that was lost once clinical remission was 
achieved (Miranda-Carus et al., 2006). Given the above observations, it certainly seems 
plausible that the increased CD4+ T cell expression of IL-15 observed at baseline in flare 
patients vs. healthy controls may be relevant in the pathogenesis of flare following DMARD 
cessation. Furthermore, the reported pro-Th17 effects of the cytokine would be in keeping 
with the increased CD4+ T cell expression of the gene encoding the pro-Th17 transcription 
factor BATF observed at the time of flare in my study. 
 
7.7.2.d SH3 domain containing RING finger 3 (SH3RF3) 
The expression of SH3 domain containing really interesting new gene (RING) finger 3 
(SH3RF3) was down-regulated in flare patients vs. healthy controls (log2 FC -1.15, 
unadjusted p = 1.13 x 10-4). SH3RF3 is a member of the SH3RF family of multi-domain 
scaffold proteins involved in cell survival and apoptosis (Kim et al., 2014b). The structurally 
related SH3RF1 is expressed at high levels in RA synovial fibroblasts, where it has an anti-
apoptotic effect (Tsuda et al., 2010). Differential exon usage and lower expression of SH3RF 
has been identified in neutrophils from children with active versus quiescent juvenile 
idiopathic arthritis (JIA) (Jiang et al., 2015). In contrast, amongst 1168 differentially-
methylated genes identified in a genome-wide methylation array study of CD4+ T cells, slight 
hypomethylation of SH3RF was observed in Han Chinese RA patients versus healthy controls 
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(Δβ -0.007, p = 1.63 x 10-7) (Guo et al., 2017). It is difficult to reconcile the biological 
significance of these findings with the results of my study. 
 
7.7.2.e Orosomucoid 1 (ORM1) 
Orosomucoid 1 (also known as α-1-acid glycoprotein) is an abundant plasma protein secreted 
by hepatocytes as part of the acute-phase response (Fournier et al., 2000) though is also 
produced outside of the liver, including by T lymphocytes during activation (Stefanini et al., 
1989). ORM1 inhibits lymphocyte proliferation in vitro (Pos et al., 1990), and exogenous 
ORM1 has a protective effect against TNF-α administration in mice (Libert et al., 1994). It 
has thus been proposed that ORM1 represents a negative-feedback loop to modulate systemic 
immunity during the acute phase response (Libert et al., 1994). Both circulating (Cylwik et 
al., 2010) and urinary (Park et al., 2016) ORM1 correlate with disease activity in RA, though 
it has been suggested based on similar fucosylation patterns that synovial ORM1 likely 
originates from the circulation rather than the synovium (Havenaar et al., 1997). In my study, 
CD4+ T cell expression of ORM1 was higher in flare patients versus healthy controls (log2 FC 
2.72, p = 1.73 x 10-4). This would be in keeping with an activated T cell phenotype described 
above, though whether ORM1 produced in this setting represents an autocrine negative 
feedback response or merely increased cellular activity is unclear. 
 
7.7.2.f CD70 
CD70 expression was up-regulated in flare patients versus healthy controls (log2 FC 1.70, 
unadjusted p = 1.85 x 10-4). The binding of surface-expressed CD70 to its ligand, CD27, 
provides a well-established costimulatory signal important in T and B cell activation (Han et 
al., 2016a). Expression of CD70 is restricted to activated dendritic cells, T cells and B cells, 
whereas CD27 is expressed primarily on naïve CD4+ and CD8+ T cells, as well as subsets of 
NK and B cells (Han et al., 2016a). High levels of surface CD70 expression have been 
observed in CD4+ T cells from the blood (Park et al., 2014) and synovial fluid (Brugnoni et 
al., 1997) of RA patients compared to controls. Surface CD70 can identify a subpopulation of 
CD4+ T cells in RA that express the key Th17 transcription factor RORγt, and produce high 
levels of IFN-γ and IL-17 after stimulation in vitro (Park et al., 2014). CD70-expressing 
CD4+ T cells have been implicated in a bystander-effect of lowering the T cell activation 
threshold in RA (Lee et al., 2007), and blockade of CD27-CD70 interaction with anti-CD70 
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antibody can ameliorate synovitis in the murine collagen-induced arthritis model (Oflazoglu 
et al., 2009). 
In a study of 54 patients with a range of autoimmune rheumatic diseases (including RA, 
systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and Sjögren’s syndrome (SS)), 
Strickland et al. (2016) used multi-parameter flow cytometry to identify a novel subset of 
CD3+CD4+CD28+CD11ahiCD70+KIR2DL4+ lymphocytes which were more abundant in the 
blood of patients than healthy controls. Furthermore, the proportion of lymphocytes positive 
for this combination of markers significantly correlated with disease severity in patients with 
SLE, RA and SS (Strickland et al., 2016). The observations of this study are of particular 
relevance given the up-regulation of both CD70 and the KIR molecule KIR2DS4 gene 
expression observed in flare patients in my study, and raise the possibility of a similar CD4+ T 
cell subset at play in the pathogenesis of RA flare. This merits further exploration by flow 
cytometry using PBMC samples from my study. 
 
7.7.2.g Comparison between contrast groups 
Of the abovementioned genes, four were up-regulated in both flare vs. healthy and remission 
vs. healthy analyses at the unadjusted p<0.001 threshold: AMBP, FGA, FGB, and ORM1. It is 
conceivable that the expression of these genes relate to disease-specific processes common to 
RA patients regardless of their outcome following subsequent DMARD cessation; 
alternatively, expression of these genes may be a consequence of DMARD cessation itself. 
However, teasing apart these two possibilities is difficult given the strong link between the 
proteins encoded by all of these genes and the acute phase response. Although only 
conjecture, it seems plausible that the expression of these genes may relate to underlying 
subclinical inflammation, particularly given their established links with the acute-phase 
response. Indeed, in a longitudinal study of RA patients treated with methotrexate, De Graaf 
et al. (1994) observed a reduction in circulating ORM1 levels, though only in those patients 
who clinically responded to methotrexate – thus suggesting a disease activity-related fall in 
ORM1 rather than a direct effect of methotrexate therapy per se. 
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7.7.3 Longitudinal analyses 
7.7.3.a Flare patients – flare versus baseline visits 
The comparison of CD4+ T cell gene expression between flare and baseline visits revealed 
two DEGs that were robust to multiple test correction, and 81 DEGs at the unadjusted 
p<0.001 threshold. These DEGs included up-regulation of genes encoding microtubular and 
centrosomal proteins, together with topoisomerase-IIα, all of which are known to play crucial 
roles in the cell cycle. The most significantly up-regulated gene by p-value was cell division 
cycle associated 7 (CDCA7), which has been implicated in the growth of lymphoblastoid and 
solid-organ malignancies (Osthus et al., 2005). Mutations in CDCA7 have also been linked to 
human immunodeficiency (Thijssen et al., 2015). MKI67, which encodes the cell-surface 
molecule Ki-67, was also up-regulated at the time of flare in these cells. This is a notable 
observation given the long-established use of this cell-surface molecule as a lymphocyte 
proliferation marker in immunology studies, especially in flow-cytometry applications 
(Palutke et al., 1987). Indeed, many of the identified DEGs have well-established roles in 
cellular proliferation, and paint a picture of a transition from relatively quiescent populations 
of CD4+ T cells at baseline, to transcriptionally active and proliferating cells at the time of 
flare. This would be in keeping with evidence to support a proliferative expansion of CD4+ T 
cells in active RA, including oligoclonal expansion and premature immunosenescence within 
the CD4+ T cell compartment (see Introduction 1.2.3a). 
Several genes not directly involved in the machinery of the cell cycle were also observed to 
be up-regulated at the time of flare, such as low-density lipoprotein receptor (LDLR), thyroid 
stimulating hormone receptor (TSHR), basic leucine zipper ATF-like transcription factor 
(BATF), and CD109. Both LDLR and TSHR play important roles in cellular metabolism, and 
their up-regulation suggests greater metabolic demands of the CD4+ T cells at the time of flare 
in keeping with a proliferative phenotype. TSHR surface expression has been observed by 
flow cytometry in a subset of naïve CD45RBhi T cells in mice, and may be important in the 
modulation of their function (Bagriacik and Klein, 2000). Furthermore, cholesterol 
metabolism has been implicated in the modulation of T cell function, and may play a role in 
regulatory versus effector T cell balance. Epidemiological studies have led to the intriguing 
observation of an apparent inverse relationship between circulating total cholesterol and LDL 
levels and cardiovascular risk in RA – an effect termed the ‘lipid paradox’ (Myasoedova et 
al., 2011). Exogenous cholesterol sulphate has been shown to inhibit T cell receptor (TCR) 
signalling by murine T cells in vitro (Wang et al., 2016), and knock-out mice deficient in 
apolipoprotein-E – a major constituent of LDL particles – develop exacerbated collagen-
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induced arthritis (Postigo et al., 2011; Alvarez et al., 2016). Therefore, the observation of 
increased LDLR expression by CD4+ T cells at the time of flare may represent a regulatory 
response that could be perturbed in the patients who experience an arthritis flare. Further 
studies to confirm an up-regulated surface expression of LDLR, and to examine the effect of 
this upon lymphocyte function ex vivo, would be useful first steps to further investigate this 
finding. 
BATF is a transcription factor that, via binding with interferon regulatory factor 4 (IRF4) and 
IRF8, plays a key role in Th17 cell differentiation (Glasmacher et al., 2012; Li et al., 2012b). 
BATF is furthermore involved in the differentiation of follicular helper T (TFH) cells and early 
effector CD8+ T cells (Murphy et al., 2013). BATF deficient mice have dramatically lower 
numbers of IL-17 producing Th17 cells, and fail to form germinal centres following antigen 
immunisation (Betz et al., 2010). Given the above observations, the up-regulation of BATF 
observed in CD4+ T cells at the time of flare may therefore represent a differentiation of these 
cells towards a Th17 phenotype. This hypothesis would is further supported by the higher 
circulating serum levels of the pro-Th17 cytokine IL-6 at the time of flare. These observations 
merit further study by confirmation of surface expression of Th17 markers by CD4+ T cells at 
the time of flare. 
CD109 is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein found on the surface of 
activated T cells, platelets and endothelial cells (Lin et al., 2002). CD109 functions as a 
negative regulator of transforming growth factor-β (TGF-β), itself a predominantly negative 
regulator of immunity. Blockade by CD109 has been associated with a poor prognostic subset 
of diffuse large B-cell lymphoma (Yokoyama et al., 2017), and may play a role in reduced 
TGF-β signalling observed in psoriasis (Litvinov et al., 2011). The longitudinal up-regulation 
of CD109 observed in my study is thus further potential evidence to support an activated 
proliferative phenotype of CD4+ T cells at the time of flare.  
 
7.7.3.b DFR patients – month six versus baseline visits 
Nineteen DEGs were observed at an unadjusted p threshold of <0.001, with substantially 
lower mean expression values than the 81 DEGs observed at the same significance threshold 
in the flare vs. baseline analysis. Furthermore, many of DEGs observed in this remission 
analysis were pseudogenes of unknown function. Functional analysis suggested 
downregulation of genes within a network of cell signalling and injury, though with very few 
edges between the identified nodes. Perplexingly, 3/9 of the protein-coding DEGs were 
  
234 
 
immunoglobulin genes, which was unexpected in this CD4+ T cell analysis. This may suggest 
contamination of some samples with B cells, though one would expect this effect to have been 
at least partly mitigated by the statistical correction for CD4+ T cell purity. Alternatively, this 
may represent genuine low-level CD4+ T cell expression of immunoglobulin-related genes – 
indeed, immunoglobulin gene expression has been observed in tissues such as human healthy 
lung epithelium, human hepatocytes in cirrhosis, and normal mouse neurons (Chen et al., 
2009). The functional significance of these observations however remains unclear, and in my 
study would first require validation of the RNAseq findings with confirmation of 
immunoglobulin chain expression at the protein level. 
Another unexpected observation was the downregulation of IL10 at month six versus baseline 
in DFR patients (log2FC -0.89, unadjusted p 5.14 x 10-4). This was mirrored by a trend 
towards higher IL10 expression at the time of flare vs. baseline in those patients who 
experienced an arthritis flare (log2FC 0.68, unadjusted p = 0.004). Given the well-established 
role of IL-10 as a predominantly immunoregulatory cytokine of crucial importance to the 
function of Tr1 cells (Pot et al., 2011), it is surprising that its expression by CD4+ T cells 
would decrease with time in those patients who maintain DFR. Nevertheless, there are two 
conceivable explanations for this observation. First, IL-10 is not exclusively 
immunoregulatory, and its role in promoting B cell proliferation is thought to be of 
importance in the pathogenesis of some autoimmune diseases such as SLE (Peng et al., 2013). 
Thus reducing IL-10 production by CD4+ T cells could help maintain remission in certain 
settings. Alternatively, lower expression of IL-10 could represent a gradual shift away from a 
regulatory Tr1-like phenotype and towards an effector state. However, the absence of any of 
the DEGs identified in the flare vs. baseline comparison would suggest that if this were 
occurring, then the CD4+ T cells are unlikely to be following a similar differentiation pathway 
to that observed in flare patients. Indeed, the functional relevance of this observed reduction 
in CD4+ T cell IL-10 production with time in the DFR patient population is hard to interpret 
in the absence of measures of inflammation and gene expression within the synovial 
compartment. 
 
7.7.4 Predictive biomarker survival analysis 
Using a similar approach as previously, univariate followed by multivariate Cox regression 
was performed using the RNAseq data in order to develop a predictive biomarker of DFR and 
flare following DMARD cessation. Cox regression was selected as the analysis model of 
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choice, as this allowed for use of a time-to-event outcome measure, rather than the binary 
grouping to flare versus DFR described above. This was anticipated to yield greater statistical 
power – indeed, unadjusted p values were on average 10-fold smaller for the Cox regression 
analysis compared to the baseline flare vs. DFR comparison. However, standard 
bioinformatics pipelines for survival analysis using RNAseq data do not currently exist, and 
adjustment for false-discovery rate using the standard method of Benjamini-Hochberg 
appeared particularly conservative when applied to the univariate Cox regression results. The 
issue of apportioning statistical significance in Cox regression analysis when using high 
dimensionality data has been highlighted in the published literature (Witten and Tibshirani, 
2010), and is addressed in detail in the final discussion chapter (see Discussion 9). 
Univariate Cox regression identified a similar set of genes associated with time-to-flare at the 
unadjusted p<0.001 threshold as compared to the standard analysis pipeline of DEGs between 
flare vs. DFR groups, thus providing a degree of internal validation of this approach. After 
stepwise backward multivariate Cox regression modelling, three genes were identified whose 
expression significantly associated with time-to-flare at the p < 0.001 threshold: 
ENSG00000228010, ENSG00000162636 and ENSG00000227070. One of these genes 
(ENSG00000162636) encodes the protein family with sequence similarity 102 member B 
(FAM102B). Whilst no publications exist concerning the function of FAM102B, the 
paralogous FAM102A (also known as Early Oestrogen-Induced Gene 1) is known to be 
involved in oestrogen signalling (Wang et al., 2004) as well as osteoclast differentiation (Choi 
et al., 2013), and is implicated in cell membrane trafficking (Zhang and Aravind, 2010). Both 
ENSG00000228010 and ENSG00000227070 are predicted to be novel antisense genes, 
though no published data relates to their putative targets or physiological function. In a 
composite score, these three genes predicted flare and sustained DFR following DMARD 
cessation, with an ROCAUC of 0.90. 
There are limitations to the statistical techniques used to generate this 3-gene predictive score, 
most notably over-fitting of the data and the lack of a validation cohort. These limitations are 
common to all of the biomarker analyses of this Thesis, and are discussed in detail later (see 
Discussion 9). A further limitation is the lack of functional annotation of the three identified 
genes, this making it impossible to assess the face validity of the score based on knowledge of 
physiological function. Nevertheless, it must be highlighted that the aim of this analysis was 
to generate a composite score for use as a predictive biomarker, rather than to inform an 
understanding of underlying biology. Indeed, it is entirely conceivable gene transcription in 
the late stages of a functional pathway – whose expression represents an integrative and 
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potentially amplified function of an array of previous signalling events - may have greater 
utility as a biomarker compared to the initial mediators in the pathway. This analysis should 
therefore be viewed as complementary to, rather than a replacement for, the previous analyses 
based on binary contrast groups, the latter of which are more suited to extrapolation to 
underlying biological function as discussed above. 
Only one other study exists in the published literature that utilises CD4+ T cell gene 
expression to predict DFR in RA. In this study, Teitsma et al. (2017) explored gene 
expression data from fluorescence-activated cell sorting (FACS)-isolated CD4+ T cells from a 
subset of 60 patients of the U-Act-Early study. In this study, DMARD-naïve patients (n = 
317) with active early RA (DAS28-ESR > 2.6) were randomised to receive tocilizumab plus 
placebo, methotrexate plus placebo, or tocilizumab plus methotrexate in a double-blind design 
(Bijlsma et al., 2016). If sustained remission was achieved – defined as DAS28-ESR < 2.6 
and ≤ 4 swollen joints for ≥ 24 weeks (though 2.6 <DAS28-ESR<3.2 on ≤2 visits during this 
period was allowed) – then DMARDs were gradually tapered to complete cessation. 
Sustained DFR was defined as a DAS28-ESR < 2.6 maintained for at least 3 months and until 
the end of the study 2-year follow-up period (though 2.6<DAS28-ESR<3.2 at a single visit 
was permitted) (Bijlsma et al., 2016). In an exploratory analysis, CD4+ T cell gene expression 
by RNAseq at baseline (i.e. before initiation of DMARD treatment) was compared between in 
60 patients who successfully achieved sustained DFR versus those who did not (tocilizumab 
only: 13 DFR and 11 non-DFR; methotrexate only: 10 DFR and 7 non-DFR; tocilizumab plus 
methotrexate: 14 DFR, 5 non-DFR) (Teitsma et al., 2017). Instead of analysing individual 
DEGs or utilising Cox regression survival analysis, the authors of this study used a network 
analysis approach to identify significantly different functional pathway modules between the 
study arms. The most significant module in each arm identified pathways involved in 
leukocyte migration and G-protein signalling (tocilizumab only arm), response to bacteria or 
biotic stimuli (methotrexate only arm), and transcription and translation (methotrexate and 
tocilizumab arm) (Teitsma et al., 2017). In contrast, RNAseq analysis CD14+ monocytes did 
not reveal any relevant significant networks. The individual differentially co-expressed genes 
in the top CD4+ T cell module of each study arm was made publically available by the 
authors, though the fold-change and statistical significance for each individual gene was not 
disclosed. Comparison of these with an extended list of DEGs identified in my study 
(unadjusted p<0.01 across all analyses) revealed only a few common genes: ORM1, IL12, 
haptoglobin (HP) and calpain 8 (CAPN8) (Table 7.14). Intriguingly, all of the common genes 
identified fell within the methotrexate-only arm analysis of the Teitsma et al. (2017) study.  
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Table 7.14 – Differentially expressed genes common to the CD4+ T cell RNAseq analysis of 
both my study and the study by Teitsma et al. (2017). HC: healthy control. 
Gene Observation in my study 
Observation by Teitsma et al. 
(2017) 
ORM1 
Up-regulated in flare vs. HC 
(log2FC 2.72, p = 1.73x 10-4) 
Up-regulated in DFR vs. HC 
(log2FC 2.43, p = 8.12 x 10-4) 
Up-regulated in DFR vs. non-DFR 
in methotrexate only arm 
IL12A 
Up-regulated at flare visit vs. 
baseline in flare patients 
(log2FC 0.69, p = 5.88 x 10-4) 
Up-regulated in DFR vs. non-DFR 
in methotrexate only arm 
HP Up-regulated in flare vs. HC (log2FC 2.28, p = 2.80 x 10-3) 
Up-regulated in DFR vs. non-DFR 
in methotrexate only arm 
CAPN8 Up-regulated in flare vs. HC 
(log2FC 1.32, p = 2.66 x 10-3) 
Up-regulated in DFR vs. non-DFR 
in methotrexate only arm 
 
Of the proteins encoded by these genes, the functional relevance of ORM1 and IL12 have 
been discussed previously in this Thesis (see Results 7.7.2.e and Results 6.5.4). Haptoglobin 
is an abundant circulating protein that functions to bind free haemoglobin. As an acute phase 
protein, haptoglobin is produced by hepatocytes during episodes of systemic inflammation 
and has been observed to mediate pro-inflammatory effects in murine skin (Shen et al., 2012) 
and cardiac (Shen et al., 2015) transplant models. However, as discussed by Huntoon et al. 
(2013), haptoglobin knock-out mice have been observed to exhibit both suppressed (Huntoon 
et al., 2008) and enhanced (Arredouani et al., 2005) immunity in different studies. 
Haptoglobin is also expressed by non-hepatic tissues, including human neutrophils 
(Theilgaard-Monch et al., 2006). Furthermore, bone marrow chimera experiments in mice 
have demonstrated that haptoglobin expression by B cells is important for a functional 
immune response (Huntoon et al., 2013). The upregulation of haptoglobin expression in flare 
versus healthy control in my study may thus reflect an immunostimulatory role of T-cell 
specific haptoglobin production. 
Calpains are a family of evolutionarily conserved calcium-dependent serine proteases, and are 
known as ‘modulator proteases’ given their predilection for limited proteolytic modification 
rather than destruction of their target proteins (Ono et al., 2016). Calpains have been 
implicated in a broad range of human diseases, and several calpain inhibitors are currently in 
clinical development (Ono et al., 2016). In human T cells, treatment with the calpain inhibitor 
E64D in vitro has been demonstrated to block IκBα degradation, itself an inhibitor of the pro-
inflammatory transcription factor nuclear factor κB (NFκB) (Ponnappan et al., 2005). 
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Although there are no published reports relating specifically to the expression of CAPN8 by 
lymphocytes, given the observations above it is theoretically plausible that the up-regulated 
expression of CAPN8 observed in flare patients vs. healthy controls in my study may be 
relevant to the susceptibility to flare following DMARD cessation. 
Direct comparison of the results of my study with those of Teitsma et al. (2017) is however 
problematic owing to the timing of sampling. Whereas CD4+ T cell samples in my study were 
collected from patients with established RA on DMARDs in clinical remission, Teitsma et al. 
(2017) collected samples from early DMARD-naïve patients with active RA. It is thus 
difficult to be certain whether upregulation of gene expression at this early time point is 
directly linked to subsequent achievement of DFR, or rather is a biomarker of response to 
DMARD therapy which, in turn, may facilitate a remission status that is permissive for the 
development of other processes relevant in the subsequent maintenance of DFR following 
DMARD cessation. 
 
7.7.5 Limitations 
Only a few DEGs were robust to multiple test correction. This is likely the result of a 
combination of both the relatively small size of the sample population, and a small magnitude 
of differential gene expression between the comparison groups. This latter possibility is 
further exemplified by the generally low mean expression levels of many of the DEGs. 
Nevertheless, despite not being robust to multiple test correction, many of these DEGs encode 
for proteins with biological plausibility for involvement in pro-inflammatory and immune 
dysregulation processes. It is important however to weigh this against the effect of cell-
specific gene expression analysis in this study – indeed, it is perhaps unsurprising that many 
of the genes identified in this RNAseq analysis of CD4+ T cells have functional roles in CD4+ 
T cell biology. 
A further limitation relevant to the longitudinal analyses is the possible effect of DMARD 
cessation itself upon CD4+ T cell gene expression, which may not necessarily be 
mechanistically linked to the pathogenesis of RA flare. This is further compounded by a 
general lack of understanding of the mechanism of action of most current DMARDs, thus 
making it hard to account for these effects in downstream analyses.  
A more general limitation of RNAseq analysis is the difficulty in ascribing a direct link 
between gene expression, protein translation and, ultimately, protein function at the cellular 
and anatomical site of disease. Although whole-genome differential gene expression analysis 
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provides unparalleled insights in to the transcriptional activity of cell populations, a wide 
variety of transcriptional regulatory mechanisms mean that mRNA abundance does not 
necessarily directly reflect protein translation. Add to this the effects of post-translational 
protein modification, and the complexities of intracellular trafficking combined with cellular 
migration and dynamic cell-cell interactions, and it becomes clear that transcriptional 
profiling lies several critical steps upstream of an actual functional response in the diseased 
tissue. Therefore, whilst observations of RNAseq analysis are undeniably illuminative and 
ideally suited to a hypothesis-free exploratory approach as adopted in this study, validation of 
findings at the protein and cellular level at the site of disease is nevertheless mandatory. 
 
7.8 Summary 
The most illuminative results from the analysis of CD4+ T cell gene expression have come 
from the longitudinal comparison of flare visit with baseline. This analysis revealed a strong 
signature of upregulation of genes involved in cellular proliferation, as well as the pro-Th17 
transcription factor BATF. These results provide evidence of activation of CD4+ T cells at the 
time of arthritis flare, and are in keeping with a phenotype of systemic inflammation in 
keeping with clinical measures of increased disease activity, and the observed increase in 
levels of acute-phase and pro-inflammatory cytokines such as IL-6 (see Results 6.5.4). 
Furthermore, comparison of baseline CD4+ T cell gene expression in flare patients versus 
healthy controls demonstrated upregulation of several genes encoding proteins known to be 
correlated with disease activity in RA, such as IL-15 and ORM1. This may suggest greater 
subclinical levels of inflammation in these patients at baseline, thus predisposing to a greater 
risk of arthritis flare upon DMARD cessation. 
In comparison, relatively little longitudinal change was seen in CD4+ T cell gene expression 
within patients who remained in DFR, or at baseline between DFR patients versus healthy 
controls. This is in keeping with the longitudinal cytokine data discussed previously (see 
Results 6.5.4), which also showed very little longitudinal change within the DFR group. 
These observations suggest a stable phenotype of remission in these patients, which is 
characterised by an absence of the inflammatory signature seen in flare patients rather than 
the presence of a pro-tolerogenic signature that actively maintains DFR. The one possible 
exception to this is the up-regulated expression of the gene encoding the immunoregulatory 
protein AMBP in DFR patients versus healthy controls – nevertheless, the same observation 
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was also seen in flare patients vs. healthy controls, thus making the functional relevance of 
this observation unclear. 
In the primary analysis of flare vs DFR patients at baseline, the comparative dearth of 
convincing DEGs likely reflects the above-mentioned limitations of the analysis, including 
small sample size, unpaired rather than paired statistical comparisons, and a smaller 
magnitude of differential gene expression in comparison to the flare event vs. baseline 
analysis. Despite these limitations, baseline expression of only three genes performed well in 
discriminating flare vs. DFR when re-applied to the same test cohort. The predictive 
performance of these genes in combination with clinical and cytokine/chemokine parameters 
will be addressed in the next chapter.  
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Chapter 8. Results 5 – Integrative Analysis 
 
8.1 Introduction 
In the previous results chapters of this Thesis, I have presented findings from complementary 
yet distinct work streams encompassing clinical, ultrasound, cytokine and gene expression 
data. For each domain, I have used the same approach of systematic variable reduction 
followed by variable combination to form composite scores, and assessment of their 
predictive utility in predicting arthritis flare following DMARD cessation. For the purposes of 
lucidity, analyses have thus far been separated according to the methodology of variable 
generation. However, this separation is somewhat artificial in real-life clinical settings, when 
a variety of variables from different domains are available for assessment. 
In this final results chapter, I aim to simultaneously analyse results from all variable domains 
in order to synthesise a global predictive biomarker score to predict RA flare and sustained 
drug-free remission following DMARD cessation. The motivations for this integrative 
analysis are two-fold. First, by combining variables from different domains I aim to create a 
global biomarker score that outperforms any of the single-domain composite scores. Second, 
the process of variable combination can be expected to lead to variable redundancy, thus 
allowing for the final variable set to be smaller than the sum of the individual domain variable 
sets. 
In performing this integrative analysis, I use the same process familiar from previous chapters 
starting with a two-step variable reduction incorporating univariate followed by stepwise 
backward multivariate Cox regression modelling. Receiver-operating characteristic (ROC) 
curve analysis is then used to further refine the variable set and select an optimum model for 
use as a predictive biomarker of flare and sustained remission following DMARD cessation. 
This process is performed for all variable domains, and then repeated with exclusion of gene 
expression data – the latter step in recognition of the difficulties inherent to translation of cell-
specific gene expression to clinical practice. 
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 The structure of the remainder of this results chapter is as follows: 
8.2 Integrative analysis 1: including gene expression data 
8.3 Integrative analysis 2: excluding gene expression data 
8.4 Sensitivity analyses 
8.5 Discussion 
8.6 Summary 
 
8.2 Integrative analysis 1: including gene expression data 
8.2.1 Variable selection 
Before starting the process of integrative analysis, a reduced variable set was defined for 
exploration. The number of variables was reduced not only to avoid unnecessary and 
laborious downstream model reduction, but also to minimise over-fitting of the expansive 
data set to the relatively small study population. 
Baseline variables were selected based upon their statistical significance in the domain-
specific backward stepwise multivariate Cox regression models described in the previous 
results chapters of this Thesis. Only those variables which were associated with time-to-flare 
in their respective multivariate models at an unadjusted significance threshold of p<0.05 (or 
p<0.001 in the case of gene expression data) were selected for integrative analysis. 
Thresholds were not set for the Cox regression coefficients, as these were expected to change 
with the merging of variable domains in the integrative analyses. No ultrasound variables 
were included in the integrative analysis, as none were significantly associated with time-to-
flare in univariate Cox regression analysis.  
In total, 11 variables were selected for integrative analysis as detailed in Table 8.1. 
As discussed previously (see Results 6.2.1), cytokine data was unavailable for one patient at 
baseline. This patient was thus excluded, leaving 43/44 patients for the main integrative 
analysis. A separate sensitivity analysis was subsequently performed with imputation of the 
missing data for this patient (see Results 8.4.1). 
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Table 8.1 – The thirteen baseline variables selected for integrative analysis. 
Domain Variable 
Clinical 
RhF positive 
ACPA positive 
ACR/EULAR Boolean remission 
Months since last change in DMARDs 
Current methotrexate 
Cytokine 
ln(MCP1+1) 
ln(IL27+1) 
ln(CRP+1) 
CD4+ T cell gene expression 
ENSG00000228010 
ENSG00000162636 
ENSG00000227070 
 
 
8.2.2 Cox regression 
The association between baseline variables and time-to-flare following DMARD cessation 
was analysed by univariate Cox regression for the 43 patients where complete data was 
available (Table 8.2). No significant deviation from proportionality of hazards was observed 
for any of the univariate variables. Given the univariate nature of this analysis, the 
coefficients and statistical significance of these variables mirror those already detailed in their 
respective results chapters – minor discrepancies reflect the exclusion of the single patient 
without cytokine data.  
Table 8.2 – Association of baseline variables with time-to-flare following DMARD-cessation, 
as analysed by univariate Cox regression. B: Cox regression coefficient. 
Variable B HRflare HRflare 95% CI Unadjusted p value 
ENSG00000228010 -1.49 0.23 0.10 – 0.50 0.0003 
ENSG00000227070 0.75 2.13 1.40 – 3.24 0.0004 
ENSG00000162636 2.47 11.8 2.33 – 60.2 0.0029 
ln(MCP1+1) 2.21 9.13 1.97 – 42.3 0.0047 
ln(CRP+1) 0.43 1.53 1.02 – 2.31 0.0421 
Months since last DMARD change -0.02 0.98 0.97 – 1.00 0.0471 
ACPA positive 0.82 2.27 0.96 – 5.37 0.0622 
RhF positive 0.77 2.15 0.91 – 5.11 0.0824 
ln(IL27+1) 0.95 2.58 0.78 – 8.53 0.1203 
ACR/EULAR remission -0.65 0.52 0.23 – 1.19 0.1223 
Current methotrexate 1.46 4.31 0.58 – 32.1 0.1535 
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All 11 baseline variables were then entered in to a multivariate Cox regression model. 
Stepwise backward selection based on Akaike information criterion (AIC) was then 
performed to fit a stepwise Cox regression model (see Methods 3.8.1). After four selection 
steps, 7 variables remained in this stepwise model (Table 8.3). 
Proportionality of hazards was again assessed for each variable in the final stepwise 
multivariate Cox regression model. A significant departure from proportional hazards was 
observed only for current methotrexate use (p = 0.006), though as noted before in Chapter 6, 
this was only notable for a single outlier with no discernible trend in the remainder of the data 
(Figure 8.1). The global Schoenfeld test was non-significant (p = 0.087), indicating 
proportionality of hazards for the model as a whole. 
Table 8.3 - Association of baseline variables with time-to-flare following DMARD-cessation 
in a backward stepwise multivariate Cox regression model. 
Variable B HRflare HRflare 95% CI Unadjusted p value 
ENSG00000227070 1.14 3.12 1.81 – 5.36 0.00004 
ENSG00000228010 -1.98 0.14 0.05 – 0.36 0.00005 
ENSG00000162636 2.82 16.72 2.24 – 125 0.00608 
ln(IL27+1) 1.92 6.85 1.61 – 29.1 0.00915 
ACR/EULAR Boolean remission -1.22 0.29 0.11 – 0.76 0.01205 
RhF positive 0.94 2.56 0.91 – 7.19 0.07470 
Current methotrexate 1.66 5.28 0.55 – 50.2 0.14779 
 
Figure 8.1 – Correlation of scaled Schoenfeld residuals ( Beta(t) ) against Kaplan-Meier-
transformed flare-free survival time for current methotrexate in the stepwise multivariate Cox 
regression model. Dashed lines indicate ± 2 standard errors of the smoothed spline fit with 4 
degrees of freedom (solid line). Discounting the single outlier, there does not appear to be any 
observable correlation between the scaled residuals and survival time. 
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8.2.3 Receiver-operating characteristic (ROC) analysis 
Five variables were significantly associated with time-to-flare at an unadjusted significance 
threshold of <0.05 in the multivariate stepwise Cox regression model: ENSG00000227070, 
ENSG00000228010, ENSG00000162636, ln(IL27+1) and baseline ACR/EULAR Boolean 
remission. Values of these five variables were multiplied by their respective stepwise 
multivariate Cox regression coefficient and then summed to create composite scores. The 
predictive performance of all 31 potential combinations of these variables to predict flare and 
remission following DMARD cessation was then compared by area under the receiver-
operating characteristic curve (ROCAUC). The ten composite scores with the highest ROCAUC 
are shown in Table 8.4 (for a full listing of all composite scores, see Appendix J). 
The composite score with the highest ROCAUC included all variables; notably, the removal of 
ln(IL27+1) resulted in only a small drop in ROCAUC (Formulae 8.1 – 8.2 and Figure 8.2). 
 
Formula 8.1 – Five-variable composite score 
Composite score = 1.14(ENSG00000227070) + 2.82 (ENSG00000162636) + 
1.92(ln[IL27+1])  
-  1.98(ENSG00000228010) - 1.22(ACR/EULAR Boolean remission) 
 
 
Formula 8.2 – Four-variable composite score 
Composite score = 1.14(ENSG00000227070) + 2.82 (ENSG00000162636)  
- 1.98(ENSG00000228010) - 1.22(ACR/EULAR Boolean remission) 
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Table 8.4 – The top ten integrative composite scores ranked by ROCAUC. Variables included 
within each score are indicated in green, and those excluded are indicated in red. 
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Figure 8.2 – ROC curves for 5-variable (A) and 4-variable (B – dropping ln(IL27+1) ) 
composite scores. Threshold values used for assessment of predictive performance are 
highlighted by crosses. 
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8.2.4 Composite score predictive performance 
The sensitivity, specificity, positive predictive value (PPV) and negative predictive value of 
each of the three composite scores detailed above are presented in Table 8.5 and Figure 8.3, 
using the same threshold values as in the main analysis. A single optimum threshold for each 
composite score was selected manually based on minimising the ROC coordinate distance 
from the top left corner of the ROC curve plot. 
Table 8.5 – Utility of the two composite scores in predicting arthritis flare following DMARD 
cessation. PPV: positive predictive value; NPV: negative predictive value. 
Composite 
score 
Threshold 
value 
ROCAUC 
(95% CI) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
5-variable 
37.41 0.96 
(0.92 – 1.00) 
0.91 
(0.78 – 1.00) 
0.95 
(0.84 – 1.00) 
0.96 
(0.87 – 1.00) 
0.90 
(0.78 – 1.00) 
4-variable 
23.16 0.95 
(0.88 – 1.00) 
0.91 
(0.78 – 1.00) 
0.89 
(0.74 – 1.00) 
0.92 
(0.81 – 1.00) 
0.89 
(0.77 – 1.00) 
 
Figure 8.3 – Predictive performance metrics of the two composite scores. 
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The confidence interval of each metric was relatively wide for both scores, reflecting the 
small sample size of the cohort. There was a slight trend towards a greater specificity and 
PPV in the 5-variable score compared to the 4-variable score, with slightly narrower 
confidence intervals for these two metrics in the 5-variable score. Nevertheless, the 
differences were modest, suggesting only a minor contribution of ln(IL27+1) to the predictive 
performance of the model. 
 
8.3  Integrative analysis 2: excluding gene expression data 
8.3.1 Variable selection 
A substantial limitation to the clinical utility of a predictive score that relies upon CD4+ T cell 
gene expression is the difficulty faced in translating such a time- and resource-consuming 
laboratory technique to routine clinical practice. A second set of integrative analyses was 
therefore performed with the exclusion of gene expression data, using the eight variables 
listed in Table 8.6. As previously, one patient with missing baseline cytokine data was 
excluded, leaving 43/44 patients available for the main no-gene analysis. 
 
8.3.2 Cox regression 
All eight variables were simultaneously entered in a multivariate Cox regression model 
followed by backward selection based on AIC to fit a stepwise Cox regression model. After 
one selection step, seven variables remained in this stepwise model (Table 8.7). 
Proportionality of hazards was assessed for each variable in the final stepwise multivariate 
Cox regression model. A significant departure from proportional hazards was observed only 
for current methotrexate use (p = 0.033) – again this was only notable for a single outlier 
(Figure 8.4). The global Schoenfeld test was non-significant (p = 0.138), indicating 
proportionality of hazards for the model as a whole. 
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Table 8.6 – The eight variables included in the no-gene integrative analysis. 
Domain Variable 
Clinical 
RhF positive 
ACPA positive 
ACR/EULAR Boolean remission 
Months since last change in DMARDs 
Current methotrexate 
Cytokine 
ln(MCP1+1) 
ln(IL27+1) 
ln(CRP+1) 
Table 8.7 - Association of baseline variables with time-to-flare following DMARD-cessation 
in the no-gene backward stepwise multivariate Cox regression model. 
Variable B HRflare HRflare 95% CI 
Unadjusted p 
value 
Months since last DMARD change -0.03 0.97 0.95 – 0.99 0.002 
ACR/EULAR Boolean remission -1.32 0.27 0.11 – 0.66 0.004 
ACPA positive 1.27 3.57 1.34 – 9.52 0.011 
ln(IL27+1) 1.39 4.03 1.17 – 14.0 0.028 
RhF positive 1.14 3.14 1.01 – 9.73 0.047 
ln(MCP1+1) 1.62 5.08 1.01 – 25.6 0.049 
Current methotrexate 2.13 8.44 0.96 – 74.4 0.055 
 
 
Figure 8.4 – Correlation of scaled Schoenfeld residuals ( Beta(t) ) against Kaplan-Meier-
transformed flare-free survival time for current methotrexate in the no-gene stepwise 
multivariate Cox regression model. Dashed lines indicate ± 2 standard errors of the smoothed 
spline fit (solid line). Discounting the single outlier, there does not appear to be any 
observable correlation between the scaled residuals and survival time. 
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8.3.3 Receiver-operating characteristic (ROC) analysis 
All seven variables from the backwards multivariate Cox regression model were advanced to 
the composite score fitting stage. Composite scores were calculated by summing the products 
of variables with their respective regression coefficient for all 127 possible combinations of 
the seven variables. The composite scores were then ranked in order of ROCAUC – the full 
ranking is presented in Appendix J, and the ten scores with the highest ROCAUC are listed in 
Table 8.8.  
Exclusion of ln(IL27+1) to create a 6-variable composite score yielded the highest ROCAUC, 
which was essentially equal to that of the full 7-variable score. Notably, the third highest 
composite score excluded both cytokine variables to leave the five clinical variables that 
formed the clinical composite score presented in Chapter 4, albeit with different coefficients 
to previously. The formulae for these three composite scores are presented in Formulae 8.3 – 
8.5. 
Formula 8.3 – Seven-variable no-gene composite score 
Composite score = 1.39(ln[IL27+1]) + 1.62(ln[MCP1+1]) + 1.14(RhF positive)  
+ 1.27(ACPA positive) +2.13(Current methotrexate) 
– 1.32(ACR/EULAR Boolean remission) 
 – 0.03(months since last DMARD change) 
Formula 8.4 – Six-variable no-gene composite score 
Composite score = 1.62(ln[MCP1+1]) + 1.14(RhF positive)  
+ 1.27(ACPA positive) +2.13(Current methotrexate) 
 – 1.32(ACR/EULAR Boolean remission) 
 – 0.03(months since last DMARD change) 
Formula 8.5 – Five-variable no-gene composite score 
Composite score = 1.14(RhF positive) + 1.27(ACPA positive) +2.13(Current methotrexate) 
 – 1.32(ACR/EULAR Boolean remission) 
 – 0.03(months since last DMARD change) 
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Table 8.8 - The top ten composite scores in the no-gene analysis ranked by ROCAUC. 
Variables included within each score are indicated in green, and those excluded are indicated 
in red. 
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ROCAUC 
       0.957 
       0.954 
       0.936 
       0.931 
       0.929 
       0.924 
       0.920 
       0.911 
       0.911 
       0.904 
 
8.3.4 Composite score predictive performance 
The sensitivity, specificity, positive predictive value (PPV) and negative predictive value of 
each of the three no-gene composite scores detailed above are presented in Table 8.9, Figure 
8.5 and Figure 8.6.  
Table 8.9 – Utility of the no-gene analysis composite scores in predicting arthritis flare 
following DMARD cessation. PPV: positive predictive value; NPV: negative predictive 
value. 
Composite 
score 
Threshold 
value 
ROCAUC 
(95% CI) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
7-variable 
20.28 0.95 
(0.90 – 1.00) 
0.96 
(0.87 – 1.00) 
0.84 
(0.68 – 1.00) 
0.88 
(0.77 – 1.00) 
0.94 
(0.83 – 1.00) 
6-variable 
9.83 0.96 
(0.90 – 1.00) 
0.96 
(0.87 – 1.00) 
0.84 
(0.68 – 1.00) 
0.88 
(0.78 – 1.00) 
0.94 
(0.83 – 1.00) 
5-variable 
0.701 0.94 
(0.87 – 1.00) 
0.91 
(0.78 – 1.00) 
0.79 
(0.58 – 0.95) 
0.85 
(0.72 – 0.96) 
0.89 
(0.75 – 1.00) 
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Figure 8.5 – ROC curves for 7-variable (A), 6-variable (B – dropping ln(IL27+1) ) and 5-
variable (C – dropping ln(IL27+1) and ln(MCP1+1) ) no-gene composite scores. Threshold 
values used for assessment of predictive performance are highlighted by crosses. 
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Figure 8.6 – Predictive performance metrics of the three composite scores in the no-gene 
analysis. 
 
The performance of the 6-variable composite score is virtually indistinguishable from that of 
the full 7-variable score. The 5-variable score showed lower point estimates for all predictive 
metrics, though the small magnitude of the differences was nonetheless impressive given its 
reliance entirely on clinical parameters. 
 
8.4 Sensitivity analyses 
8.4.1 Imputation of missing cytokine data 
In the above analyses, one patient was excluded owing to lack of baseline cytokine data. In a 
sensitivity analysis, missing cytokine data was imputed for this patient using the study 
population median for each cytokine variable. The above analyses were then repeated with the 
inclusion of gene expression data to ascertain whether the additional clinical and gene 
expression data gained by inclusion of this patient had any effect upon the results. 
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The sensitivity analysis used the same five-variable composite score (Formula 8.1), 
coefficients and threshold values as in the main analysis (Results 8.2). The predictive 
performance of the composite scores after imputation was indeed very similar to that of the 
main analysis (Table 8.10) 
Table 8.10 – Utility of the composite scores in the cytokine imputation sensitivity analysis for 
predicting arthritis flare following DMARD cessation. PPV: positive predictive value; NPV: 
negative predictive value. 
Composite 
score 
Threshold 
value 
ROCAUC 
(95% CI) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
5-variable 
no imputation 
37.41 0.96 
(0.92 – 1.00) 
0.91 
(0.78 – 1.00) 
0.95 
(0.84 – 1.00) 
0.96 
(0.87 – 1.00) 
0.90 
(0.78 – 1.00) 
5-variable 
with 
imputation 
37.41 0.96 
(0.90 – 1.00) 
0.91 
(0.78 – 1.00) 
0.90 
(0.75 – 1.00) 
0.91 
(0.81 – 1.00) 
0.90 
(0.78 – 1.00) 
 
8.4.2 Substitution of high-sensitivity CRP (hsCRP) values 
The local clinical laboratory assay used for measuring serum CRP concentration has a lower 
limit of detection (LLOD) of 5mg/L. As specified in the study protocol, CRP values below 
this LLOD were treated as zero for the purposes of DAS28-CRP calculation. However, this 
raises the possibility of under-estimation of disease activity, with the possibility of false-
classification of low-grade arthritis flare as remission. To address this concern, another 
sensitivity analysis was performed whereby the CRP concentration was substituted in 
borderline cases for that measured by the high-sensitivity CRP (hsCRP) 
electrochemiluminescence assay included on the MSD plates.  
Of the 184 study visits, only 7 visits (involving 4 patients) were identified where hsCRP 
measurement had potential to result in a rise of DAS28-CRP from below to above the 
remission threshold of 2.4. Substituting hsCRP values for these visits resulted in no change to 
remission status in 3/7 visits, and a reclassification from remission to flare in 4/7 visits (3 
patients). Two patients – who both maintained drug-free remission to six months in the main 
analysis – were reclassified as DAS28-CRP>2.4 at the baseline visit, and were thus excluded 
from this sensitivity analysis. The remaining patient – who was classified as arthritis flare at 
176 days after DMARD cessation – was reclassified from remission to flare at day 78 in the 
sensitivity analysis. 
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Following exclusion/reclassification of these three patients as described above, the original 5 
variable composite score (Formula 8.1) was applied with the additional exclusion of the 
patient with missing baseline cytokine/chemokine data as previously described (Results 8.2). 
A minor adjustment to the threshold value was necessary to maximise the predictive utility of 
the sensitivity analysis model. The predictive performance of the composite score after hsCRP 
substitution was very similar to that of the main analysis (Table 8.10). This suggests that any 
effect of underestimation of disease activity as a result of the LLOD of the clinical CRP assay 
had negligible effect upon the predictive utility of the composite biomarker score. 
Table 8.11 – Utility of the composite scores in the hsCRP substitution sensitivity analysis for 
predicting arthritis flare following DMARD cessation. PPV: positive predictive value; NPV: 
negative predictive value. 
Composite 
score 
Threshold 
value 
ROCAUC 
(95% CI) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
5-variable 
main analysis 
37.410 0.96 
(0.92 – 1.00) 
0.91 
(0.78 – 1.00) 
0.95 
(0.84 – 1.00) 
0.96 
(0.87 – 1.00) 
0.90 
(0.78 – 1.00) 
5-variable 
hsCRP 
substitution 
37.406 0.96 
(0.91 – 1.00) 
0.91 
(0.78 – 1.00) 
0.94 
(0.82 – 1.00) 
0.96 
(0.87 – 1.00) 
0.89 
(0.76 – 1.00) 
 
8.5 Discussion 
In this integrative analysis, variables from the composite biomarker scores of clinical, 
cytokine and RNAseq domains were combined together in a multivariate Cox regression 
model, with backwards stepwise selection used to create a final model with five variables: 
three gene expression (ENSG00000228010, ENSG00000162636 and ENSG00000227070), 
one cytokine (IL-27), and one clinical (ACR/EULAR Boolean remission). Whereas little is 
known regarding the role of the three gene variables, the relevance of IL-27 and 
ACR/EULAR Boolean remission in the context of DFR has been extensively discussed (see 
Results 6.5.3 and Results 4.9.4d). 
When re-applied to the study population, this 5-variable composite score demonstrated a high 
predictive utility for outcome following DMARD cessation: ROCAUC 0.96 (95% CI 0.92 – 
1.00), sensitivity 0.91 (0.78 – 1.00), specificity 0.95 (0.84 – 1.00), PPV 0.96 (0.87 – 1.00), 
NPV 0.90 (0.78 – 1.00). Thus, in this study population, patients with a negative test score had 
a 90% chance of remaining in DFR at the end of the six-month follow-up period, versus only 
4% for those with a positive score. Such a score would undoubtedly be of great utility in 
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helping guide DMARD withdrawal in the clinic, and would represent a quantum leap beyond 
the approximately even chance of flare that would otherwise be predicted in the absence of a 
predictive biomarker based on outcome of the entire non-stratified study population. 
However, potential over-fitting of data as a consequence of dimension reduction (see 
Discussion 9), together with wide confidence intervals around the point estimates of 
predictive metrics, mandates the validation of this composite score in an independent patient 
population to assess its true predictive performance in the clinic. It is also important to note 
that PPV and NPV are both influenced by the prevalence of flare within the test population. 
Therefore, different rates of flare in a subsequent validation cohort may substantially 
influence the PPV and NPV of the composite score. 
A pragmatic limitation of this composite score is its reliance on gene expression data, and the 
inherent difficulties this creates in future translation to clinical practice. The isolation of CD4+ 
T cells, RNA extraction, and subsequent transcriptional analysis represents a laborious 
package of laboratory work that requires time, technical expertise and an array of laboratory 
equipment. Even if only mRNA relating to the three genes of interest were measured using 
focussed techniques such as reverse transcriptase quantitative polymerase chain reaction (RT-
qPCR), there would still be several processing steps required from whole blood to CD4+ T 
cell-specific gene expression measurement. It would thus be challenging to incorporate these 
steps within a fully automated system, which would be the preferable form of delivery of the 
assay if used in clinical laboratory settings. 
Despite this limitation, recent technological advances enable novel approaches to the 
measurement of expression of a limited number of genes within a specific cellular subset, 
which may be more amenable to future clinical translation. Of particular note is the recently- 
marketed PrimeFlow™ RNA assay (Affymetrix eBisocience Ltd.), which uses intracellular in 
situ-hybridisation of fluorescent probes to target genes in a system which is compatible with 
existing flow-cytometry equipment (Affymetrix eBioscience, 2017). Using this technique, it 
is possible to measure the intracellular abundance of up to four RNA targets in combination 
with cell-surface protein markers, thus allowing the measurement of cell-specific gene 
expression without the need for cell subset isolation or RNA extraction. Such an approach 
would be more suited to large-scale throughput and automation in clinical applications. 
It is particularly striking to note that a 6-variable composite score devoid of any gene 
expression data performs similarly to composite score including gene-expression data. This 
raises the possibility of a predictive biomarker based only on clinical autoantibody and 
cytokine variables, thus circumventing the technical difficulties in measuring cell-specific 
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gene expression. It is prudent however to note some cautionary aspects of this no-gene model 
which may have bearing upon its performance in subsequent validation studies. First, the no-
gene composite score relies heavily upon the inclusion of current methotrexate, with the 
greatest coefficient of any of the variables in the model. This is potentially problematic given 
the limitations of this variable and potential for over-fitting given cofounding factors, as 
discussed previously (see Results 4.9.4.c). Furthermore, the reliance on a greater number of 
variables in the no-gene score (6) versus the composite score with gene expression (5) further 
increases the risk of over-fitting of the data. However, even if the no-gene composite score 
demonstrates suboptimal performance in validation studies, it may nevertheless still be of use 
in settings where laboratory resources are limited. Indeed, it is such resource-limited 
healthcare systems where the economic benefits of DMARD cessation would have arguably 
the greatest impact. 
Visual summaries of the three key composite scores are presented in Figures 8.7 and 8.8. 
Nevertheless, direct comparison of the scores is complicated by the wide confidence intervals 
around each metric, a reflection of the small size of the study population. 
 
 
Figure 8.7 – Receiver operating characteristic curves for the three composite scores 
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Figure 8.8 - Predictive performance metrics of the three composite scores. 
 
8.6 Summary 
In this final results chapter, I have presented an integrative analysis encompassing variables 
from three complementary domains including clinical, circulating cytokine and CD4+ T cell 
gene expression data. I have described a systematic approach to variable reduction, followed 
by combination of variables to form composite scores. Optimum combinations of variables 
were then identified based on their utility in predicting flare versus drug-free remission 
following DMARD cessation. This process was performed both with and without gene 
expression data. Finally, to account for missing cytokine data in one patient and a high LLOD 
for the clinical CRP assay, sensitivity analyses were performed with median imputation of the 
missing cytokine data and substitution with hsCRP data respectively. The results of these 
sensitivity analyses were corroborative of the main analyses. 
There are undoubtedly limitations to this analysis, most notably a lack of statistical power and 
over-fitting of data, which I will address in detail in the next chapter. These results clearly 
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require further study and validation in an independent cohort before generalisation to wider 
patient populations can be inferred. Nonetheless, these observations provide a tantalising first 
insight in to the use of such biomarker composite scores in identifying patients who may 
benefit from DMARD withdrawal in the setting of RA remission. 
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Chapter 9. General Discussion 
 
9.1 Study evaluation 
There are several notable strengths of this study. First, this study addresses a question of key 
clinical, economic, scientific, and patient-centred importance – i.e. when is it appropriate to 
stop DMARD therapy in RA patients in remission? DMARD therapy, whilst effective, carries 
risks of potentially severe side effects and requires inconvenient and expensive regular blood 
monitoring. The observation that just under half of the patients in this study were able to 
maintain DFR for six months after DMARD cessation is further evidence to support a strategy 
of step-down therapy in these patients, with consequent minimisation of drug-related adverse 
events and healthcare costs. The insights that this study provides to the immunological events 
underlying the emergence of RA flare are novel and, if validated, may also be relevant to the 
study of other immune-mediated inflammatory diseases that follow a relapsing-remitting 
course. Furthermore, many RA patients would value the opportunity to decrease and stop 
their DMARD therapy. This study has provided an opportunity for 44 patients to attempt this 
with close monitoring and clinical support, and provides an evidence base upon which to 
extend this approach to a larger validation cohort and, ultimately, the wider patient 
population. 
There are several limitations to this study, some of which are specific to each individual 
domain and have been addressed in detail in the previous sections. However, some limitations 
are generic and are of relevance to all domains of this study, and are addressed below. 
 
9.1.1 High dimensionality of data 
A challenge throughout this study has been the high dimensionality of data relative to the size 
of the study population. With the inclusion of whole genome RNAseq data, the number of 
variables is at least 3 log-fold greater than the number of patients in the study. This presents 
not only a pragmatic difficulty in reducing the number of variables to a manageable number in 
a logical and robust manner, but also raises substantial problems with over-fitting of data in 
the predictive models. 
The handling of high-dimensional data is not unique to this study, and is commonly 
encountered in bioinformatics studies of gene expression. Established data pipelines and 
workflows have been developed to address this issue, and several open-source computer 
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packages exist to facilitate this, such as those used in the binary group analyses of RNAseq 
data in this study. Nevertheless, integrative analyses across multiple variable domains brings 
additional challenges, such as normalisation across different outcome measures and ascribing 
hierarchical importance to different variable domains. These challenges are difficult to tackle 
with an ‘off-the-shelf’ solution, and although a few computer packages have been developed 
to address these issues a supervised approach is still required to adequately address biological, 
technical and statistical issues specific to the individual research project (Kristensen et al., 
2014). 
It was desirable to use Cox regression survival analysis in this study, as such an approach is 
ideally suited to the outcome event and study design. Rather than defining outcome as flare or 
remission after a duration of follow-up largely dictated by the available study resources, 
survival analysis allows for discrimination of patients based on time-to-flare. This more 
nuanced approach not only yields greater statistical power, but also is arguably more suited to 
the underlying biological processes as variables that are associated with a shorter time-to-flare 
are, in effect, given greater weighting in the final analysis. Nevertheless, survival analysis 
using high-dimensional data is no less challenging than alternative analytical approaches. 
In a comprehensive review of the topic, Witten and Tibshirani (2010) identify four main 
approaches to variable selection when dealing with high-dimensional data in survival 
analyses: discrete feature selection, shrinkage, clustering and variance-based methods (Table 
9.1). The approach I have used in this study is based upon discrete feature selection, whereby 
variables are first selected based upon their statistical significance in univariate Cox 
regression, followed by stepwise fitting of a multivariate Cox regression model. This 
approach has the advantages of relative conceptual simplicity, and allows variables across 
different domains to be analysed simultaneously for their effect on survival time. However, 
this approach is also prone to over-fitting and can result in models dominated by closely-
correlated variables (Witten and Tibshirani, 2010). This was partly addressed in my analysis 
by the adoption of a smaller multivariate significance threshold in the gene expression 
analysis (uncorrected p < 0.001 versus <0.05). Nonetheless, the final composite score is 
dominated by gene expression variables, whereas an alternative no-gene score performs with 
almost equal predictive value (albeit with one more variable). The true test of predictive 
utility lies in validation of the biomarker score in an independent patient cohort regardless of 
the analytical approach used. Indeed, this study has been conducted with a candid exploratory 
ethos throughout, aiming to identify potential biomarkers of DFR and flare as hypotheses for 
further research, rather than present the results as a final definitive fait accomplit. 
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Table 9.1 – Approaches to variable selection in survival analysis of high-dimensionality data. 
Adapted from Witten and Tibshirani (2010). Lasso: least absolute shrinkage and selection 
operator) 
Approach Typical statistical methods 
Discrete feature selection 
Univariate threshold selection 
Stepwise selection 
Shrinkage (penalisation) of coefficients 
Ridge regression 
Lasso 
Clustering Hierarchical clustering 
Variance-based methods 
Principal components analysis 
Partial least squares analysis 
 
9.1.2 Size and heterogeneity of the patient cohort 
A limitation throughout this study has been the small size of the study cohort. Owing to 
under-recruitment only 44 patients discontinued DMARDs, which was below the target of 60 
patients at the design stage. Removal of the requirement for absence of baseline power 
Doppler signal would have allowed this target to be achieved, and in retrospect perhaps would 
have been a better study design. However, the decision to exclude PD-positive patients from 
DMARD withdrawal was made on logical grounds (see Results 5.6.1), and if more patients 
had discontinued DMARDs then less laboratory processing would have been possible given 
the limited study budget. For example, longitudinal RNAseq analysis – arguably the most 
informative aspect of this study with regards to underlying biology – would not have been 
possible. 
There was considerable heterogeneity within the study population across a range of 
parameters, including disease duration, baseline DMARD therapy and relative stability of 
remission at baseline (the latter indicated by the surrogate measures of time since last steroid 
and time since last change in DMARD therapy). It is possible that such variation between 
patients led to greater variance in the measured variables, and thus served to reduce the 
statistical power of the analysis. This was unavoidable, and any further restrictions in the 
study eligibility criteria would resulted in lower study recruitment. In fact, the study 
population is broadly representative of a standard rheumatology outpatient population, and 
thus represents a ‘real-world’ study whose findings are more likely to be generalizable to the 
wider patient population than a study with highly selective recruitment. One exception to this 
is for younger patients under the age of 50 years, who are relatively under-represented in this 
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study cohort. Validation of the findings of this study in a younger cohort would therefore be 
important to determine whether they hold true in this age range. 
 
9.1.3 Immunopathological subpopulations 
One area of particular potential weakness in my statistical analysis is seen in the context of 
immunopathological subpopulations. As discussed above, there was substantial heterogeneity 
in demographic factors within the study population. It is thus conceivable that distinct subsets 
exist within the study population, underscored by heterogeneous immunopathological 
pathways of inflammation in those patients who experience an arthritis flare. Such subgroups 
of patients may be equally at risk of arthritis flare upon DMARD cessation, though the 
immunological measures of this may substantially differ between subgroups. Indeed, such 
subgrouping is perhaps suggested by the observation of a small group of patients who flare at 
the end of the study period (as opposed to the median of 48 days). If such subgrouping by 
immunopathology of flare does indeed exist, then this will have had the effect of diluting the 
magnitude of any observed differences between flare and DFR my analyses, which treat all 
flare events as equal. 
An alternative analytic approach would therefore be to use hierarchical clustering to group 
patients based on similarities in their predictive variables, and then explore the outcomes 
observed in each group. If subpopulations exist within the dataset, and if members of these 
populations were sufficiently similar with regards to their measured variables, then this 
approach could help identify distinct immunopathological pathways to arthritis flare – 
particularly if then extended to longitudinal analysis at the individual patient level. However, 
such an approach would risk being statistically underpowered in this small study, and any 
results would potentially be of less utility as a biomarker for clinical use, where a universal 
marker incorporating variables from all major subpopulations would arguably be preferable. 
Nevertheless, cluster analysis – especially utilising the high-dimensional CD4+ T cell gene 
expression data – would be a logical extension to the analyses presented in this Thesis. 
 
9.1.4 Remission definition 
 The use of DAS28-CRP < 2.4 as the clinical remission criterion for this study could be 
criticised as being too lenient in comparison to alternative measures such as ACR/EULAR 
Boolean remission. Indeed, the latter criterion was used as the initial definition of remission 
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when the study was conceived, though was quickly amended to DAS28-CRP < 2.4 when it 
became apparent that the strict VASpatient < 10/100 threshold was difficult to achieve in 
practice, an observation made by many independent research groups (see Methods 3.2). The 
change to DAS28-CRP remission early in the course of the study resulted in the re-
classification of only one patient, who exited the study in DAS28-CRP remission before the 
amendment was enacted. This patient was treated as censored in remission for the purposes of 
survival analysis, and excluded from analyses using binary outcome measures. 
A further problem arose with the change to DAS28-CRP remission criteria in the handling of 
CRP levels less than 5mg/L, the lower limit of detection of the assay used by the local 
hospital clinical biochemistry service. To deal with this, a pragmatic decision was taken to use 
a value of zero for all CRP measurements below this detectable threshold, though with a risk 
of underestimating disease activity in some patients. However, only 7/184 study visits were 
potentially affected, and a sensitivity analysis using hsCRP values measured by MSD 
electrochemiluminescence demonstrated no apparent influence upon the predictive 
performance of the final composite biomarker score. However, it is important to note that the 
MSD hsCRP assay is manufactured for diagnostic use only, and was not performed in this 
study in line with the necessary quality assurance or accreditation required for a diagnostic 
clinical test. Future studies would benefit from use of a clinical-grade hsCRP assay, which 
would then be suitable for use in disease activity assessment as part of the primary study 
outcome measure. 
 
9.1.5 Frequency of follow-up visits 
The schedule of visits at 0, 1, 3, and 6 months following DMARD cessation was based on an 
assumption that the majority of flare events would occur between three and six months of 
follow-up. The fact that flare events occurred much earlier than anticipated resulted in fewer 
longitudinal samples available for patients who experienced an arthritis flare. This was further 
compounded by the lack of collection of research bloods at the month one visit in the original 
study protocol, which was subsequently amended. The net result was therefore a reduced 
number of samples available for longitudinal analysis within the flare group, thus prohibiting 
a meaningful analysis using more powerful longitudinal statistical techniques, such as 
smoothing splines and multilevel hierarchical modelling. However, the limited study budget 
prevented the addition of further visits to the study schedule, and an analysis of change in 
variables from baseline to final study visit was still possible using the existing dataset. 
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9.1.6 Anatomical compartment 
Both cytokine and CD4+ T cell gene expression data were obtained from peripheral blood 
samples. This represents a convenient and minimally invasive method of biological sampling, 
which could be easily translated to routine clinical practice. However, it is difficult to directly 
infer the pathophysiological processes occurring at the disease site by the study of circulating 
cytokines and lymphocytes. The upregulation of genes by circulating CD4+ T cells does not 
necessarily mean the same expression profile is present in synovial T cells, nor is the profile 
of circulating cytokines and chemokines likely to precisely reflect the milieu within the joint 
capsule. It is even conceivable that, in some situations, a circulating immune parameter may 
inversely reflect processes within the joint. For example, when a pathological subset of CD4+ 
T cell is recruited to the synovial compartment, measures of circulating lymphocyte 
populations may only reveal a reduced proportion of that subset in the circulation. This is 
clearly a rather extreme scenario, and in most cases it should be possible to draw some 
conclusions as to the immune processes within the joint by the study of circulating 
lymphocytes and immune mediators. However, a deeper understanding of the 
pathophysiological processes in arthritis flare would undoubtedly be gained by examination 
of synovial fluid and tissue, though this was not feasible within the limited resources of this 
study. 
Perhaps an even more fundamental limitation lies in the choice of cell type for RNA 
sequencing. It was hoped that by restricting gene expression analysis solely to CD4+ T cells, 
an increase in signal-to-noise ratio would be achieved, thus increasing sensitivity for the 
detection of more subtle changes in gene expression. Although the decision to focus on CD4+ 
T cells was a rational decision based on evidence of the importance of these cells in the 
pathogenesis of RA (see Introduction 1.2.3), highly relevant changes in gene expression in 
alternative cell types may have been overlooked. These include – though are not limited to – 
B cells, CD8+ T cells, NK cells, and antigen-presenting cells such as synovial macrophages 
and dendritic cells. Furthermore, the use of bulk RNAseq techniques permits only a global 
view of gene expression, rather than expression at the individual cell level. Single cell 
RNAseq technology is now becoming more widely available, and in combination with 
fluorescence-activated cell sorting (FACS) isolation of cells based on surface protein 
expression would permit the identification of distinct populations of immune cells that may be 
relevant in RA pathogenesis, which would otherwise be impossible to distinguish using a bulk 
RNAseq approach. 
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9.2 Placing this study in context: pathophysiological insights and clinical impact 
This Thesis represents the culmination of an ambitious three-year programme of research that 
aimed to identify previously uncharacterised biomarkers of drug-free remission and flare in 
RA. To achieve this, a novel experimental model of DMARD cessation was utilised in the 
setting of a controlled clinical trial design to study the immunological processes both before 
and after withdrawal of immunosuppression. Data were collected from a range of different 
domains including clinical, ultrasound, cytokine and CD4+ T cell gene expression, and 
combined together to create an integrative overview of immune biology. Furthermore, the 
study design allowed not only for the identification of baseline biomarkers predictive of 
outcome following DMARD withdrawal, but also provided a unique insight in to the 
longitudinal changes that occur at the point of flare at an individual patient level. 
The key findings of this study that relate to the underlying pathobiology of disease flare in RA 
are: 
1. Circulating CD4+ T cells display an activated phenotype at the time of arthritis flare, 
characterised by up-regulation of genes involved in the cell cycle. 
2. Th17 differentiation may be an important event in the pathogenesis of RA flare, as 
evidenced by increased circulating IL-6, and the expression of genes encoding IL-15 
and the Th17 transcription factor BATF by circulating CD4+ T cells. 
3. Gene expression analysis suggests that distinct subpopulations of circulating CD4+ T 
cells may be discernible by surface marker expression at the time of flare, notably: 
CD70, CD109, KIR2DS4, LDLR and TSHR. 
4. Patients who maintain DFR appear to be characterised by absence of the pro-
inflammatory signals that predispose to disease relapse in the flare group, rather than 
the presence of active pro-tolerogenic mechanisms that maintain remission. 
 
In addition to the above observations, this study also demonstrates for the first time the 
feasibility of a multi-domain composite biomarker for predicting DFR and flare following 
DMARD cessation in RA. If successfully validated in an independent cohort, such a 
composite biomarker holds promise in guiding an individualised approach to withdrawal of 
DMARD therapy once remission is achieved. This would not only avoid medication side 
effects and reduce healthcare costs, but would also be greatly valued by patients living with 
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RA. Furthermore, the combination of a remission biomarker together with a biomarker of 
DMARD response opens possibilities of new future paradigms for the treatment of RA. For 
example, a biomarker predictive of response to a particular biologic therapy, combined with a 
biomarker of remission, would permit the rapid initiation of biologics as a first line therapy in 
patients with severe RA, followed by a rapid de-escalation of therapy once stable remission is 
achieved. Such an approach would permit, in suitable patients, the use of biologic agents as 
short-term therapies to induce remission early in the course of disease, rather than the current 
paradigm of long-term treatment used at later disease stages. 
 
9.3 Future directions 
As discussed previously in this chapter, there are several avenues for future research based on 
both the existing data and stored biological samples of this study. Further alternative analyses 
of the CD4+ T cell RNAseq data are possible, which have potential to shed further light on the 
functional significance of the findings to-date. For example, unsupervised clustering analysis 
may be illuminative of specific subpopulations of patients with distinct immunopathological 
pathways to flare. In silico analysis of predicted targets for the two uncharacterised antisense 
genes (ENSG00000228010 and ENSG00000227070) within the final composite score may 
shed light on their biological role, which may in turn help to provide further internal 
functional validation of the predictive model. 
Using flow cytometry, it should be possible to explore whether up-regulation of genes that 
encode surface expressed markers is reflected by increased protein expression at the cell 
surface. By combining these markers with standard phenotypical markers, and contrasting the 
expression of these at baseline and flare visit, it may be possible to characterise novel 
lymphocyte subsets that expand and become activated at the time of arthritis flare. If such 
subsets exist, then FACS sorting combined with single-cell RNAseq technology would allow 
for the transcriptional characterisation of these cells, thus providing further insight to the 
immune processes underlying RA flare with an unprecedented level of detail. With careful 
experimental design, all of this should be technically possible using existing cryopreserved 
PBMC samples from this study. 
Cryopreserved CD4+ T cell DNA also provides the opportunity for epigenetic analysis of 
circulating CD4+ T cells both as a baseline predictor of flare versus DFR, and to better 
understand the mechanisms underlying differential gene expression at the time of arthritis 
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flare. Epigenetic modification affecting the expression of DEGs identified in the CD4+ T cell 
RNAseq analysis would also provide further internal validation of these observations within 
the study cohort. 
The most important next step for future research is to validate the findings of this study in a 
larger independent study population. Such validation would allow for an assessment of over-
fitting in the composite biomarker score and, if successful, would provide confidence in the 
predictive performance of the score necessary for translation of the technique to clinical 
practice. Indeed, such a validation exercise is already underway in the form of the future 
Bio-FLARE study (Biological Factors that Limit sustAined Remission in rhEumatoid 
arthritis), a £3.5 million collaborative multi-centre clinical study funded by the Medical 
Research Council and conducted by Newcastle, Birmingham and Glasgow Universities as 
constituent partners of the Arthritis Research UK Centre of Excellence in RA Pathogenesis. 
The Bio-FLARE study, supported by pilot data from my study, will adopt a similar 
experimental model of DMARD cessation though in a much larger cohort of 160 patients. A 
more intensive visit schedule in the initial phases of the study will be possible, and synovial 
biopsies will be taken at baseline and time of flare to provide crucial insight to the 
pathophysiological events occurring within the joint synovium. The Bio-FLARE study 
therefore provides an ideal validation cohort, as well as allowing for a far more detailed 
analysis of the immunological events that presage RA flare than was possible with the limited 
resources available for my study. If successfully validated, future research efforts will need to 
focus on the translation of the predictive biomarker to clinical practice. Consideration will 
need to be given to the technical feasibility of the assays involved, and their amenability to 
high-throughput automation. Indeed, factors such as cost and assay reliability can be expected 
to play a significant role in the decision of which variables to include in a clinical test beyond 
simple predictive performance alone. 
In summary, a wide array of future research is possible based on the findings of this study, 
which have already directly led to a large multi-centre follow-on study. If successful, this 
comprehensive programme of future research promises to yield exciting and novel insights in 
to the pathogenesis of RA flare, the maintenance of RA remission, and future possibility of 
individualised tapering and withdrawal of DMARD therapy for RA patients in remission.  
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Appendix A. Health Assessment Questionnaire Disability Index (HAQ-DI) 
 
The HAQ-DI questionnaire completed by patients in this study is reproduced below. The 
questionnaire is protected under copyright by Stanford University, although it is made freely 
available in the public domain for research (Bruce and Fries, 2003). For discussion, see 
Methods 3.5.1. 
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Appendix B. Ultrasound scoring template 
 
The ultrasound scoring template used in this study is reproduced below. For discussion, see 
Methods 3.6. 
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Appendix C. List of laboratory reagents and equipment 
 
The laboratory reagents and equipment used in this project together with manufacturer and 
catalogue number details are listed below. For discussion, see Chapter 3. 
 
CD4+ T cell isolation 
 
RoboSep™ automated cell separator Stemcell 20000 (discontinued) 
Rosettesep™  human monocyte depletion 
cocktail 
Stemcell 15668 
HetaSep™ Stemcell 07906 
RoboSep™ Human Whole Blood CD4 
Positive Selection Kit 
Stemcell 18082RF 
RoboSep™ buffer Stemcell 20104 
RoboSep™ filter tips Stemcell 20125 
Falcon™ 14ml round bottom polystyrene 
tubes 
Becton Dickinson 
Biosciences 
352057 
 
CD4+ T cell lysis and RNA/DNA extraction 
 
RNase AWAY™ Molecular BioProducts 7003 
Buffer RLT Plus Qiagen 1053393    
β-mercaptoethanol Sigma-Aldrich M3148 
QIAshredder spin column Qiagen 79656    
Allprep™ DNA/RNA/miRNA Universal 
Kit 
Qiagen 80224 
NanoDrop™ ND1000 UV 
spectrophotometer 
Thermo Fisher Scientific 1660 
 
Next-generation RNA sequencing 
 
Tapestation™ 4200 Agilent G2991AA 
ScreenTape™ tube strips   
TruSeq™ Stranded mRNA HT Sample 
Prep Kit 
Illumina RS-122-2103 
Agencourt™ AMPure™ XP Beads Beckman Coulter Genomics 
A63881 
NextSeq™ 500 Illumina SY-415-1001 
NextSeq™ 500 High-Output Kit Illumina FC-404-1005 
 
PBMC isolation 
 
Lymphoprep™ Axis-Shield 1114544 
EASYstrainer™ 70µm nylon filter Breiner Bio-One 542070 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich D2650 
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Flow cytometry 
 
FACSCanto™ II flow cytometer Becton Dickinson Biosciences 
338962 
Fluorescein isothiocyanate (FITC) Mouse 
Anti-Human CD4 v4  antibody (clone  
L120) 
Becton Dickinson 
Biosciences 
340422 
R-phycoerythrin (PE) Mouse Anti-Human 
CD14  antibody (clone  M5E2) 
Becton Dickinson 
Biosciences 
555398 
Allophycocyanin (APC) Mouse Anti-
Human CD19 antibody (clone  HIB19) 
Becton Dickinson 
Biosciences 
555415 
Pacific Blue™ (PB) Mouse Anti-Human 
CD3 antibody (clone  UCHT1) 
Becton Dickinson 
Biosciences 
558117 
Dulbecco’s phosphate buffered saline 
(DPBS), calcium- and magnesium-free 
Lonza BE17-513F 
Bovine serum albumin (BSA) Sigma-Aldrich A9647 
Ethylenediaminetetraacetic acid (EDTA), 
0.5mM, endotoxin-free 
Thermo Fisher Scientific 11561575 
Sodium azide Sigma-Aldrich S2002 
Flow cytometry buffer DPBS + 0.5% BSA + 1mM EDTA + 0.01% sodium azide 
Flow cytometry 
antibody mixture 
34.5µL flow cytometry buffer + 2µL human IgG + 5µL 
CD4v4-FITC + 2.5µL CD14-PE + 5µL CD19-APC + 1µL 
CD3-PB 
 
Plasma separation 
 
cOmplete™ mini protease inhibitor 
cocktail tablets 
Roche 4693124001 
 
Cytokine/chemokine multiplex electrochemiluminescence assays 
 
V-PLEX™ human cytokine 30-plex kit Meso Scale Diagnostics K15054D-1 
V-PLEX™ Th17 panel 1 (human) kit Meso Scale Diagnostics K15085D-1 
V-PLEX™ Plus vascular injury panel 2 
(human) kit 
Meso Scale Diagnostics K15198G-1 
MESO™ QuickPlex SQ120 Meso Scale Diagnostics AI0AA-0 
 
General reagents 
 
Hanks buffered saline solution (HBSS) 
with Phenol Red, calcium- and 
magnesium-free 
Lonza BE10-543F 
Vacuette™ K3 EDTA 9ml tube Greiner Bio-One  
455036 
Vacuette™ Z Serum Separator Clot 
Activator tube 
Greiner Bio-One 
 
455071 
TEMPUS™ tube Applied Biosystems 4342792 
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Appendix D. Patient demographics for entire study cohort 
 
The demographics of all patients recruited to the study (i.e. including patients who stopped 
DMARDs and those who were ineligible for DMARD cessation) is presented below. For 
discussion, see Results 4.4.1. 
Demographic Value 
Number of patients recruited 74 
Satisfied 2010 ACR/EULAR RA diagnostic criteria: 
n(%) 70 (95%) 
Satisfied 1987 ACR RA diagnostic criteria: n(%) 67 (91%) 
Age: median (IQR) [range] 67 (56 – 72) [35 – 86] 
Female: n(%) 42 (57%) 
Years since RA diagnosis: median (IQR) [range] 6 (3 – 12) [1 – 40] 
Symptom duration in months prior to first 
rheumatology review: median (IQR) [range] 5 (2.5 – 10) [1 – 204] 
Months from first rheumatology review to starting first 
DMARD: median (IQR) [range] 1 (0 – 4) [0 – 210] 
Months since last steroid: median (IQR) [range] 30 (13 – 48) [0 – 152] 
Months since last change in DMARDs: median (IQR) 
[range] 24 (13.3 – 49.5) [2 – 132] 
Current smoker: n (%) 8 (11%) 
Previous smoker: n (%) 36 (49%) 
Never smoker: n(%) 30 (41%) 
Weekly alcohol unit intake: median (IQR) [range] 4 (0 – 10) [0 – 50] 
Total DMARDs since diagnosis: median [range] 2 [1 – 5] 
Current MTX monotherapy: n(%) 40 (54%) 
Current SFZ monotherapy: n(%) 9 (12%) 
Current HCQ monotherapy: n(%) 1 (1%) 
Current MTX+SFZ: n(%) 6 (8%) 
Current MTX+HCQ: n(%) 11 (15%) 
Current SFZ+HCQ: n(%) 3 (4%) 
Current MTX+SFZ+HCQ: n(%) 4 (5%) 
RhF positive: n(%) 44 (59%) 
ACPA positive: n(%) 41 (55%) 
RhF or ACPA positive: n(%) 52 (70%) 
RhF and ACPA positive: n(%) 33 (45%) 
Baseline 28 SJC: median (IQR) [range] 0 (0 – 0) [0 – 3] 
Baseline 28 TJC: median (IQR) [range] 0 (0 – 0) [0 – 10] 
Baseline patient VAS (mm): median (IQR) [range] 5 (1 – 15) [0 – 35] 
Baseline CRP in mg/L: median (IQR) [range] 0 (0 – 0) [0 – 13] 
Baseline ESR in mm/hr: median (IQR) [range] 9 (5 – 20) [1 – 77] 
Baseline DAS28-CRP: median (IQR) [range] 1.17 (1.00 – 1.81) [0.96 – 3.49] 
Baseline DAS28-ESR: median (IQR) [range] 1.85 (1.23 – 2.24) [0.48 – 4.37] 
ACR/EULAR Boolean remission: n(%) 40 (54%) 
Presence of joint erosion on baseline 7-joint ultrasound 
scan: n(%) 51 (69%) 
 
  
275 
 
Appendix E. Clinical composite score ROC analysis 
 
Composite clinical biomarker scores ranked by area under the receiver-operating 
characteristic curve (ROCAUC). Variables included within each score are indicated in green, 
and those excluded are indicated in red. For discussion, see Results 4.7. 
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ROCAUC 
      0.850 
      0.848 
      0.837 
      0.833 
      0.805 
      0.798 
      0.787 
      0.786 
      0.782 
      0.777 
      0.774 
      0.772 
      0.767 
      0.762 
      0.761 
      0.759 
      0.758 
      0.757 
      0.756 
      0.746 
      0.743 
      0.739 
      0.739 
      0.736 
      0.734 
      0.733 
      0.733 
      0.732 
      0.732 
      0.728 
      0.720 
      0.717 
      0.709 
      0.707 
      0.707 
      0.705 
      0.703 
      0.702 
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Appendix E (continued) 
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ROCAUC 
      0.700 
      0.695 
      0.690 
      0.689 
      0.679 
      0.676 
      0.675 
      0.675 
      0.675 
      0.674 
      0.672 
      0.667 
      0.666 
      0.665 
      0.653 
      0.639 
      0.638 
      0.623 
      0.618 
      0.611 
      0.607 
      0.603 
      0.601 
      0.601 
      0.538 
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Appendix F. Association of clinical variables with ultrasound findings at 
baseline. 
 
For discussion of the data presented in these tables, see Results 5.4. 
Table F.1 – Association of clinical parameters with the presence of joint GS in the setting of 
RA clinical remission by multivariate ordinal regression. BH: Benjamini-Hochberg; OR: odds 
ratio of increase in total joint GS score. 
Variable OR 95% CI Unadjusted p-value 
BH adjusted 
p-value 
Male sex 5.04 1.47 – 17.26 0.010 0.139 
ESR (mm/hr) 1.05 1.00 – 1.09 0.038 0.245 
Smoking pack years 1.03 1.00 – 1.07 0.052 0.245 
CRP (mg/L) 0.84 0.69 – 1.03 0.091 0.264 
RhF positive 0.38 0.12 – 1.21 0.101 0.264 
Disease duration (years) 1.06 0.99 – 1.15 0.113 0.264 
TJC28 0.54 0.21 – 1.40 0.207 0.414 
ACPA positive 2.14 0.54 – 8.48 0.278 0.486 
Age 0.98 0.94 – 1.03 0.379 0.589 
ACR/EULAR Boolean remission 0.57 0.10 – 3.15 0.519 0.727 
HAQ-DI score 0.78 0.25 – 2.43 0.664 0.845 
Weekly alcohol unit intake 1.01 0.94 – 1.10 0.736 0.859 
Patient VAS 1.00 0.93 – 1.09 0.954 0.985 
SJC28 1.01 0.33 – 3.09 0.985 0.985 
 
Table F.2 – Association of clinical parameters with the presence of joint PD in the setting of 
RA clinical remission by multivariate ordinal regression. BH: Benjamini-Hochberg; OR: odds 
ratio of increase in total joint PD score. 
Variable OR 95% CI Unadjusted p-value 
BH adjusted 
p-value 
Sex 0.24 0.05 – 1.24 0.088 0.907 
Age 1.04 0.97 – 1.12 0.228 0.907 
Disease duration (years) 1.01 0.91 – 1.11 0.856 0.979 
Smoking pack years 0.99 0.93 – 1.04 0.608 0.907 
Weekly alcohol unit intake 1.03 0.93 – 1.13 0.623 0.907 
RhF positive 1.26 0.26 – 6.06 0.773 0.979 
ACPA positive 1.03 0.16 – 6.50 0.979 0.979 
ACR/EULAR Boolean remission 0.30 0.03 – 3.11 0.315 0.907 
HAQ-DI score 0.66 0.11 – 3.88 0.648 0.907 
ESR (mm/hr) 0.98 0.92 – 1.05 0.594 0.907 
CRP (mg/L) 0.99 0.78 – 1.26 0.952 0.979 
SJC28 0.50 0.11 – 2.18 0.353 0.907 
TJC28 0.49 0.11 – 2.16 0.348 0.907 
Patient VAS 0.96 0.85 – 1.08 0.460 0.907 
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Table F.3 – Association of clinical parameters with the presence of tendon GS in the setting of 
RA clinical remission by multivariate ordinal regression. BH: Benjamini-Hochberg; OR: odds 
ratio of increase in total tendon GS score. 
Variable OR 95% CI Unadjusted p-value 
BH adjusted 
p-value 
SJC28 5.37 1.46 – 19.72 0.011 0.159 
Weekly alcohol unit intake 0.88 0.77 – 1.00 0.044 0.307 
TJC28 0.32 0.09 – 1.21 0.094 0.439 
ACR/EULAR Boolean remission 3.90 0.40 – 37.96 0.241 0.614 
ESR (mm/hr) 0.97 0.92 – 1.02 0.267 0.614 
CRP (mg/L) 0.86 0.66 – 1.13 0.293 0.614 
Sex 0.51 0.12 – 2.10 0.349 0.614 
RhF positive 0.52 0.13 – 2.04 0.351 0.614 
Patient VAS 1.05 0.94 – 1.16 0.395 0.614 
HAQ-DI score 1.77 0.38 – 8.33 0.468 0.632 
Age 1.02 0.96 – 1.09 0.513 0.632 
Disease duration (years) 0.97 0.89 – 1.07 0.542 0.632 
Smoking pack years 1.01 0.96 – 1.05 0.725 0.781 
ACPA positive 1.21 0.24 – 6.11 0.816 0.816 
 
Table F.4 – Association of clinical parameters with the presence of erosions in the setting of 
RA clinical remission by multivariate ordinal regression. BH: Benjamini-Hochberg; OR: odds 
ratio of increase in total erosion score. 
Variable OR 95% CI 
Unadjusted p-
value 
BH adjusted 
p-value 
Disease duration (years) 1.16 1.06 – 1.27 0.002 0.024 
TJC28 0.17 0.05 – 0.56 0.004 0.025 
ESR (mm/hr) 0.92 0.85 – 0.99 0.022 0.101 
Weekly alcohol unit intake 0.93 0.85 – 1.02 0.117 0.357 
CRP (mg/L) 1.17 0.95 – 1.42 0.134 0.357 
RhF positive 0.42 0.12 – 1.48 0.177 0.357 
HAQ-DI score 2.19 0.67 – 7.19 0.195 0.357 
SJC28 2.20 0.65 – 7.45 0.204 0.357 
Patient VAS 1.04 0.95 – 1.15 0.400 0.622 
Age 0.98 0.93 – 1.04 0.540 0.740 
Smoking pack years 0.99 0.95 – 1.03 0.581 0.740 
ACR/EULAR Boolean remission 1.30 0.18 – 9.12 0.793 0.926 
Sex 1.06 0.31 – 3.56 0.930 0.973 
ACPA positive 1.03 0.24 – 4.47 0.973 0.973 
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Appendix G. Cytokine/chemokine calibrator variation 
 
The percentage coefficient of variation for the calibrators for each analyte on each 
electrochemiluminescence plate are presented in the tables below. Seven calibrator solutions 
of known concentration were provided by the manufacturer, and were ran in duplicate on each 
plate. The manufacturer states that the %CV is typically less than 20% for repeat 
measurements – the %CV of calibrator pairs (CV1-7) that exceeded this threshold are 
highlighted in red. For discussion, see Results 6.2.2. 
Plate 1 
MSD plate Assay CV 1 CV 2 CV 3 CV 4 CV 5 CV 6 CV 7 
Cytokine panel 1 
(human) 
GM-CSF 2.4 3.6 0.6 4.3 1.9 8.1 1.6 
IL-12/IL-
23p40 
subunit 
4.2 2.4 1.9 2.9 0.8 1.3 2.2 
IL-15 3.3 1.5 1.2 0.6 1.7 1.6 1.6 
IL-16 2.1 1.6 4.3 4.8 0.9 6.3 0 
IL-17A 1.7 0.9 2.1 2.3 2.7 1.6 5.1 
IL-1α 16.6 0.5 0.4 4.5 3.7 18.3 12.6 
IL-5 0.6 1.4 2.1 2.8 0.1 1.2 7.9 
IL-7 6.9 2.8 2.6 4.2 3.3 3.1 0 
TNF-β 0.3 2.4 0.5 0.1 4.3 2.7 22.8 
VEGF 3.1 0.6 1 1.4 1.3 3.5 0 
Chemokine 
panel 1 (human) 
Eotaxin 1.3 1.4 0.4 7.2 8.4 78.4 40.2 
Eotaxin-3 5.9 3.7 9.3 2.1 6 6.9 32.6 
IL-8(HA) 3.1 2.2 22.1 13.1 19.4 31.8 0 
IP-10 3.7 1.9 3.4 5.8 2.6 2.9 0.9 
MCP-1 0.4 1.1 3.8 1 6 2.8 42 
MCP-4 0.8 1.7 3.1 8.3 13.1 31.2 0 
MDC 4.8 5 1.5 3.4 3.1 5.3 122 
MIP-1α 5.4 1.6 0.5 1.7 2.5 19.6 0 
MIP-1β 3 1.5 3.9 3.3 1.5 7.8 43.8 
TARC 2.6 4.1 27.6 22.5 21.1 22.6 0 
Proinflammatory 
panel 1 (human) 
IFN-γ 8 6.3 0.8 3 0.9 35.9 79.9 
IL-10 1.5 2.1 2.7 5.6 1.1 1.7 60.8 
IL-12p70 
subunit 28.2 0.3 33.6 5.6 40.4 0 0 
IL-13 7.5 2 12.1 2.8 0 0 0 
IL-1β 3.6 4.7 9.3 5.5 0.6 8.8 20.6 
IL-2 3.9 16.8 16.5 23.1 0.5 20.2 34.9 
IL-4 4.2 64.4 4.3 1.4 3.6 6.6 73.4 
IL-6 5 15.5 41.9 5.2 0.7 14.8 0 
IL-8 16.1 7.6 22 2.6 31.8 2.2 0 
TNF-α 32.2 5.9 65.8 22.3 76.5 0 0 
Th17 panel 1 
(human) 
IL-17A 2.1 0.9 6.1 4.2 3.4 4.4 7.1 
IL-21 3.5 2.6 0.9 2.1 1 6.7 52.6 
IL-22 7 0.7 3.6 0.8 2.4 6.1 9.6 
IL-23 5.5 5.6 3.1 1.6 0.4 1.9 10.5 
IL-27 7.3 4.5 7.8 4 0.9 0.4 8.2 
MIP-3α 3.4 4.7 11.6 7 4.4 15 0 
IL-31 0.7 5.1 6.1 8.3 3.4 7.6 9.5 
Vascular injury 
panel 2 (human) 
CRP 0.3 4.9 3.3 10 3.7 4.8 13.3 
ICAM-1 9.1 9 7.9 14.3 7 12.9 16 
SAA 7.8 5.7 5.7 22 9.2 7.6 64 
VCAM-1 10 6.8 4.4 8.3 5.9 6.2 37.9 
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Plate 2 
MSD plate Assay CV 1 CV 2 CV 3 CV 4 CV 5 CV 6 CV 7 
Cytokine panel 1 
(human) 
GM-CSF 0.9 10.9 0.3 2 2.5 14.4 7.7 
IL-12/IL-
23p40 
subunit 
1.3 0.2 0.7 0.8 1.2 1.2 5.3 
IL-15 1.4 2.1 0.5 2 0.9 2 6.5 
IL-16 1.2 6 0.4 3.1 8 51.4 0 
IL-17A 3.2 0.5 0.4 1.4 1.1 0.5 0.8 
IL-1α 8.9 13.2 5.1 6.1 26.1 0.4 48.7 
IL-5 3.7 0.7 4.4 3.7 3.5 0.1 13.6 
IL-7 2.7 3.2 1.7 3.9 2 6.1 4.4 
TNF-β 2.3 1.7 1.9 1.9 0.4 3.5 13.9 
VEGF 2.2 0.6 3.6 3 2.1 11.8 0 
Chemokine 
panel 1 (human) 
Eotaxin 1.2 2.4 0.3 5.4 9.2 20.2 0 
Eotaxin-3 3.4 4.8 0.8 1.8 7.7 14.1 6.8 
IL-8(HA) 4.5 8.8 1.5 15.4 7.6 32.9 0 
IP-10 10.2 5.1 2.7 0.4 2.8 0.4 0.1 
MCP-1 0.5 3.2 3.1 4.4 3 6.6 2.7 
MCP-4 2.3 2.5 2.8 4.6 4.5 0 0 
MDC 9.1 1.2 5.9 5.1 1.3 2.5 134.8 
MIP-1α 1.6 1.3 0.6 2.5 9.1 2.6 0 
MIP-1β 2.8 1.8 0.1 0.8 1.6 3.2 13.3 
TARC 0.8 11.9 0 0.4 1.4 11.2 0.9 
Proinflammatory 
panel 1 (human) 
IFN-γ 46.9 4 40.4 68 1.1 0 88.3 
IL-10 0.2 0.8 0.8 1.3 3.2 0.6 2.5 
IL-12p70 
subunit 85.3 7.3 0.8 4.7 16.8 0 45.5 
IL-13 6.3 1.6 4.6 25.6 6.1 0 9.9 
IL-1β 13 2.1 4.9 0.3 3.4 7.3 7.2 
IL-2 9.7 0.7 7.3 0.5 2.9 13.3 1 
IL-4 56 1.2 8 12.5 3.9 19.9 12.6 
IL-6 5.9 6 10.3 4 0.8 3.4 19.2 
IL-8 12.9 6.2 5.5 0.2 33.6 7.6 10.9 
TNF-α 100.2 26.6 40.4 27 5.4 15.8 0 
Th17 panel 1 
(human) 
IL-17A 10 2.2 3.5 2.6 2.3 4.8 5.5 
IL-21 1 5.5 4.7 4.4 1.4 0.3 14.4 
IL-22 1.6 2.5 0.7 0.7 1.5 0.9 35.1 
IL-23 1.5 0.6 0.9 0.7 2.4 5.2 4.8 
IL-27 4.9 1.5 1.7 3 2.8 25.5 0 
MIP-3α 3.3 0.1 0.7 2.2 0.2 10.3 82.7 
IL-31 2 1.8 1.8 1.5 3.7 0.3 9.6 
Vascular injury 
panel 2 (human) 
CRP 11.1 1.3 0.7 2.5 3.7 2.9 5 
ICAM-1 0.3 3 4.8 1.8 7.8 14 21.3 
SAA 1.1 2.7 1.1 0.7 0.5 16.9 12.9 
VCAM-1 1.7 0.1 0.5 0.5 0.1 0.8 8.5 
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Appendix H. Cytokine/chemokine equilibration 
 
Linear regression was used to assess the correlation between cytokine/chemokine 
concentrations in duplicated samples present on both paired electrochemiluminescence plates, 
and then applied to equilibrate readings on the two plates. The regression coefficient (m), 
constant (c), and R2 values for each analyte are detailed in the table below. For discussion, see 
Results 6.2.5. NA: regression not possible owing to ≤2 samples available for regression. 
 
Assay 
Number of samples 
available for 
regression 
m c R2 
Eotaxin 35 0.992 -0.077 0.961 
Eotaxin3 15 1.040 -0.240 0.965 
IP10 35 0.997 -0.040 0.985 
MCP1 35 0.960 0.140 0.902 
MCP4 35 0.922 0.400 0.933 
MDC 35 0.925 0.481 0.945 
MIP1α 28 0.244 2.162 0.083 
MIP1β 35 0.964 0.137 0.978 
TARC 35 1.025 -0.293 0.953 
GMCSF 0 NA NA NA 
IL12/23p40 35 0.963 0.226 0.973 
IL15 35 0.879 0.209 0.901 
IL16 35 0.904 0.610 0.843 
IL17A 4 1.027 -0.030 0.968 
IL1α 0 NA NA NA 
IL5 3 1.551 -0.180 0.789 
IL7 35 0.861 0.501 0.925 
TNFβ 0 NA NA NA 
VEGF 35 0.978 0.192 0.974 
IFNγ 28 0.972 0.285 0.956 
IL10 11 0.917 0.142 0.834 
IL12p70 0 NA NA NA 
IL13 0 NA NA NA 
IL1β 2 NA NA NA 
IL2 2 NA NA NA 
IL4 0 NA NA NA 
IL6 8 0.913 0.069 0.994 
IL8 33 0.980 -0.585 0.955 
TNFα 33 0.910 0.179 0.800 
IL21 0 NA NA NA 
IL22 19 0.977 0.003 0.964 
IL23 0 NA NA NA 
IL27 19 0.958 0.325 0.852 
MIP3α 19 0.919 0.305 0.843 
IL31 0 NA NA NA 
CRP 6 1.096 -0.952 0.969 
ICAM1 5 1.099 -1.214 0.979 
SAA 5 0.911 1.006 0.749 
VCAM1 5 0.999 -0.145 0.994 
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Appendix I. Differential gene expression supplementary tables 
 
For discussion, see Chapter 7. 
Table I.1 – Unabbreviated list of differentially expressed genes at baseline between flare 
patients and healthy controls, using an unadjusted significance threshold of p<0.001. Positive 
log-fold change indicates higher expression in the patient group, whereas negative log-fold 
change indicates higher expression in the control group. HGNC: HUGO gene nomenclature 
committee; lincRNA: long intergenic non-coding RNA; * = significant after FDR adjustment. 
Ensembl gene ID Log2FC Unadjusted p-value HGNC symbol Description 
ENSG00000171560 2.42 1.05E-07 FGA fibrinogen alpha chain *  
ENSG00000106927 2.13 1.21E-06 AMBP alpha-1-microglobulin/bikunin precursor * 
ENSG00000171564 2.00 3.19E-06 FGB fibrinogen beta chain * 
ENSG00000163631 4.07 8.15E-06 ALB albumin  
 
ENSG00000182489 -2.85 2.50E-05 XKRX Kell Blood Group Complex Subunit-Related, X-Linked 
ENSG00000198538 -1.30 2.89E-05 ZNF28 zinc finger protein 28  
ENSG00000223551 1.87 3.22E-05 TMSB4XP4 thymosin beta 4, X-linked pseudogene 4  
ENSG00000226029 0.78 8.16E-05 LINC01772 long intergenic non-protein coding RNA 1772  
ENSG00000141622 1.47 9.25E-05 RNF165 ring finger protein 165  
ENSG00000251411 2.32 1.08E-04 
 
(known processed pseudogene) 
ENSG00000197841 -0.93 1.11E-04 ZNF181 zinc finger protein 181  
ENSG00000164136 1.25 1.13E-04 IL15 interleukin 15  
ENSG00000172985 -1.15 1.13E-04 SH3RF3 SH3 domain containing ring finger 3  
ENSG00000247311 1.85 1.18E-04 
 
(novel antisense) 
ENSG00000112139 6.09 1.35E-04 MDGA1 MAM domain containing glycosylphosphatidylinositol anchor 1  
ENSG00000088538 0.85 1.52E-04 DOCK3 dedicator of cytokinesis 3  
ENSG00000131080 1.84 1.68E-04 EDA2R ectodysplasin A2 receptor  
ENSG00000229314 2.72 1.73E-04 ORM1 orosomucoid 1  
ENSG00000125726 1.70 1.85E-04 CD70 CD70 molecule  
ENSG00000152242 0.60 2.01E-04 C18orf25 chromosome 18 open reading frame 25  
ENSG00000261115 1.94 2.31E-04 TMEM178B transmembrane protein 178B  
ENSG00000172349 -0.64 2.52E-04 IL16 interleukin 16  
ENSG00000229473 1.63 2.60E-04 RGS17P1 regulator of G-protein signaling 17 pseudogene 1  
ENSG00000185010 1.07 2.65E-04 F8 coagulation factor VIII  
ENSG00000267939 2.31 2.77E-04 
 
(novel lincRNA) 
ENSG00000279148 1.87 2.77E-04 
 
(known TEC) 
ENSG00000265293 1.64 2.79E-04 ARGFXP2 arginine-fifty homeobox pseudogene 2  
ENSG00000261487 1.59 3.00E-04 
 
(known processed transcript) 
ENSG00000197180 1.29 3.01E-04 
 
uncharacterized protein BC009467  
ENSG00000169398 -0.82 3.29E-04 PTK2 protein tyrosine kinase 2  
ENSG00000082213 -0.70 3.48E-04 C5orf22 chromosome 5 open reading frame 22  
ENSG00000072110 -0.76 3.82E-04 ACTN1 actinin alpha 1  
ENSG00000228382 1.91 3.96E-04 ITPKB-IT1 Inositol-Trisphosphate 3-Kinase B intronic transcript 1  
ENSG00000131969 1.92 3.98E-04 ABHD12B abhydrolase domain containing 12B  
ENSG00000149557 2.77 4.12E-04 FEZ1 fasciculation and elongation protein zeta 1  
ENSG00000259657 1.35 4.33E-04 PIGHP1 phosphatidylinositol glycan anchor biosynthesis class H pseudogene 1  
ENSG00000165259 1.94 4.42E-04 HDX highly divergent homeobox  
ENSG00000264739 2.16 5.08E-04 
 
(novel antisense) 
ENSG00000162892 -0.61 5.55E-04 IL24 interleukin 24  
ENSG00000115129 1.15 5.65E-04 TP53I3 tumor protein p53 inducible protein 3  
ENSG00000244588 2.25 5.89E-04 RAD21L1 Double-Strand-Break Repair Protein Rad21  cohesin complex component like 1  
ENSG00000272329 1.85 6.00E-04 
 
(known lincRNA) 
ENSG00000154655 1.66 6.13E-04 L3MBTL4 l(3)mbt-like 4 (Drosophila)  
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Table I.1 (continued) 
Ensembl gene ID Log2FC Unadjusted p-value HGNC symbol Description 
ENSG00000272630 1.09 6.41E-04 
 
(known lincRNA) 
ENSG00000171115 -0.81 6.78E-04 GIMAP8 GTPase, IMAP family member 8  
ENSG00000205786 1.13 6.86E-04 LINC01531 long intergenic non-protein coding RNA 1531  
ENSG00000278356 1.34 7.01E-04 
 
(known sense intronic) 
ENSG00000159882 -0.67 7.02E-04 ZNF230 zinc finger protein 230  
ENSG00000246016 1.95 7.53E-04 LINC01513 long intergenic non-protein coding RNA 1513  
ENSG00000272086 1.27 7.64E-04 
 
(novel lincRNA) 
ENSG00000271447 -1.47 7.73E-04 MMP28 matrix metallopeptidase 28  
ENSG00000160318 3.03 8.05E-04 CLDND2 claudin domain containing 2  
ENSG00000271680 -1.73 8.45E-04 
 
(novel processed pseudogene) 
ENSG00000273598 -1.89 8.69E-04 
 
(novel unprocessed pseudogene) 
ENSG00000162946 -0.65 8.87E-04 DISC1 disrupted in schizophrenia 1  
ENSG00000228543 2.14 9.03E-04 
 
(known lincRNA) 
ENSG00000151729 0.64 9.34E-04 SLC25A4 solute carrier family 25 member 4  
ENSG00000219433 -1.71 9.71E-04 BTBD10P2 BTB domain containing 10 pseudogene 2  
Table I.2 – Unabbreviated list of differentially expressed genes at baseline between remission 
patients and healthy controls, using an unadjusted significance threshold of p<0.001. Positive 
log-fold change indicates higher expression in the patient group, whereas negative log-fold 
change indicates higher expression in the control group.  HGNC: HUGO gene nomenclature 
committee; lincRNA: long intergenic non-coding RNA; TEC: to be experimentally 
confirmed. 
Ensembl gene ID Log2FC Unadjusted p-value 
HGNC 
symbol Description 
ENSG00000106927 2.05 3.31E-06 AMBP alpha-1-microglobulin/bikunin precursor  
ENSG00000226029 0.92 5.02E-06 LINC01772 long intergenic non-protein coding RNA 1772  
ENSG00000112139 
7.13 1.09E-05 MDGA1 meprin, A-5 protein, and receptor protein-tyrosine 
phosphatase mu (MAM) domain containing 
glycosylphosphatidylinositol anchor 1  
ENSG00000247311 2.06 2.19E-05 
 
(novel antisense) 
ENSG00000198538 -1.33 2.21E-05 ZNF28 zinc finger protein 28  
ENSG00000163631 3.88 2.24E-05 ALB albumin  
ENSG00000171560 1.87 2.79E-05 FGA fibrinogen alpha chain  
ENSG00000171564 1.74 4.48E-05 FGB fibrinogen beta chain  
ENSG00000256913 1.67 5.94E-05 
 
(novel processed pseudogene) 
ENSG00000259657 1.54 6.92E-05 PIGHP1 phosphatidylinositol glycan anchor biosynthesis class H pseudogene 1  
ENSG00000265293 1.75 1.24E-04 ARGFXP2 arginine-fifty homeobox pseudogene 2  
ENSG00000204380 2.30 1.55E-04 PKP4-AS1 Plakophilin 4 - antisense RNA 1 
ENSG00000228382 2.06 1.59E-04 ITPKB-IT1 Inositol-Trisphosphate 3-Kinase B - intronic transcript 1  
ENSG00000279148 1.92 2.10E-04 
 
(known TEC) 
ENSG00000214081 -2.58 2.24E-04 CYP4F30P cytochrome P450 family 4 subfamily F member 30, pseudogene  
ENSG00000165259 2.05 2.48E-04 HDX highly divergent homeobox  
ENSG00000251411 2.19 2.70E-04 
 
(known processed pseudogene) 
ENSG00000154099 0.98 3.28E-04 DNAAF1 dynein axonemal assembly factor 1  
ENSG00000261487 1.58 3.77E-04 
 
(novel processed transcript) 
ENSG00000253676 1.79 3.77E-04 TAGLN2P1 transgelin 2 pseudogene 1  
ENSG00000267795 2.13 4.60E-04 SMIM22 small integral membrane protein 22  
ENSG00000163659 1.04 4.65E-04 TIPARP 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) inducible poly(ADP-ribose) polymerase  
ENSG00000141622 1.32 4.66E-04 RNF165 ring finger protein 165  
ENSG00000115129 1.18 4.67E-04 TP53I3 tumor protein p53 inducible protein 3  
ENSG00000165202 -1.84 5.22E-04 OR1Q1 olfactory receptor family 1 subfamily Q member 1  
ENSG00000246016 2.02 5.28E-04 LINC01513 long intergenic non-protein coding RNA 1513  
ENSG00000266992 -3.61 5.64E-04 DHX40P1 DEAH-box helicase 40 pseudogene 1  
ENSG00000159882 -0.68 5.68E-04 ZNF230 zinc finger protein 230  
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Table I.2 (continued) 
Ensembl gene ID Log2FC Unadjusted p-value 
HGNC 
symbol Description 
ENSG00000272086 1.31 5.71E-04 
 
(novel lincRNA) 
ENSG00000267939 2.17 6.42E-04 
 
(novel lincRNA) 
ENSG00000219797 0.81 6.48E-04 PPIAP9 peptidylprolyl isomerase A pseudogene 9  
ENSG00000264548 1.75 6.61E-04 
 
(novel antisense) 
ENSG00000273598 -1.95 6.67E-04 
 
(novel unprocessed pseudogene) 
ENSG00000228918 2.03 6.68E-04 LINC01344 long intergenic non-protein coding RNA 1344  
ENSG00000235217 -0.59 7.60E-04 TSPY26P testis specific protein, Y-linked 26, pseudogene  
ENSG00000229314 2.43 8.12E-04 ORM1 orosomucoid 1  
ENSG00000205765 -0.88 8.20E-04 C5orf51 chromosome 5 open reading frame 51  
ENSG00000250656 2.00 9.24E-04 ST3GAL1P1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 pseudogene 1  
ENSG00000069696 1.97 9.30E-04 DRD4 dopamine receptor D4  
 
Table I.3 – Unabbreviated list of differentially expressed genes between flare versus baseline 
visits in 17 patients who experienced an arthritis flare, using an unadjusted significance 
threshold of p<0.001. Positive log-fold change indicates higher expression at the flare visit, 
whereas negative log-fold change indicates higher expression at baseline.  HGNC: HUGO 
gene nomenclature committee; lincRNA: long intergenic non-coding RNA; TEC: to be 
experimentally confirmed.* = significant after multiple test correction (p<0.05). 
Ensembl gene ID Log2FC Unadjusted p-value 
HGNC 
symbol Description 
ENSG00000144354 1.05 2.79E-07 CDCA7 cell division cycle associated 7 * 
ENSG00000130164 0.79 1.47E-06 LDLR low density lipoprotein receptor * 
ENSG00000165409 1.19 8.59E-06 TSHR thyroid stimulating hormone receptor 
ENSG00000171533 1.69 9.98E-06 MAP6 microtubule associated protein 6 
ENSG00000137474 1.37 1E-05 MYO7A myosin VIIA 
ENSG00000156127 0.78 1.47E-05 BATF basic leucine zipper ATF-like transcription factor 
ENSG00000251537 1.80 1.89E-05 
 
(known protein coding) 
ENSG00000088325 1.10 2.07E-05 TPX2 TPX2, microtubule nucleation factor 
ENSG00000156535 0.72 2.15E-05 CD109 CD109 molecule 
ENSG00000138180 1.36 2.6E-05 CEP55 centrosomal protein 55 
ENSG00000137812 0.83 2.97E-05 KNL1 kinetochore scaffold 1 
ENSG00000216819 -1.48 3.5E-05 TUBB2BP1 tubulin beta 2B class IIb pseudogene 1 
ENSG00000131747 1.21 3.91E-05 TOP2A topoisomerase (DNA) II alpha 
ENSG00000170312 1.02 3.91E-05 CDK1 cyclin dependent kinase 1 
ENSG00000148773 1.53 4.2E-05 MKI67 marker of proliferation Ki-67 
ENSG00000267496 -0.90 4.34E-05 FAM215A family with sequence similarity 215 member A (non-protein coding) 
ENSG00000263218 1.72 4.62E-05 
 
(known antisense RNA) 
ENSG00000237649 1.14 4.98E-05 KIFC1 kinesin family member C1 
ENSG00000137804 0.91 5.56E-05 NUSAP1 nucleolar and spindle associated protein 1 
ENSG00000175063 1.59 9.31E-05 UBE2C ubiquitin conjugating enzyme E2 C 
ENSG00000176890 1.11 9.61E-05 TYMS thymidylate synthetase 
ENSG00000213297 -2.05 0.000101 ZNF625-
ZNF20 
ZNF625-ZNF20 readthrough (NMD candidate) 
ENSG00000226310 -1.28 0.000124 
 
(known antisense RNA) 
ENSG00000060982 0.72 0.000127 BCAT1 branched chain amino acid transaminase 1 
ENSG00000024422 -1.18 0.000131 EHD2 EH domain containing 2 
ENSG00000186187 0.59 0.000133 ZNRF1 zinc and ring finger 1 
ENSG00000184661 1.39 0.000136 CDCA2 cell division cycle associated 2 
ENSG00000163808 1.17 0.000137 KIF15 kinesin family member 15 
ENSG00000270111 -0.74 0.000144 
 
(known LincRNA) 
ENSG00000178999 0.95 0.000153 AURKB aurora kinase B 
ENSG00000114346 0.59 0.000169 ECT2 epithelial cell transforming 2 
ENSG00000251211 1.19 0.000177 
 
(processed pseudogene) 
ENSG00000066279 1.06 0.000178 ASPM abnormal spindle microtubule assembly 
ENSG00000035499 0.98 0.000235 DEPDC1B DEP domain containing 1B 
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Table I.3 (continued) 
Ensembl gene ID Log2FC Unadjusted p-value 
HGNC 
symbol Description 
ENSG00000109805 1.12 0.000248 NCAPG non-SMC condensin I complex subunit G 
ENSG00000165304 0.94 0.000259 MELK maternal embryonic leucine zipper kinase 
ENSG00000228792 -1.05 0.000281 
 
(known LincRNA) 
ENSG00000230266 1.16 0.000286 XXYLT1-AS2 
XXYLT1 antisense RNA 2 
ENSG00000271817 -1.21 0.000307 
 
Small nucleolar RNA U3 
ENSG00000007968 0.79 0.000307 E2F2 E2F transcription factor 2 
ENSG00000126787 1.53 0.000309 DLGAP5 DLG associated protein 5 
ENSG00000248564 1.12 0.000338 
 
(processed pseudogene) 
ENSG00000175267 0.93 0.000341 VWA3A von Willebrand factor A domain containing 3A 
ENSG00000138160 0.85 0.000342 KIF11 kinesin family member 11 
ENSG00000171848 1.35 0.000358 RRM2 ribonucleotide reductase regulatory subunit M2 
ENSG00000136982 1.30 0.00036 DSCC1 DNA replication and sister chromatid cohesion 1 
ENSG00000177602 0.89 0.000372 GSG2 germ cell associated 2, haspin 
ENSG00000101057 1.22 0.000386 MYBL2 MYB proto-oncogene like 2 
ENSG00000270116 -1.28 0.000402 
 
(sense intronic) 
ENSG00000250091 0.60 0.000415 DNAH10OS dynein axonemal heavy chain 10 opposite strand 
ENSG00000145386 1.06 0.000423 CCNA2 cyclin A2 
ENSG00000212663 1.22 0.000424 
 
(known LincRNA) 
ENSG00000094804 1.09 0.000425 CDC6 cell division cycle 6 
ENSG00000243761 -0.99 0.000429 
 
(processed pseudogene) 
ENSG00000156970 0.95 0.00043 BUB1B BUB1 mitotic checkpoint serine/threonine kinase B 
ENSG00000241790 1.79 0.000462 ENO1P4 enolase 1 pseudogene 4 
ENSG00000146670 1.14 0.00052 CDCA5 cell division cycle associated 5 
ENSG00000117724 0.64 0.000528 CENPF centromere protein F 
ENSG00000160207 -1.01 0.000555 HSF2BP heat shock transcription factor 2 binding protein 
ENSG00000228665 -0.62 0.000557 
 
(processed pseudogene) 
ENSG00000168811 0.69 0.000588 IL12A interleukin 12A 
ENSG00000117399 1.41 0.000624 CDC20 cell division cycle 20 
ENSG00000093009 1.15 0.000625 CDC45 cell division cycle 45 
ENSG00000168078 1.51 0.00065 PBK PDZ binding kinase 
ENSG00000072571 1.15 0.000676 HMMR hyaluronan mediated motility receptor 
ENSG00000121152 0.71 0.000708 NCAPH non-SMC condensin I complex subunit H 
ENSG00000109674 1.17 0.000717 NEIL3 nei like DNA glycosylase 3 
ENSG00000089685 1.17 0.000723 BIRC5 baculoviral IAP repeat containing 5 
ENSG00000279416 -1.13 0.000761 
 
(TEC) 
ENSG00000213885 -0.80 0.000763 RPL13AP7 ribosomal protein L13a pseudogene 7 
ENSG00000259212 0.69 0.000766 
 
(known antisense RNA) 
ENSG00000138696 1.08 0.00077 BMPR1B bone morphogenetic protein receptor type 1B 
ENSG00000157456 1.20 0.000817 CCNB2 cyclin B2 
ENSG00000118193 0.72 0.000835 KIF14 kinesin family member 14 
ENSG00000011347 -0.92 0.000844 SYT7 synaptotagmin 7 
ENSG00000090889 1.11 0.000858 KIF4A kinesin family member 4A 
ENSG00000138778 0.73 0.000895 CENPE centromere protein E 
ENSG00000188223 -2.39 0.000911 
 
(known protein coding) 
ENSG00000169679 0.71 0.000922 BUB1 BUB1 mitotic checkpoint serine/threonine kinase 
ENSG00000235688 1.20 0.000926 
 
(known antisense RNA) 
ENSG00000186340 -1.03 0.000962 THBS2 thrombospondin 2 
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Appendix J. ROC analysis for integrative biomarker scores 
 
For discussion, see Chapter 8. 
Table J.1 – Area under the receiver operating characteristic curve (ROCAUC) of 31 
combinations of the five variables from the stepwise multivariate Cox regression model that 
included gene expression data. Variables included within each score are indicated in green, 
and those excluded are indicated in red. 
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Table J.2 - Area under the receiver operating characteristic curve (ROCAUC) of 31 
combinations of the seven variables from the stepwise multivariate Cox regression model that 
excluded gene expression data. Variables included within each score are indicated in green, 
and those excluded are indicated in red. 
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       0.911 
       0.911 
       0.904 
       0.902 
       0.899 
       0.897 
       0.890 
       0.888 
       0.886 
       0.883 
       0.879 
       0.876 
       0.874 
       0.874 
       0.870 
       0.867 
       0.867 
       0.863 
       0.863 
       0.860 
       0.860 
       0.858 
       0.856 
       0.856 
       0.851 
       0.849 
       0.847 
       0.844 
       0.844 
       0.842 
       0.842 
       0.842 
       0.840 
       0.840 
       0.840 
       0.839 
       0.838 
       0.838 
       0.835 
       0.833 
       0.833 
       0.831 
       0.831 
       0.831 
       0.831 
       0.828 
       0.826 
       0.815 
       0.815 
       0.815 
       0.812 
       0.810 
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Table J.2 (continued) 
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ROCAUC 
       0.808 
       0.805 
       0.803 
       0.801 
       0.799 
       0.799 
       0.796 
       0.796 
       0.795 
       0.794 
       0.789 
       0.789 
       0.787 
       0.785 
       0.783 
       0.780 
       0.780 
       0.778 
       0.778 
       0.776 
       0.771 
       0.771 
       0.769 
       0.769 
       0.769 
       0.764 
       0.762 
       0.760 
       0.757 
       0.757 
       0.755 
       0.755 
       0.753 
       0.751 
       0.747 
       0.745 
       0.744 
       0.744 
       0.744 
       0.741 
       0.739 
       0.739 
       0.737 
       0.733 
       0.732 
       0.725 
       0.725 
       0.721 
       0.721 
       0.720 
       0.711 
       0.707 
       0.706 
       0.705 
       0.705 
       0.703 
       0.695 
       0.693 
       0.691 
       0.686 
       0.682 
       0.659 
       0.658 
       0.634 
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Table J.2 (continued) 
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ROCAUC 
       0.616 
       0.616 
       0.613 
       0.610 
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